

**(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. AU 2015342990 B2

(54) Title
Enzymatically polymerized gelling dextrans

(51) International Patent Classification(s)
C08B 37/02 (2006.01)

(21) Application No: **2015342990** (22) Date of Filing: **2015.11.05**

(87) WIPO No: **WO16/073732**

(30) Priority Data

(31) Number **62/075,460** (32) Date **2014.11.05** (33) Country **US**

(43) Publication Date: **2016.05.12**
(44) Accepted Journal Date: **2019.08.29**

(71) Applicant(s)
E. I. du Pont de Nemours and Company

(72) Inventor(s)
Nambiar, Rakesh;Guan, Rong;Cheng, Qiong;Dicosimo, Robert;Paullin, Jayme L.;Liang, Yuanfeng;Powley, Charles R.;Brun, Yefim

(74) Agent / Attorney
Houlihan² Pty Ltd, PO Box 611, BALWYN NORTH, VIC, 3104, AU

(56) Related Art
**ELINALVA M. PAULO ET AL, "Production, extraction and characterization of exopolysaccharides produced by the native Leuconostoc pseudomesenteroides R2 strain", ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS, (2012), vol. 84, no. 2, pp 495 - 508
CN 103992978 A**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2016/073732 A1

(43) International Publication Date

12 May 2016 (12.05.2016)

(51) International Patent Classification:

C08B 37/02 (2006.01)

(21) International Application Number:

PCT/US2015/059261

(22) International Filing Date:

5 November 2015 (05.11.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/075,460 5 November 2014 (05.11.2014) US

(71) Applicant: E. I. DU PONT DE NEMOURS AND COMPANY [US/US]; Chestnut Run Plaza, 974 Centre Road, P.O. Box 2915, Wilmington, Delaware 19805 (US).

(72) Inventors: NAMBIAR, Rakesh; 39 Doe Run Court, West Chester, Pennsylvania 19382 (US). GUAN, Rong; 1824 Faulkland Road, Wilmington, Delaware 19805 (US). CHENG, Qiong; 4 Collins Drive, Wilmington, Delaware 19803 (US). DICOSIMO, Robert; 1607 Masters Way, Chadds Ford, Delaware 19317-9720 (US). PAULLIN, Jayme L.; 2308 Wilson Avenue, Claymont, Delaware 19703 (US). LIANG, Yuanfeng; 9 Concord Crossing Lane, Chadds Ford, US 19317 (US). POWLEY, Charles R.; 172 Landis Way N, Wilmington, Delaware 19803 (US). BRUN, Yefim; 500 Rockwood Road, Wilmington, Delaware 19802 (US).

(74) Agent: CHESIRE, Dennis; E. I. du Pont de Nemours and Company, Legal Patent Records Center, Chestnut Run Plaza 721/2340, 974 Centre Road, PO Box 2915, Wilmington, Delaware 19805 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

[Continued on next page]

(54) Title: ENZYMATICALY POLYMERIZED GELLING DEXTRANS




FIG. 1

(57) Abstract: Compositions are disclosed herein comprising dextran that comprises (i) 87-93 wt% glucose linked at positions 1 and 6; (ii) 0.1 -1.2 wt% glucose linked at positions 1 and 3; (iii) 0.1 -0.7 wt% glucose linked at positions 1 and 4; (iv) 7.7-8.6 wt% glucose linked at positions 1, 3 and 6; and (v) about 0.4-1.7 wt% glucose linked at (a) positions 1, 2 and 6, or (b) positions 1, 4 and 6. Aqueous forms of this composition have enhanced viscosity profiles. Further disclosed are methods of using compositions comprising dextran, such as increasing the viscosity of an aqueous composition. Enzymatic reactions for producing dextran are also disclosed.

WO 2016/073732 A1



- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

TITLE

ENZYMATICALLY POLYMERIZED GELLING DEXTRANS

This application claims the benefit of U.S. Provisional Application No. 62/075,460 (filed November 5, 2014), which is incorporated herein by reference

5 in its entirety.

FIELD OF INVENTION

The present disclosure is in the field of polysaccharides. For example, the disclosure pertains to certain dextran polymers, reactions comprising glucosyltransferase enzymes that synthesize these polymers, and use of the

10 polymers in various applications.

REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY

The official copy of the sequence listing is submitted electronically via EFS-Web as an ASCII formatted sequence listing with a file named 20151105_CL6294USNP_SequenceListing.txt created on November 5, 2015, and having a size of 164 kilobytes and is filed concurrently with the specification.

15 The sequence listing contained in this ASCII-formatted document is part of the specification and is herein incorporated by reference in its entirety.

BACKGROUND

Driven by a desire to find new structural polysaccharides using enzymatic

20 syntheses or genetic engineering of microorganisms, researchers have discovered polysaccharides that are biodegradable and can be made economically from renewably sourced feedstocks. One such family of polysaccharides are alpha-glucans, which are polymers comprising glucose monomers linked by alpha-glycosidic bonds.

25 Dextrans represent a family of complex, branched alpha-glucans generally comprising chains of alpha-1,6-linked glucose monomers, with periodic side chains (branches) linked to the straight chains by alpha-1,3-linkage (Ivan et al., *Macromolecules* 33:5730-5739). Production of dextrans is typically done through fermentation of sucrose with bacteria (e.g., *Leuconostoc* or *Streptococcus*

30 species), where sucrose serves as the source of glucose for dextran polymerization (Naessens et al., *J. Chem. Technol. Biotechnol.* 80:845-860;

5 Sarwat et al., *Int. J. Biol. Sci.* 4:379-386; Onilude et al., *Int. Food Res. J.* 20:1645-1651). Although dextrans are used in several applications given their high solubility in water (e.g., adjuvants, stabilizers), this high solubility can negatively affect their general utility as thickening agents in hydrocolloid

5 applications.

Thus, there is interest in developing new, higher viscosity dextran polymers that are more amenable to high viscosity applications. In turn, there is also interest in identifying glucosyltransferase enzymes that can synthesize such dextran polymers.

10 **SUMMARY OF INVENTION**

In one embodiment, the disclosure concerns a composition comprising dextran that comprises:

- (i) about 87-93 wt% glucose linked at positions 1 and 6;
- (ii) about 0.1-1.2 wt% glucose linked at positions 1 and 3;
- 15 (iii) about 0.1-0.7 wt% glucose linked at positions 1 and 4;
- (iv) about 7.7-8.6 wt% glucose linked at positions 1, 3 and 6; and
- (v) about 0.4-1.7 wt% glucose linked at:
 - (a) positions 1, 2 and 6, or
 - (b) positions 1, 4 and 6;

20 wherein the weight-average molecular weight (Mw) of the dextran is about 50-200 million Daltons, the z-average radius of gyration of the dextran is about 200-280 nm, and the dextran optionally is not a product of a *Leuconostoc mesenteroides* glucosyltransferase enzyme.

In another embodiment, the dextran comprises: (i) about 89.5-90.5 wt% 25 glucose linked at positions 1 and 6; (ii) about 0.4-0.9 wt% glucose linked at positions 1 and 3; (iii) about 0.3-0.5 wt% glucose linked at positions 1 and 4; (iv) about 8.0-8.3 wt% glucose linked at positions 1, 3 and 6; and (v) about 0.7-1.4 wt% glucose linked at: (a) positions 1, 2 and 6, or (b) positions 1, 4 and 6.

30 In another embodiment, the dextran comprises chains (long chains) linked together within a branching structure, wherein said chains are similar in length

and comprise substantially alpha-1,6-glucosidic linkages. The average length of the chains is about 10-50 monomeric units in another embodiment.

In another embodiment, the dextran is a product of a glucosyltransferase enzyme comprising an amino acid sequence that is at least 90% identical to SEQ

5 ID NO:1, SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, or SEQ ID NO:17.

In another embodiment, the composition is an aqueous composition having a viscosity of at least about 25 cPs.

In another embodiment, the Mw of the dextran is about 80-120 million

10 Daltons.

In another embodiment, the z-average radius of gyration of the dextran is about 230-250 nm.

In another embodiment, the composition is in the form of a food product, personal care product, pharmaceutical product, household product, or industrial 15 product. In another embodiment, the composition is in the form of a confectionery.

In another embodiment, the disclosure concerns a method for increasing the viscosity of an aqueous composition. This method comprises contacting at least one dextran compound as disclosed herein with an aqueous composition.

20 The contacting step in this method results in increasing the viscosity of the aqueous composition, in comparison to the viscosity of the aqueous composition before the contacting step.

In another embodiment, the disclosure concerns a method of treating a material. This method comprises contacting a material with an aqueous 25 composition comprising at least one dextran compound disclosed herein.

In another embodiment, the disclosure concerns an enzymatic reaction comprising water, sucrose and a glucosyltransferase enzyme comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, or SEQ ID NO:17, wherein 30 the glucosyltransferase enzyme synthesizes a dextran compound as disclosed herein.

In another embodiment, the disclosure concerns a method of producing dextran comprising the step of contacting at least water, sucrose, and a glucosyltransferase enzyme comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:9, SEQ 5 ID NO:13, or SEQ ID NO:17, thereby producing dextran as disclosed herein.. This dextran can optionally be isolated.

In another embodiment, the viscosity of the dextran produced in the method is increased by decreasing the amount of sucrose in step (a).

BRIEF DESCRIPTION OF THE DRAWINGS AND SEQUENCES

10 FIG. 1: HPLC analysis of sucrose consumption by a glucosyltransferase reaction comprising 100 g/L sucrose and a 0768 gtf (SEQ ID NO:1). Refer to Example 2.

FIG. 2A: Map of plasmid pZZHB583 used to express 2919 gtf (SEQ ID NO:5) in *B. subtilis*. Refer to Example 3.

FIG. 2B: Map of plasmid pZZHB582 used to express 2918 gtf (SEQ ID NO:9) in 15 *B. subtilis*. Refer to Example 4.

FIG. 2C: Map of plasmid pZZHB584 used to express 2920 gtf (SEQ ID NO:13) in *B. subtilis*. Refer to Example 5.

FIG. 2D: Map of plasmid pZZHB585 used to express 2921 (SEQ ID NO:17) gtf in *B. subtilis*. Refer to Example 6.

20 FIG. 3: HPLC analysis of sucrose consumption by a reaction comprising a commercially available dextran sucrase. Refer to Example 7.

Table 1. Summary of Nucleic Acid and Protein SEQ ID Numbers

Description	Nucleic acid SEQ ID NO.	Protein SEQ ID NO.
“0768 gtf”, <i>Leuconostoc pseudomesenteroides</i> . Mature form of GENBANK Identification No. 497964659.		1 (1447 aa)
“0768 gtf”, <i>Leuconostoc pseudomesenteroides</i> . Mature form of GENBANK Identification No. 497964659, but including a start methionine and additional N- and C-terminal amino acids.		2 (1457 aa)
WciGtf1, <i>Weissella cibaria</i> . Full length form	3 (4347 bases)	4 (1448 aa)

comprising signal sequence. GENBANK Accession No. ZP_08417432 (amino acid sequence).		
"2919 gtf", <i>Weissella cibaria</i> . Mature form of GENBANK Identification No. ZP_08417432.		5 (1422 aa)
"2919 gtf", <i>Weissella cibaria</i> . Sequence optimized for expression in <i>B. subtilis</i> . Encodes 2919 gtf with a heterologous signal sequence and additional N-terminal amino acids.	6 (4269 bases)	
LfeGtf1, <i>Lactobacillus fermentum</i> . Full length form comprising signal sequence. GENBANK Accession No. AAU08008 (amino acid sequence).	7 (4392 bases)	8 (1463 aa)
"2918 gtf", <i>Lactobacillus fermentum</i> . Mature form of GENBANK Identification No. AAU08008.		9 (1426 aa)
"2918 gtf", <i>Lactobacillus fermentum</i> . Sequence optimized for expression in <i>B. subtilis</i> . Encodes 2918 gtf with a heterologous signal sequence and additional N-terminal amino acids.	10 (4281 bases)	
SsoGtf4, <i>Streptococcus sobrinus</i> . Full length form comprising signal sequence. GENBANK Accession No. AAX76986 (amino acid sequence).	11 (4521 bases)	12 (1506 aa)
"2920 gtf", <i>Streptococcus sobrinus</i> . Mature form of GENBANK Identification No. AAX76986.		13 (1465 aa)
"2920 gtf", <i>Streptococcus sobrinus</i> . Sequence optimized for expression in <i>B. subtilis</i> . Encodes 2920 gtf with a heterologous signal sequence and additional N-terminal amino acids.	14 (4398 bases)	
SdoGtf7, <i>Streptococcus downei</i> . Full length form comprising signal sequence. GENBANK Accession No. ZP_08549987.1 (amino acid sequence).	15 (4360 bases)	16 (1453 aa)
"2921 gtf", <i>Streptococcus downei</i> . Mature form of GENBANK Identification No. ZP_08549987.1.		17 (1409 aa)
"2921 gtf", <i>Streptococcus downei</i> . Sequence optimized for expression in <i>B. subtilis</i> . Encodes 2921 gtf with a heterologous signal sequence and additional N-terminal amino acids.	18 (4230 bases)	

DETAILED DESCRIPTION

The disclosures of all cited patent and non-patent literature are incorporated herein by reference in their entirety.

5 Unless otherwise disclosed, the terms "a" and "an" as used herein are intended to encompass one or more (i.e., at least one) of a referenced feature.

The term “glucan” herein refers to a polysaccharide of D-glucose monomers that are linked by glucosidic linkages, which are a type of glycosidic linkage. An “alpha-glucan” herein refers to a glucan in which the constituent D-glucose monomers are alpha-D-glucose monomers.

5 The terms “dextran”, “dextran polymer”, “dextran compound” and the like are used interchangeably herein and refer to complex, branched alpha-glucans generally comprising chains of substantially (mostly) alpha-1,6-linked glucose monomers, with side chains (branches) linked mainly by alpha-1,3-linkage. The term “gelling dextran” herein refers to the ability of one or more dextrans
10 disclosed herein to form a viscous solution or gel-like composition (i) during enzymatic dextran synthesis and, optionally, (ii) when such synthesized dextran is isolated (e.g., >90% pure) and then placed in an aqueous composition.

Dextran “long chains” herein can comprise “substantially [or mostly] alpha-1,6-glucosidic linkages”, meaning that they can have at least about 98.0% alpha-
15 1,6-glucosidic linkages in some aspects. Dextran herein can comprise a “branching structure” (branched structure) in some aspects. It is contemplated that in this structure, long chains branch from other long chains, likely in an iterative manner (e.g., a long chain can be a branch from another long chain, which in turn can itself be a branch from another long chain, and so on). It is
20 contemplated that long chains in this structure can be “similar in length”, meaning that the length (DP [degree of polymerization]) of at least 70% of all the long chains in a branching structure is within plus/minus 30% of the mean length of all the long chains of the branching structure.

Dextran in some embodiments can also comprise “short chains” branching
25 from the long chains, typically being one to three glucose monomers in length, and comprising less than about 10% of all the glucose monomers of a dextran polymer. Such short chains typically comprise alpha-1,2-, alpha-1,3-, and/or alpha-1,4-glucosidic linkages (it is believed that there can also be a small percentage of such non-alpha-1,6 linkages in long chains in some aspects).


30 The terms “glycosidic linkage” and “glycosidic bond” are used interchangeably herein and refer to the covalent bond that joins a carbohydrate

molecule to another carbohydrate molecule. The terms “glucosidic linkage” and “glucosidic bond” are used interchangeably herein and refer to a glucosidic linkage between two glucose molecules. The term “alpha-1,6-glucosidic linkage” as used herein refers to the covalent bond that joins alpha-D-glucose molecules 5 to each other through carbons 1 and 6 on adjacent alpha-D-glucose rings. The term “alpha-1,3-glucosidic linkage” as used herein refers to the covalent bond that joins alpha-D-glucose molecules to each other through carbons 1 and 3 on adjacent alpha-D-glucose rings. The term “alpha-1,2-glucosidic linkage” as used herein refers to the covalent bond that joins alpha-D-glucose molecules to each 10 other through carbons 1 and 2 on adjacent alpha-D-glucose rings. The term “alpha-1,4-glucosidic linkage” as used herein refers to the covalent bond that joins alpha-D-glucose molecules to each other through carbons 1 and 4 on adjacent alpha-D-glucose rings. Herein, “alpha-D-glucose” will be referred to as “glucose.” All glucosidic linkages disclosed herein are alpha-glucosidic linkages, 15 except where otherwise noted.

“Glucose (glucose monomers) linked at positions 1 and 6” herein refers to a glucose monomer of dextran in which only carbons 1 and 6 of the glucose monomer are involved in respective glucosidic linkages with two adjacent glucose monomers. This definition likewise applies to glucose (i) “linked at 20 positions 1 and 3”, and (ii) “linked at positions 1 and 4”, taking into account, accordingly, the different carbon positions involved in each respective linkage.

“Glucose (glucose monomers) linked at positions 1, 3 and 6” herein refers to a glucose monomer of dextran in which carbons 1, 3 and 6 of the glucose monomer are involved in respective glucosidic linkages with three adjacent 25 glucose monomers. A glucose linked only at positions 1, 3 and 6 is a branch point. This definition likewise applies to glucose linked at (i) positions 1, 2 and 6, and (ii) positions 1, 4 and 6, but taking into account, accordingly, the different carbon positions involved in each respective linkage.

Glucose positions (glucose carbon positions) 1, 2, 3, 4 and 6 herein are as 30 known in the art (depicted in the following structure):



The glycosidic linkage profile of a dextran herein can be determined using any method known in the art. For example, a linkage profile can be determined using methods that use nuclear magnetic resonance (NMR) spectroscopy (e.g.,

5 ^{13}C NMR or ^1H NMR). These and other methods that can be used are disclosed in Food Carbohydrates: Chemistry, Physical Properties, and Applications (S. W. Cui, Ed., Chapter 3, S. W. Cui, Structural Analysis of Polysaccharides, Taylor & Francis Group LLC, Boca Raton, FL, 2005), which is incorporated herein by reference.

10 The term “sucrose” herein refers to a non-reducing disaccharide composed of an alpha-D-glucose molecule and a beta-D-fructose molecule linked by an alpha-1,2-glycosidic bond. Sucrose is known commonly as table sugar.

15 The “molecular weight” of dextran herein can be represented as number-average molecular weight (M_n) or as weight-average molecular weight (M_w), the units of which are in Daltons or grams/mole. Alternatively, molecular weight can be represented as DP_w (weight average degree of polymerization) or DP_n (number average degree of polymerization). Various means are known in the art for calculating these molecular weight measurements such as with high-pressure liquid chromatography (HPLC), size exclusion chromatography (SEC), or gel 20 permeation chromatography (GPC).

25 The term “radius of gyration” (R_g) herein refers to the mean radius of dextran, and is calculated as the root-mean-square distance of a dextran molecule’s components (atoms) from the molecule’s center of gravity. R_g can be provided in Angstrom or nanometer (nm) units, for example. The “z-average radius of gyration” of dextran herein refers to the R_g of dextran as measured using light scattering (e.g., MALS). Methods for measuring z-average R_g are known and can be used herein, accordingly. For example, z-average R_g can be

measured as disclosed in U.S. Patent No. 7531073, U.S. Patent Appl. Publ. Nos. 2010/0003515 and 2009/0046274, Wyatt (*Anal. Chim. Acta* 272:1-40), and Mori and Barth (Size Exclusion Chromatography, Springer-Verlag, Berlin, 1999), all of which are incorporated herein by reference.

5 The terms “glucosyltransferase enzyme”, “gtf enzyme”, “gtf enzyme catalyst”, “gtf”, “glucansucrase” and the like are used interchangeably herein. The activity of a gtf enzyme herein catalyzes the reaction of the substrate sucrose to make the products glucan and fructose. A gtf enzyme that produces a dextran (a type of glucan) can also be referred to as a dextranucrase. Other 10 products (byproducts) of a gtf reaction can include glucose (where glucose is hydrolyzed from the glucosyl-gtf enzyme intermediate complex), and various soluble oligosaccharides (e.g., DP2-DP7) such as leucrose, Wild type forms of glucosyltransferase enzymes generally contain (in the N-terminal to C-terminal direction) a signal peptide, a variable domain, a catalytic domain, and a glucan- 15 binding domain. A gtf herein is classified under the glycoside hydrolase family 70 (GH70) according to the CAZy (Carbohydrate-Active EnZymes) database (Cantarel et al., *Nucleic Acids Res.* 37:D233-238, 2009).

The terms “glucosyltransferase catalytic domain” and “catalytic domain” are used interchangeably herein and refer to the domain of a glucosyltransferase 20 enzyme that provides glucan-producing activity to the glucosyltransferase enzyme.

The terms “gtf reaction”, “gtf reaction solution”, “glucosyltransferase reaction”, “enzymatic reaction”, “dextran synthesis reaction”, “dextran reaction” and the like are used interchangeably herein and refer to a reaction that is 25 performed by a glucosyltransferase enzyme. A gtf reaction as used herein generally refers to a reaction initially comprising at least one active glucosyltransferase enzyme in a solution comprising sucrose and water, and optionally other components. Other components that can be in a gtf reaction after it has commenced include fructose, glucose, soluble oligosaccharides (e.g., 30 DP2-DP7) such as leucrose, and dextran products. It is in a gtf reaction where the step of contacting water, sucrose and a glucosyltransferase enzyme is

performed. The term “under suitable gtf reaction conditions” as used herein, refers to gtf reaction conditions that support conversion of sucrose to dextran via glucosyltransferase enzyme activity. A gtf reaction herein is not naturally occurring.

5 A “control” gtf reaction as used herein can refer to a reaction using a glucosyltransferase not comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, or SEQ ID NO:17. All the other features (e.g., sucrose concentration, temperature, pH, time) of a control reaction solution can be the same as the 10 reaction to which it is being compared.

The “percent dry solids” of a gtf reaction refers to the wt% of all the sugars in a gtf reaction. The percent dry solids of a gtf reaction can be calculated, for example, based on the amount of sucrose used to prepare the reaction.

15 The “yield” of dextran by a gtf reaction herein represents the weight of dextran product expressed as a percentage of the weight of sucrose substrate that is converted in the reaction. For example, if 100 g of sucrose in a reaction solution is converted to products, and 10 g of the products is dextran, the yield of the dextran would be 10%. This yield calculation can be considered as a measure of selectivity of the reaction toward dextran.

20 The terms “percent by volume”, “volume percent”, “vol %”, “v/v %” and the like are used interchangeably herein. The percent by volume of a solute in a solution can be determined using the formula: $[(\text{volume of solute})/(\text{volume of solution})] \times 100\%$.

25 The terms “percent by weight”, “weight percentage (wt%)”, “weight-weight percentage (% w/w)” and the like are used interchangeably herein. Percent by weight refers to the percentage of a material on a mass basis as it is comprised in a composition, mixture, or solution.

30 The term “increased” as used herein can refer to a quantity or activity that is at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 50%, 100%, or 200% more than the quantity or activity for which the increased quantity or activity is being compared.

The terms “increased”, “elevated”, “enhanced”, “greater than”, “improved” and the like are used interchangeably herein.

The terms “polynucleotide”, “polynucleotide sequence”, and “nucleic acid sequence” are used interchangeably herein. These terms encompass nucleotide

5 sequences and the like. A polynucleotide may be a polymer of DNA or RNA that is single- or double-stranded, that optionally contains synthetic, non-natural or altered nucleotide bases. A polynucleotide may be comprised of one or more segments of cDNA, genomic DNA, synthetic DNA, or mixtures thereof.

The term “gene” as used herein refers to a DNA polynucleotide sequence

10 that expresses an RNA (RNA is transcribed from the DNA polynucleotide sequence) from a coding region (coding sequence), which RNA can be a messenger RNA (encoding a protein) or a non-protein-coding RNA. A gene may refer to the coding region alone, or may include regulatory sequences upstream and/or downstream to the coding region (e.g., promoters, 5'-untranslated regions,

15 3'-transcription terminator regions). A coding region encoding a protein can alternatively be referred to herein as an “open reading frame” (ORF). A gene that is “native” or “endogenous” refers to a gene as found in nature with its own regulatory sequences; such a gene is located in its natural location in the genome of a host cell. A “chimeric” gene refers to any gene that is not a native

20 gene, comprising regulatory and coding sequences that are not found together in nature (i.e., the regulatory and coding regions are heterologous with each other). Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner

25 different than that found in nature. A “foreign” or “heterologous” gene refers to a gene that is introduced into a host organism by gene transfer. Foreign genes can comprise native genes inserted into a non-native organism, native genes introduced into a new location within the native host, or chimeric genes.

Polynucleotide sequences in certain embodiments disclosed herein are
30 heterologous. A “transgene” is a gene that has been introduced into the genome by a transformation procedure. A “codon-optimized” open reading frame has its

frequency of codon usage designed to mimic the frequency of preferred codon usage of the host cell.

The term “recombinant” or “heterologous” as used herein refers to an artificial combination of two otherwise separated segments of sequence, e.g., by chemical synthesis or by the manipulation of isolated segments of nucleic acids by genetic engineering techniques. The terms “recombinant”, “transgenic”, “transformed”, “engineered” or “modified for exogenous gene expression” are used interchangeably herein.

A native amino acid sequence or polynucleotide sequence is naturally occurring, whereas a non-native amino acid sequence or polynucleotide sequence does not occur in nature.

“Regulatory sequences” as used herein refer to nucleotide sequences located upstream of a gene’s transcription start site (e.g., promoter), 5’ untranslated regions, and 3’ non-coding regions, and which may influence the transcription, processing or stability, or translation of an RNA transcribed from the gene. Regulatory sequences herein may include promoters, enhancers, silencers, 5’ untranslated leader sequences, introns, polyadenylation recognition sequences, RNA processing sites, effector binding sites, stem-loop structures, and other elements involved in regulation of gene expression. One or more regulatory elements herein may be heterologous to a coding region herein.

Methods for preparing recombinant constructs/vectors herein can follow standard recombinant DNA and molecular cloning techniques as described by J. Sambrook and D. Russell (Molecular Cloning: A Laboratory Manual, 3rd Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2001); T.J.

Silhavy et al. (Experiments with Gene Fusions, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1984); and F.M. Ausubel et al. (Short Protocols in Molecular Biology, 5th Ed. Current Protocols, John Wiley and Sons, Inc., NY, 2002).

The terms “sequence identity” or “identity” as used herein with respect to polynucleotide or polypeptide sequences refer to the nucleic acid bases or amino acid residues in two sequences that are the same when aligned for maximum

correspondence over a specified comparison window. Thus, “percentage of sequence identity” or “percent identity” refers to the value determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide or polypeptide sequence in the comparison 5 window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, 10 dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the results by 100 to yield the percentage of sequence identity. It would be understood that, when calculating sequence identity between a DNA sequence and an RNA sequence, T residues of the DNA sequence align with, and can be considered “identical” with, U residues of the 15 RNA sequence. For purposes of determining percent complementarity of first and second polynucleotides, one can obtain this by determining (i) the percent identity between the first polynucleotide and the complement sequence of the second polynucleotide (or vice versa), for example, and/or (ii) the percentage of bases between the first and second polynucleotides that would create canonical 20 Watson and Crick base pairs.

The Basic Local Alignment Search Tool (BLAST) algorithm, which is available online at the National Center for Biotechnology Information (NCBI) website, may be used, for example, to measure percent identity between or among two or more of the polynucleotide sequences (BLASTN algorithm) or 25 polypeptide sequences (BLASTP algorithm) disclosed herein. Alternatively, percent identity between sequences may be performed using a Clustal algorithm (e.g., ClustalW, ClustalV, or Clustal-Omega). For multiple alignments using a Clustal method of alignment, the default values may correspond to GAP PENALTY=10 and GAP LENGTH PENALTY=10. Default parameters for 30 pairwise alignments and calculation of percent identity of protein sequences using a Clustal method may be KTUPLE=1, GAP PENALTY=3, WINDOW=5

and DIAGONALS SAVED=5. For nucleic acids, these parameters may be KTUPLE=2, GAP PENALTY=5, WINDOW=4 and DIAGONALS SAVED=4.

Alternatively still, percent identity between sequences may be performed using an EMBOSS algorithm (e.g., needle) with parameters such as GAP OPEN=10,

5 GAP EXTEND=0.5, END GAP PENALTY=false, END GAP OPEN=10, END
GAP EXTEND=0.5 using a BLOSUM matrix (e.g., BLOSUM62).

Various polypeptide amino acid sequences and polynucleotide sequences are disclosed herein as features of certain embodiments. Variants of these sequences that are at least about 70-85%, 85-90%, or 90%-95% identical to the

10 sequences disclosed herein can be used. Alternatively, a variant amino acid sequence or polynucleotide sequence can have at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a sequence disclosed herein. The variant amino acid sequence or

15 polynucleotide sequence may have the same function/activity of the disclosed sequence, or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the function/activity of the disclosed sequence. Any polypeptide amino acid sequence disclosed herein not beginning with a methionine can typically further comprise at least a start-methionine at the
20 N-terminus of the amino acid sequence. Any polypeptide amino acid sequence disclosed herein beginning with a methionine can optionally be considered without this methionine residue (i.e., a polypeptide sequence can be referred to in reference to the position-2 residue to the C-terminal residue of the sequence).

The term “isolated” as used herein refers to any cellular component that

25 has been completely or partially purified from its native source (e.g., an isolated polynucleotide or polypeptide molecule). In some instances, an isolated polynucleotide or polypeptide molecule is part of a greater composition, buffer system or reagent mix. For example, an isolated polynucleotide or polypeptide molecule can be comprised within a cell or organism in a heterologous manner.
30 Another example is an isolated glucosyltransferase enzyme or reaction.

“Isolated” herein can also characterize a dextran compound. As such, dextran

compounds of the present disclosure are synthetic, man-made compounds, and/or exhibit properties not believed to naturally occur.

An “aqueous composition” herein has a liquid component that comprises at least about 10 wt% water, for example. Examples of aqueous compositions 5 include mixtures, solutions, dispersions (e.g., colloidal dispersions), suspensions and emulsions, for example. Aqueous compositions in certain embodiments comprise dextran that is dissolved in the aqueous composition (i.e., in solution, and typically has viscosity).

As used herein, the term “colloidal dispersion” refers to a heterogeneous 10 system having a dispersed phase and a dispersion medium, i.e., microscopically dispersed insoluble particles are suspended throughout another substance (e.g., an aqueous composition such as water or aqueous solution). An example of a colloidal dispersion herein is a hydrocolloid. All, or a portion of, the particles of a colloidal dispersion such as a hydrocolloid can comprise certain dextran 15 compounds of the present disclosure. The terms “dispersant” and “dispersion agent” are used interchangeably herein to refer to a material that promotes the formation and/or stabilization of a dispersion.

The terms “hydrocolloid” and “hydrogel” are used interchangeably herein. A hydrocolloid refers to a colloid system in which water is the dispersion medium.

20 The term “aqueous solution” herein refers to a solution in which the solvent comprises water. An aqueous solution can serve as a dispersant in certain aspects herein. Dextran compounds in certain embodiments can be dissolved, dispersed, or mixed within an aqueous solution.

The terms “dispersant”, “dispersion agent” and the like are used 25 interchangeably herein to refer to a material that promotes the formation and stabilization of a dispersion of one substance in another. A “dispersion” herein refers to an aqueous composition comprising one or more particles (e.g., any ingredient of a personal care product, pharmaceutical product, food product, household product, or industrial product disclosed herein) that are scattered, or 30 uniformly scattered, throughout the aqueous composition.

The term “viscosity” as used herein refers to the measure of the extent to which a fluid or an aqueous composition such as a hydrocolloid resists a force tending to cause it to flow. Various units of viscosity that can be used herein include centipoise (cPs) and Pascal-second (Pa·s). A centipoise is one one-
5 hundredth of a poise; one poise is equal to $0.100 \text{ kg} \cdot \text{m}^{-1} \cdot \text{s}^{-1}$. Thus, the terms “viscosity modifier”, “viscosity-modifying agent” and the like as used herein refer to anything that can alter/modify the viscosity of a fluid or aqueous composition.

The term “shear thinning behavior” as used herein refers to a decrease in the viscosity of an aqueous composition as shear rate increases. The term
10 “shear thickening behavior” as used herein refers to an increase in the viscosity of an aqueous composition as shear rate increases. “Shear rate” herein refers to the rate at which a progressive shearing deformation is applied to an aqueous composition. A shearing deformation can be applied rotationally.

The term “contacting” as used herein with respect to methods of
15 increasing the viscosity of an aqueous composition refers to any action that results in bringing together an aqueous composition with a dextran. Contacting can be performed by any means known in the art, such as dissolving, mixing, shaking, or homogenization, for example.

The terms “confectionery”, “confection”, “sweets”, “sweetmeat”, “candy”
20 and the like are used interchangeably herein. A confectionery refers to any flavored food product having a sweet taste, the consistency of which may be hard or soft, which is typically consumed by sucking and/or by chewing within the oral cavity. A confectionery can contain sugar or otherwise be sugar-free.

The terms “fabric”, “textile”, “cloth” and the like are used interchangeably
25 herein to refer to a woven material having a network of natural and/or artificial fibers. Such fibers can be thread or yarn, for example.

A “fabric care composition” herein is any composition suitable for treating fabric in some manner. Examples of such a composition include laundry detergents and fabric softeners.

30 The terms “heavy duty detergent”, “all-purpose detergent” and the like are used interchangeably herein to refer to a detergent useful for regular washing of

white and colored textiles at any temperature. The terms “low duty detergent” or “fine fabric detergent” are used interchangeably herein to refer to a detergent useful for the care of delicate fabrics such as viscose, wool, silk, microfiber or other fabric requiring special care. “Special care” can include conditions of using

5 excess water, low agitation, and/or no bleach, for example.

A “detergent composition” herein typically comprises at least one surfactant (detergent compound) and/or at least one builder. A “surfactant” herein refers to a substance that tends to reduce the surface tension of a liquid in which the substance is dissolved. A surfactant may act as a detergent, wetting agent, emulsifier, foaming agent, and/or dispersant, for example.

10

The terms “anti-redeposition agent”, “anti-soil redeposition agent”, “anti-greying agent” and the like herein refer to agents that help keep soils from redepositing onto clothing in laundry wash water after these soils have been removed, therefore preventing greying/discoloration of laundry. Anti-redeposition agents can function by helping keep soil dispersed in wash water and/or by blocking attachment of soil onto fabric surfaces.

15

An “oral care composition” herein is any composition suitable for treating an soft or hard surface in the oral cavity such as dental (teeth) and/or gum surfaces.

20 The term “adsorption” herein refers to the adhesion of a compound (e.g., dextran herein) to the surface of a material.

The terms “cellulase”, “cellulase enzyme” and the like are used interchangeably herein to refer to an enzyme that hydrolyzes beta-1,4-D-glucosidic linkages in cellulose, thereby partially or completely degrading cellulose. Cellulase can alternatively be referred to as “beta-1,4-glucanase”, for example, and can have endocellulase activity (EC 3.2.1.4), exocellulase activity (EC 3.2.1.91), or cellobiase activity (EC 3.2.1.21). “Cellulose” refers to an insoluble polysaccharide having a linear chain of beta-1,4-linked D-glucose monomeric units.

There is interest in developing new, high viscosity dextran polymers, which are more amenable to gelling applications. In turn, there is also interest in identifying glucosyltransferase enzymes that can synthesize such dextran polymers.

5 Embodiments of the present disclosure concern a composition comprising a dextran that comprises:

- (i) about 87-93 wt% glucose linked at positions 1 and 6;
- (ii) about 0.1-1.2 wt% glucose linked at positions 1 and 3;
- (iii) about 0.1-0.7 wt% glucose linked at positions 1 and 4;
- 10 (iv) about 7.7-8.6 wt% glucose linked at positions 1, 3 and 6; and
- (v) about 0.4-1.7 wt% glucose linked at: (a) positions 1, 2 and 6, or (b) positions 1, 4 and 6.

The weight-average molecular weight (Mw) and z-average radius of gyration of such dextran is about 50-200 million Daltons and about 200-280 nm, 15 respectively. Also, such dextran optionally is not a product of a *Leuconostoc mesenteroides* glucosyltransferase enzyme.

An example of this composition is a glucosyltransferase reaction in which a dextran with the above linkage, weight and size profile is synthesized. Significantly, this dextran exhibits high viscosity in aqueous compositions, even 20 at relatively low concentrations of the dextran. It is believed that this high viscosity profile is unique in comparison to viscosity profiles of previously disclosed dextran polymers.

A dextran herein can comprise (i) about 87-93 wt% glucose linked only at 25 positions 1 and 6; (ii) about 0.1-1.2 wt% glucose linked only at positions 1 and 3; (iii) about 0.1-0.7 wt% glucose linked only at positions 1 and 4; (iv) about 7.7-8.6 wt% glucose linked only at positions 1, 3 and 6; and (v) about 0.4-1.7 wt% glucose linked only at: (a) positions 1, 2 and 6, or (b) positions 1, 4 and 6. In certain embodiments, a dextran can comprise (i) about 89.5-90.5 wt% glucose 30 linked only at positions 1 and 6; (ii) about 0.4-0.9 wt% glucose linked only at positions 1 and 3; (iii) about 0.3-0.5 wt% glucose linked only at positions 1 and 4;

(iv) about 8.0-8.3 wt% glucose linked only at positions 1, 3 and 6; and (v) about 0.7-1.4 wt% glucose linked only at: (a) positions 1, 2 and 6, or (b) positions 1, 4 and 6.

A dextran in some aspects of the present disclosure can comprise about

5 87, 87.5, 88, 88.5, 89, 89.5, 90, 90.5, 91, 91.5, 92, 92.5, or 93 wt% glucose linked only at positions 1 and 6. There can be about 87-92.5, 87-92, 87-91.5, 87-91, 87-90.5, 87-90, 87.5-92.5, 87.5-92, 87.5-91.5, 87.5-91, 87.5-90.5, 87.5-90, 88-92.5, 88-92, 88-91.5, 88-91, 88-90.5, 88-90, 88.5-92.5, 88.5-92, 88.5-91.5, 88.5-91, 88.5-90.5, 88.5-90, 89-92.5, 89-92, 89-91.5, 89-91, 89-90.5, 89-90, 10 89.5-92.5, 89.5-92, 89.5-91.5, 89.5-91, or 89.5-90.5 wt% glucose linked only at positions 1 and 6, in some instances.

A dextran in some aspects can comprise about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, or 1.2 wt% glucose linked only at positions 1 and 3. There can be about 0.1-1.2, 0.1-1.0, 0.1-0.8, 0.3-1.2, 0.3-1.0, 0.3-0.8, 0.4-1.2, 0.4-1.0, 15 0.4-0.8, 0.5-1.2, 0.5-1.0, 0.5-0.8, 0.6-1.2, 0.6-1.0, or 0.6-0.8 wt% glucose linked only at positions 1 and 3, in some instances.

A dextran in some aspects can comprise about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, or 0.7 wt% glucose linked only at positions 1 and 4. There can be about 0.1-0.7, 0.1-0.6, 0.1-0.5, 0.1-0.4, 0.2-0.7, 0.2-0.6, 0.2-0.5, 0.2-0.4, 0.3-0.7, 0.3-0.6, 0.3-20 0.5, or 0.3-0.4 wt% glucose linked only at positions 1 and 4, in some instances.

A dextran in some aspects can comprise about 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, or 8.6 wt% glucose linked only at positions 1, 3 and 6. There can be about 7.7-8.6, 7.7-8.5, 7.7-8.4, 7.7-8.3, 7.7-8.2, 7.8-8.6, 7.8-8.5, 7.8-8.4, 7.8-8.3, 7.8-8.2, 7.9-8.6, 7.9-8.5, 7.9-8.4, 7.9-8.3, 7.9-8.2, 8.0-8.6, 8.0-8.5, 8.0-8.4, 25 8.0-8.3, 8.0-8.2, 8.1-8.6, 8.1-8.5, 8.1-8.1, 8.1-8.3, or 8.1-8.2 wt% glucose linked only at positions 1, 3 and 6, in some instances.

A dextran in some aspects can comprise about 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, or 1.7 wt% glucose linked only at (a) positions 1, 2 and 6, or (b) positions 1, 4 and 6. There can be about 0.4-1.7, 0.4-1.6, 0.4-1.5, 30 0.4-1.4, 0.4-1.3, 0.5-1.7, 0.5-1.6, 0.5-1.5, 0.5-1.4, 0.5-1.3, 0.6-1.7, 0.6-1.6, 0.6-1.5, 0.6-1.4, 0.6-1.3, 0.7-1.7, 0.7-1.6, 0.7-1.5, 0.7-1.4, 0.7-1.3, 0.8-1.7, 0.8-1.6,

0.8-1.5, 0.8-1.4, 0.8-1.3 wt% glucose linked only at (a) positions 1, 2 and 6, or (b) positions 1, 4 and 6, in some instances.

The glucosidic linkage profile of dextran can be determined using dextran produced following any protocol disclosed herein. An example of a suitable

5 linkage determination protocol can be similar to, or the same as, the protocol disclosed in Example 9: For example, an 0768 gtf enzyme reaction that has been deactivated by heating the reaction at about 70-90 °C (e.g., 80 °C) for about 5-30 minutes (e.g., 10 minutes) is placed into dialysis tubing (e.g., made with regenerated cellulose) with an MWCO of 12-14 kDa (e.g., Spectra/Por® 4

10 Dialysis Tubing, Part No. 132706, Spectrum Laboratories, Inc.). The deactivated reaction is then dialyzed against a large volume of water (e.g., 3-5 L) at about 20-25 °C (room temp) over about 4-10 days (e.g., 7 days); this water can be exchanged every day during the dialysis. The dextran product is then (i) precipitated by mixing the dialyzed deactivated reaction with about 1-2x (1.5x)

15 reaction volume of 100% methanol, (ii) washed at least two times with the same volume of 100% methanol, and (iii) dried at about 40-50 °C (e.g., 45 °C) (optionally under a vacuum). A dissolvable amount of dry dextran is dissolved in dimethyl sulfoxide (DMSO) or DMSO/5% LiCl, after which all free hydroxyl groups are methylated (e.g., by sequential addition of a NaOH/DMSO slurry

20 followed with iodomethane). The methylated dextran is then extracted (e.g., into methylene chloride) and hydrolyzed to monomeric units using aqueous trifluoroacetic acid (TFA) at about 110-125 °C (e.g., 120 °C). The TFA is then evaporated and reductive ring opening is done using sodium borodeuteride. The hydroxyl groups created by hydrolyzing the glycosidic linkages are then

25 acetylated by treating with acetyl chloride and TFA at a temperature of about 40-60 °C (e.g., 50 °C). Next, the derivatizing reagents are evaporated and the resulting methylated/acetylated monomers are reconstituted in acetonitrile; this preparation is then analyzed by GC/MS using an appropriate column (e.g., biscyanopropyl cyanopropylphenyl polysiloxane). The relative positioning of the

30 methyl and acetyl functionalities render species with distinctive retention time indices and mass spectra that can be compared to published databases. In this

way, the derivatives of the monomeric units indicate how each monomer was originally linked in the dextran polymer.

It is believed that dextran herein may be a branched structure in which there are long chains (containing mostly or all alpha-1,6-linkages) that iteratively

- 5 branch from each other (e.g., a long chain can be a branch from another long chain, which in turn can itself be a branch from another long chain, and so on). The branched structure may also comprise short branches from the long chains; these short chains are believed to mostly comprise alpha-1,3 and -1,4 linkages, for example. Branch points in the dextran, whether from a long chain branching
- 10 from another long chain, or a short chain branching from a long chain, appear to comprise alpha-1,3, -1,4, or -1,2 linkages off of a glucose involved in alpha-1,6 linkage. On average, about 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 15-35%, 15-30%, 15-25%, 15-20%, 20-35%, 20-30%, 20-25%, 25-35%, or 25-30% of all branch points of dextran in some embodiments branch into
- 15 long chains. Most (>98% or 99%) or all the other branch points branch into short chains.

The long chains of a dextran branching structure can be similar in length in some aspects. By being similar in length, it is meant that the length (DP) of at least 70%, 75%, 80%, 85%, or 90% of all the long chains in a branching structure

- 20 is within plus/minus 15% (or 10%, 5%) of the mean length of all the long chains of the branching structure. In some aspects, the mean length (average length) of the long chains is about 10-50 DP (i.e., 10-50 glucose monomers). For example, the mean individual length of the long chains can be about 10, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 10-50, 10-40, 10-30, 10-25, 10-20, 15-
- 25 50, 15-40, 15-30, 15-25, 15-20, 20-50, 20-40, 20-30, or 20-25 DP.

Dextran long chains in certain embodiments can comprise substantially alpha-1,6-glucosidic linkages and a small amount (less than 2.0%) of alpha-1,3- and/or alpha-1,4-glucosidic linkages. For example, dextran long chains can comprise about, or at least about, 98%, 98.25%, 98.5%, 98.75%, 99%, 99.25%, 99.5%, 99.75%, or 99.9% alpha-1,6-glucosidic linkages. A dextran long chain in certain embodiments does not comprise alpha-1,4-glucosidic linkages (i.e., such

a long chain has mostly alpha-1,6 linkages and a small amount of alpha-1,3 linkages). Conversely, a dextran long chain in some embodiments does not comprise alpha-1,3-glucosidic linkages (i.e., such a long chain has mostly alpha-1,6 linkages and a small amount of alpha-1,4 linkages). Any dextran long chain

5 of the above embodiments may further not comprise alpha-1,2-glucosidic linkages, for example. Still in some aspects, a dextran long chain can comprise 100% alpha-1,6-glucosidic linkages (excepting the linkage used by such long chain to branch from another chain).

Short chains of a dextran molecule in some aspects are one to three

10 glucose monomers in length and comprise less than about 5-10% of all the glucose monomers of the dextran polymer. At least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or all of, short chains herein are 1-3 glucose monomers in length. The short chains of a dextran molecule can comprise less than about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of all the glucose 15 monomers of the dextran molecule, for example.

Short chains of a dextran molecule in some aspects can comprise alpha-1,2-, alpha-1,3-, and/or alpha-1,4-glucosidic linkages. Short chains, when considered all together (not individually) may comprise (i) all three of these linkages, or (ii) alpha-1,3- and alpha-1,4-glucosidic linkages, for example. It is

20 believed that short chains of a dextran molecule herein can be heterogeneous (i.e., showing some variation in linkage profile) or homogeneous (i.e., sharing similar or same linkage profile) with respect to the other short chains of the dextran.

25 Dextran in certain embodiments can have an Mw of about, or at least about, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, or 200 million (or any integer between 50 and 200 million) (or any range between two of these values).. The Mw of dextran can be about 50-200, 60-200, 70-200, 80-200, 90-30 200, 100-200, 110-200, 120-200, 50-180, 60-180, 70-180, 80-180, 90-180, 100-180, 110-180, 120-180, 50-160, 60-160, 70-160, 80-160, 90-160, 100-160, 110-

160, 120-160, 50-140, 60-140, 70-140, 80-140, 90-140, 100-140, 110-140, 120-140, 50-120, 60-120, 70-120, 80-120, 90-120, 100-120, 110-120, 50-110, 60-110, 70-110, 80-110, 90-110, 100-110, 50-100, 60-100, 70-100, 80-100, 90-100, or 95-105 million, for example. Any of these Mw's can be represented in DPw, if

5 desired, by dividing Mw by 162.14.

The z-average radius of gyration of a dextran herein can be about 200-280 nm. For example, the z-average R_g can be about 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, or 280 nm (or any integer between 200-280 nm). As other examples, the z-average R_g can be about 200-280, 200-270, 200-260, 200-250, 200-240, 200-230, 220-280, 220-270, 220-260, 10 220-250, 220-240, 220-230, 230-280, 230-270, 230-260, 230-250, 230-240, 240-280, 240-270, 240-260, 240-250, 250-280, 250-270, or 250-260 nm.

The Mw and/or z-average R_g of dextran in some aspects can be measured following a protocol similar to, or the same as, the protocol disclosed 15 in Example 9. For example, a Mw and/or z-average R_g herein can be measured by first dissolving dextran produced by an 0768 gtf at 0.4-0.6 mg/mL (e.g., ~0.5 mg/mL) in 0.05-1.0 M (e.g., ~0.075 M) Tris(hydroxymethyl)aminomethane buffer with 150-250 ppm (e.g., ~200 ppm) NaN_3 . Solvation of dry dextran can be achieved by shaking for 12-18 hours at 45-55 °C (e.g., ~50 °C). The resulting 20 dextran solution can be entered into a suitable flow injection chromatographic apparatus comprising a separation module (e.g., Alliance™ 2695 separation module from Waters Corporation, Milford, MA) coupled with three online detectors: a differential refractometer (e.g., Waters 2414 refractive index detector), a multiangle light scattering (MALS) photometer (e.g., Heleos™-2 18-angle multiangle MALS photometer) equipped with a quasielastic light scattering (QELS) detector (e.g., QELS detector from Wyatt Technologies, Santa Barbara, CA), and a differential capillary viscometer (e.g., ViscoStar™ differential capillary viscometer from Wyatt). Two suitable size-exclusion columns (e.g., AQUAGEL-25 OH GUARD columns from Agilent Technologies, Santa Clara, CA) can be used 30 to separate the dextran polymer peak from the injection peak, where the mobile phase can be the same as the sample solvent (above), the flow rate can be

about 0.2 mL/min, the injection volumes can be about 0.1 mL, and column temperature can be about 30°C. Suitable software can be used for data acquisition (e.g., Empower™ version 3 software from Waters) and for multidetector data reduction (Astra™ version 6 software from Wyatt). MALS data

5 can provide weight-average molecular weight (Mw) and z-average radius of gyration (Rg), and QELS data can provide z-average hydrodynamic radius, for example.

A dextran herein can be a product of a glucosyltransferase enzyme

comprising, or consisting of, an amino acid sequence that is 100% identical to, or

10 at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to,

SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, or

SEQ ID NO:17 (and have gtf activity). Non-limiting examples of a

glucosyltransferase enzyme comprising SEQ ID NO:1 (or a related sequence)

include glucosyltransferase enzymes comprising, or consisting of, an amino acid

15 sequence that is 100% identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%,

96%, 97%, 98%, or 99% identical to, SEQ ID NO:2 (and have gtf activity).

Production of dextran can be accomplished with a gtf reaction as disclosed

herein, for example. Dextran as disclosed in the instant detailed description

(e.g., molecular weight, linkage and branching profile) can optionally be

20 characterized as a product of a glucosyltransferase enzyme comprising or consisting of SEQ ID NO:1 or 2 (or a related sequence thereof that is at least 90% identical [above]). In some other embodiments, a glucosyltransferase enzyme comprises or consists of an amino acid sequence that is 100% identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%

25 identical to, the secreted portion (i.e., signal peptide removed) of the amino acid sequence encoded by SEQ ID NO:6, 10, 14, or 18.

A glucosyltransferase enzyme herein may be from various microbial sources, such as a bacteria or fungus. Examples of bacterial glucosyltransferase enzymes are those derived from a *Streptococcus* species, *Leuconostoc* species,

30 *Lactobacillus* species, or *Weissella* species. Examples of *Streptococcus* species include *S. sobrinus*, *S. downei*, *S. salivarius*, *S. dentiroussetti*, *S. mutans*, *S.*

oralis, *S. gallolyticus* and *S. sanguinis*. Examples of *Leuconostoc* species include *L. pseudomesenteroides*, *L. mesenteroides*, *L. amelibiosum*, *L. argentinum*, *L. carnosum*, *L. citreum*, *L. cremoris*, *L. dextranicum* and *L. fructosum*. Examples of *Lactobacillus* species include *L. fermentum*, *L.*

5 *acidophilus*, *L. delbrueckii*, *L. helveticus*, *L. salivarius*, *L. casei*, *L. curvatus*, *L. plantarum*, *L. sakei*, *L. brevis*, *L. buchneri* and *L. reuteri*. Examples of *Weissella* species include *W. cibaria*, *W. confusa*, *W. halotolerans*, *W. hellenica*, *W. kandleri*, *W. kimchii*, *W. koreensis*, *W. minor*, *W. paramesenteroides*, *W. soli* and *W. thailandensis*. A glucosyltransferase in some aspects is not from *L.*

10 *mesenteroides*.

Examples of glucosyltransferase enzymes herein can be any of the amino acid sequences disclosed herein and that further include 1-300 (or any integer there between [e.g., 10, 15, 20, 25, 30, 35, 40, 45, or 50]) residues on the N-terminus and/or C-terminus. Such additional residues may be from a

15 corresponding wild type sequence from which the glucosyltransferase enzyme is derived, or may be a heterologous sequence such as an epitope tag (at either N- or C-terminus) or a heterologous signal peptide (at N-terminus), for example.

A glucosyltransferase enzyme used to produce dextran herein is typically in a mature form lacking an N-terminal signal peptide. An expression system for 20 producing a mature glucosyltransferase enzyme herein may employ an enzyme-encoding polynucleotide that further comprises sequence encoding an N-terminal signal peptide to direct extra-cellular secretion. The signal peptide in such embodiments is cleaved from the enzyme during the secretion process. The signal peptide may either be native or heterologous to the glucosyltransferase.

25 An example of a signal peptide useful herein is one from a bacterial (e.g., a *Bacillus* species such as *B. subtilis*) or fungal species. An example of a bacterial signal peptide is an aprE signal peptide, such as one from *Bacillus* (e.g., *B. subtilis*, see Vogtentanz et al., *Protein Expr. Purif.* 55:40-52, which is incorporated herein by reference).

30 SEQ ID NO:1, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13 and SEQ ID NO:17 are examples of mature glucosyltransferase enzymes that lack an N-

terminal signal peptide. Since these and related amino acid sequences do not begin with a methionine residue, it would be understood that an N-terminal start-methionine is preferably added to the sequence (directly or via an intervening heterologous amino acid sequence such as an epitope) if expressing any of

5 these enzymes without using a signal peptide (such as with an expression system where the enzyme is expressed intracellularly and obtained from a cell lysate).

A glucosyltransferase enzyme in certain embodiments can be produced by any means known in the art. For example, a glucosyltransferase enzyme can 10 be produced recombinantly in a heterologous expression system, such as a microbial heterologous expression system. Examples of heterologous expression systems include bacterial (e.g., *E. coli* such as TOP10, MG1655, or BL21 DE3; *Bacillus* sp. such as *B. subtilis*) and eukaryotic (e.g., yeasts such as *Pichia* sp. and *Saccharomyces* sp.) expression systems.

15 A glucosyltransferase enzyme disclosed herein may be used in any purification state (e.g., pure or non-pure). For example, the glucosyltransferase enzyme may be purified and/or isolated prior to its use. Examples of glucosyltransferase enzymes that are non-pure include those in the form of a cell lysate. A cell lysate or extract may be prepared from a bacteria (e.g., *E. coli*) 20 used to heterologously express the enzyme. For example, the bacteria may be subjected to disruption using a French pressure cell. In alternative embodiments, bacteria may be homogenized with a homogenizer (e.g., APV, Rannie, Gaulin). A glucosyltransferase enzyme is typically soluble in these types of preparations. A bacterial cell lysate, extract, or homogenate herein may be used at about 0.15- 25 0.3% (v/v) in a reaction for producing dextran from sucrose.

A heterologous gene expression system for expressing a glucosyltransferase enzyme herein can be designed for protein secretion, for example. A glucosyltransferase enzyme typically comprises a signal peptide in such embodiments. A glucosyltransferase enzyme in some embodiments does 30 not occur in nature; for example, an enzyme herein is not believed to be one that

is naturally secreted (i.e., mature form) from a microbe (from which the glucosyltransferase enzyme herein could possibly have been derived).

The activity of a glucosyltransferase enzyme herein can be determined using any method known in the art. For example, glucosyltransferase enzyme 5 activity can be determined by measuring the production of reducing sugars (fructose and glucose) in a reaction containing sucrose (~50 g/L), dextran T10 (~1 mg/mL) and potassium phosphate buffer (~pH 6.5, 50 mM), where the solution is held at ~22-25 °C for ~24-30 hours. The reducing sugars can be measured by adding 0.01 mL of the reaction to a mixture containing ~1 N NaOH 10 and ~0.1% triphenyltetrazolium chloride and then monitoring the increase in absorbance at OD_{480nm} for ~five minutes. Also for instance, a unit of an enzyme such as gtf 0768 (comprising SEQ ID NO:1) herein can be defined as the amount of enzyme required to consume 1 g of sucrose in 1 hour at 26 °C, pH 6.5, and with 100 g/L of sucrose.

15 A dextran as presently disclosed can be a product of a glucosyltransferase as comprised in a glucosyltransferase reaction.

The temperature of a glucosyltransferase reaction herein can be controlled, if desired. In certain embodiments, the temperature is between about 20 5 °C to about 50 °C. The temperature in certain other embodiments is between about 20 °C to about 40 °C. Alternatively, the temperature may be about 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 °C. The temperature of a glucosyltransferase reaction herein may be maintained using various means known in the art. For example, the temperature can be maintained by placing the vessel containing the reaction in an air or water bath 25 incubator set at the desired temperature.

The initial concentration of sucrose in a glucosyltransferase reaction herein can be about 20 g/L to 900 g/L, 20 g/L to 400 g/L, 75 g/L to 175 g/L, or 50 g/L to 150 g/L. The initial concentration of sucrose can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 200, 300, 400, 500, 600, 700, 30 800, 900, 50-150, 75-125, 90-110, 50-500, 100-500, 200-500, 300-500, 400-500, 50-400, 100-400, 200-400, 300-400, 50-300, 100-300, 200-300, 50-200, 100-

200, or 50-100 g/L (or any integer between 20 and 900 g/L), for example. “Initial concentration of sucrose” refers to the sucrose concentration in a gtf reaction just after all the reaction components have been added (at least water, sucrose, glucosyltransferase enzyme).

5 Sucrose used in a glucosyltransferase reaction herein can be highly pure ($\geq 99.5\%$) or be of any other purity or grade. For example, sucrose can have a purity of at least 99.0%, or can be reagent grade sucrose. As another example, incompletely refined sucrose can be used. Incompletely refined sucrose herein refers to sucrose that has not been processed to white refined sucrose. Thus,

10 incompletely refined sucrose can be completely unrefined or partially refined. Examples of unrefined sucrose are “raw sucrose” (“raw sugar”) and solutions thereof. Examples of partially refined sucrose have not gone through one, two, three, or more crystallization steps. The ICUMSA (International Commission for Uniform Methods of Sugar Analysis) of incompletely refined sucrose herein can

15 be greater than 150, for example. Sucrose herein may be derived from any renewable sugar source such as sugar cane, sugar beets, cassava, sweet sorghum, or corn. Suitable forms of sucrose useful herein are crystalline form or non-crystalline form (e.g., syrup, cane juice, beet juice), for example. Additional suitable forms of incompletely refined sucrose are disclosed in U.S. Appl. Publ.

20 No. 2015/0275256, which is incorporated herein by reference.

Methods of determining ICUMSA values for sucrose are well known in the art and disclosed by the International Commission for Uniform Methods of Sugar Analysis in ICUMSA Methods of Sugar Analysis: Official and Tentative Methods Recommended by the International Commission for Uniform Methods of Sugar Analysis (ICUMSA) (Ed. H.C.S. de Whalley, Elsevier Pub. Co., 1964), for

25 example, which is incorporated herein by reference. ICUMSA can be measured, for example, by ICUMSA Method GS1/3-7 as described by R.J. McCowage, R.M. Urquhart and M.L. Burge (Determination of the Solution Colour of Raw Sugars, Brown Sugars and Coloured Syrups at pH 7.0 – Official, Verlag Dr Albert Bartens, 2011 revision), which is incorporated herein by reference.

The pH of a glucosyltransferase reaction in certain embodiments can be between about 4.0 to about 8.0. Alternatively, the pH can be about 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, or 8.0. The pH can be adjusted or controlled by the addition or incorporation of a suitable buffer, including but not limited to:

5 phosphate, tris, citrate, or a combination thereof. Buffer concentration in a gtf reaction can be from 0 mM to about 100 mM, or about 10, 20, or 50 mM, for example.

A glucosyltransferase reaction can be contained within any vessel suitable for applying one or more of the reaction conditions disclosed herein. For 10 example, a glucosyltransferase reaction herein may be in a stainless steel, plastic, or glass vessel or container of a size suitable to contain a particular reaction. Such a vessel can optionally be equipped with a stirring device.

A glucosyltransferase reaction herein can optionally be agitated via stirring or orbital shaking, for example. Such agitation can be at about 50, 60, 70, 80, 15 90, 100, 110, 120, 130, 140, 150, 50-150, 60-140, 70-130, 80-120, or 90-110 rpm, for example.

The concentration of glucosyltransferase enzyme in a reaction can be at least about 15, 20, 25, 30, 35, or 40 U/L, for example. In some embodiments, 15-35, 15-30, 15-25, 20-35, 20-30, 20-25, 25-35, 25-30, or 30-35 U/L of 20 glucosyltransferase can be used.

A glucosyltransferase reaction herein can take about 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 30, 36, 48, 60, 72, 84, 96, 18-30, 20-28, or 22-26 hours to complete. Reaction time may depend, for example, on certain parameters such as the amount of sucrose and glucosyltransferase enzyme used in the reaction.

25 All the features herein defining a glucosyltransferase reaction can be combined, accordingly. Simply as an example, a reaction using an 0768 glucosyltransferase (comprising SEQ ID NO:1 or related sequence thereof) can initially contain 90-110 g/L (e.g., ~100 g/L) sucrose, 10-30 mM (e.g., ~20 mM) sodium phosphate buffer at pH 6.0-7.0 (e.g., ~pH 6.5), and 20-30 U/L (e.g., ~25 30 U/L) enzyme. Such a reaction can be held for about 20-28 hours (e.g., ~24 hours) with 50-150 rpm (e.g., ~100 rpm) shaking at 24-28 °C (e.g., ~26 °C).

In some embodiments, a glucosyltransferase reaction comprising a gtf 0768 enzyme (SEQ ID NO:1 or related sequences) and any amount of sucrose disclosed herein can be complete (e.g., 95% or more initially provided sucrose depleted) in less than about 24, 22, 20, 18, or 16 hours after initiating the reaction. Depletion of sucrose in such a reaction can be about, or at least about, 3, 4, 5, 6, 7, 8, 9, or 10 times faster than a same or similar reaction, but which comprises a *Leuconostoc mesenteroides* dextran sucrase instead of a gtf 0768 enzyme, for example.

A composition comprising a dextran herein can be non-aqueous (e.g., a dry composition). Examples of such embodiments include powders, granules, microcapsules, flakes, or any other form of particulate matter. Other examples include larger compositions such as pellets, bars, kernels, beads, tablets, sticks, or other agglomerates. A non-aqueous or dry composition herein typically has less than 3, 2, 1, 0.5, or 0.1 wt% water comprised therein. The amount of dextran herein in a non-aqueous or dry composition can be about, or at least about, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.5, or 99.9 wt%, for example. A non-aqueous composition herein can be in the form of a household product, personal care product, pharmaceutical product, industrial product, or food product, for example.

In certain embodiments of the present disclosure, a composition comprising a dextran can be an aqueous composition having a viscosity of about, or at least about, 25 cPs. Alternatively, an aqueous composition herein can have a viscosity of about, or at least about, 25, 50, 75, 100, 250, 500, 750, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 11000, 12000, 13000, 14000, 15000, 16000, 17000, 18000, 19000, 20000, 25000, 30000, 35000, 40000, 45000, or 50000 cPs (or any integer between 25 and 50000 cPs), for example. Examples of aqueous compositions include hydrocolloids and aqueous solutions.

Viscosity can be measured with an aqueous composition herein at any temperature between about 3 °C to about 110 °C (or any integer between 3 and 110 °C). Alternatively, viscosity can be measured at a temperature between about 4 °C to 30 °C, or about 20 °C to 25 °C, for example. Viscosity can be 5 measured at atmospheric pressure (about 760 torr) or any other higher or lower pressure.

The viscosity of an aqueous composition disclosed herein can be measured using a viscometer or rheometer, or using any other means known in the art. It would be understood by those skilled in the art that a viscometer or 10 rheometer can be used to measure the viscosity of aqueous compositions herein that exhibits rheological behavior (i.e., having viscosities that vary with flow conditions). The viscosity of such embodiments can be measured at a rotational shear rate of about 0.1 to 1000 rpm (revolutions per minute), for example. Alternatively, viscosity can be measured at a rotational shear rate of about 10, 15 60, 150, 250, or 600 rpm.

In certain embodiments, viscosity can be measured with an aqueous composition in which the constituent dextran was synthesized. For example, viscosity can be measured for a gtf reaction herein that is at or near completion. Viscosity can thus be measured with an aqueous composition in which the 20 constituent dextran is not purified (e.g., other components in the composition, aside from water, are present at greater than 1, 5, or 10 wt%); such a composition can contain one or more salts, buffers, proteins (e.g., gtf enzymes), sugars (e.g., fructose, glucose, leucrose, oligosaccharides).

The pH of an aqueous composition disclosed herein can be between 25 about 2.0 to about 12.0, for example. Alternatively, pH can be about 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 11.0, 12.0; or between 5.0 to about 12.0; or between about 4.0 and 8.0; or between about 5.0 and 8.0, for example.

An aqueous composition herein such as a hydrocolloid or aqueous solution can comprise a solvent having about, or at least about, 10 wt% water. In 30 other embodiments, a solvent is about, or at least about, 20, 30, 40, 50, 60, 70,

80, 90, or 100 wt% water (or any integer value between 10 and 100 wt%), for example.

A dextran herein can be present in an aqueous composition at a wt% of about, or at least about, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0,

5 1.2, 1.4, 1.6, 1.8, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, or 90 wt%, for example. Example 8 below 10 demonstrates that dextran in certain aspects provides high viscosity to aqueous solutions at relatively low concentrations of the dextran. Thus, certain embodiments of the present disclosure are drawn to aqueous compositions with less than about 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, or 0.5 wt% dextran herein.

15 An aqueous composition herein can comprise other components in addition to dextran. For example, an aqueous composition can comprise one or more salts such as a sodium salt (e.g., NaCl, Na₂SO₄). Other non-limiting examples of salts include those having (i) an aluminum, ammonium, barium, calcium, chromium (II or III), copper (I or II), iron (II or III), hydrogen, lead (II), 20 lithium, magnesium, manganese (II or III), mercury (I or II), potassium, silver, sodium strontium, tin (II or IV), or zinc cation, and (ii) an acetate, borate, bromate, bromide, carbonate, chlorate, chloride, chlorite, chromate, cyanamide, cyanide, dichromate, dihydrogen phosphate, ferricyanide, ferrocyanide, fluoride, hydrogen carbonate, hydrogen phosphate, hydrogen sulfate, hydrogen sulfide, 25 hydrogen sulfite, hydride, hydroxide, hypochlorite, iodate, iodide, nitrate, nitride, nitrite, oxalate, oxide, perchlorate, permanganate, peroxide, phosphate, phosphide, phosphite, silicate, stannate, stannite, sulfate, sulfide, sulfite, tartrate, or thiocyanate anion. Thus, any salt having a cation from (i) above and an anion from (ii) above can be in an aqueous composition, for example. A salt can be 30 present in an aqueous composition herein at a wt% of about .01 to about 10.00 (or any hundredth increment between .01 and 10.00), for example.

A composition herein may optionally contain one or more active enzymes.

Non-limiting examples of suitable enzymes include proteases, cellulases, hemicellulases, peroxidases, lipolytic enzymes (e.g., metallolipolytic enzymes),

5 xylanases, lipases, phospholipases, esterases (e.g., arylesterase, polyesterase), perhydrolases, cutinases, pectinases, pectate lyases, mannanases, keratinases, reductases, oxidases (e.g., choline oxidase), phenoloxidases, lipoxygenases, ligninases, pullulanases, tannases, pentosanases, malanases, beta-glucanases, arabinosidases, hyaluronidases, chondroitinases, laccases, metalloproteinases, 10 amadoriases, glucoamylases, arabinofuranosidases, phytases, isomerases, transferases and amylases. If an enzyme(s) is included, it may be comprised in a composition herein at about 0.0001-0.1 wt% (e.g., 0.01-0.03 wt%) active enzyme (e.g., calculated as pure enzyme protein), for example.

A cellulase herein can have endocellulase activity (EC 3.2.1.4),

15 exocellulase activity (EC 3.2.1.91), or cellobiase activity (EC 3.2.1.21). A cellulase herein is an “active cellulase” having activity under suitable conditions for maintaining cellulase activity; it is within the skill of the art to determine such suitable conditions.

A cellulase herein may be derived from any microbial source, such as a

20 bacteria or fungus. Chemically-modified cellulases or protein-engineered mutant cellulases are included. Suitable cellulases include, but are not limited to, cellulases from the genera *Bacillus*, *Pseudomonas*, *Streptomyces*, *Trichoderma*, *Humicola*, *Fusarium*, *Thielavia* and *Acremonium*. As other examples, a cellulase may be derived from *Humicola insolens*, *Myceliophthora thermophila* or *Fusarium oxysporum*; these and other cellulases are disclosed in U.S. Patent Nos. 4435307, 5648263, 5691178, 5776757 and 7604974, which are all incorporated herein by reference. Exemplary *Trichoderma reesei* cellulases are disclosed in U.S. Patent Nos. 4689297, 5814501, 5324649, and International Patent Appl. Publ. Nos. WO92/06221 and WO92/06165, all of which are incorporated herein 30 by reference. Exemplary *Bacillus* cellulases are disclosed in U.S. Patent No. 6562612, which is incorporated herein by reference. A cellulase, such as any of

the foregoing, preferably is in a mature form lacking an N-terminal signal peptide. Commercially available cellulases useful herein include CELLUZYME® and CAREZYME® (Novozymes A/S); CLAZINASE® and PURADAX® HA (DuPont Industrial Biosciences), and KAC-500(B)® (Kao Corporation).

5 Alternatively, a cellulase herein may be produced by any means known in the art, such as described in U.S. Patent Nos. 4435307, 5776757 and 7604974, which are incorporated herein by reference. For example, a cellulase may be produced recombinantly in a heterologous expression system, such as a microbial or fungal heterologous expression system. Examples of heterologous
10 expression systems include bacterial (e.g., *E. coli*, *Bacillus* sp.) and eukaryotic systems. Eukaryotic systems can employ yeast (e.g., *Pichia* sp., *Saccharomyces* sp.) or fungal (e.g., *Trichoderma* sp. such as *T. reesei*, *Aspergillus* species such as *A. niger*) expression systems, for example.

One or more cellulases can be directly added as an ingredient when
15 preparing a composition disclosed herein. Alternatively, one or more cellulases can be indirectly (inadvertently) provided in the disclosed composition. For example, cellulase can be provided in a composition herein by virtue of being present in a non-cellulase enzyme preparation used for preparing a composition. Cellulase in compositions in which cellulase is indirectly provided thereto can be
20 present at about 0.1-10 ppb (e.g., less than 1 ppm), for example. A contemplated benefit of a composition herein, by virtue of employing a dextran compound, is that non-cellulase enzyme preparations that might have background cellulase activity can be used without concern that the desired effects of the dextran will be negated by the background cellulase activity.

25 A cellulase in certain embodiments can be thermostable. Cellulase thermostability refers to the ability of the enzyme to retain activity after exposure to an elevated temperature (e.g. about 60-70 °C) for a period of time (e.g., about 30-60 minutes). The thermostability of a cellulase can be measured by its half-life (t_{1/2}) given in minutes, hours, or days, during which time period half the
30 cellulase activity is lost under defined conditions.

A cellulase in certain embodiments can be stable to a wide range of pH values (e.g. neutral or alkaline pH such as pH of ~7.0 to ~11.0). Such enzymes can remain stable for a predetermined period of time (e.g., at least about 15 min., 30 min., or 1 hour) under such pH conditions.

5 At least one, two, or more cellulases may be included in the composition. The total amount of cellulase in a composition herein typically is an amount that is suitable for the purpose of using cellulase in the composition (an "effective amount"). For example, an effective amount of cellulase in a composition intended for improving the feel and/or appearance of a cellulose-containing fabric

10 is an amount that produces measurable improvements in the feel of the fabric (e.g., improving fabric smoothness and/or appearance, removing pills and fibrils which tend to reduce fabric appearance sharpness). As another example, an effective amount of cellulase in a fabric stonewashing composition herein is that amount which will provide the desired effect (e.g., to produce a worn and faded

15 look in seams and on fabric panels). The amount of cellulase in a composition herein can also depend on the process parameters in which the composition is employed (e.g., equipment, temperature, time, and the like) and cellulase activity, for example. The effective concentration of cellulase in an aqueous composition in which a fabric is treated can be readily determined by a skilled artisan. In

20 fabric care processes, cellulase can be present in an aqueous composition (e.g., wash liquor) in which a fabric is treated in a concentration that is minimally about 0.01-0.1 ppm total cellulase protein, or about 0.1-10 ppb total cellulase protein (e.g., less than 1 ppm), to maximally about 100, 200, 500, 1000, 2000, 3000, 4000, or 5000 ppm total cellulase protein, for example.

25 Dextran polymers provided herein are believed to be mostly or completely stable (resistant) to being degraded by cellulase. For example, the percent degradation of a dextran herein by one or more cellulases is believed to be less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1%, or is 0%. Such percent degradation can be determined, for example, by comparing the molecular weight

30 of dextran polymer before and after treatment with a cellulase for a period of time (e.g., ~24 hours).

Aqueous compositions in certain embodiments are believed to have shear thinning behavior or shear thickening behavior. Shear thinning behavior is observed as a decrease in viscosity of the aqueous composition as shear rate

5 increases, whereas shear thickening behavior is observed as an increase in viscosity of the aqueous composition as shear rate increases. Modification of the shear thinning behavior or shear thickening behavior of an aqueous composition herein can be due to the admixture of a dextran to the aqueous composition. Thus, one or more dextran compounds of the present disclosure can be added to

10 an aqueous composition to modify its rheological profile (i.e., the flow properties of an aqueous liquid, solution, or mixture are modified). Also, one or more dextran compounds can be added to an aqueous composition to modify its viscosity.

The rheological properties of aqueous compositions herein can be

15 observed by measuring viscosity over an increasing rotational shear rate (e.g., from about 0.1 rpm to about 1000 rpm). For example, shear thinning behavior of an aqueous composition disclosed herein can be observed as a decrease in viscosity (cPs) by about, or at least about, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% (or any 20 integer between 5% and 95%) as the rotational shear rate increases from about 10 rpm to 60 rpm, 10 rpm to 150 rpm, 10 rpm to 250 rpm, 60 rpm to 150 rpm, 60 rpm to 250 rpm, or 150 rpm to 250 rpm. As another example, shear thickening behavior of an aqueous composition disclosed herein can be observed as an increase in viscosity (cPs) by about, or at least about, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 25%, 100%, 125%, 150%, 175%, or 200% (or any integer between 5% and 200%) as the rotational shear rate increases from about 10 rpm to 60 rpm, 10 rpm to 150 rpm, 10 rpm to 250 rpm, 60 rpm to 150 rpm, 60 rpm to 250 rpm, or 150 rpm to 250 rpm.

An aqueous composition disclosed herein can be in the form of, and/or comprised in, a food product, personal care product, pharmaceutical product, household product, or industrial product, such as any of those products described below. Dextran compounds herein can be used as thickening agents

5 in each of these products. Such a thickening agent may be used in conjunction with one or more other types of thickening agents if desired, such as those disclosed in U.S. Patent No. 8541041, the disclosure of which is incorporated herein by reference in its entirety.

Dextran compounds disclosed herein are believed to be useful for 10 providing one or more of the following physical properties to a personal care product, pharmaceutical product, household product, industrial product, or food product: thickening, freeze/thaw stability, lubricity, moisture retention and release, texture, consistency, shape retention, emulsification, binding, suspension, dispersion, gelation, reduced mineral hardness, for example.

15 Examples of a concentration or amount of a dextran in a product can be any of the weight percentages provided herein, for example.

Personal care products herein are not particularly limited and include, for example, skin care compositions, cosmetic compositions, antifungal compositions, and antibacterial compositions. Personal care products herein 20 may be in the form of, for example, lotions, creams, pastes, balms, ointments, pomades, gels, liquids, combinations of these and the like. The personal care products disclosed herein can include at least one active ingredient, if desired. An active ingredient is generally recognized as an ingredient that causes an intended pharmacological effect.

25 In certain embodiments, a skin care product can be applied to skin for addressing skin damage related to a lack of moisture. A skin care product may also be used to address the visual appearance of skin (e.g., reduce the appearance of flaky, cracked, and/or red skin) and/or the tactile feel of the skin (e.g., reduce roughness and/or dryness of the skin while improved the softness 30 and subtleness of the skin). A skin care product typically may include at least one active ingredient for the treatment or prevention of skin ailments, providing a

cosmetic effect, or for providing a moisturizing benefit to skin, such as zinc oxide, petrolatum, white petrolatum, mineral oil, cod liver oil, lanolin, dimethicone, hard fat, vitamin A, allantoin, calamine, kaolin, glycerin, or colloidal oatmeal, and combinations of these. A skin care product may include one or more natural

5 moisturizing factors such as ceramides, hyaluronic acid, glycerin, squalane, amino acids, cholesterol, fatty acids, triglycerides, phospholipids, glycosphingolipids, urea, linoleic acid, glycosaminoglycans, mucopolysaccharide, sodium lactate, or sodium pyrrolidone carboxylate, for example. Other ingredients that may be included in a skin care product include, without limitation, 10 glycerides, apricot kernel oil, canola oil, squalane, squalene, coconut oil, corn oil, jojoba oil, jojoba wax, lecithin, olive oil, safflower oil, sesame oil, shea butter, soybean oil, sweet almond oil, sunflower oil, tea tree oil, shea butter, palm oil, cholesterol, cholesterol esters, wax esters, fatty acids, and orange oil.

15 A personal care product herein can also be in the form of makeup, lipstick, mascara, rouge, foundation, blush, eyeliner, lip liner, lip gloss, other cosmetics, sunscreen, sun block, nail polish, nail conditioner, bath gel, shower gel, body wash, face wash, lip balm, skin conditioner, cold cream, moisturizer, body spray, soap, body scrub, exfoliant, astringent, scruffing lotion, depilatory, permanent waving solution, antidandruff formulation, antiperspirant composition, deodorant, 20 shaving product, pre-shaving product, after-shaving product, cleanser, skin gel, rinse, dentifrice composition, toothpaste, or mouthwash, for example. An example of a personal care product (e.g., a cleanser, soap, scrub, cosmetic) comprises a carrier or exfoliation agent (e.g., jojoba beads [jojoba ester beads]) (e.g., about 1-10, 3-7, 4-6, or 5 wt%); such an agent may optionally be dispersed 25 within the product.

 A personal care product in some aspects can be a hair care product. Examples of hair care products herein include shampoo, hair conditioner (leave-in or rinse-out), cream rinse, hair dye, hair coloring product, hair shine product, hair serum, hair anti-frizz product, hair split-end repair product, mousse, hair 30 spray, and styling gel. A hair care product can be in the form of a liquid, paste, gel, solid, or powder in some embodiments. A hair care product as presently

disclosed typically comprises one or more of the following ingredients, which are generally used to formulate hair care products: anionic surfactants such as polyoxyethylenelauryl ether sodium sulfate; cationic surfactants such as stearyltrimethylammonium chloride and/or distearyltrimethylammonium chloride;

5 nonionic surfactants such as glycetyl monostearate, sorbitan monopalmitate and/or polyoxyethylenecetyl ether; wetting agents such as propylene glycol, 1,3-butylene glycol, glycerin, sorbitol, pyroglutamic acid salts, amino acids and/or trimethylglycine; hydrocarbons such as liquid paraffins, petrolatum, solid paraffins, squalane and/or olefin oligomers; higher alcohols such as stearyl

10 alcohol and/or cetyl alcohol; superfatting agents; antidandruff agents; disinfectants; anti-inflammatory agents; crude drugs; water-soluble polymers such as methyl cellulose, hydroxycellulose and/or partially deacetylated chitin (in addition to one or more dextrans as disclosed herein); antiseptics such as paraben; ultra-violet light absorbers; pearlizing agents; pH adjustors; perfumes;

15 and pigments.

A pharmaceutical product herein can be in the form of an emulsion, liquid, elixir, gel, suspension, solution, cream, or ointment, for example. Also, a pharmaceutical product herein can be in the form of any of the personal care products disclosed herein, such as an antibacterial or antifungal composition. A pharmaceutical product can further comprise one or more pharmaceutically acceptable carriers, diluents, and/or pharmaceutically acceptable salts. A dextran compound disclosed herein can also be used in capsules, encapsulants, tablet coatings, and as an excipients for medicaments and drugs.

Non-limiting examples of food products herein include vegetable, meat, and soy patties; reformed seafood; reformed cheese sticks; cream soups; gravies and sauces; salad dressing; mayonnaise; onion rings; jams, jellies, and syrups; pie filling; potato products such as French fries and extruded fries; batters for fried foods, pancakes/waffles and cakes; pet foods; confectioneries (candy); beverages; frozen desserts; ice cream; cultured dairy products such as cottage cheese, yogurt, cheeses, and sour creams; cake icing and glazes; whipped topping; leavened and unleavened baked goods; and the like.

In certain embodiments, dextran herein can be comprised in a foodstuff or any other ingestible material (e.g., enteral pharmaceutical preparation) in an amount that provides the desired degree of thickening and/or dispersion. For example, the concentration or amount of dextran in a product can be about 0.1-3
5 wt%, 0.1-4 wt%, 0.1-5 wt%, or 0.1-10 wt%.

A household and/or industrial product herein can be in the form of drywall tape-joint compounds; mortars; grouts; cement plasters; spray plasters; cement stucco; adhesives; pastes; wall/ceiling texturizers; binders and processing aids for tape casting, extrusion forming, injection molding and ceramics; spray
10 adherents and suspending/dispersing aids for pesticides, herbicides, and fertilizers; fabric care products such as fabric softeners and laundry detergents; hard surface cleaners; air fresheners; polymer emulsions; gels such as water-based gels; surfactant solutions; paints such as water-based paints; protective coatings; adhesives; sealants and caulk; inks such as water-based ink; metal-
15 working fluids; or emulsion-based metal cleaning fluids used in electroplating, phosphatizing, galvanizing and/or general metal cleaning operations, for example.

A dextran compound disclosed herein can be comprised in a personal care product, pharmaceutical product, household product, or industrial product in
20 an amount that provides a desired degree of thickening and/or dispersion, for example. Examples of a concentration or amount of a dextran compound in a product can be any of the weight percentages provided above, for example.

An aqueous composition in some aspects can comprise about 0.5-2.0
25 wt% dextran herein (e.g., ~1.0 wt%), about 15-25 wt% (e.g., ~20 wt%) of moisturizer such as oil (e.g., mineral oil), about 4-6 wt% (~5 wt%) surfactant/emulsifier (e.g., one or both of sorbitan monooleate or polysorbate 80, such as ~2.6 wt% sorbitan monooleate and ~2.4 wt% polysorbate 80), optionally 0.25-1.0 wt% (e.g., 0.5 wt%) preservative (e.g., preservative comprising one or more of propylene glycol, diazolidinyl urea, methylparaben, or propylparaben
30 [e.g., Germaben® II]), and optionally one or more other ingredients. Such compositions can be in the form of an emulsion, for example. In these and some

other related aspects, dextran as presently disclosed can be used as a substitute for compounds (e.g., xanthan gum, crosslinked polyacrylic acid polymers such as Carbopol® Ultrez 10) typically used to provide viscosity to certain consumer products such as personal care (e.g., lotion), food, and/or pharmaceutical

5 products. Still in some aspects the sensory experience rating of an aqueous composition (e.g., personal care item such as lotion), as measured by ASTM E1490-3 ("Standard Practice for Descriptive Skinfoel Analysis of Creams and Lotions", ASTM International, West Conshohocken, PA, 2003, DOI: 10.1520/E1490-03, incorporated herein by reference), can be less than about 8, 10 7, or 6, where each of rub-out sliminess, afterfeel stickiness, pick-up stringiness and pick-up stickiness are measured in the evaluation.

A food product herein can be in the form of a confectionery, for example. A confectionery herein can contain one or more sugars (e.g., sucrose, fructose, dextrose) for sweetening, or otherwise be sugar-free.

15 Examples of confectioneries herein include boiled sugars (hard boiled candies [i.e., hard candy]), dragees, jelly candies, gums, licorice, chews, caramels, toffee, fudge, chewing gums, bubble gums, nougat, chewy pastes, halawa, tablets, lozenges, icing, frosting, pudding, and gels (e.g., fruit gels, gelatin dessert). Other examples of confectioneries include aerated 20 confectioneries such as marshmallows, and baked confectioneries.

A confectionery herein can optionally be prepared with chocolate, in any form (e.g., bars, candies, bonbons, truffles, lentils). A confectionery can be coated with chocolate, sugar-coated, candied, glazed, and/or film-coated, for example. Film-coating processes typically comprise applying to the surface of a 25 confectionery a film-forming liquid composition which becomes, after drying, a protective film. This film-coating serves, for example, to protect the active principles contained in the confectionery; to protect the confectionery itself from moisture, shocks, and/or friability; and/or to confer the confectionery attractive visual properties (e.g., shine, uniform color, smooth surface).

30 In certain embodiments, a confectionery can be filled with a filling that is liquid, pasty, solid, or powdered. Dextran herein can be comprised in such a

filling, in which case dextran is optionally also included in the confectionery component being filled.

A confectionery herein is optionally sugar-free, comprising no sugar and typically instead having one or more artificial and/or non-sugar sweeteners

5 (optionally non-caloric) (e.g., aspartame, saccharin, STEVIA, SUCRALOSE). A sugar-free confectionery in certain embodiments can comprise one or more polyols (e.g., erythritol, glycerol, lactitol, mannitol, maltitol, xylitol), soluble fibers, and/or proteins in place of sugar.

A food product herein can be in the form of a pet food, for example. A pet

10 food herein can be a food for a domesticated animal such as a dog or cat (or any other companion animal), for example. A pet food in certain embodiments provides to a domestic animal one or more of the following: necessary dietary requirements, treats (e.g., dog biscuits), food supplements. Examples of pet food include dry pet food (e.g., kernels, kibbles), semi-moist compositions, wet

15 pet food (e.g., canned pet food), or any combination thereof. Wet pet food typically has a moisture content over 65%. Semi-moist pet food typically has a moisture content of 20-65% and can include humectants such as propylene glycol, potassium sorbate, and ingredients that prevent microbial growth (bacteria and mold). Dry pet food typically has a moisture content less than 20% and its

20 processing usually includes extruding, drying and/or baking. A pet food can optionally be in the form of a gravy, yogurt, powder, suspension, chew, or treat (e.g., biscuits); all these compositions can also be used as pet food supplements, if desired. Pet treats can be semi-moist chewable treats; dry treats; chewable bones; baked, extruded or stamped treats; or confection treats, for example.

25 Examples of pet food compositions/formulations in which a dextran herein can be added include those disclosed in U.S. Patent Appl. Publ. Nos. 2013/0280352 and 2010/0159103, and U.S. Patent No. 6977084, which are all incorporated herein by reference.

30 Compositions disclosed herein can be in the form of a fabric care composition. A fabric care composition herein can be used for hand wash,

machine wash and/or other purposes such as soaking and/or pretreatment of fabrics, for example. A fabric care composition may take the form of, for example, a laundry detergent; fabric conditioner; any wash-, rinse-, or dryer-added product; unit dose or spray. Fabric care compositions in a liquid form may

5 be in the form of an aqueous composition as disclosed herein. In other aspects, a fabric care composition can be in a dry form such as a granular detergent or dryer-added fabric softener sheet. Other non-limiting examples of fabric care compositions herein include: granular or powder-form all-purpose or heavy-duty washing agents; liquid, gel or paste-form all-purpose or heavy-duty washing agents; liquid or dry fine-fabric (e.g. delicates) detergents; cleaning auxiliaries such as bleach additives, "stain-stick", or pre-treatments; substrate-laden products such as dry and wetted wipes, pads, or sponges; sprays and mists.

10

A detergent composition herein may be in any useful form, e.g., as powders, granules, pastes, bars, unit dose, or liquid. A liquid detergent may be

15 aqueous, typically containing up to about 70 wt% of water and 0 wt% to about 30 wt% of organic solvent. It may also be in the form of a compact gel type containing only about 30 wt% water.

A detergent composition herein typically comprises one or more surfactants, wherein the surfactant is selected from nonionic surfactants, anionic surfactants, cationic surfactants, amphoteric surfactants, zwitterionic surfactants, semi-polar nonionic surfactants and mixtures thereof. In some embodiments, the surfactant is present at a level of from about 0.1% to about 60%, while in alternative embodiments the level is from about 1% to about 50%, while in still further embodiments the level is from about 5% to about 40%, by weight of the detergent composition. A detergent will usually contain 0 wt% to about 50 wt% of an anionic surfactant such as linear alkylbenzenesulfonate (LAS), alpha-olefinsulfonate (AOS), alkyl sulfate (fatty alcohol sulfate) (AS), alcohol ethoxysulfate (AEOS or AES), secondary alkanesulfonates (SAS), alpha-sulfo fatty acid methyl esters, alkyl- or alkenylsuccinic acid, or soap. In addition, a detergent composition may optionally contain 0 wt% to about 40 wt% of a nonionic surfactant such as alcohol ethoxylate (AEO or AE), carboxylated alcohol

ethoxylates, nonylphenol ethoxylate, alkylpolyglycoside, alkyldimethylamineoxide, ethoxylated fatty acid monoethanolamide, fatty acid monoethanolamide, or polyhydroxy alkyl fatty acid amide (as described for example in WO92/06154, which is incorporated herein by reference).

5 A detergent composition herein typically comprises one or more detergent builders or builder systems. One or more oxidized poly alpha-1,3-glucan compounds can be included as a builder, for example. In some aspects, oxidized poly alpha-1,3-glucan can be included as a co-builder, in which it is used together with one or more additional builders such as any disclosed herein.

10 Oxidized poly alpha-1,3-glucan compounds for use herein are disclosed in U.S. Patent Appl. Publ. No. 2015/0259439. In some embodiments incorporating at least one builder, the cleaning compositions comprise at least about 1%, from about 3% to about 60%, or even from about 5% to about 40%, builder by weight of the composition. Builders (in addition to oxidized poly alpha-1,3-glucan) include, but are not limited to, alkali metal, ammonium and alkanolammonium salts of polyphosphates, alkali metal silicates, alkaline earth and alkali metal carbonates, aluminosilicates, polycarboxylate compounds, ether hydroxypolycarboxylates, copolymers of maleic anhydride with ethylene or vinyl methyl ether, 1, 3, 5-trihydroxy benzene-2, 4, 6-trisulphonic acid, and

15 carboxymethyloxysuccinic acid, various alkali metal, ammonium and substituted ammonium salts of polyacetic acids such as ethylenediamine tetraacetic acid and nitrilotriacetic acid, as well as polycarboxylates such as mellitic acid, succinic acid, citric acid, oxydisuccinic acid, polymaleic acid, benzene 1,3,5-tricarboxylic acid, carboxymethyloxysuccinic acid, and soluble salts thereof. Indeed, it is

20 contemplated that any suitable builder will find use in various embodiments of the present disclosure. Additional examples of a detergent builder or complexing agent include zeolite, diphosphate, triphosphate, phosphonate, citrate, nitrilotriacetic acid (NTA), ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTMPA), alkyl- or alkenylsuccinic acid,

25 soluble silicates or layered silicates (e.g., SKS-6 from Hoechst).

30

In some embodiments, builders form water-soluble hardness ion complexes (e.g., sequestering builders), such as citrates and polyphosphates (e.g., sodium tripolyphosphate and sodium tripolyphosphate hexahydrate, potassium tripolyphosphate, and mixed sodium and potassium tripolyphosphate, etc.). It is contemplated that any suitable builder will find use in the present disclosure, including those known in the art (See, e.g., EP2100949).

In some embodiments, suitable builders can include phosphate builders and non-phosphate builders. In some embodiments, a builder is a phosphate builder. In some embodiments, a builder is a non-phosphate builder. A builder can be used in a level of from 0.1% to 80%, or from 5% to 60%, or from 10% to 50%, by weight of the composition. In some embodiments, the product comprises a mixture of phosphate and non-phosphate builders. Suitable phosphate builders include mono-phosphates, di-phosphates, tri-polyphosphates or oligomeric-polyphosphates, including the alkali metal salts of these compounds, including the sodium salts. In some embodiments, a builder can be sodium tripolyphosphate (STPP). Additionally, the composition can comprise carbonate and/or citrate, preferably citrate that helps to achieve a neutral pH composition. Other suitable non-phosphate builders include homopolymers and copolymers of polycarboxylic acids and their partially or completely neutralized salts, monomeric polycarboxylic acids and hydroxycarboxylic acids and their salts. In some embodiments, salts of the above mentioned compounds include ammonium and/or alkali metal salts, i.e., lithium, sodium, and potassium salts, including sodium salts. Suitable polycarboxylic acids include acyclic, alicyclic, hetero-cyclic and aromatic carboxylic acids, wherein in some embodiments, they can contain at least two carboxyl groups which are in each case separated from one another by, in some instances, no more than two carbon atoms.

A detergent composition herein can comprise at least one chelating agent. Suitable chelating agents include, but are not limited to copper, iron and/or manganese chelating agents and mixtures thereof. In embodiments in which at least one chelating agent is used, the composition comprises from about 0.1% to

about 15%, or even from about 3.0% to about 10%, chelating agent by weight of the composition.

A detergent composition herein can comprise at least one deposition aid. Suitable deposition aids include, but are not limited to, polyethylene glycol, 5 polypropylene glycol, polycarboxylate, soil release polymers such as polytelephthalic acid, clays such as kaolinite, montmorillonite, atapulgite, illite, bentonite, halloysite, and mixtures thereof.

A detergent composition herein can comprise one or more dye transfer inhibiting agents. Suitable polymeric dye transfer inhibiting agents include, but 10 are not limited to, polyvinylpyrrolidone polymers, polyamine N-oxide polymers, copolymers of N-vinylpyrrolidone and N-vinylimidazole, polyvinyloxazolidones and polyvinylimidazoles or mixtures thereof. Additional dye transfer inhibiting agents include manganese phthalocyanine, peroxidases, polyvinylpyrrolidone polymers, polyamine N-oxide polymers, copolymers of N-vinylpyrrolidone and N- 15 vinylimidazole, polyvinyloxazolidones and polyvinylimidazoles and/or mixtures thereof; chelating agents examples of which include ethylene-diamine-tetraacetic acid (EDTA); diethylene triamine penta methylene phosphonic acid (DTPMP); hydroxy-ethane diphosphonic acid (HEDP); ethylenediamine N,N'-disuccinic acid (EDDS); methyl glycine diacetic acid (MGDA); diethylene triamine penta acetic 20 acid (DTPA); propylene diamine tetracetic acid (PDT A); 2-hydroxypyridine-N-oxide (HPNO); or methyl glycine diacetic acid (MGDA); glutamic acid N,N-diacetic acid (N,N-dicarboxymethyl glutamic acid tetrasodium salt (GLDA); nitrilotriacetic acid (NTA); 4,5-dihydroxy-m-benzenedisulfonic acid; citric acid and any salts thereof; N-hydroxyethyl ethylenediaminetri-acetic acid (HEDTA), 25 triethylenetetraaminehexaacetic acid (TTHA), N-hydroxyethyliminodiacetic acid (HEIDA), dihydroxyethylglycine (DHEG), ethylenediaminetrapropionic acid (EDTP) and derivatives thereof, which can be used alone or in combination with any of the above. In embodiments in which at least one dye transfer inhibiting agent is used, a composition herein may comprise from about 0.0001% to about 30 10%, from about 0.01% to about 5%, or even from about 0.1% to about 3%, by weight of the composition.

A detergent composition herein can comprise silicates. In some of these embodiments, sodium silicates (e.g., sodium disilicate, sodium metasilicate, and/or crystalline phyllosilicates) find use. In some embodiments, silicates are present at a level of from about 1% to about 20% by weight of the composition.

5 In some embodiments, silicates are present at a level of from about 5% to about 15% by weight of the composition.

A detergent composition herein can comprise dispersants. Suitable water-soluble organic materials include, but are not limited to the homo- or co-polymeric acids or their salts, in which the polycarboxylic acid comprises at least 10 two carboxyl radicals separated from each other by not more than two carbon atoms.

A detergent composition herein may additionally comprise one or more enzymes. Examples of enzymes include proteases, cellulases, hemicellulases, peroxidases, lipolytic enzymes (e.g., metallolipolytic enzymes), xylanases,

15 lipases, phospholipases, esterases (e.g., arylesterase, polyesterase), perhydrolases, cutinases, pectinases, pectate lyases, mannanases, keratinases, reductases, oxidases (e.g., choline oxidase, phenoloxidase), phenoloxidases, lipoxygenases, ligninases, pullulanases, tannases, pentosanases, malanases, beta-glucanases, arabinosidases, hyaluronidases, chondroitinases, laccases, 20 metalloproteinases, amadoriases, glucoamylases, alpha-amylases, beta-amylases, galactosidases, galactanases, catalases, carageenases, hyaluronidases, keratinases, lactases, ligninases, peroxidases, phosphatases, polygalacturonases, pullulanases, rhamnogalactouronases, tannases, transglutaminases, xyloglucanases, xylosidases, metalloproteases, 25 arabinofuranosidases, phytases, isomerases, transferases and/or amylases in any combination.

Any cellulase disclosed above is contemplated for use in the disclosed detergent compositions. Suitable cellulases include, but are not limited to Humicola insolens cellulases (See e.g., U.S. Pat. No. 4435307). Exemplary

30 cellulases contemplated for use herein are those having color care benefit for a textile. Examples of cellulases that provide a color care benefit are disclosed in

EP0495257, EP0531372, EP531315, WO96/11262, WO96/29397, WO94/07998; WO98/12307; WO95/24471, WO98/08940, and U.S. Patent Nos. 5457046, 5686593 and 5763254, all of which are incorporated herein by reference.

Examples of commercially available cellulases useful in a detergent include

5 CELLUSOFT[®], CELLUCLEAN[®], CELLUZYME[®], and CAREZYME[®] (Novo Nordisk A/S and Novozymes A/S); CLAZINASE[®], PURADAX HA[®], and REVITALENZ[™] (DuPont Industrial Biosciences); BIOTOUCH[®] (AB Enzymes); and KAC-500(B)[™] (Kao Corporation). Additional cellulases are disclosed in, e.g., US7595182, US8569033, US7138263, US3844890, US4435307,

10 US4435307, and GB2095275.

In some embodiments, a detergent composition can comprise one or more enzymes (e.g., any disclosed herein), each at a level from about 0.00001% to about 10% by weight of the composition and the balance of cleaning adjunct materials by weight of composition. In some other embodiments, a detergent composition can also comprise each enzyme at a level of about 0.0001% to about 10%, about 0.001% to about 5%, about 0.001% to about 2%, or about 0.005% to about 0.5%, by weight of the composition.

Suitable proteases include those of animal, vegetable or microbial origin. In some embodiments, microbial proteases are used. In some embodiments, 20 chemically or genetically modified mutants are included. In some embodiments, the protease is a serine protease, preferably an alkaline microbial protease or a trypsin-like protease. Examples of alkaline proteases include subtilisins, especially those derived from *Bacillus* (e.g., subtilisin, lentin, amyloliquefaciens, subtilisin Carlsberg, subtilisin 309, subtilisin 147 and subtilisin 168). Additional 25 examples include those mutant proteases described in U.S. Pat. Nos. RE34606, 5955340, 5700676, 6312936 and 6482628, all of which are incorporated herein by reference. Additional protease examples include, but are not limited to, trypsin (e.g., of porcine or bovine origin), and the *Fusarium* protease described in WO89/06270. In some embodiments, commercially available protease enzymes 30 include, but are not limited to, MAXATASE[®], MAXACAL[™], MAXAPEM[™], OPTICLEAN[®], OPTIMASE[®], PROPERASE[®], PURAFECT[®], PURAFECT[®] OXP,

PURAMAX™, EXCELLASE™, PREFERENZ™ proteases (e.g. P100, P110, P280), EFFECTENZ™ proteases (e.g. P1000, P1050, P2000), EXCELLENZ™ proteases (e.g. P1000), ULTIMASE®, and PURAFAST™ (Genencor); ALCALASE®, SAVINASE®, PRIMASE®, DURAZYM™, POLARZYME®,

5 OVOZYME®, KANNASE®, LIQUANASE®, NEUTRASE®, RELASE® and ESPERASE® (Novozymes); BLAP™ and BLAP™ variants (Henkel Kommanditgesellschaft auf Aktien, Duesseldorf, Germany), and KAP (B. alkalophilus subtilisin; Kao Corp., Tokyo, Japan). Various proteases are described in WO95/23221, WO92/21760, WO09/149200, WO09/149144,

10 WO09/149145, WO11/072099, WO10/056640, WO10/056653, WO11/140364, WO12/151534, U.S. Pat. Publ. No. 2008/0090747, and U.S. Pat. Nos. 5801039, 5340735, 5500364, 5855625, RE34606, 5955340, 5700676, 6312936, 6482628, 8530219, and various other patents. In some further embodiments, neutral metalloproteases find use in the present disclosure, including but not limited to,

15 the neutral metalloproteases described in WO1999014341, WO1999033960, WO1999014342, WO1999034003, WO2007044993, WO2009058303 and WO2009058661, all of which are incorporated herein by reference. Exemplary metalloproteases include nprE, the recombinant form of neutral metalloprotease expressed in *Bacillus subtilis* (See e.g., WO07/044993), and PMN, the purified

20 neutral metalloprotease from *Bacillus amyloliquefaciens*.

Suitable mannanases include, but are not limited to, those of bacterial or fungal origin. Chemically or genetically modified mutants are included in some embodiments. Various mannanases are known which find use in the present disclosure (See, e.g., U.S. Pat. Nos. 6566114, 6602842, and 6440991, all of

25 which are incorporated herein by reference). Commercially available mannanases that find use in the present disclosure include, but are not limited to MANNASTAR®, PURABRITE™, and MANNAWAY®.

Suitable lipases include those of bacterial or fungal origin. Chemically modified, proteolytically modified, or protein engineered mutants are included.

30 Examples of useful lipases include those from the genera *Humicola* (e.g., *H. lanuginosa*, EP258068 and EP305216; *H. insolens*, WO96/13580),

Pseudomonas (e.g., *P. alcaligenes* or *P. pseudoalcaligenes*, EP218272; *P. cepacia*, EP331376; *P. stutzeri*, GB1372034; *P. fluorescens* and *Pseudomonas* sp. strain SD 705, WO95/06720 and WO96/27002; *P. wisconsinensis*, WO96/12012); and *Bacillus* (e.g., *B. subtilis*, Dartois et al., *Biochemica et*

5 *Biophysica Acta* 1131:253-360; *B. stearothermophilus*, JP64/744992; *B. pumilus*, WO91/16422). Furthermore, a number of cloned lipases find use in some embodiments of the present disclosure, including but not limited to, *Penicillium camembertii* lipase (See, Yamaguchi et al., *Gene* 103:61-67 [1991]), *Geotrichum candidum* lipase (See, Schimada et al., *J. Biochem.*, 106:383-388 [1989]), and 10 various *Rhizopus* lipases such as *R. delemar* lipase (See, Hass et al., *Gene* 109:117-113 [1991]), a *R. niveus* lipase (Kugimiya et al., *Biosci. Biotech. Biochem.* 56:716-719 [1992]) and *R. oryzae* lipase. Additional lipases useful herein include, for example, those disclosed in WO92/05249, WO94/01541, WO95/35381, WO96/00292, WO95/30744, WO94/25578, WO95/14783, 15 WO95/22615, WO97/04079, WO97/07202, EP407225 and EP260105. Other types of lipase polypeptide enzymes such as cutinases also find use in some embodiments of the present disclosure, including but not limited to, cutinase derived from *Pseudomonas mendocina* (See, WO88/09367), and cutinase derived from *Fusarium solani pisi* (See, WO90/09446). Examples of certain 20 commercially available lipase enzymes useful herein include M1 LIPASE™, LUMA FAST™, and LIPOMAX™ (Genencor); LIPEX®, LIPOLASE® and LIPOLASE® ULTRA (Novozymes); and LIPASE P™ "Amano" (Amano Pharmaceutical Co. Ltd., Japan).

Suitable polyesterases include, for example, those disclosed in

25 WO01/34899, WO01/14629 and U.S. Patent No. 6933140.

A detergent composition herein can also comprise 2,6-beta-D-fructan hydrolase, which is effective for removal/cleaning of certain biofilms present on household and/or industrial textiles/laundry.

Suitable amylases include, but are not limited to those of bacterial or 30 fungal origin. Chemically or genetically modified mutants are included in some embodiments. Amylases that find use in the present disclosure, include, but are

not limited to, alpha-amylases obtained from *B. licheniformis* (See e.g., GB1296839). Additional suitable amylases include those disclosed in WO9510603, WO9526397, WO9623874, WO9623873, WO9741213, WO9919467, WO0060060, WO0029560, WO9923211, WO9946399,

5 WO0060058, WO0060059, WO9942567, WO0114532, WO02092797, WO0166712, WO0188107, WO0196537, WO0210355, WO9402597, WO0231124, WO9943793, WO9943794, WO2004113551, WO2005001064, WO2005003311, WO0164852, WO2006063594, WO2006066594, WO2006066596, WO2006012899, WO2008092919, WO2008000825,

10 WO2005018336, WO2005066338, WO2009140504, WO2005019443, WO2010091221, WO2010088447, WO0134784, WO2006012902, WO2006031554, WO2006136161, WO2008101894, WO2010059413, WO2011098531, WO2011080352, WO2011080353, WO2011080354, WO2011082425, WO2011082429, WO2011076123, WO2011087836,

15 WO2011076897, WO94183314, WO9535382, WO9909183, WO9826078, WO9902702, WO9743424, WO9929876, WO9100353, WO9605295, WO9630481, WO9710342, WO2008088493, WO2009149419, WO2009061381, WO2009100102, WO2010104675, WO2010117511, and WO2010115021, all of which are incorporated herein by reference.

20 Suitable amylases include, for example, commercially available amylases such as STAINZYME[®], STAINZYME PLUS[®], NATALASE[®], DURAMYL[®], TERMAMYL[®], TERMAMYL ULTRA[®], FUNGAMYL[®] and BAN[™] (Novo Nordisk A/S and Novozymes A/S); RAPIDASE[®], POWERASE[®], PURASTAR[®] and PREFERENZ[™] (DuPont Industrial Biosciences).

25 Suitable peroxidases/oxidases contemplated for use in the compositions include those of plant, bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Examples of peroxidases useful herein include those from the genus *Coprinus* (e.g., *C. cinereus*, WO93/24618, WO95/10602, and WO98/15257), as well as those referenced in

30 WO2005056782, WO2007106293, WO2008063400, WO2008106214, and

WO2008106215. Commercially available peroxidases useful herein include, for example, GUARDZYME™ (Novo Nordisk A/S and Novozymes A/S).

In some embodiments, peroxidases are used in combination with hydrogen peroxide or a source thereof (e.g., a percarbonate, perborate or persulfate) in the compositions of the present disclosure. In some alternative embodiments, oxidases are used in combination with oxygen. Both types of enzymes are used for “solution bleaching” (i.e., to prevent transfer of a textile dye from a dyed fabric to another fabric when the fabrics are washed together in a wash liquor), preferably together with an enhancing agent (See e.g., WO94/12621 and WO95/01426). Suitable peroxidases/oxidases include, but are not limited to, those of plant, bacterial or fungal origin. Chemically or genetically modified mutants are included in some embodiments.

Enzymes that may be comprised in a detergent composition herein may be stabilized using conventional stabilizing agents, e.g., a polyol such as propylene glycol or glycerol; a sugar or sugar alcohol; lactic acid; boric acid or a boric acid derivative (e.g., an aromatic borate ester).

A detergent composition in certain embodiments may comprise one or more other types of polymers in addition to a dextran as disclosed herein. Examples of other types of polymers useful herein include carboxymethyl cellulose (CMC), poly(vinylpyrrolidone) (PVP), polyethylene glycol (PEG), poly(vinyl alcohol) (PVA), polycarboxylates such as polyacrylates, maleic/acrylic acid copolymers and lauryl methacrylate/acrylic acid copolymers.

A detergent composition herein may contain a bleaching system. For example, a bleaching system can comprise an H₂O₂ source such as perborate or percarbonate, which may be combined with a peracid-forming bleach activator such as tetraacetyl ethylenediamine (TAED) or nonanoyloxybenzenesulfonate (NOBS). Alternatively, a bleaching system may comprise peroxyacids (e.g., amide, imide, or sulfone type peroxyacids). Alternatively still, a bleaching system can be an enzymatic bleaching system comprising perhydrolase, for example, such as the system described in WO2005/056783.

A detergent composition herein may also contain conventional detergent ingredients such as fabric conditioners, clays, foam boosters, suds suppressors, anti-corrosion agents, soil-suspending agents, anti-soil redeposition agents, dyes, bactericides, tarnish inhibitors, optical brighteners, or perfumes. The pH of

5 a detergent composition herein (measured in aqueous solution at use concentration) is usually neutral or alkaline (e.g., pH of about 7.0 to about 11.0).

It is believed that a dextran herein can be included as an anti-redeposition agent and/or clay soil removal agent in a detergent composition such as a fabric care composition, if desired (such agents can optionally be characterized as

10 whiteness maintenance agents in certain aspects). Examples of other suitable anti-redeposition and/or clay soil removal agents herein include polyethoxy zwitterionic surfactants, water-soluble copolymers of acrylic or methacrylic acid with acrylic or methacrylic acid-ethylene oxide condensates (e.g., U.S. Pat. No. 3719647), cellulose derivatives such as carboxymethylcellulose and

15 hydroxypropylcellulose (e.g., U.S. Pat. Nos. 3597416 and 3523088), and mixtures comprising nonionic alkyl polyethoxy surfactant, polyethoxy alkyl quaternary cationic surfactant and fatty amide surfactant (e.g., U.S. Pat. No. 4228044). Non-limiting examples of other suitable anti-redeposition and clay soil removal agents are disclosed in U.S. Pat. Nos. 4597898 and 4891160, and Int.

20 Pat. Appl. Publ. No. WO95/32272, all of which are incorporated herein by reference.

Particular forms of detergent compositions that can be adapted for purposes disclosed herein are disclosed in, for example, US20090209445A1, US20100081598A1, US7001878B2, EP1504994B1, WO2001085888A2,

25 WO2003089562A1, WO2009098659A1, WO2009098660A1, WO2009112992A1, WO2009124160A1, WO2009152031A1, WO2010059483A1, WO2010088112A1, WO2010090915A1, WO2010135238A1, WO2011094687A1, WO2011094690A1, WO2011127102A1, WO2011163428A1, WO2008000567A1, WO2006045391A1, WO2006007911A1, WO2012027404A1, EP1740690B1, WO2012059336A1,

30 US6730646B1, WO2008087426A1, WO2010116139A1, and WO2012104613A1, all of which are incorporated herein by reference.

Laundry detergent compositions herein can optionally be heavy duty (all purpose) laundry detergent compositions. Exemplary heavy duty laundry detergent compositions comprise a deterotive surfactant (10%-40% wt/wt), including an anionic deterotive surfactant (selected from a group of linear or branched or random chain, substituted or unsubstituted alkyl sulphates, alkyl sulphonates, alkyl alkoxylated sulphate, alkyl phosphates, alkyl phosphonates, alkyl carboxylates, and/or mixtures thereof), and optionally non-ionic surfactant (selected from a group of linear or branched or random chain, substituted or unsubstituted alkyl alkoxylated alcohol, e.g., C8-C18 alkyl ethoxylated alcohols and/or C6-C12 alkyl phenol alkoxylates), where the weight ratio of anionic deterotive surfactant (with a hydrophilic index (Hlc) of from 6.0 to 9) to non-ionic deterotive surfactant is greater than 1:1. Suitable deterotive surfactants also include cationic deterotive surfactants (selected from a group of alkyl pyridinium compounds, alkyl quaternary ammonium compounds, alkyl quaternary phosphonium compounds, alkyl ternary sulphonium compounds, and/or mixtures thereof); zwitterionic and/or amphoteric deterotive surfactants (selected from a group of alkanolamine sulpho-betaines); ampholytic surfactants; semi-polar non-ionic surfactants and mixtures thereof.

A detergent herein such as a heavy duty laundry detergent composition may optionally include, a surfactancy boosting polymer consisting of amphiphilic alkoxylated grease cleaning polymers (selected from a group of alkoxylated polymers having branched hydrophilic and hydrophobic properties, such as alkoxylated polyalkylenimines in the range of 0.05 wt% - 10 wt%) and/or random graft polymers (typically comprising of hydrophilic backbone comprising monomers selected from the group consisting of: unsaturated C1-C6 carboxylic acids, ethers, alcohols, aldehydes, ketones, esters, sugar units, alkoxy units, maleic anhydride, saturated polyalcohols such as glycerol, and mixtures thereof; and hydrophobic side chain(s) selected from the group consisting of: C4-C25 alkyl group, polypropylene, polybutylene, vinyl ester of a saturated C1-C6 mono-carboxylic acid, C1-C6 alkyl ester of acrylic or methacrylic acid, and mixtures thereof).

A detergent herein such as a heavy duty laundry detergent composition may optionally include additional polymers such as soil release polymers (including anionically end-capped polyesters, for example SRP1, polymers comprising at least one monomer unit selected from saccharide, dicarboxylic acid, polyol and 5 combinations thereof, in random or block configuration, ethylene terephthalate-based polymers and co-polymers thereof in random or block configuration, for example REPEL-O-TEX SF, SF-2 AND SRP6, TEXCARE SRA100, SRA300, SRN100, SRN170, SRN240, SRN300 AND SRN325, MARLOQUEST SL), anti-redeposition agent(s) herein (0.1 wt% to 10 wt%), include carboxylate polymers, 10 such as polymers comprising at least one monomer selected from acrylic acid, maleic acid (or maleic anhydride), fumaric acid, itaconic acid, aconitic acid, mesaconic acid, citraconic acid, methylenemalonic acid, and any mixture thereof, vinylpyrrolidone homopolymer, and/or polyethylene glycol, molecular weight in the range of from 500 to 100,000 Da); and polymeric carboxylate (such as 15 maleate/acrylate random copolymer or polyacrylate homopolymer).

A detergent herein such as a heavy duty laundry detergent composition may optionally further include saturated or unsaturated fatty acids, preferably saturated or unsaturated C12-C24 fatty acids (0 wt% to 10 wt%); deposition aids in addition to a dextran compound disclosed herein (examples for which include 20 polysaccharides, cellulosic polymers, poly diallyl dimethyl ammonium halides (DADMAC), and co-polymers of DAD MAC with vinyl pyrrolidone, acrylamides, imidazoles, imidazolinium halides, and mixtures thereof, in random or block configuration, cationic guar gum, cationic starch, cationic polyacrylamides, and mixtures thereof.

25 A detergent herein such as a heavy duty laundry detergent composition may optionally further include dye transfer inhibiting agents, examples of which include manganese phthalocyanine, peroxidases, polyvinylpyrrolidone polymers, polyamine N-oxide polymers, copolymers of N-vinylpyrrolidone and N-vinylimidazole, polyvinyloxazolidones and polyvinylimidazoles and/or mixtures 30 thereof; chelating agents, examples of which include ethylene-diamine-tetraacetic acid (EDTA), diethylene triamine penta methylene phosphonic acid

(DTPMP), hydroxy-ethane diphosphonic acid (HEDP), ethylenediamine N,N'-disuccinic acid (EDDS), methyl glycine diacetic acid (MGDA), diethylene triamine penta acetic acid (DTPA), propylene diamine tetracetic acid (PDTA), 2-hydroxypyridine-N-oxide (HPNO), or methyl glycine diacetic acid (MGDA),

5 glutamic acid N,N-diacetic acid (N,N-dicarboxymethyl glutamic acid tetrasodium salt (GLDA), nitrilotriacetic acid (NTA), 4,5-dihydroxy-m-benzenedisulfonic acid, citric acid and any salts thereof, N-hydroxyethylenediaminetriacetic acid (HEDTA), triethylenetetraaminehexaacetic acid (TTHA), N-hydroxyethyliminodiacetic acid (HEIDA), dihydroxyethylglycine (DHEG),

10 ethylenediaminetetrapropionic acid (EDTP), and derivatives thereof.

A detergent herein such as a heavy duty laundry detergent composition may optionally include silicone or fatty-acid based suds suppressors; hueing dyes, calcium and magnesium cations, visual signaling ingredients, anti-foam (0.001 wt% to about 4.0 wt%), and/or a structurant/thickener (0.01 wt% to 5 wt%)

15 selected from the group consisting of diglycerides and triglycerides, ethylene glycol distearate, microcrystalline cellulose, microfiber cellulose, biopolymers, xanthan gum, gellan gum, and mixtures thereof). Such structurant/thickener would be, in certain embodiments, in addition to the one or more dextran compounds comprised in the detergent. A structurant can also be referred to as

20 a structural agent.

A detergent herein can be in the form of a heavy duty dry/solid laundry detergent composition, for example. Such a detergent may include: (i) a deteritive surfactant, such as any anionic deteritive surfactant disclosed herein, any non-ionic deteritive surfactant disclosed herein, any cationic deteritive

25 surfactant disclosed herein, any zwitterionic and/or amphoteric deteritive surfactant disclosed herein, any ampholytic surfactant, any semi-polar non-ionic surfactant, and mixtures thereof; (ii) a builder, such as any phosphate-free builder (e.g., zeolite builders in the range of 0 wt% to less than 10 wt%), any phosphate builder (e.g., sodium tri-polyphosphate in the range of 0 wt% to less

30 than 10 wt%), citric acid, citrate salts and nitrilotriacetic acid, any silicate salt (e.g., sodium or potassium silicate or sodium meta-silicate in the range of 0 wt%

to less than 10 wt%); any carbonate salt (e.g., sodium carbonate and/or sodium bicarbonate in the range of 0 wt% to less than 80 wt%), and mixtures thereof; (iii) a bleaching agent, such as any photobleach (e.g., sulfonated zinc phthalocyanines, sulfonated aluminum phthalocyanines, xanthenes dyes, and mixtures thereof), any hydrophobic or hydrophilic bleach activator (e.g., 5 dodecanoyl oxybenzene sulfonate, decanoyl oxybenzene sulfonate, decanoyl oxybenzoic acid or salts thereof, 3,5,5-trimethyl hexanoyl oxybenzene sulfonate, tetraacetyl ethylene diamine-TAED, nonanoyloxybenzene sulfonate-NOBS, nitrile quats, and mixtures thereof), any source of hydrogen peroxide (e.g., inorganic 10 perhydrate salts, examples of which include mono or tetra hydrate sodium salt of perborate, percarbonate, persulfate, perphosphate, or persilicate), any preformed hydrophilic and/or hydrophobic peracids (e.g., percarboxylic acids and salts, percarbonic acids and salts, perimidic acids and salts, peroxyomonosulfuric acids and salts, and mixtures thereof); and/or (iv) any other components such as a 15 bleach catalyst (e.g., imine bleach boosters examples of which include iminium cations and polyions, iminium zwitterions, modified amines, modified amine oxides, N-sulphonyl imines, N-phosphonyl imines, N-acyl imines, thiadiazole dioxides, perfluoroimines, cyclic sugar ketones, and mixtures thereof), and a metal-containing bleach catalyst (e.g., copper, iron, titanium, ruthenium, 20 tungsten, molybdenum, or manganese cations along with an auxiliary metal cations such as zinc or aluminum and a sequestrate such as EDTA, ethylenediaminetetra(methylenephosphonic acid)).

Compositions disclosed herein can be in the form of a dishwashing 25 detergent composition, for example. Examples of dishwashing detergents include automatic dishwashing detergents (typically used in dishwasher machines) and hand-washing dish detergents. A dishwashing detergent composition can be in any dry or liquid/aqueous form as disclosed herein, for example. Components that may be included in certain embodiments of a 30 dishwashing detergent composition include, for example, one or more of a phosphate; oxygen- or chlorine-based bleaching agent; non-ionic surfactant;

alkaline salt (e.g., metasilicates, alkali metal hydroxides, sodium carbonate); any active enzyme disclosed herein; anti-corrosion agent (e.g., sodium silicate); anti-foaming agent; additives to slow down the removal of glaze and patterns from ceramics; perfume; anti-caking agent (in granular detergent); starch (in tablet-based detergents); gelling agent (in liquid/gel based detergents); and/or sand (powdered detergents).

Dishwashing detergents such as an automatic dishwasher detergent or liquid dishwashing detergent can comprise (i) a non-ionic surfactant, including any ethoxylated non-ionic surfactant, alcohol alkoxylated surfactant, epoxy-

10 capped poly(oxyalkylated) alcohol, or amine oxide surfactant present in an amount from 0 to 10 wt%; (ii) a builder, in the range of about 5-60 wt%, including any phosphate builder (e.g., mono-phosphates, di-phosphates, tri-polyphosphates, other oligomeric-polyphosphates, sodium tripolyphosphate-STPP), any phosphate-free builder (e.g., amino acid-based compounds including

15 methyl-glycine-diacetic acid [MGDA] and salts or derivatives thereof, glutamic-N,N-diacetic acid [GLDA] and salts or derivatives thereof, iminodisuccinic acid (IDS) and salts or derivatives thereof, carboxy methyl inulin and salts or derivatives thereof, nitrilotriacetic acid [NTA], diethylene triamine penta acetic acid [DTPA], B-alaninediacetic acid [B-ADA] and salts thereof), homopolymers

20 and copolymers of poly-carboxylic acids and partially or completely neutralized salts thereof, monomeric polycarboxylic acids and hydroxycarboxylic acids and salts thereof in the range of 0.5 wt% to 50 wt%, or sulfonated/carboxylated polymers in the range of about 0.1 wt% to about 50 wt%; (iii) a drying aid in the range of about 0.1 wt% to about 10 wt% (e.g., polyesters, especially anionic

25 polyesters, optionally together with further monomers with 3 to 6 functionalities – typically acid, alcohol or ester functionalities which are conducive to polycondensation, polycarbonate-, polyurethane- and/or polyurea-polyorganosiloxane compounds or precursor compounds thereof, particularly of the reactive cyclic carbonate and urea type); (iv) a silicate in the range from

30 about 1 wt% to about 20 wt% (e.g., sodium or potassium silicates such as sodium disilicate, sodium meta-silicate and crystalline phyllosilicates); (v) an

inorganic bleach (e.g., perhydrate salts such as perborate, percarbonate, perphosphate, persulfate and persilicate salts) and/or an organic bleach (e.g., organic peroxyacids such as diacyl- and tetraacylperoxides, especially diperoxydodecanedioic acid, diperoxytetradecanedioic acid, and

5 diperoxyhexadecanedioic acid); (vi) a bleach activator (e.g., organic peracid precursors in the range from about 0.1 wt% to about 10 wt%) and/or bleach catalyst (e.g., manganese triazacyclononane and related complexes; Co, Cu, Mn, and Fe bispyridylamine and related complexes; and pentamine acetate cobalt(III) and related complexes); (vii) a metal care agent in the range from
10 about 0.1 wt% to 5 wt% (e.g., benzatriazoles, metal salts and complexes, and/or silicates); and/or (viii) any active enzyme disclosed herein in the range from about 0.01 to 5.0 mg of active enzyme per gram of automatic dishwashing detergent composition, and an enzyme stabilizer component (e.g., oligosaccharides, polysaccharides, and inorganic divalent metal salts).

15

Various examples of detergent formulations comprising at least one dextran herein are disclosed below (1-19):

1) A detergent composition formulated as a granulate having a bulk density of at least 600 g/L comprising: linear alkylbenzenesulfonate (calculated 20 as acid) at about 7-12 wt%; alcohol ethoxysulfate (e.g., C12-18 alcohol, 1-2 ethylene oxide [EO]) or alkyl sulfate (e.g., C16-18) at about 1-4 wt%; alcohol ethoxylate (e.g., C14-15 alcohol) at about 5-9 wt%; sodium carbonate at about 14-20 wt%; soluble silicate (e.g., $\text{Na}_2\text{O } 2\text{SiO}_2$) at about 2-6 wt%; zeolite (e.g., NaAlSiO_4) at about 15-22 wt%; sodium sulfate at about 0-6 wt%; sodium
25 citrate/citric acid at about 0-15 wt%; sodium perborate at about 11-18 wt%; TAED at about 2-6 wt%; dextran herein up to about 2 wt%; other polymers (e.g., maleic/acrylic acid copolymer, PVP, PEG) at about 0-3 wt%; optionally an enzyme(s) (calculated as pure enzyme protein) at about 0.0001-0.1 wt%; and minor ingredients (e.g., suds suppressors, perfumes, optical brightener,
30 photobleach) at about 0-5 wt%.

2) A detergent composition formulated as a granulate having a bulk density of at least 600 g/L comprising: linear alkylbenzenesulfonate (calculated as acid) at about 6-11 wt%; alcohol ethoxysulfate (e.g., C12-18 alcohol, 1-2 EO) or alkyl sulfate (e.g., C16-18) at about 1-3 wt%; alcohol ethoxylate (e.g., C14-15 alcohol) at about 5-9 wt%; sodium carbonate at about 15-21 wt%; soluble silicate (e.g., Na₂O 2SiO₂) at about 1-4 wt%; zeolite (e.g., NaAlSiO₄) at about 24-34 wt%; sodium sulfate at about 4-10 wt%; sodium citrate/citric acid at about 0-15 wt%; sodium perborate at about 11-18 wt%; TAED at about 2-6 wt%; dextran herein up to about 2 wt%; other polymers (e.g., maleic/acrylic acid copolymer, PVP, PEG) at about 1-6 wt%; optionally an enzyme(s) (calculated as pure enzyme protein) at about 0.0001-0.1 wt%; and minor ingredients (e.g., suds suppressors, perfumes, optical brightener, photobleach) at about 0-5 wt%.

3) A detergent composition formulated as a granulate having a bulk density of at least 600 g/L comprising: linear alkylbenzenesulfonate (calculated as acid) at about 5-9 wt%; alcohol ethoxysulfate (e.g., C12-18 alcohol, 7 EO) at about 7-14 wt%; soap as fatty acid (e.g., C16-22 fatty acid) at about 1-3 wt%; sodium carbonate at about 10-17 wt%; soluble silicate (e.g., Na₂O 2SiO₂) at about 3-9 wt%; zeolite (e.g., NaAlSiO₄) at about 23-33 wt%; sodium sulfate at about 0-4 wt%; sodium perborate at about 8-16 wt%; TAED at about 2-8 wt%; phosphonate (e.g., EDTMPA) at about 0-1 wt%; dextran herein up to about 2 wt%; other polymers (e.g., maleic/acrylic acid copolymer, PVP, PEG) at about 0-3 wt%; optionally an enzyme(s) (calculated as pure enzyme protein) at about 0.0001-0.1 wt%; and minor ingredients (e.g., suds suppressors, perfumes, optical brightener) at about 0-5 wt%.

4) A detergent composition formulated as a granulate having a bulk density of at least 600 g/L comprising: linear alkylbenzenesulfonate (calculated as acid) at about 8-12 wt%; alcohol ethoxylate (e.g., C12-18 alcohol, 7 EO) at about 10-25 wt%; sodium carbonate at about 14-22 wt%; soluble silicate (e.g., Na₂O 2SiO₂) at about 1-5 wt%; zeolite (e.g., NaAlSiO₄) at about 25-35 wt%; sodium sulfate at about 0-10 wt%; sodium perborate at about 8-16 wt%; TAED at about 2-8 wt%; phosphonate (e.g., EDTMPA) at about 0-1 wt%; dextran herein

up to about 2 wt%; other polymers (e.g., maleic/acrylic acid copolymer, PVP, PEG) at about 1-3 wt%; optionally an enzyme(s) (calculated as pure enzyme protein) at about 0.0001-0.1 wt%; and minor ingredients (e.g., suds suppressors, perfumes) at about 0-5 wt%.

5 5) An aqueous liquid detergent composition comprising: linear alkylbenzenesulfonate (calculated as acid) at about 15-21 wt%; alcohol ethoxylate (e.g., C12-18 alcohol, 7 EO; or C12-15 alcohol, 5 EO) at about 12-18 wt%; soap as fatty acid (e.g., oleic acid) at about 3-13 wt%; alkenylsuccinic acid (C12-14) at about 0-13 wt%; aminoethanol at about 8-18 wt%; citric acid at about 10 2-8 wt%; phosphonate at about 0-3 wt%; dextran herein up to about 2 wt%; other polymers (e.g., PVP, PEG) at about 0-3 wt%; borate at about 0-2 wt%; ethanol at about 0-3 wt%; propylene glycol at about 8-14 wt%; optionally an enzyme(s) (calculated as pure enzyme protein) at about 0.0001-0.1 wt%; and minor 15 ingredients (e.g., dispersants, suds suppressors, perfume, optical brightener) at about 0-5 wt%.

6) An aqueous structured liquid detergent composition comprising: linear alkylbenzenesulfonate (calculated as acid) at about 15-21 wt%; alcohol ethoxylate (e.g., C12-18 alcohol, 7 EO; or C12-15 alcohol, 5 EO) at about 3-9 wt%; soap as fatty acid (e.g., oleic acid) at about 3-10 wt%; zeolite (e.g., 20 NaAlSiO₄) at about 14-22 wt%; potassium citrate about 9-18 wt%; borate at about 0-2 wt%; dextran herein up to about 2 wt%; other polymers (e.g., PVP, PEG) at about 0-3 wt%; ethanol at about 0-3 wt%; anchoring polymers (e.g., lauryl methacrylate/acrylic acid copolymer, molar ratio 25:1, MW 3800) at about 0-3 wt%; glycerol at about 0-5 wt%; optionally an enzyme(s) (calculated as pure 25 enzyme protein) at about 0.0001-0.1 wt%; and minor ingredients (e.g., dispersants, suds suppressors, perfume, optical brightener) at about 0-5 wt%.

7) A detergent composition formulated as a granulate having a bulk density of at least 600 g/L comprising: fatty alcohol sulfate at about 5-10 wt%, ethoxylated fatty acid monoethanolamide at about 3-9 wt%; soap as fatty acid at 30 about 0-3 wt%; sodium carbonate at about 5-10 wt%; soluble silicate (e.g., Na₂O 2SiO₂) at about 1-4 wt%; zeolite (e.g., NaAlSiO₄) at about 20-40 wt%; sodium

sulfate at about 2-8 wt%; sodium perborate at about 12-18 wt%; TAED at about 2-7 wt%; dextran herein up to about 2 wt%; other polymers (e.g., maleic/acrylic acid copolymer, PEG) at about 1-5 wt%; optionally an enzyme(s) (calculated as pure enzyme protein) at about 0.0001-0.1 wt%; and minor ingredients (e.g.,

5 optical brightener, suds suppressors, perfumes) at about 0-5 wt%.

8) A detergent composition formulated as a granulate comprising: linear alkylbenzenesulfonate (calculated as acid) at about 8-14 wt%; ethoxylated fatty acid monoethanolamide at about 5-11 wt%; soap as fatty acid at about 0-3 wt%; sodium carbonate at about 4-10 wt%; soluble silicate (e.g., $\text{Na}_2\text{O } 2\text{SiO}_2$) at about

10 1-4 wt%; zeolite (e.g., NaAlSiO_4) at about 30-50 wt%; sodium sulfate at about 3-11 wt%; sodium citrate at about 5-12 wt%; dextran herein up to about 2 wt%; other polymers (e.g., PVP, maleic/acrylic acid copolymer, PEG) at about 1-5 wt%; optionally an enzyme(s) (calculated as pure enzyme protein) at about 0.0001-0.1 wt%; and minor ingredients (e.g., suds suppressors, perfumes) at

15 about 0-5 wt%.

9) A detergent composition formulated as a granulate comprising: linear alkylbenzenesulfonate (calculated as acid) at about 6-12 wt%; nonionic surfactant at about 1-4 wt%; soap as fatty acid at about 2-6 wt%; sodium carbonate at about 14-22 wt%; zeolite (e.g., NaAlSiO_4) at about 18-32 wt%;

20 sodium sulfate at about 5-20 wt%; sodium citrate at about 3-8 wt%; sodium perborate at about 4-9 wt%; bleach activator (e.g., NOBS or TAED) at about 1-5 wt%; dextran herein up to about 2 wt%; other polymers (e.g., polycarboxylate or PEG) at about 1-5 wt%; optionally an enzyme(s) (calculated as pure enzyme protein) at about 0.0001-0.1 wt%; and minor ingredients (e.g., optical brightener, perfume) at about 0-5 wt%.

25 10) An aqueous liquid detergent composition comprising: linear alkylbenzenesulfonate (calculated as acid) at about 15-23 wt%; alcohol ethoxysulfate (e.g., C12-15 alcohol, 2-3 EO) at about 8-15 wt%; alcohol ethoxylate (e.g., C12-15 alcohol, 7 EO; or C12-15 alcohol, 5 EO) at about 3-9 wt%; soap as fatty acid (e.g., lauric acid) at about 0-3 wt%; aminoethanol at about 1-5 wt%; sodium citrate at about 5-10 wt%; hydrotrope (e.g., sodium

toluenesulfonate) at about 2-6 wt%; borate at about 0-2 wt%; dextran herein up to about 1 wt%; ethanol at about 1-3 wt%; propylene glycol at about 2-5 wt%; optionally an enzyme(s) (calculated as pure enzyme protein) at about 0.0001-0.1 wt%; and minor ingredients (e.g., dispersants, perfume, optical brighteners) at

5 about 0-5 wt%.

11) An aqueous liquid detergent composition comprising: linear alkylbenzenesulfonate (calculated as acid) at about 20-32 wt%; alcohol ethoxylate (e.g., C12-15 alcohol, 7 EO; or C12-15 alcohol, 5 EO) at about 6-12 wt%; aminoethanol at about 2-6 wt%; citric acid at about 8-14 wt%; borate at

10 about 1-3 wt%; dextran herein up to about 2 wt%; ethanol at about 1-3 wt%; propylene glycol at about 2-5 wt%; other polymers (e.g., maleic/acrylic acid copolymer, anchoring polymer such as lauryl methacrylate/acrylic acid copolymer) at about 0-3 wt%; glycerol at about 3-8 wt%; optionally an enzyme(s) (calculated as pure enzyme protein) at about 0.0001-0.1 wt%; and minor

15 ingredients (e.g., hydrotropes, dispersants, perfume, optical brighteners) at about 0-5 wt%.

12) A detergent composition formulated as a granulate having a bulk density of at least 600 g/L comprising: anionic surfactant (e.g., linear alkylbenzenesulfonate, alkyl sulfate, alpha-olefinsulfonate, alpha-sulfo fatty acid

20 methyl esters, alkanesulfonates, soap) at about 25-40 wt%; nonionic surfactant (e.g., alcohol ethoxylate) at about 1-10 wt%; sodium carbonate at about 8-25 wt%; soluble silicate (e.g., Na₂O 2SiO₂) at about 5-15 wt%; sodium sulfate at about 0-5 wt%; zeolite (NaAlSiO₄) at about 15-28 wt%; sodium perborate at about 0-20 wt%; bleach activator (e.g., TAED or NOBS) at about 0-5 wt%;

25 dextran herein up to about 2 wt%; optionally an enzyme(s) (calculated as pure enzyme protein) at about 0.0001-0.1 wt%; and minor ingredients (e.g., perfume, optical brighteners) at about 0-3 wt%.

13) Detergent compositions as described in (1)-(12) above, but in which all or part of the linear alkylbenzenesulfonate is replaced by C12-C18 alkyl

30 sulfate.

- 14) A detergent composition formulated as a granulate having a bulk density of at least 600 g/L comprising: C12-C18 alkyl sulfate at about 9-15 wt%; alcohol ethoxylate at about 3-6 wt%; polyhydroxy alkyl fatty acid amide at about 1-5 wt%; zeolite (e.g., NaAlSiO₄) at about 10-20 wt%; layered disilicate (e.g.,
5 SK56 from Hoechst) at about 10-20 wt%; sodium carbonate at about 3-12 wt%; soluble silicate (e.g., Na₂O 2SiO₂) at 0-6 wt%; sodium citrate at about 4-8 wt%; sodium percarbonate at about 13-22 wt%; TAED at about 3-8 wt%; dextran herein up to about 2 wt%; other polymers (e.g., polycarboxylates and PVP) at about 0-5 wt%; optionally an enzyme(s) (calculated as pure enzyme protein) at
10 about 0.0001-0.1 wt%; and minor ingredients (e.g., optical brightener, photobleach, perfume, suds suppressors) at about 0-5 wt%.
- 15) A detergent composition formulated as a granulate having a bulk density of at least 600 g/L comprising: C12-C18 alkyl sulfate at about 4-8 wt%; alcohol ethoxylate at about 11-15 wt%; soap at about 1-4 wt%; zeolite MAP or
15 zeolite A at about 35-45 wt%; sodium carbonate at about 2-8 wt%; soluble silicate (e.g., Na₂O 2SiO₂) at 0-4 wt%; sodium percarbonate at about 13-22 wt%; TAED at about 1-8 wt%; dextran herein up to about 3 wt%; other polymers (e.g., polycarboxylates and PVP) at about 0-3 wt%; optionally an enzyme(s) (calculated as pure enzyme protein) at about 0.0001-0.1 wt%; and minor
20 ingredients (e.g., optical brightener, phosphonate, perfume) at about 0-3 wt%.
- 16) Detergent formulations as described in (1)-(15) above, but that contain a stabilized or encapsulated peracid, either as an additional component or as a substitute for an already specified bleach system(s).
- 17) Detergent compositions as described in (1), (3), (7), (9) and (12)
25 above, but in which perborate is replaced by percarbonate.
- 18) Detergent compositions as described in (1), (3), (7), (9), (12), (14) and (15) above, but that additionally contain a manganese catalyst. A manganese catalyst, for example, is one of the compounds described by Hage et al. (1994, *Nature* 369:637-639), which is incorporated herein by reference.
- 19) Detergent compositions formulated as a non-aqueous detergent liquid
30 comprising a liquid non-ionic surfactant (e.g., a linear alkoxylated primary

alcohol), a builder system (e.g., phosphate), dextran herein, optionally an enzyme(s), and alkali. The detergent may also comprise an anionic surfactant and/or bleach system.

It is believed that numerous commercially available detergent formulations 5 can be adapted to include a dextran compound disclosed herein. Examples include PUREX® ULTRAPACKS (Henkel), FINISH® QUANTUM (Reckitt Benckiser), CLOROX™ 2 PACKS (Clorox), OXICLEAN MAX FORCE POWER PAKS (Church & Dwight), TIDE® STAIN RELEASE, CASCADE® ACTIONPACS, and TIDE® PODS™ (Procter & Gamble).

10

Compositions disclosed herein can be in the form of an oral care composition, for example. Examples of oral care compositions include dentifrices, toothpaste, mouth wash, mouth rinse, chewing gum, and edible strips that provide some form of oral care (e.g., treatment or prevention of cavities

15 [dental caries], gingivitis, plaque, tartar, and/or periodontal disease). An oral care composition can also be for treating an “oral surface”, which encompasses any soft or hard surface within the oral cavity including surfaces of the tongue, hard and soft palate, buccal mucosa, gums and dental surfaces. A “dental surface” herein is a surface of a natural tooth or a hard surface of artificial dentition 20 including a crown, cap, filling, bridge, denture, or dental implant, for example.

An oral care composition herein can comprise about 0.01-15.0 wt% (e.g., ~0.1-10 wt% or ~0.1-5.0 wt%, ~0.1-2.0 wt%) of one or more dextran ether compounds as disclosed herein, for example. One or more dextran ether compounds comprised in an oral care composition can sometimes be provided

25 therein as a thickening agent and/or dispersion agent, which may be useful to impart a desired consistency and/or mouth feel to the composition. One or more other thickening or dispersion agents can also be provided in an oral care composition herein, such as a carboxyvinyl polymer, carrageenan (e.g., L-carrageenan), natural gum (e.g., karaya, xanthan, gum arabic, tragacanth), 30 colloidal magnesium aluminum silicate, or colloidal silica, for example.

An oral care composition herein may be a toothpaste or other dentifrice, for example. Such compositions, as well as any other oral care composition herein, can additionally comprise, without limitation, one or more of an anticaries agent, antimicrobial or antibacterial agent, anticalculus or tartar control agent, 5 surfactant, abrasive, pH-modifying agent, foam modulator, humectant, flavorant, sweetener, pigment/colorant, whitening agent, and/or other suitable components. Examples of oral care compositions to which one or more dextran compounds can be added are disclosed in U.S. Patent Appl. Publ. Nos. 2006/0134025, 2002/0022006 and 2008/0057007, which are incorporated herein by reference.

10 An anticaries agent herein can be an orally acceptable source of fluoride ions. Suitable sources of fluoride ions include fluoride, monofluorophosphate and fluorosilicate salts as well as amine fluorides, including olaflur (N'-octadecyltrimethylendiamine-N,N,N'- tris(2-ethanol)-dihydrofluoride), for example. An anticaries agent can be present in an amount providing a total of about 100- 15 20000 ppm, about 200-5000 ppm, or about 500-2500 ppm, fluoride ions to the composition, for example. In oral care compositions in which sodium fluoride is the sole source of fluoride ions, an amount of about 0.01-5.0 wt%, about 0.05-1.0 wt%, or about 0.1-0.5 wt%, sodium fluoride can be present in the composition, for example.

20 An antimicrobial or antibacterial agent suitable for use in an oral care composition herein includes, for example, phenolic compounds (e.g., 4-allylcatechol; p-hydroxybenzoic acid esters such as benzylparaben, butylparaben, ethylparaben, methylparaben and propylparaben; 2-benzylphenol; butylated hydroxyanisole; butylated hydroxytoluene; capsaicin; carvacrol; 25 creosol; eugenol; guaiacol; halogenated bisphenolics such as hexachlorophene and bromochlorophene; 4-hexylresorcinol; 8-hydroxyquinoline and salts thereof; salicylic acid esters such as methyl salicylate, methyl salicylate and phenyl salicylate; phenol; pyrocatechol; salicylanilide; thymol; halogenated diphenylether compounds such as triclosan and triclosan monophosphate), copper (II) 30 compounds (e.g., copper (II) chloride, fluoride, sulfate and hydroxide), zinc ion sources (e.g., zinc acetate, citrate, gluconate, glycinate, oxide, and sulfate),

phthalic acid and salts thereof (e.g., magnesium monopotassium phthalate), hexetidine, octenidine, sanguinarine, benzalkonium chloride, domiphen bromide, alkylpyridinium chlorides (e.g. cetylpyridinium chloride, tetradecylpyridinium chloride, N-tetradecyl-4-ethylpyridinium chloride), iodine, sulfonamides,

5 bisbiguanides (e.g., alexidine, chlorhexidine, chlorhexidine digluconate), piperidino derivatives (e.g., delmopinol, octapinol), magnolia extract, grapeseed extract, rosemary extract, menthol, geraniol, citral, eucalyptol, antibiotics (e.g., augmentin, amoxicillin, tetracycline, doxycycline, minocycline, metronidazole, neomycin, kanamycin, clindamycin), and/or any antibacterial agents disclosed in

10 U.S. Patent No. 5776435, which is incorporated herein by reference. One or more antimicrobial agents can optionally be present at about 0.01-10 wt% (e.g., 0.1-3 wt%), for example, in the disclosed oral care composition.

An anticalculus or tartar control agent suitable for use in an oral care composition herein includes, for example, phosphates and polyphosphates (e.g., 15 pyrophosphates), polyaminopropanesulfonic acid (AMPS), zinc citrate trihydrate, polypeptides (e.g., polyaspartic and polyglutamic acids), polyolefin sulfonates, polyolefin phosphates, diphosphonates (e.g., azacycloalkane-2,2-diphosphonates such as azacycloheptane-2,2-diphosphonic acid), N-methyl azacyclopentane-2,3-diphosphonic acid, ethane-1-hydroxy-1,1-diphosphonic acid (EHDP), ethane-20 1-amino-1,1-diphosphonate, and/or phosphonoalkane carboxylic acids and salts thereof (e.g., their alkali metal and ammonium salts). Useful inorganic phosphate and polyphosphate salts include, for example, monobasic, dibasic and tribasic sodium phosphates, sodium tripolyphosphate, tetrapolyphosphate, mono-, di-, tri- and tetra-sodium pyrophosphates, disodium dihydrogen pyrophosphate, sodium 25 trimetaphosphate, sodium hexametaphosphate, or any of these in which sodium is replaced by potassium or ammonium. Other useful anticalculus agents in certain embodiments include anionic polycarboxylate polymers (e.g., polymers or copolymers of acrylic acid, methacrylic, and maleic anhydride such as polyvinyl methyl ether/maleic anhydride copolymers). Still other useful anticalculus agents 30 include sequestering agents such as hydroxycarboxylic acids (e.g., citric, fumaric, malic, glutaric and oxalic acids and salts thereof) and

aminopolycarboxylic acids (e.g., EDTA). One or more anticalculus or tartar control agents can optionally be present at about 0.01-50 wt% (e.g., about 0.05-25 wt% or about 0.1-15 wt%), for example, in the disclosed oral care composition.

5 A surfactant suitable for use in an oral care composition herein may be anionic, non-ionic, or amphoteric, for example. Suitable anionic surfactants include, without limitation, water-soluble salts of C₈₋₂₀ alkyl sulfates, sulfonated monoglycerides of C₈₋₂₀ fatty acids, sarcosinates, and taurates. Examples of anionic surfactants include sodium lauryl sulfate, sodium coconut monoglyceride 10 sulfonate, sodium lauryl sarcosinate, sodium lauryl isoethionate, sodium laureth carboxylate and sodium dodecyl benzenesulfonate. Suitable non-ionic surfactants include, without limitation, poloxamers, polyoxyethylene sorbitan esters, fatty alcohol ethoxylates, alkylphenol ethoxylates, tertiary amine oxides, tertiary phosphine oxides, and dialkyl sulfoxides. Suitable amphoteric surfactants 15 include, without limitation, derivatives of C₈₋₂₀ aliphatic secondary and tertiary amines having an anionic group such as a carboxylate, sulfate, sulfonate, phosphate or phosphonate. An example of a suitable amphoteric surfactant is cocoamidopropyl betaine. One or more surfactants are optionally present in a total amount of about 0.01-10 wt% (e.g., about 0.05-5.0 wt% or about 0.1-2.0 20 wt%), for example, in the disclosed oral care composition.

An abrasive suitable for use in an oral care composition herein may include, for example, silica (e.g., silica gel, hydrated silica, precipitated silica), alumina, insoluble phosphates, calcium carbonate, and resinous abrasives (e.g., a urea-formaldehyde condensation product). Examples of insoluble phosphates 25 useful as abrasives herein are orthophosphates, polymetaphosphates and pyrophosphates, and include dicalcium orthophosphate dihydrate, calcium pyrophosphate, beta-calcium pyrophosphate, tricalcium phosphate, calcium polymetaphosphate and insoluble sodium polymetaphosphate. One or more abrasives are optionally present in a total amount of about 5-70 wt% (e.g., about 30 10-56 wt% or about 15-30 wt%), for example, in the disclosed oral care

composition. The average particle size of an abrasive in certain embodiments is about 0.1-30 microns (e.g., about 1-20 microns or about 5-15 microns).

An oral care composition in certain embodiments may comprise at least one pH-modifying agent. Such agents may be selected to acidify, make more basic, or buffer the pH of a composition to a pH range of about 2-10 (e.g., pH ranging from about 2-8, 3-9, 4-8, 5-7, 6-10, or 7-9). Examples of pH-modifying agents useful herein include, without limitation, carboxylic, phosphoric and sulfonic acids; acid salts (e.g., monosodium citrate, disodium citrate, monosodium malate); alkali metal hydroxides (e.g. sodium hydroxide, carbonates such as sodium carbonate, bicarbonates, sesquicarbonates); borates; silicates; phosphates (e.g., monosodium phosphate, trisodium phosphate, pyrophosphate salts); and imidazole.

A foam modulator suitable for use in an oral care composition herein may be a polyethylene glycol (PEG), for example. High molecular weight PEGs are suitable, including those having an average molecular weight of about 200000-7000000 (e.g., about 500000-5000000 or about 1000000-2500000), for example. One or more PEGs are optionally present in a total amount of about 0.1-10 wt% (e.g. about 0.2-5.0 wt% or about 0.25-2.0 wt%), for example, in the disclosed oral care composition.

An oral care composition in certain embodiments may comprise at least one humectant. A humectant in certain embodiments may be a polyhydric alcohol such as glycerin, sorbitol, xylitol, or a low molecular weight PEG. Most suitable humectants also may function as a sweetener herein. One or more humectants are optionally present in a total amount of about 1.0-70 wt% (e.g., about 1.0-50 wt%, about 2-25 wt%, or about 5-15 wt%), for example, in the disclosed oral care composition.

A natural or artificial sweetener may optionally be comprised in an oral care composition herein. Examples of suitable sweeteners include dextrose, sucrose, maltose, dextrin, invert sugar, mannose, xylose, ribose, fructose, levulose, galactose, corn syrup (e.g., high fructose corn syrup or corn syrup solids), partially hydrolyzed starch, hydrogenated starch hydrolysate, sorbitol,

mannitol, xylitol, maltitol, isomalt, aspartame, neotame, saccharin and salts thereof, dipeptide-based intense sweeteners, and cyclamates. One or more sweeteners are optionally present in a total amount of about 0.005-5.0 wt%, for example, in the disclosed oral care composition.

5 A natural or artificial flavorant may optionally be comprised in an oral care composition herein. Examples of suitable flavorants include vanillin; sage; marjoram; parsley oil; spearmint oil; cinnamon oil; oil of wintergreen (methylsalicylate); peppermint oil; clove oil; bay oil; anise oil; eucalyptus oil; citrus oils; fruit oils; essences such as those derived from lemon, orange, lime, 10 grapefruit, apricot, banana, grape, apple, strawberry, cherry, or pineapple; bean- and nut-derived flavors such as coffee, cocoa, cola, peanut, or almond; and adsorbed and encapsulated flavorants. Also encompassed within flavorants herein are ingredients that provide fragrance and/or other sensory effect in the mouth, including cooling or warming effects. Such ingredients include, without 15 limitation, menthol, menthyl acetate, menthyl lactate, camphor, eucalyptus oil, eucalyptol, anethole, eugenol, cassia, oxanone, Irisone[®], propenyl guaiethol, thymol, linalool, benzaldehyde, cinnamaldehyde, N-ethyl-p-menthan-3- carboxamine, N,2,3-trimethyl-2-isopropylbutanamide, 3-(1-menthoxy)-propane- 1,2-diol, cinnamaldehyde glycerol acetal (CGA), and menthone glycerol acetal 20 (MGA). One or more flavorants are optionally present in a total amount of about 0.01-5.0 wt% (e.g., about 0.1-2.5 wt%), for example, in the disclosed oral care composition.

An oral care composition in certain embodiments may comprise at least one bicarbonate salt. Any orally acceptable bicarbonate can be used, including 25 alkali metal bicarbonates such as sodium or potassium bicarbonate, and ammonium bicarbonate, for example. One or more bicarbonate salts are optionally present in a total amount of about 0.1-50 wt% (e.g., about 1-20 wt%), for example, in the disclosed oral care composition.

An oral care composition in certain embodiments may comprise at least 30 one whitening agent and/or colorant. A suitable whitening agent is a peroxide compound such as any of those disclosed in U.S. Patent No. 8540971, which is

incorporated herein by reference. Suitable colorants herein include pigments, dyes, lakes and agents imparting a particular luster or reflectivity such as pearlizing agents, for example. Specific examples of colorants useful herein include talc; mica; magnesium carbonate; calcium carbonate; magnesium silicate; magnesium aluminum silicate; silica; titanium dioxide; zinc oxide; red, yellow, brown and black iron oxides; ferric ammonium ferrocyanide; manganese violet; ultramarine; titanated mica; and bismuth oxychloride. One or more colorants are optionally present in a total amount of about 0.001-20 wt% (e.g., about 0.01-10 wt% or about 0.1-5.0 wt%), for example, in the disclosed oral care composition.

Additional components that can optionally be included in an oral composition herein include one or more enzymes (above), vitamins, and anti-adhesion agents, for example. Examples of vitamins useful herein include vitamin C, vitamin E, vitamin B5, and folic acid. Examples of suitable anti-adhesion agents include solbrol, ficin, and quorum-sensing inhibitors.

The present disclosure also concerns a method for increasing the viscosity of an aqueous composition. This method comprises contacting at least one dextran compound as presently disclosed with the aqueous composition.

20 The contacting step in this method results in increasing the viscosity of the aqueous composition, in comparison to the viscosity of the aqueous composition before the contacting step.

An aqueous composition herein can be water (e.g., de-ionized water), an aqueous solution, or a hydrocolloid, for example. The viscosity of an aqueous composition before the contacting step, measured at about 20-25 °C, can be about 0-10000 cPs (or any integer between 0-10000 cPs), for example. Since the aqueous composition can be a hydrocolloid or the like in certain embodiments, it should be apparent that the method can be used to increase the viscosity of aqueous compositions that are already viscous.

30 Contacting dextran herein with an aqueous composition increases the viscosity of the aqueous composition in certain embodiments. This increase in

viscosity can be an increase of at least about 1%, 10%, 100%, 1000%, 100000%, or 1000000% (or any integer between 1% and 1000000%), for example, compared to the viscosity of the aqueous composition before the contacting step. It should be apparent that very large percent increases in

5 viscosity can be obtained with the disclosed method when the aqueous composition has little to no viscosity before the contacting step. An increase in viscosity can be determined, for example, by comparing the viscosity of the aqueous composition obtained by the method (i.e., after the contacting step) with the viscosity of the aqueous composition as it had existed before the method

10 (i.e., before the contacting step).

Contacting dextran herein with an aqueous composition increases the shear thinning behavior or shear thickening behavior of the aqueous composition in certain embodiments. Thus, dextran rheologically modifies the aqueous composition in these embodiments. The increase in shear thinning behavior or shear thickening behavior can be an increase of at least about 1%, 10%, 100%, 1000%, 100000%, or 1000000% (or any integer between 1% and 1000000%), for example, compared to the shear thinning behavior or shear thickening behavior of the aqueous composition before the contacting step. It should be apparent that very large percent increases in rheologic modification can be obtained with

15 the disclosed method when the aqueous composition has little to no rheologic behavior before the contacting step.

20

The contacting step in a method for increasing the viscosity of an aqueous composition can be performed by mixing or dissolving any dextran as presently disclosed in the aqueous composition by any means known in the art. For

25 example, mixing or dissolving can be performed manually or with a machine (e.g., industrial mixer or blender, orbital shaker, stir plate, homogenizer, sonicator, bead mill). Mixing or dissolving can comprise a homogenization step in certain embodiments. Homogenization (as well as any other type of mixing) can be performed for about 5 to 60, 5 to 30, 10 to 60, 10 to 30, 5 to 15, or 10 to

30 15 seconds (or any integer between 5 and 60 seconds), or longer periods of time as necessary to mix dextran with the aqueous composition. A homogenizer can

be used at about 5000 to 30000 rpm, 10000 to 30000 rpm, 15000 to 30000 rpm, 15000 to 25000 rpm, or 20000 rpm (or any integer between 5000 and 30000 rpm), for example.

After a dextran herein is mixed with or dissolved into an aqueous

5 composition, the resulting aqueous composition may be filtered, or may not be filtered. For example, an aqueous composition prepared with a homogenization step may or may not be filtered.

Certain embodiments of the above method can be used to prepare an aqueous composition disclosed herein, such as a food product (e.g., a

10 confectionery such as a candy filling), pharmaceutical product (e.g., excipient), household product (e.g., laundry detergent, fabric softener, dishwasher detergent), personal care product (e.g., a water-containing dentifrice such as toothpaste), or industrial product.

15 The present disclosure also concerns a method of treating a material. This method comprises contacting a material with an aqueous composition comprising at least one dextran compound as disclosed herein.

A material contacted with an aqueous composition in a contacting method herein can comprise a fabric in certain embodiments. A fabric herein can

20 comprise natural fibers, synthetic fibers, semi-synthetic fibers, or any combination thereof. A semi-synthetic fiber herein is produced using naturally occurring material that has been chemically derivatized, an example of which is rayon. Non-limiting examples of fabric types herein include fabrics made of (i) cellulosic fibers such as cotton (e.g., broadcloth, canvas, chambray, chenille, 25 chintz, corduroy, cretonne, damask, denim, flannel, gingham, jacquard, knit, matelassé, oxford, percale, poplin, plissé, sateen, seersucker, sheers, terry cloth, twill, velvet), rayon (e.g., viscose, modal, lyocell), linen, and Tencel®; (ii) proteinaceous fibers such as silk, wool and related mammalian fibers; (iii) synthetic fibers such as polyester, acrylic, nylon, and the like; (iv) long vegetable 30 fibers from jute, flax, ramie, coir, kapok, sisal, henequen, abaca, hemp and sunn; and (v) any combination of a fabric of (i)-(iv). Fabric comprising a combination of

fiber types (e.g., natural and synthetic) include those with both a cotton fiber and polyester, for example. Materials/articles containing one or more fabrics herein include, for example, clothing, curtains, drapes, upholstery, carpeting, bed linens, bath linens, tablecloths, sleeping bags, tents, car interiors, etc. Other materials 5 comprising natural and/or synthetic fibers include, for example, non-woven fabrics, paddings, paper, and foams.

An aqueous composition that is contacted with a fabric can be, for example, a fabric care composition (e.g., laundry detergent, fabric softener). Thus, a treatment method in certain embodiments can be considered a fabric 10 care method or laundry method if employing a fabric care composition therein. A fabric care composition herein is contemplated to effect one or more of the following fabric care benefits (i.e., surface substantive effects): wrinkle removal, wrinkle reduction, wrinkle resistance, fabric wear reduction, fabric wear resistance, fabric pilling reduction, extended fabric life, fabric color maintenance, 15 fabric color fading reduction, reduced dye transfer, fabric color restoration, fabric soiling reduction, fabric soil release, fabric shape retention, fabric smoothness enhancement, anti-redeposition of soil on fabric, anti-greying of laundry, improved fabric hand/handle, and/or fabric shrinkage reduction.

Examples of conditions (e.g., time, temperature, wash/rinse volumes) for 20 conducting a fabric care method or laundry method herein are disclosed in WO1997/003161 and U.S. Patent Nos. 4794661, 4580421 and 5945394, which are incorporated herein by reference. In other examples, a material comprising fabric can be contacted with an aqueous composition herein: (i) for at least about 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, or 120 minutes; (ii) at a 25 temperature of at least about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, or 95 °C (e.g., for laundry wash or rinse: a “cold” temperature of about 15-30 °C, a “warm” temperature of about 30-50 °C, a “hot” temperature of about 50-95 °C); (iii) at a pH of about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 (e.g., pH range of about 2-12, or about 3-11); (iv) at a salt (e.g., NaCl) concentration of at 30 least about 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, or 4.0 wt%; or any combination of (i)-(iv).

The contacting step in a fabric care method or laundry method can comprise any of washing, soaking, and/or rinsing steps, for example. Contacting a material or fabric in still further embodiments can be performed by any means known in the art, such as dissolving, mixing, shaking, spraying, treating,

5 immersing, flushing, pouring on or in, combining, painting, coating, applying, affixing to, and/or communicating an effective amount of a dextran compound herein with the fabric or material. In still further embodiments, contacting may be used to treat a fabric to provide a surface substantive effect. As used herein, the term "fabric hand" or "handle" refers to a person's tactile sensory response

10 towards fabric which may be physical, physiological, psychological, social or any combination thereof. In one embodiment, the fabric hand may be measured using a PhabrOmeter® System for measuring relative hand value (available from Nu Cybertek, Inc. Davis, CA) (American Association of Textile Chemists and Colorists (AATCC test method "202-2012, Relative Hand Value of Textiles:

15 Instrumental Method").)

In certain embodiments of treating a material comprising fabric, a dextran compound component(s) of the aqueous composition adsorbs to the fabric. This feature is believed to render dextran compounds herein useful as anti-redeposition agents and/or anti-greying agents in fabric care compositions

20 disclosed (in addition to their viscosity-modifying effect). An anti-redeposition agent or anti-greying agent herein helps keep soil from redepositing onto clothing in wash water after the soil has been removed. It is further contemplated that adsorption of one or more dextran compounds herein to a fabric enhances mechanical properties of the fabric.

25 Adsorption of a dextran compound to a fabric herein can be measured using a colorimetric technique (e.g., Dubois et al., 1956, *Anal. Chem.* 28:350-356; Zemljič et al., 2006, *Lenzinger Berichte* 85:68-76; both incorporated herein by reference), for example, or any other method known in the art.

30 Other materials that can be contacted in the above treatment method include surfaces that can be treated with a dish detergent (e.g., automatic dishwashing detergent or hand dish detergent). Examples of such materials

include surfaces of dishes, glasses, pots, pans, baking dishes, utensils and flatware made from ceramic material, china, metal, glass, plastic (e.g., polyethylene, polypropylene, polystyrene, etc.) and wood (collectively referred to herein as “tableware”). Thus, the treatment method in certain embodiments can

5 be considered a dishwashing method or tableware washing method, for example. Examples of conditions (e.g., time, temperature, wash volume) for conducting a dishwashing or tableware washing method herein are disclosed in U.S. Patent No. 8575083, which is incorporated herein by reference. In other examples, a tableware article can be contacted with an aqueous composition herein under a

10 suitable set of conditions such as any of those disclosed above with regard to contacting a fabric-comprising material.

Other materials that can be contacted in the above treatment method include oral surfaces such as any soft or hard surface within the oral cavity including surfaces of the tongue, hard and soft palate, buccal mucosa, gums and

15 dental surfaces (e.g., natural tooth or a hard surface of artificial dentition such as a crown, cap, filling, bridge, denture, or dental implant). Thus, a treatment method in certain embodiments can be considered an oral care method or dental care method, for example. Conditions (e.g., time, temperature) for contacting an oral surface with an aqueous composition herein should be suitable for the

20 intended purpose of making such contact. Other surfaces that can be contacted in a treatment method also include a surface of the integumentary system such as skin, hair or nails.

Thus, certain embodiments of the present disclosure concern material (e.g., fabric) that comprises a dextran compound herein. Such material can be

25 produced following a material treatment method as disclosed herein, for example. A material may comprise a dextran compound in certain embodiments if the compound is adsorbed to, or otherwise in contact with, the surface of the material.

Certain embodiments of a method of treating a material herein further

30 comprise a drying step, in which a material is dried after being contacted with the aqueous composition. A drying step can be performed directly after the

contacting step, or following one or more additional steps that might follow the contacting step (e.g., drying of a fabric after being rinsed, in water for example, following a wash in an aqueous composition herein). Drying can be performed by any of several means known in the art, such as air drying (e.g., ~20-25 °C), or
5 at a temperature of at least about 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 170, 175, 180, or 200 °C, for example. A material that has been dried herein typically has less than 3, 2, 1, 0.5, or 0.1 wt% water comprised therein. Fabric is a preferred material for conducting an optional drying step.

An aqueous composition used in a treatment method herein can be any
10 aqueous composition disclosed herein, such as in the above embodiments or in the below Examples. Thus, the dextran component(s) of an aqueous composition can be any as disclosed herein. Examples of aqueous compositions include detergents (e.g., laundry detergent or dish detergent) and water-containing dentifrices such as toothpaste.

15

The present disclosure also concerns an enzymatic reaction comprising water, sucrose and a glucosyltransferase enzyme comprising, or consisting of, an amino acid sequence that is at least 90% identical to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, or SEQ ID NO:17. The
20 glucosyltransferase enzyme synthesizes dextran as presently disclosed. Significantly, dextran synthesized in this gtf reaction exhibits high viscosity in aqueous compositions, even at relatively low concentrations of the dextran. It is believed that this high viscosity profile is unique in comparison to viscosity profiles of previously disclosed dextran polymers.

25

Dextran synthesized in an enzymatic reaction herein can be as characterized (e.g., molecular weight, linkage and branching profile) in the above disclosure regarding dextran as produced by a glucosyltransferase enzyme. A glucosyltransferase enzyme in an enzymatic reaction herein can be as characterized in the above disclosure regarding dextran as produced by a
30 glucosyltransferase enzyme.

One or more different glucosyltransferase enzymes may be used in an enzymatic reaction herein. A single glucosyltransferase enzyme (e.g., gtf 0768) is used in some cases, as opposed to situations in which multiple enzymes may be present (e.g., a bacterial or yeast fermentation). An enzymatic reaction can

5 be as characterized (e.g., initial sucrose concentration and sucrose type, pH, temperature, time) in the above disclosure regarding dextran as produced by a glucosyltransferase enzyme. Also, any features presently disclosed of a method of producing dextran can apply to a glucosyltransferase reaction.

The present disclosure also concerns a method for producing dextran comprising the step of contacting at least water, sucrose, and a glucosyltransferase enzyme comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, or SEQ ID NO:17. This contacting step results in production of dextran as presently disclosed. Dextran produced in the contacting step can 15 optionally be isolated.

Dextran synthesized in a synthesis method herein can be as characterized (e.g., molecular weight, linkage and branching profile) in the above disclosure regarding dextran as produced by a glucosyltransferase enzyme. A glucosyltransferase enzyme in a synthesis method herein can be as 20 characterized in the above disclosure regarding dextran as produced by a glucosyltransferase enzyme. Any features of an enzymatic reaction as disclosed above can apply to the instant synthesis method.

The contacting step in a method herein of producing dextran comprises providing an enzymatic reaction comprising water, sucrose and any

25 glucosyltransferase enzyme disclosed herein. The contacting step of the disclosed method can be performed in any number of ways. For example, the desired amount of sucrose can first be dissolved in water (optionally, other components may also be added at this stage of preparation, such as buffer components), followed by addition of one or more glucosyltransferase enzymes.

30 The solution may be kept still, or agitated via stirring or orbital shaking, for example.

The reaction can be, and typically is, cell-free. Thus, a dextran herein is not isolated from a cell, such as a bacteria (e.g., *L. mesenteroides*), in some aspects.

Completion of a glucosyltransferase reaction in certain embodiments can

5 be gauged, for example, by determining whether reaction viscosity is no longer increasing and/or by measuring the amount of sucrose left in the reaction (residual sucrose), where a percent sucrose consumption of over about 90% can indicate reaction completion. Typically, a reaction of the disclosed process can take about 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 30, 36, 48, 60, 72, 84, or 96 hours
10 to complete. Reaction time may depend, for example, on certain parameters such as the amount of sucrose and glucosyltransferase enzyme used in the reaction.

The yield of dextran produced in a glucosyltransferase reaction in certain embodiments can be about, or at least about, 10%, 15%, 20%, 25%, 30%, 35%,
15 40%, or 45%, based on the weight of the sucrose used in the reaction.

Dextran produced in the disclosed method may optionally be isolated. For example, dextran may be precipitated with alcohol (e.g., 90-100% methanol, ethanol, or isopropanol) and then separated from the supernatant, which may comprise water, fructose, and optionally one or more of residual sucrose and byproduct (e.g., glucose; leucrose and other soluble oligosaccharides). Such separation can be by centrifugation or filtration, for example. Precipitated dextran can optionally be washed one or more times (e.g., 2-4 times; 2, 3, 4 or more times) with alcohol (e.g., 70-100%, or at least 70%, 80%, 90%, 95%, or 100% methanol, ethanol, or isopropanol). In other examples, dextran isolation can comprise using an ultrafiltration and/or dialysis technique (i.e., a molecular weight cut-off technique), such as disclosed in U.S. Patent Appl. Publ. No. 2014/0142294 and U.S. Patent No. 6977249, which are incorporated herein by reference. Measurements of certain dextran features herein (e.g., linkage profile, molecular weight) can be made with dextran isolated as above, if desired.

30 A dextran synthesis method herein is believed to be useful for producing dextran with increased or decreased viscosity, depending on the amount of

sucrose used in the method. In general, the lower the sucrose concentration used in a glucosyltransferase reaction, the higher the viscosity of the dextran product, and vice versa. Any sucrose concentration disclosed herein can be used in a glucosyltransferase reaction, where the dextran product of the reaction

5 has a viscosity that is greater than that of a dextran product produced in a reaction comprising a higher sucrose concentration, and vice versa. In certain aspects, any viscosity disclosed herein can be used to characterize embodiments of this method, and an increase in viscosity can be at least about 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 20-, 50-, 100-, 150-, 200-, or 250-fold higher. A
10 glucosyltransferase enzyme in certain embodiments of this method can be gtf 0768 (comprising SEQ ID NO:1 or related sequences).

Non-limiting examples of compositions and methods disclosed herein include:

1. A composition comprising dextran, wherein the dextran comprises:

15 (i) about 87-93 wt% glucose linked at positions 1 and 6;
(ii) about 0.1-1.2 wt% glucose linked at positions 1 and 3;
(iii) about 0.1-0.7 wt% glucose linked at positions 1 and 4;
(iv) about 7.7-8.6 wt% glucose linked at positions 1, 3 and 6; and
(v) about 0.4-1.7 wt% glucose linked at:
20 (a) positions 1, 2 and 6, or
(b) positions 1, 4 and 6;

wherein the weight-average molecular weight (Mw) of the dextran is about 50-200 million Daltons, the z-average radius of gyration of the dextran is about 200-280 nm, and the dextran optionally is not a product of a *Leuconostoc mesenteroides* glucosyltransferase enzyme.

25 2. The composition of embodiment 1, wherein the dextran comprises:

(i) about 89.5-90.5 wt% glucose linked at positions 1 and 6;
(ii) about 0.4-0.9 wt% glucose linked at positions 1 and 3;
(iii) about 0.3-0.5 wt% glucose linked at positions 1 and 4;
30 (iv) about 8.0-8.3 wt% glucose linked at positions 1, 3 and 6; and
(v) about 0.7-1.4 wt% glucose linked at:

- (a) positions 1, 2 and 6, or
- (b) positions 1, 4 and 6.

3. The composition of embodiment 1 or 2, wherein the dextran comprises chains linked together within a branching structure, wherein the chains are

5 similar in length and comprise substantially alpha-1,6-glucosidic linkages.

4. The composition of embodiment 1, 2, or 3, wherein the average length of the chains is about 10-50 monomeric units.

5. The composition of embodiment 1, 2, 3, or 4, wherein the dextran is a product of a glucosyltransferase enzyme comprising an amino acid sequence

10 that is at least 90% identical to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, or SEQ ID NO:17.

6. The composition of embodiment 1, 2, 3, 4, or 5, wherein the composition is an aqueous composition having a viscosity of at least about 25 cPs.

7. The composition of embodiment 1, 2, 3, 4, 5, or 6, wherein the Mw of the 15 dextran is about 80-120 million Daltons.

8. The composition of embodiment 1, 2, 3, 4, 5, 6, or 7, wherein the z-average radius of gyration of the dextran is about 230-250 nm.

9. The composition of embodiment 1, 2, 3, 4, 5, 6, 7, or 8, wherein the 20 composition is in the form of a food product, personal care product, pharmaceutical product, household product, or industrial product.

10. The composition of embodiment 9, wherein the composition is in the form of a confectionery.

11. A method for increasing the viscosity of an aqueous composition, the 25 method comprising: contacting dextran according to any of embodiments 1-8 with the aqueous composition, wherein the viscosity of the aqueous composition is increased by the dextran compared to the viscosity of the aqueous composition before the contacting step.

12. A method of treating a material, the method comprising: contacting a 30 material with an aqueous composition comprising dextran according to any of embodiments 1-8.

13. An enzymatic reaction comprising water, sucrose and a glucosyltransferase enzyme comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, or SEQ ID NO:17, wherein the glucosyltransferase enzyme

5 synthesizes dextran according to any of embodiments 1-8.

14. A method for producing dextran, the method comprising:

a) contacting at least water, sucrose, and a glucosyltransferase enzyme comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, or SEQ ID

10 NO:17, whereby dextran according to any of embodiments 1-8 is produced; and

b) optionally, isolating the dextran produced in step (a).

15. The method of embodiment 14, wherein the viscosity of the dextran produced in the method is increased by decreasing the amount of sucrose in step (a).

15

EXAMPLES

The present disclosure is further defined in Examples 1-6 and 8-11. It should be understood that these Examples, while indicating certain preferred aspects of the disclosure, are given by way of illustration only. From the above 20 discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this disclosure, and without departing from the spirit and scope thereof, can make various changes and modifications to adapt the disclosure to various uses and conditions.

GENERAL METHODS

25 Cloning and Expression of Glucosyltransferase Enzymes in *Bacillus subtilis*

Each glucosyltransferase used in Examples 3-6 was prepared as follows.

A plasmid encoding the gtf enzyme (pZZHB582, pZZHB583, pZZHB584, or pZZHB585, which allow for gtf expression and secretion from *B. subtilis*; see FIGs. 2A-D) was amplified using Illustra TempliPhi® 100 Amplification Kit (GE

30 Healthcare Life Sciences, NJ). Competent *B. subtilis* cells (Δ spolIE, Δ aprE, Δ nprE, degUHy32, Δ scoC, Δ nprB, Δ vpr, Δ epr, Δ wprA, Δ mpr, Δ ispA, Δ bpr) were

transformed with the amplification product. Cells were plated on Luria Agar plates supplemented with 5 ppm chloramphenicol. Colonies from the transformation plate were inoculated into 5 mL LB medium and incubated at 37 °C overnight. Aliquots (25-50 µL) from each culture were then transferred to 250-5 mL shake flasks containing 30 mL of Grant's II Medium supplemented with 5 ppm chloramphenicol and incubated at 30 °C with shaking (280 rpm) for 24 hours. Cells were harvested by centrifugation at 14000 rpm for 1 hour. Supernatants were analyzed by SDS-PAGE for secreted gtf product and further dialyzed three times against a solution containing 20 mM Tris, pH 7.5 for a total of 20 hours. Dialyzed samples were aliquoted at 25 mL per 50-mL conical centrifuge tube, and the tubes were placed at an angle at -80 °C for about 1 hour. Once the samples were frozen, the tube lid was removed and replaced with PARAFILM that was pierced 5-10 times with a high-gauge needle. The PARAFILM-covered frozen samples were lyophilized in a FreeZone® Freeze Dry System (Labconco Corp., Kansas City, MO) according to the manufacturer's instruction.

Stock Solutions of Glucosyltransferase Enzymes

An enzyme stock solution was made for each gtf by adding 10 mL of molecular grade H₂O into each 50-mL conical centrifuge tube containing 20 lyophilized enzyme powder.

EXAMPLE 1

Expression of a Glucosyltransferase (0768) in *E. coli* and Production of Active Crude Enzyme Lysate

This Example describes expression of a mature glucosyltransferase (gtf) 25 enzyme in *E. coli*. Crude cell lysate of an *E. coli* expression strain was produced and showed gel product-forming activity in the presence of sucrose.

A putative YG repeat-containing hydrolase (categorized in GENBANK under GI number 339480768, but now having GI number 497964659) with 1484 amino acids was identified from *Leuconostoc pseudomesenteroides* strain 30 KCTC3652 by whole genome shotgun sequencing. This putative glucosyltransferase (designated herein as gtf 0768) belongs to the GH70 family

of glycosyl hydrolases containing a glucan-binding domain. The N-terminal 37 amino acid segment of gtf 0768 was deduced as the signal peptide of the enzyme by the SIGNALP 4.0 program (Petersen et al., *Nature Methods* 8:785-786). The mature form of gtf 0768 is represented by SEQ ID NO:1.

5 To construct a plasmid for bacterial expression of gtf 0768, a DNA sequence encoding a mature form of the gtf without the signal peptide was synthesized by GenScript USA Inc. (Piscataway, NJ). The synthesized sequence was subcloned into the NheI and HindIII sites of the pET23D+ vector (NOVAGEN®; Merck KGaA, Darmstadt, Germany). The 0768 gtf (SEQ ID NO:2) 10 encoded by this construct included a start methionine and 3 additional amino acids (Ala-Ser-Ala) at the N-terminus, and 6 histidine residues at the C-terminus, compared to the wild type mature (predicted) form of gtf 0768 (SEQ ID NO:1) (i.e., SEQ ID NO:1 is comprised in SEQ ID NO:2). The plasmid construct was 15 sequence-confirmed and transformed into *E. coli* BL21 DE3 host cells with ampicillin selection, resulting in expression strain EC0052.

Cells of EC0052 and a control strain containing only empty pET23D+ vector were grown in LB medium with 100 µg/mL ampicillin to OD₆₀₀ ~0.5, and then induced with 1 mM IPTG at 37 °C for 3 hours or alternatively induced at 23 °C overnight. Following this induction period, cells were collected by 20 centrifugation at 4000xg for 10 min and resuspended in PBS buffer pH 6.8. The cells were then lysed by passing through a French Press at 14,000 psi (~96.53 MPa) twice, afterwhich cell debris was pelleted by centrifugation at 15,000xg for 20 min. The supernatants of each crude cell lysate were aliquoted and frozen at -80 °C.

25 The activity of crude cell lysate from EC0052 cells was checked by reaction with sucrose. A control reaction was set up similarly using cell lysate prepared from cells containing the empty vector. Each sucrose reaction was set up using 10% (v/v) of cell lysate with 100 g/L sucrose, 10 mM sodium citrate pH 5, and 1 mM CaCl₂. After incubation of the reactions at 37 °C for a few hours, a 30 gel-like product, believed to be a dextran, was formed in the tube in which EC0052 cell lysate had been added. No gel-like product was formed in the

control reaction. HPLC analysis confirmed that sucrose was consumed in the reaction containing EC0052 cell lysate, and not in the control reaction. This result suggested that the EC0052 crude cell lysate expressed active gtf 0768 enzyme, and that this gtf produced a dextran product having high viscosity.

5 Thus, reactions comprising water, sucrose and an enzyme comprising SEQ ID NO:1 synthesized a gelling product, believed to be a dextran. This result demonstrated that gtf 0768 likely has glucosyltransferase activity.

EXAMPLE 2

Reaction of Sucrose with Gtf 0768 and Analysis of a Gelling Dextran Reaction

10 Product

This Example describes additional reactions comprising water, sucrose and gtf 0768, supplementing the results provided in Example 1. Also, this Example provides glycosidic linkage analysis of the gelling product synthesized by gtf 0768, showing that this product is a type of dextran.

15 Reagents for preparing gtf reactions:

- Sucrose (Sigma Prod. No. S-9378).
- Sodium phosphate buffer stock (200 mM) (pH 5.5): prepare 250 mL in water using sodium phosphate monobasic monohydrate (Sigma Prod. No. S9638) and sodium phosphate dibasic heptahydrate (Sigma Prod. No. S9390), accordingly.
- Gtf 0768 enzyme solution (cell lysate as prepared in Example 1).

Conditions of three gtf reactions:

A 1000-mL reaction was prepared containing 2.72 g of sodium phosphate buffer stock (pH 5.5), 100 g/L sucrose, and 2 mL of gtf 0768 enzyme solution.

25 The reaction was stirred at 26 °C for 20 hours, and became viscous. The gtf enzyme was deactivated by heating the reaction at 80 °C for 10 minutes. The deactivated viscous reaction was then mixed with 3 liters of 100% methanol to precipitate the viscous product. A white precipitate was formed, which was then filtered, followed by four washes with 120 ml of 100% methanol. The solid 30 product was dried at room temperature under vacuum in an oven for 72 hours.

A 725-mL reaction was prepared containing 1.97 g of sodium phosphate buffer, 300 g/L sucrose, and 1.45 mL of gtf 0768 enzyme solution. The reaction was stirred at 26 °C for 20 hours, and became viscous. The gtf enzyme was deactivated by adding methanol to the reaction mixture. The deactivated

5 reaction was then mixed with 3 liters of 100% methanol to precipitate the viscous product. A white precipitate was formed, which was then filtered, followed by four washes with 120 mL of 100% methanol. The solid product was dried at room temperature under vacuum in an oven for 72 hours.

A 200-mL reaction was prepared containing 0.544 g of sodium phosphate 10 buffer, 400 g/L sucrose, and 0.4 mL of gtf 0768 enzyme solution. The reaction was stirred at 26 °C for 20 hours, and became viscous. The gtf enzyme was deactivated by adding methanol to the reaction mixture. The deactivated reaction was then mixed with 3 liters of 100% methanol to precipitate the viscous 15 product. A white precipitate was formed, which was then filtered, followed by four washes with 120 mL of 100% methanol. The solid product was dried at room temperature under vacuum in an oven for 72 hours.

A 200-mL reaction was prepared containing 0.544 g of sodium phosphate 20 buffer, 800 g/L sucrose, and 0.4 mL of gtf 0768 enzyme solution. The reaction was stirred at 26 °C for 20 hours, and became viscous. The gtf enzyme was deactivated by adding methanol to the reaction mixture. The deactivated reaction was then mixed with 3 liters of 100% methanol to precipitate the viscous product. A white precipitate was formed, which was then filtered, followed by four washes with 120 ml of 100% methanol. The solid product was dried at room 25 temperature under vacuum in an oven for 72 hours.

25 Samples (100 µL) of each reaction were taken at 0, 2, 4, and 18 hours, respectively. The gtf enzyme was deactivated in each sample by heating at 80 °C for 10 minutes. Each sample was then diluted 10-fold with water and centrifuged at 14,000 rpm for 5 minutes, after which 200 µL of supernatant was used for HPLC analysis to measure sucrose consumption during the reaction.

30 The following HPLC conditions were applied for analyzing each sample: column (AMINEX HPX-87C carbohydrate column, 300 x 7.8 mm, Bio-Rad, No. 125-

0095), eluent (water), flow rate (0.6 mL/min), temperature (85 °C), refractive index detector. HPLC analysis of the samples indicated substantial sucrose consumption during the 0768 gtf reaction (FIG. 1, reaction comprising 100 g/L sucrose) (this sucrose consumption occurred significantly faster than the sucrose

5 consumption observed in a reaction using a dextran sucrase obtained from a commercial source – refer to Example 7).

HPLC was also used to analyze other products of the reaction comprising 100 g/L sucrose. Polymer yield was back-calculated by subtracting the amount of all other saccharides left in the reaction from the amount of the starting

10 sucrose. The back-calculated number was consistent with the viscous product dry weight analysis. Sucrose, leucrose, glucose and fructose were quantified by HPLC with an HPX-87C column (HPLC conditions as described above). DP2-7 disaccharides were quantified by HPLC with the following conditions: column (AMINEX HPX-42A carbohydrate column, 300 x 7.8 mm, Bio-Rad, No. 125-

15 0097), eluent (water), flow rate (0.6 mL/min), temperature (85 °C), refractive index detector. These HPLC analyses indicated that the glucosyl-containing saccharide products of the 0768 gtf reaction consisted of 91% polymer product, 1% glucose, 6.5% leucrose, and 1.5% DP2-7 oligosaccharides.

The glycosidic linkage profile of the gelling polymer product of the reaction

20 comprising 100 g/L sucrose was determined by ¹³C NMR. Dry polymer (25-30 mg) as prepared above was dissolved in 1 mL of deuterated DMSO containing 3 wt% LiCl with stirring at 50 °C. Using a glass pipet, 0.8 mL of the preparation was transferred into a 5-mm NMR tube. A quantitative ¹³C NMR spectrum was acquired using a Bruker Avance (Billerica, MA) 500 MHz NMR spectrometer

25 equipped with a CPDul cryoprobe, at a spectral frequency of 125.76 MHz, using a spectral window of 26041.7 Hz. An inverse-gated decoupling pulse sequence using waltz decoupling was used with an acquisition time of 0.629 second, an inter-pulse delay of 5 seconds, and 6000 pulses. The time domain data were transformed using an exponential multiplication of 2.0 Hz.

30 The NMR results indicated that the gelling polymer product comprised about 90% alpha-1,6-glucosidic linkages, about 4-5% alpha-1,3-glucosidic

linkages, and about 5-6% alpha-1,4 and -1,2 glucosidic linkages. The main chain(s) of the polymer product appeared to mostly comprise alpha-1,6-glucosidic linkages, but also a very small amount of alpha-1,3 and -1,4 glucosidic linkages. Other alpha-1,3 and -1,4 glucosidic linkages, and all of the alpha-1,2-
5 glucosidic linkages, appeared to be in branches off the main chain(s). The gelling product thus appears to be a gelling dextran.

A different protocol (not the above ^{13}C NMR procedure) is presently recommended herein for determining the linkage profile of dextran produced by gtf 0768. This protocol is disclosed below in Example 9, indicating a linkage
10 profile similar to that disclosed in this Example.

The number-average molecular weight (M_n) and weight-average molecular weight (M_w) of the gelling dextran product of the reaction comprising 100 g/L sucrose was determined by size-exclusion chromatography (SEC). Dry polymer as prepared above was dissolved in DMAc and 5% LiCl (0.5 mg/mL)
15 with shaking overnight at 100 °C. The chromatographic system used was an AllianceTM 2695 separation module from Waters Corporation (Milford, MA) coupled with three on-line detectors: a differential refractometer 2410 from Waters, a HeleosTM 8+ multiangle light scattering photometer from Wyatt Technologies (Santa Barbara, CA), and a ViscoStarTM differential capillary
20 viscometer from Wyatt. Columns used for SEC were four styrene-divinyl benzene columns from Shodex (Japan) and two linear KD-806M, KD-802 and KD-801 columns to improve resolution at the low molecular weight region of a polymer distribution. The mobile phase was DMAc with 0.11% LiCl. The chromatographic conditions used were 50 °C in the column and detector
25 compartments, 40 °C in the sample and injector compartment, a flow rate of 0.5 mL/min, and an injection volume of 100 μL . The software packages used for data reduction were EmpowerTM version 3 from Waters (calibration with broad glucan polymer standard) and Astra[®] version 6 from Wyatt (triple detection method with column calibration). It was determined from this procedure that the
30 gelling dextran product had an M_n of 2229400 and an M_w of 5365700.

A different protocol (not the above SEC procedure) is presently recommended herein for determining the molecular weight of dextran produced by gtf 0768. This protocol is disclosed below in Example 9, indicating a molecular weight more than one order of magnitude greater than the molecular weight disclosed in this Example.

Thus, reactions comprising water, sucrose and an enzyme comprising SEQ ID NO:1 synthesized a gelling dextran product, as determined by the product's predominant alpha-1,6 glucosidic linkage profile. Example 8 below discloses comparing the viscosity of this product versus the viscosities of certain 10 commercially available dextrans. Example 9 discloses further production of dextran with a gtf enzyme comprising SEQ ID NO:1, along with yield, molecular weight, and linkage analysis of the dextran.

EXAMPLE 3

Expression of a Glucosyltransferase (2919) and Use Thereof to Produce a Gelling Dextran Product

This Example describes expression of a mature *Weissella cibaria* glucosyltransferase (gtf) enzyme in *B. subtilis*. Also, this Example shows that this enzyme produces a gelling product, likely a dextran, when used in a reaction containing water and sucrose.

20 A glucosyltransferase gene, WciGtf1, was identified from *Weissella cibaria* KACC 11862. The nucleic acid sequence of this gene (positions 23315 to 27661 of GENBANK Accession No. NZ_AEKT01000035.1) is set forth in SEQ ID NO:3 and encodes the protein sequence of SEQ ID NO:4 (GENBANK Accession No. ZP_08417432). At the N-terminus of the WciGtf1 protein (SEQ ID NO:4) is a 25 signal peptide of 26 amino acids, as predicted by the SIGNALP 4.0 program (Petersen et al., *Nature Methods* 8:785-786). This indicates that WciGtf1 (SEQ ID NO:4) is a secreted protein. The mature, secreted form of the WciGtf1 protein is herein referred to as 2919 gtf, and is set forth in SEQ ID NO:5.

The nucleotide sequence encoding 2919 gtf was optimized for expression 30 in *B. subtilis*. The optimized sequence (SEQ ID NO:6) was synthesized by Generay (Shanghai, China), and inserted into plasmid p2JM103BBI (Vogtentanz

et al., *Protein Expr. Purif.* 55:40-52), resulting in plasmid pZZHB583 (FIG. 2A). Plasmid pZZHB583 contains an aprE promoter operably linked to a sequence encoding (i) an aprE signal sequence used to direct heterologous protein (2919 gtf in this case) secretion in *B. subtilis*, (ii) Ala-Gly-Lys to facilitate the secretion, 5 and (iii) 2919 gtf (SEQ ID NO:5) (i-iii are fused together in the amino-to-carboxy direction).

Plasmid pZZHB583 was transformed into *B. subtilis* cells for 2919 gtf expression and purification (see General Methods).

The activity of 2919 gtf (SEQ ID NO:5) was determined in a 250-mL 10 reaction at room temperature comprising 100 g/L sucrose, 20 mM sodium phosphate buffer (pH 5.5), and 6.25 mL of enzyme stock. The reaction was carried out at room temperature with shaking (150 rpm) for 48 hours.

Samples (100 μ L) were taken from the reaction at 0, 1, 3, 5, 24, and 48 15 hour time points, respectively. Enzyme was deactivated by heating each sample at 80 °C for 10 minutes. Samples were diluted 10-fold with water and centrifuged at 14000 rpm for 5 minutes. Supernatant (200 μ L) was used for HPLC analysis.

The concentrations of leucrose, glucose, and fructose in the gtf reaction 20 were determined using HPLC, which was performed with an Agilent 1260 chromatography system equipped with an AMINEX HPX-87C column (300 x 7.8 mm) placed in a thermostatted column compartment at 85 °C, and a refractive index detector. HPLC elution was carried out with Milli-Q® water at 0.6 mL/min. Sucrose, leucrose, glucose, and fructose were identified by comparison with corresponding standards. Their concentrations were calculated based on a peak area standard curves. Sucrose was consumed almost completely by the end of 25 the reaction. Aside from a viscous dextran product, 2919 gtf (SEQ ID NO:5) produced mostly fructose (~50%), and small amounts of leucrose (~5%) and glucose (~1%).

The concentration of oligosaccharides (DP2-DP7) in the gtf reaction was 30 determined by HPLC analysis, which was performed with an Agilent 1260 chromatography system equipped with an AMINEX HPX-42A column (300 x 7.8 mm) placed in a thermostatted column compartment at 85 °C, and a refractive

index detector. HPLC elution was carried out with Milli-Q® water at 0.6 mL/min. Formation of oligosaccharides was identified by comparison with corresponding standards. The concentration of the oligosaccharides was calculated based on standard curves from peak area. 2919 gtf (SEQ ID NO:5) produced a small amount of DP2-DP7 oligosaccharides (~3%) by the end of the reaction.

Thus, reactions comprising water, sucrose and an enzyme comprising SEQ ID NO:5 synthesized a gelling product, which is believed to be a dextran polymer. Experimental results demonstrated that gtf 2919 likely has glucosyltransferase activity.

10 EXAMPLE 4

Expression of a Glucosyltransferase (2918) and Use Thereof to Produce a Gelling Dextran Product

This Example describes expression of a mature *Lactobacillus fermentum* glucosyltransferase (gtf) enzyme in *B. subtilis*. Also, this Example shows that 15 this enzyme produces a gelling product, likely a dextran, when used in a reaction containing water and sucrose.

A glucosyltransferase gene, LfeGtf1, was identified from *Lactobacillus fermentum*. The nucleic acid sequence of this gene (positions 618 to 5009 of GENBANK Accession No. AY697433.1) is set forth in SEQ ID NO:7 and encodes 20 the protein sequence of SEQ ID NO:8 (GENBANK Accession No. AAU08008). At the N-terminus of the LfeGtf1 protein (SEQ ID NO:8) is a signal peptide of 37 amino acids, as predicted by the SIGNALP 4.0 program. This indicates that LfeGtf1 (SEQ ID NO:8) is a secreted protein. The mature, secreted form of the LfeGtf1 protein is herein referred to as 2918 gtf, and is set forth in SEQ ID NO:9.

25 The nucleotide sequence encoding 2918 gtf was optimized for expression in *B. subtilis*. The optimized sequence (SEQ ID NO:10) was synthesized by Generay (Shanghai, China), and inserted into plasmid p2JM103BBI, resulting in plasmid pZZHB582 (FIG. 2B). Plasmid pZZHB582 contains an aprE promoter operably linked to a sequence encoding (i) an aprE signal sequence used to 30 direct heterologous protein (2918 gtf in this case) secretion in *B. subtilis*, (ii) Ala-

Gly-Lys to facilitate the secretion, and (iii) 2918 gtf (SEQ ID NO:9) (i-iii are fused together in the amino-to-carboxy direction).

Plasmid pZZHB582 was transformed into *B. subtilis* cells for 2918 gtf expression and purification (see General Methods).

5 The activity of 2918 gtf (SEQ ID NO:9) was determined in a 250-mL reaction at room temperature comprising 100 g/L sucrose, 20 mM sodium phosphate buffer (pH 5.5), and 6.25 mL of enzyme stock. The reaction was carried out at room temperature with shaking (150 rpm) for 6 days.

10 Samples (100 μ L) were taken from the reaction at 0, 1, 3, 5, 24, 48 and 144 hour time points, respectively. Enzyme was deactivated by heating each sample at 80 °C for 10 minutes. Samples were diluted 10-fold with water and centrifuged at 14000 rpm for 5 minutes. Supernatant (200 μ L) was used for HPLC analysis.

15 The concentrations of sucrose, leucrose, glucose, fructose and oligosaccharides (DP2-DP7) in the gtf reaction were determined using HPLC procedures as described in Example 3. Sucrose was consumed almost completely by the end of the reaction. Aside from a viscous dextran product, 2918 gtf (SEQ ID NO:9) produced mostly fructose (~50%), and small amounts of leucrose (~5%) and glucose (~1%). 2918 gtf (SEQ ID NO:9) produced a small 20 amount of DP2-DP7 oligosaccharides (~1%).

25 Thus, reactions comprising water, sucrose and an enzyme comprising SEQ ID NO:9 synthesized a gelling product, which is believed to be a dextran polymer. Experimental results demonstrated that gtf 2920 likely has glucosyltransferase activity.

25 EXAMPLE 5

Expression of a Glucosyltransferase (2920) and Use Thereof to Produce a Gelling Dextran Product

30 This Example describes expression of a mature *Streptococcus sobrinus* glucosyltransferase (gtf) enzyme in *B. subtilis*. Also, this Example shows that this enzyme produces a gelling product, likely a dextran, when used in a reaction containing water and sucrose.

A glucosyltransferase gene, SsoGtf4, was identified from *Streptococcus sobrinus* B13N. The nucleic acid sequence of this gene (positions 198 to 4718 of GENBANK Accession No. AY966490) is set forth in SEQ ID NO:11 and encodes the protein sequence of SEQ ID NO:12 (GENBANK Accession No. AAX76986).

5 At the N-terminus of the SsoGtf4 protein (SEQ ID NO:12) is a signal peptide of 41 amino acids, as predicted by the SIGNALP 4.0 program. This indicates that SsoGtf4 (SEQ ID NO:12) is a secreted protein. The mature, secreted form of the SsoGtf4 protein is herein referred to as 2920 gtf, and is set forth in SEQ ID NO:13.

10 The nucleotide sequence encoding 2920 gtf was optimized for expression in *B. subtilis*. The optimized sequence (SEQ ID NO:14) was synthesized by Generay (Shanghai, China), and inserted into plasmid p2JM103BBI, resulting in plasmid pZZHB584 (FIG. 2C). Plasmid pZZHB584 contains an aprE promoter operably linked to a sequence encoding (i) an aprE signal sequence used to 15 direct heterologous protein (2920 gtf in this case) secretion in *B. subtilis*, (ii) Ala-Gly-Lys to facilitate the secretion, and (iii) 2920 gtf (SEQ ID NO:13) (i-iii are fused together in the amino-to-carboxy direction).

Plasmid pZZHB584 was transformed into *B. subtilis* cells for 2920 gtf expression and purification (see General Methods).

20 The activity of 2920 gtf (SEQ ID NO:13) was determined in a 250-mL reaction at room temperature comprising 100 g/L sucrose, 20 mM sodium phosphate buffer (pH 5.5), and 6.25 mL of enzyme stock. The reaction was carried out at room temperature with shaking (150 rpm) for 6 days.

25 Samples (100 μ L) were taken from the reaction at 0, 1, 3, 5, 24, 48, 72 and 144 hour time points, respectively. Enzyme was deactivated by heating each sample at 80 °C for 10 minutes. Samples were diluted 10-fold with water and centrifuged at 14000 rpm for 5 minutes. Supernatant (200 μ L) was used for HPLC analysis.

30 The concentrations of sucrose, leucrose, glucose, fructose and oligosaccharides (DP2-DP7) in the gtf reaction were determined using HPLC procedures as described in Example 3. Sucrose was consumed almost

completely by the end of the reaction. Aside from a viscous dextran product, 2920 gtf (SEQ ID NO:13) produced mostly fructose (~50%), leucrose (~20%), and a small amount of glucose (~3%). 2920 gtf (SEQ ID NO:13) produced a small amount of DP2-DP7 oligosaccharides (~1%).

5 Thus, reactions comprising water, sucrose and an enzyme comprising SEQ ID NO:13 synthesized a gelling product, which is believed to be a dextran polymer. Experimental results demonstrated that gtf 2920 likely has glucosyltransferase activity.

EXAMPLE 6

10 Expression of a Glucosyltransferase (2921) and Use Thereof to Produce a Gelling Dextran Product

This Example describes expression of a mature *Streptococcus downei* glucosyltransferase (gtf) enzyme in *B. subtilis*. Also, this Example shows that this enzyme produces a gelling product, likely a dextran, when used in a reaction 15 containing water and sucrose.

A glucosyltransferase gene, SdoGtf7, was identified from *Streptococcus downei* MFe28. The nucleic acid sequence of this gene (positions 16 to 2375 of GENBANK Accession No. AB476746) is set forth in SEQ ID NO:15 and encodes the protein sequence of SEQ ID NO:16 (GENBANK Accession No. 20 ZP_08549987.1). At the N-terminus of the SdoGtf7 protein (SEQ ID NO:16) is a signal peptide of 44 amino acids, as predicted by the SIGNALP 4.0 program. This indicates that SdoGtf7 protein (SEQ ID NO:16) is a secreted protein. The mature, secreted form of the SdoGtf7 protein is herein referred to as 2921 gtf, and is set forth in SEQ ID NO:17.

25 The nucleotide sequence encoding 2921 gtf was optimized for expression in *B. subtilis*. The optimized sequence (SEQ ID NO:18) was synthesized by Generay (Shanghai, China), and inserted into plasmid p2JM103BBI, resulting in plasmid pZZHB585 (FIG. 2D). Plasmid pZZHB585 contains an aprE promoter operably linked to a sequence encoding (i) an aprE signal sequence used to 30 direct heterologous protein (2921 gtf in this case) secretion in *B. subtilis*, (ii) Ala-

Gly-Lys to facilitate the secretion, and (iii) 2921 gtf (SEQ ID NO:17) (i-iii are fused together in the amino-to-carboxy direction).

Plasmid pZZHB585 was transformed into *B. subtilis* cells for 2921 gtf expression and purification (see General Methods).

5 The activity of 2921 gtf (SEQ ID NO:17) was determined in a 250-mL reaction at room temperature comprising 100 g/L sucrose, 20 mM sodium phosphate buffer (pH 5.5), and 6.25 mL of enzyme stock. The reaction was carried out at room temperature with shaking (150 rpm) for 8 days.

10 Samples (100 μ L) were taken from the reaction at the reaction start and on 1, 2, 3, 6, 7 and 8 day time points, respectively. Enzyme was deactivated by heating each sample at 80 °C for 10 minutes. Samples were diluted 10-fold with water and centrifuged at 14000 rpm for 5 minutes. Supernatant (200 μ L) was used for HPLC analysis.

15 The concentrations of sucrose, leucrose, glucose, fructose and oligosaccharides (DP2-DP7) in the gtf reaction were determined using HPLC procedures as described in Example 3. About 43% sucrose remained in the reaction on day 8. Aside from a viscous dextran product, 2921 gtf (SEQ ID NO:17) produced mostly fructose (~31%), leucrose (~6%), and glucose (~3%). No obvious production of DP2-DP7 oligosaccharides was observed.

20 Thus, reactions comprising water, sucrose and an enzyme comprising SEQ ID NO:17 synthesized a gelling product, which is believed to be a dextran polymer. Experimental results demonstrated that gtf 2921 likely has glucosyltransferase activity.

EXAMPLE 7 (Comparative)

25 Production of Dextran Using Commercially Available Dextran Sucrase

This Example describes synthesizing dextran using a commercially available dextran sucrase in reactions comprising water and sucrose. The dextran produced in this was analyzed in Example 8 in comparison to the gelling dextran products synthesized in Examples 1-6.

30 Reagents for preparing dextran sucrase reaction:

- Sucrose (Sigma Prod. No. S-9378). 400 g/L stock solution was prepared.

- Sodium phosphate buffer stock (200 mM) (pH 5.5): prepare 250 mL in water using sodium phosphate monobasic monohydrate (Sigma Prod. No.

5 S9638) and sodium phosphate dibasic heptahydrate (Sigma Prod. No. S9390), accordingly.

- Dextran sucrase, lyophilized powder, \geq 100 units/mg protein, from *Leuconostoc mesenteroides* (Sigma Prod. No. D9909).

A 50-mL reaction was prepared containing 20 mM sodium phosphate (pH 10 5.5), 110 g/L sucrose, and 10 units of dextran sucrase from Sigma-Aldrich. The dextran sucrase was added last when preparing the reaction. The reaction was carried out in a 125-mL capped shake flask at 26 °C with shaking (100 rpm) for 7 days. Samples (100 μ L) of the reaction were taken at 0, 3, 6, 24, 48 and 168 hours, respectively. The dextran sucrase was deactivated in each sample by 15 heating at 80 °C for 10 minutes. Each sample was then diluted 10-fold with water and centrifuged at 14,000 rpm for 5 minutes, afterwhich 200 μ L of supernatant was used for HPLC analysis to measure sucrose consumption during the reaction.

The following HPLC conditions were applied for analyzing each sample: 20 column (AMINEX HPX-87C carbohydrate column, 300 x 7.8 mm, Bio-Rad, No. 125-0095), eluent (water), flow rate (0.6 mL/min), temperature (85 °C), refractive index detector. HPLC analysis of the samples indicated sucrose consumption during the dextran sucrase reaction (FIG. 3). It is notable that the sucrose consumption rate by the commercial dextran sucrase was much slower 25 compared to the sucrose consumption rate of gtf 0768 (Example 2). Specifically, while gtf 0768 depleted most sucrose after about 17-18 hours of reaction time (FIG. 1), commercial dextran sucrase depleted only about 20% of sucrose within this same time period, and required about 168 hours to deplete all or most sucrose.

30 HPLC was also used to analyze other products of the reaction. Dextran yield was back-calculated by subtracting the amount of all other saccharides left

in the reaction from the amount of the starting sucrose. The back-calculated number was consistent with dextran dry weight analysis. Sucrose, leucrose, glucose, fructose, and DP2-7 disaccharides were quantified by HPLC as described in Example 2. These HPLC analyses indicated that the saccharide 5 products of the commercial dextran sucrase reaction consisted of 49% dextran, 0.3% sucrose, 44% fructose, 1% glucose, 5% leucrose, and 1% DP2-7 oligosaccharides.

The dextran produced in this Example was analyzed in Example 8 in comparison to the gelling dextran products synthesized in Examples 1-6.

10

EXAMPLE 8

Viscosity of Dextran Samples

This Example describes measuring the viscosities of the dextran polymers produced in Examples 1-7, as well as the viscosity of dextran obtained from a commercial source. Viscosity measurements were made at various shear rates.

15

Dextran polymer samples were prepared as described in Examples 1-7. Specifically, enzymatic reactions were conducted, afterwhich polymer was methanol-precipitated and washed with methanol (100%) four times, and then dried. Solutions (2 wt% and/or 3 wt%) of each sample were prepared by adding the appropriate amount of polymer to de-ionized (DI) water. Each preparation 20 was then mixed using a bench top vortexer until polymer was fully in solution. Each of these samples is referred to in Tables 2 and 3 (below) as "After PPT" (after precipitation). A 2 wt% solution of dextran ($M_w = 956978$) obtained from TCI America (Portland, OR; catalogue No. D0061) was similarly prepared; this dextran is referred to below as "commercial dextran".

25

To determine the viscosity of each polymer solution at various shear rates, each solution was subjected to various shear rates using a viscometer while the temperature was held constant at 20 °C. Also, polymer samples obtained directly, without precipitation, from each of the enzymatic reactions described in Examples 1-7 were subjected to various shear rates (referred to in Tables 2 and 30 3 as "Before PPT"). The shear rate was increased using a gradient program

which increased from 0-10 rpm and the shear rate was increased by 0.17 (1/s) every 30 seconds. The results of this experiment are listed in Table 2.

Table 2
Viscosity of Certain Dextran Solutions at Various Shear Rates

Dextran Sample ^a	Viscosity (cPs) @ 0.17 rpm	Viscosity (cPs) @ 1.03 rpm	Viscosity (cPs) @ 2.62 rpm	Viscosity (cPs) @ 4.22 rpm
Gtf 0768 (SEQ ID NO:1) Before PPT (Example 2, 100 g/L sucrose reaction)	47976.13	11376.70	12956.11	14390.76
Gtf 0768 (SEQ ID NO:1) After PPT – 3 wt% (Example 2, 100 g/L sucrose reaction)		15778.40	6245.31 ^b	4119.58 ^b
Gtf 0768 (SEQ ID NO:1) After PPT – 2 wt% (Example 2, 100 g/L sucrose reaction)		4091.84	3417.10	2874.10
Gtf 2918 (SEQ ID NO:9) Before PPT (Example 4)		n/a ^b	n/a ^b	n/a ^b
Gtf 2919 (SEQ ID NO:5) Before PPT (Example 3)		98864	38671	25580
Gtf 2920 (SEQ ID NO:13) Before PPT (Example 5)		3874.85	4205.66	4119.58 ^b
Gtf 2920 (SEQ ID NO:13) After PPT – 3 wt% (Example 5)		6168.76	3294.43	2288.24
Gtf 2921 (SEQ ID NO:17) Before PPT (Example 6)		3533.86	2143.72	1748.95
Gtf 2921 (SEQ ID NO:17) After PPT – 3 wt% (Example 6)		4634.32	2780.4	1984.89
Commercial dextran sucrose Before PPT (Example 7)	16759.42			

5 ^a Polymer samples are listed according to the respective enzyme used to synthesize the sample.

^b Measurement was outside the specification limits of the viscometer.

Polymer samples were also subjected to various higher shear rates using a viscometer while the temperature was held constant at 20 °C.. The shear rate

5 was increased using a gradient program which increased from 10-250 rpm and the shear rate was increased by 7.36 (1/s) every 20 seconds. The results of this experiment are listed in Table 3.

Table 3

Viscosity of Certain Dextran Solutions at Various Shear Rates

Dextran Sample ^a	Viscosity (cPs) @ 14.72 rpm	Viscosity (cPs) @ 102.9 rpm	Viscosity (cPs) @ 250 rpm
Gtf 2918 (SEQ ID NO:9) After PPT – 3 wt% (Example 4)	149.95	69.68	48.97
Gtf 2919 (SEQ ID NO:5) After PPT – 3 wt% (Example 3)	80.82	41.23	29.49
2 wt% Commercial dextran	241.41	105.28	68.88
Commercial dextran sucrase After PPT – 2 wt% (Example 7)	11.09 ^b	10.31 ^b	8.27
	Viscosity (cPs) @ 14.11 rpm	Viscosity (cPs) @ 98.69 rpm	Viscosity (cPs) @ 162.1 rpm
Gtf 0768 (SEQ ID NO:1) After PPT – 2 wt% (Example 2, 400 g/L sucrose reaction)	49.89	23.61	18.32
Gtf 0768 (SEQ ID NO:1) After PPT – 2 wt% (Example 2, 800 g/L sucrose reaction)	5.44	2.72	1.58

10 ^a Polymer samples are listed according to the respective enzyme used to synthesize the sample. Alternatively, dextran obtained from a commercial source was analyzed (“Commercial dextran”).

^b Measurement was outside the specification limits of the viscometer.

These data demonstrate that solutions of the dextran product of a glucosyltransferase comprising SEQ ID NO:1 can in most cases exhibit increased viscosity even after precipitation and resolation, as compared to the viscosities of commercially obtained dextran and the dextran product of a

5 commercially obtained dextran sucrase. This observation also appears to apply to the respective polymer products of glucosyltransferases comprising SEQ ID NO:5, 9, 13, or 17.

It is also noteworthy that, based on Tables 2-3, as the amount of sucrose in a gtf 0768 reaction is decreased from 800 g/L to 100 g/L, the viscosity of the 10 dextran product appears to increase. Specifically, Table 3 indicates (at 14.11 rpm/2 wt% loading) viscosities of 5.44 cPs and 49.89 cPs for dextran products of reactions comprising 800 and 400 g/L sucrose, respectively, and Table 2 (gtf 0768, 2 wt% loading) may indicate a viscosity of about 957 cPs (exponential extrapolated at a rotation of 14.11 rpm) for dextran product of a reaction 15 comprising 100 g/L sucrose. This result suggests that the viscosity of a dextran product can be controlled by modifying the level of sucrose initially provided to reaction.

EXAMPLE 9

Further Production and Analysis of Dextran Synthesized by Gtf 0768

20 This Example is in addition to Example 2, describing another reaction comprising water, sucrose and gtf 0768. Also, this Example provides additional linkage and molecular weight analyses of the gelling product synthesized by gtf 0768, showing that this product is a type of dextran.

Reagents for preparing gtf reaction:

25 -Sucrose (Sigma Prod. No. S-9378).
-Sodium phosphate buffer stock (1 M, pH 6.5, Teknova Cat No: S0276).
-Gtf 0768 enzyme solution (cell lysate as prepared in Example 1).

Gtf reaction conditions:

A 50-mL reaction was prepared containing 20 mM sodium phosphate 30 buffer (buffer was diluted 50-fold with ddH₂O from 1 M stock, pH 6.5), 100 g/L sucrose, and 0.1 mL of gtf 0768 enzyme solution. The reaction was shaken at

100 rpm in an incubator shaker (Innova, Model 4000) at 26 °C for 43 hours; the reaction became viscous after about 24 hours.

The gtf enzyme was deactivated by heating the reaction at 80 °C for 10 minutes. The deactivated viscous reaction was then mixed with 75 mL of 100% 5 methanol to precipitate the viscous product. A white precipitate was formed.

After carefully decanting the supernatant, the white precipitate was washed twice with 75 mL of 100% methanol. The solid product was dried at 45 °C under vacuum in an oven for 48 hours.

Samples (1 mL) of the reaction were taken at 0, 0.5, 1, 2, and 24 hours, 10 respectively. The gtf enzyme was deactivated in each sample by heating at 80 °C for 10 minutes. Each sample was then diluted 10-fold with sterile water. 500 µL of diluted sample was transferred into a centrifuge tube filter (SPIN-X, 0.45-µm Nylon, 2.0 mL Polypropylene Tube, Costar # 8170) and centrifuged at 12,000 rpm in a table centrifuge for 60 minutes, after which 200 µL of flowthrough was 15 used for HPLC analysis to measure sucrose consumption during the reaction.

The following HPLC conditions were applied for analyzing each sample: column (AMINEX HPX-87C carbohydrate column, 300 x 7.8 mm, Bio-Rad, No. 125-0095), eluent (water), flow rate (0.6 mL/min), temperature (85 °C), refractive index detector. HPLC analysis of the samples indicated substantial sucrose 20 consumption during the 0768 gtf reaction.

HPLC was also used to analyze other products of the reaction. Polymer yield was back-calculated by subtracting the amount of all other saccharides left in the reaction from the amount of the starting sucrose. The back-calculated number was consistent with the viscous product dry weight analysis. Sucrose, 25 leucrose, glucose and fructose were quantified by HPLC with an HPX-87C column (HPLC conditions as described above). DP2-7 oligosaccharides were quantified by HPLC with the following conditions: column (AMINEX HPX-42A carbohydrate column, 300 x 7.8 mm, Bio-Rad, No. 125-0097), eluent (water), flow rate (0.6 mL/min), temperature (85 °C), refractive index detector. These 30 HPLC analyses indicated that the glucosyl-containing saccharide products of the

0768 gtf reaction consisted of 92.3% polymer product, 1.3% glucose, 5.0% leucrose, and 1.4% DP2-7 oligosaccharides.

A sample of dry dextran powder product (~0.2 g) of the above reaction was used for molecular weight analysis. Molecular weight was determined by a

5 flow injection chromatographic method using an Alliance™ 2695 separation module from Waters Corporation (Milford, MA) coupled with three online detectors: a differential refractometer 2414 from Waters, a Heleos™-2 18-angle multiangle light scattering (MALS) photometer with quasielastic light scattering (QELS) detector from Wyatt Technologies (Santa Barbara, CA), and a

10 ViscoStar™ differential capillary viscometer from Wyatt. The dry dextran powder was dissolved at 0.5 mg/mL in aqueous Tris (Tris[hydroxymethyl]aminomethane) buffer (0.075 M) containing 200 ppm NaN₃. The dissolution of dextran was achieved by shaking overnight at 50 °C. Two AQUAGEL-OH GUARD columns from Agilent Technologies (Santa Clara , CA) were used to separate the dextran

15 polymer peak from the injection peak. The mobile base for this procedure was the same as the dextran solvent, the flow rate was 0.2 mL/min, the injection volume was 0.1 mL, and the column temperature was 30 °C. Empower™ version 3 software from Waters was used for data acquisition, and Astra™ version 6 software from Wyatt was used for multidetector data reduction. It was

20 determined from this work that the dextran polymer product had a weight-average molecular weight (Mw) of 1.022 (+/- 0.025) x 10⁸ g/mol (i.e., roughly 100 million Daltons) (from MALS analysis), a z-average radius of gyration of 243.33 (+/-0.42) nm (from MALS analysis), and a z-average hydrodynamic radius of 215 nm (from QELS analysis). It was also determined from QELS analysis that the

25 dextran has a standard deviation of particle size distribution (PSD) of about 0.259, indicating that the dextran likely is polydisperse in terms of hydrodynamic size.

For glycosidic linkage analysis purposes, a 50-mL gtf reaction was prepared as described above in this Example, except that the reaction time was 30 24 hours (reaction had become viscous). The gtf enzyme was deactivated by heating the reaction at 80 °C for 10 minutes. The deactivated viscous reaction

was then placed into a regenerated cellulose sturdy dialysis tubing with a molecular weight cut-off (MWCO) of 12-14 kDa (Spectra/Por® 4 Dialysis Tubing, Part No. 132706, Spectrum Laboratories, Inc.) and dialyzed against 4 L of filter water at room temperature over one week. Water was exchanged every day

5 during this dialysis. The dialyzed viscous reaction was then precipitated and dried as described above in this Example. About 0.2 g of dry powder was submitted for GC/MS linkage analysis.

Linkage analysis was performed according to methods described by Pettolino et al. (*Nature Protocols* 7:1590-1607), which is incorporated herein by reference. Briefly, a dry dextran sample was dissolved in dimethyl sulfoxide (DMSO) or 5% lithium chloride in DMSO, then all free hydroxyl groups were methylated by sequential addition of a sodium hydroxide/DMSO slurry followed by iodomethane. The methylated polymer was then extracted into methylene chloride and hydrolyzed to monomeric units using aqueous trifluoroacetic acid (TFA) at 120 °C. The TFA was then evaporated from the sample and reductive ring opening was done using sodium borodeuteride, which also labeled the reducing end with a deuterium atom. The hydroxyl groups created by hydrolyzing the glycosidic linkages were then acetylated by treating with acetyl chloride and TFA at a temperature of 50 °C. Finally, the derivatizing reagents were evaporated and the resulting methylated/acetylated monomers were reconstituted in acetonitrile and analyzed by gas chromatography with mass spectrometry (GC/MS) using a bis(cyanopropyl) cyanopropylphenyl polysiloxane column. The relative positioning of the methyl and acetyl functionalities, along with the deuterium label, yielded species that have distinctive retention time indices and mass spectra that can be compared to published databases. In this way, the derivatives of the monomeric units indicated how each monomer was originally linked in the dextran polymer and whether the monomer was a branch point. The results of analyzing these samples (dextran initially dissolved in DMSO or DMSO/5% LiCl) are provided in Table 4.

Table 4
Linkage Profile of Gtf 0768 Dextran Product

Sample	Wt%/Mol% of Glucose Monomers in Dextran				
	3-glc ^a	6-glc ^b	4-glc ^c	3,6-glc ^d	2,6- + 4,6-glc ^e
DMSO	0.4	90.2	0.4	8.3	0.7
DMSO/5% LiCl	0.9	89.3	0.4	8.0	1.4

^a Glucose monomer linked at carbon positions 1 and 3.

^b Glucose monomer linked at carbon positions 1 and 6.

^c Glucose monomer linked at carbon positions 1 and 4.

^d Glucose monomer linked at carbon positions 1, 3 and 6.

^e Glucose monomer linked at carbon positions 1, 2 and 6, or 1, 4 and 6.

In general, the results in Table 4 indicate that the dextran product

10 analyzed above comprises:

- (i) about 87-93 wt% glucose linked only at positions 1 and 6;
- (ii) about 0.1-1.2 wt% glucose linked only at positions 1 and 3;
- (iii) about 0.1-0.7 wt% glucose linked only at positions 1 and 4;
- (iv) about 7.7-8.6 wt% glucose linked only at positions 1, 3 and 6; and
- 15 (v) about 0.4-1.7 wt% glucose linked only at (a) positions 1, 2 and 6, or (b) positions 1, 4 and 6.

Based on this information and some other studies (data not shown), it is contemplated that this product is a branched structure in which there are long chains (containing mostly or all alpha-1,6-linkages) of about 20 DP in length

20 (average) that iteratively branch from each other (e.g., a long chain can be a branch from another long chain, which in turn can itself be a branch from another long chain, and so on). The branched structure also appears to comprise short branches from the long chains; these short chains are believed to be 1-3 DP in length and mostly comprise alpha-1,3 and -1,4 linkages, for example. Branch 25 points in the dextran, whether from a long chain branching from another long chain, or a short chain branching from a long chain, appear to comprise alpha-1,3, -1,4, or -1,2 linkages off of a glucose involved in alpha-1,6 linkage. Roughly 25% of all the branch points of the dextran branched into a long chain.

Thus, reactions comprising water, sucrose and an enzyme comprising SEQ ID NO:1 synthesized a very large gelling dextran product, as determined by the product's high Mw and predominant alpha-1,6 glucosidic linkage profile.

EXAMPLE 10

5 Formulation Comprising Dextran Synthesized by Gtf 0768

This Example discloses a formulation comprising the dextran product of gtf 0768. This formulation was shown to have better sensory characteristics (or "feel") compared to formulations comprising certain compounds (xanthan gum, Carbopol[®]) commonly used for providing viscosity to certain consumer products
10 (e.g., personal care compositions such as lotion).

Three different emulsions were prepared and compared against each other in a skinfeel study, as follows.

Dextran-Based Emulsion: Dextran was produced using gtf 0768 (comprising SEQ ID NO:1) in a reaction similar to the reaction disclosed in
15 Example 9. At room temperature, polysorbate 80, sorbitan monooleate and mineral oil (Phase B, Table 5) were combined in a small vessel, and mixed by hand until homogeneous. Phase B was slowly added to water (Phase A, Table 5) under moderate propeller mixing. The mixture was homogenized at 5000-9000 rpm for approximately 5-10 minutes. Dextran (Phase C, Table 5) was then
20 added under moderate propeller mixing. Germaben[®] II (Phase D, Table 5) was then added as a preservative under moderate propeller mixing. The dextran could optionally have been pre-hydrated using a portion of the water from phase A.

Table 5
Dextran-Based Emulsion

Ingredients	% Activity	wt % (Desired)	wt % (Neat)	Grams
Phase A				
Water (deionized)			73.50	73.50
Phase B				
Polysorbate 80	100.00	2.43	2.43	2.43
Sorbitan Monooleate	100.00	2.57	2.57	2.57
Mineral Oil	100.00	20.00	20.00	20.00
Phase C				
Dextran	100.00	1.00	1.00	1.00
Phase D				
Germaben® II	100.00	0.50	0.50	0.50
			100.00	100.00

5 **Xanthan Gum-Based Emulsion (Control 1):** At room temperature, xanthan gum and water (Phase A, Table 6) were combined under moderate propeller mixing until homogeneous. Polysorbate 80, sorbitan monooleate and mineral oil (Phase B, Table 6) were combined in a small vessel, and mixed by hand until homogeneous. Phase B was slowly added to Phase A under
 10 moderate propeller mixing. The mixture was homogenized at 5000-9000 rpm for approximately 5-10 minutes. Germaben® II (Phase C, Table 6) was then added as a preservative under moderate propeller mixing.

Table 6
Xanthan Gum-Based Emulsion

Ingredients	% Activity	wt % (Desired)	wt % (Neat)	Grams
Phase A				
Water (deionized)			74.00	74.00
Xanthan Gum	100.00	0.50	0.50	0.50
Phase B				
Polysorbate 80	100.00	2.43	2.43	2.43
Sorbitan Monooleate	100.00	2.57	2.57	2.57
Mineral Oil	100.00	20.00	20.00	20.00
Phase C				
Germaben® II	100.00	0.50	0.50	0.50
			100.00	100.00

5 **Carbopol® Ultrez 10-Based Emulsion (Control 2):** At room temperature, Carbopol® Ultrez 10 and water (Phase A, Table 7) were combined under moderate propeller mixing until homogeneous. Polysorbate 80, sorbitan monooleate and mineral oil (Phase B, Table 7) were combined in a small vessel, and mixed by hand until homogeneous. Phase B was slowly added to Phase A
10 under moderate propeller mixing. The mixture was homogenized at 5000-9000 rpm for approximately 5-10 minutes. Germaben® II (Phase C, Table 7) was then added as a preservative under moderate propeller mixing. A 20-wt% solution of sodium hydroxide was used to neutralize the emulsion to pH 5.5.

Table 7
Carbopol® Ultrez 10-Based Emulsion

Ingredients	% Activity	wt % (Desired)	wt % (Neat)	Grams
Phase A				
Water (deionized)			74.00	74.00
Carbopol® Ultrez 10	100.00	0.50	0.50	0.50
Phase B				
Polysorbate 80	100.00	2.43	2.43	2.43
Sorbitan Monooleate	100.00	2.57	2.57	2.57
Mineral Oil	100.00	20.00	20.00	20.00
Phase C				
Germaben® II	100.00	0.50	0.50	0.50
			100.00	100.00

5 **Skinfeel Analysis and Results:** A double-blind, skinfeel analysis was performed according to ASTM E1490-3 ("Standard Practice for Descriptive Skinfeel Analysis of Creams and Lotions", ASTM International, West Conshohocken, PA, 2003, DOI: 10.1520/E1490-03, incorporated herein by reference) to compare each of the above emulsions. The primary attributes 10 evaluated in this study were rub-out sliminess, afterfeel stickiness, pick-up stringiness and pick-up stickiness. Panelists assessed attributes on a scale from 1-5, where 1 exhibits the least of the attribute and 5 exhibits the most of the attribute. The results are reported in Table 8 below as an average value of the panelists' ratings for each attribute. The sum average of these values (Σ , Table 15 8) indicates that the overall sensory experience for emulsions (e.g., lotions) produced with dextran as presently disclosed exceeds the results of similar emulsions produced with either xanthan gum or Carbopol® Ultrez 10.

Table 8
Carbopol® Ultrez 10-Based Emulsion

Skinfeel Attribute	Average Rating		
	Dextran	Xanthan Gum	Carbopol® Ultrez 10
Rub-Out Sliminess	2	3	2
Afterfeel Stickiness	2	2	3
Pick-Up Stringiness	1	3	3
Pick-Up Stickiness	2	3	2
Σ	7	11	10

It is noteworthy that the dextran-containing emulsion scored better than

5 the control emulsions in the skinfeel analysis, especially since there was two-times the amount of dextran (1 wt%) in the emulsion compared to the amount of xanthan gum (0.5 wt%) or Carbopol® Ultrez 10 (0.5 wt%) in the control emulsions.

Thus, dextran produced by gtf 0768 (comprising SEQ ID NO:1) can be
10 suitable for use in compositions where enhanced sensory characteristics are desirable, such as in personal care and food products, for example.

EXAMPLE 11

Dextran-Comprising Cleanser with Suspended Particles

This Example discloses a cleanser comprising the dextran product of gtf
15 0768. Jojoba ester beads could be suspended in this composition, indicating that the dextran can function as a dispersant.

Dextran was produced using gtf 0768 (comprising SEQ ID NO:1) in a reaction similar to the reaction disclosed in Example 9. At room temperature water, dextran, glycerin, polysorbate 20, cocamidopropyl betaine, PPG-2
20 hydroxyethyl cocamide and disodium EDTA were combined according to the formulation in Table 9, and mixed by hand until homogeneous. Jojoba beads were then added and mixing was continued until the beads were homogeneously dispersed. The dextran could optionally have been pre-hydrated using a portion of the water component.

Table 9
Dextran-Based Jojoba Bead Suspension

Ingredient	% Activity	wt% (Desired)	wt% (Neat)	Grams
Water (deionized)			22.95	22.95
Dextran	100	5	5	5
Glycerin	100	10	10	10
Polysorbate 20	100	5.25	5.25	5.25
Cocamidopropyl Betaine	35.97	20	55.6	55.6
PPG-2 Hydroxyethyl Cocamide	100	1	1	1
Disodium EDTA	100	0.1	0.1	0.1
Jojoba Ester Beads	100	0.1	0.1	0.1
			100	100

Thus, dextran produced by gtf 0768 (comprising SEQ ID NO:1) can be
5 used as a dispersant in aqueous compositions such as certain personal care
products.

The claims defining the invention are as follows:

1. A composition comprising dextran, wherein said dextran comprises:
 - (i) about 87-93 wt% glucose linked at positions 1 and 6;
 - (ii) about 0.1-1.2 wt% glucose linked at positions 1 and 3;
 - (iii) about 0.1-0.7 wt% glucose linked at positions 1 and 4;
 - (iv) about 7.7-8.6 wt% glucose linked at positions 1, 3 and 6; and
 - (v) about 0.4-1.7 wt% glucose linked at:
 - (a) positions 1, 2 and 6, or
 - (b) positions 1, 4 and 6;

wherein the weight-average molecular weight (Mw) of said dextran is about 50-200 million Daltons, and the z-average radius of gyration of said dextran is about 200-280 nm.

- 5 2. The composition of claim 1, wherein the dextran comprises:
 - (i) about 89.5-90.5 wt% glucose linked at positions 1 and 6;
 - (ii) about 0.4-0.9 wt% glucose linked at positions 1 and 3;
 - (iii) about 0.3-0.5 wt% glucose linked at positions 1 and 4;
 - (iv) about 8.0-8.3 wt% glucose linked at positions 1, 3 and 6; and
 - (v) about 0.7-1.4 wt% glucose linked at:
 - (a) positions 1, 2 and 6, or
 - (b) positions 1, 4 and 6.
3. The composition of claim 1 or claim 2, wherein the dextran comprises chains linked together within a branching structure, wherein said chains are similar in length and comprise substantially alpha-1,6-glucosidic linkages.
4. The composition of claim 3, wherein the average length of the chains is about 10-50 monomeric units.

5. The composition of any one of claims 1 to 4, wherein the dextran is a product of a glucosyltransferase enzyme comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:1 or SEQ ID NO:2.
- 5 6. The composition of any one of claims 1 to 5, wherein the composition is an aqueous composition.
7. The composition of any one of claims 1 to 6, wherein the Mw of the dextran is about 80-120 million Daltons.
8. The composition of any one of claims 1 to 7, wherein the z-average radius of gyration of said dextran is about 230-250 nm.
9. The composition of any one of claims 1 to 8, wherein the composition is in the form of a food product, personal care product, pharmaceutical product, household product, or industrial product.
10. The composition of claim 9, wherein the composition is in the form of a confectionery.
11. An isolated enzymatic reaction comprising water, sucrose and a glucosyltransferase enzyme comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:1 or SEQ ID NO:2, wherein the glucosyltransferase enzyme synthesizes dextran.
12. The isolated enzymatic reaction of claim 11, wherein the reaction is (i) cell-free and/or (ii) comprises only one glucosyltransferase.
13. The isolated enzymatic reaction of claim 11 or claim 12, wherein the glucosyltransferase enzyme comprises an amino acid sequence that is at least 95% identical to SEQ ID NO:1 or SEQ ID NO:2

14. A method for producing dextran, said method comprising:
contacting at least water, sucrose, and a glucosyltransferase enzyme in an isolated reaction, wherein the glucosyltransferase enzyme comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:1 or SEQ ID NO:2, whereby dextran is produced.

15. The method of claim 14 further comprising the step of isolating the dextran produced.

16. The method of claim 14 or claim 15, wherein the reaction is (i) cell-free and/or (ii) comprises only one glucosyltransferase.

17. The method of any one of claims 14 to 16, wherein the glucosyltransferase enzyme comprises an amino acid sequence that is at least 95% identical to SEQ ID NO:1 or SEQ ID NO:2.

18. The method of any one of claims 14 to 17, wherein the viscosity of the dextran produced in the method is increased by decreasing the amount of sucrose.

19. Dextran as produced in the isolated enzymatic reaction of any one of claims 11 to 13, or as produced by the method of any one of claims 14 to 18.

20. A method for increasing the viscosity of an aqueous composition, the method comprising:
contacting dextran according to any one of claims 1 to 5, 7, 8, or 19 with the aqueous composition, wherein the viscosity of the aqueous composition is increased by said dextran compared to the viscosity of the aqueous composition before the contacting step.

21. A method of treating a material, said method comprising:
contacting a material with an aqueous composition comprising dextran according to any one of claims 1 to 5, 7, 8, or 19.






FIG. 1

**FIG. 2A****FIG. 2B**




FIG. 2C




FIG. 2D




FIG. 3

20151105_CL6294WO_PCT_SequenceListing
SEQUENCE LISTING

<110> E. I. du Pont de Nemours and Company
Nambiar, Rakesh
<120> ENZYMATICALLY POLYMERIZED GELLING DEXTRANS
<130> CL6294
<150> US 62/075,460
<151> 2014-11-05
<160> 18
<170> PatentIn version 3.5
<210> 1
<211> 1447
<212> PRT
<213> Leuconostoc pseudomesenteroides

<220>
<221> MISC_FEATURE
<222> (1)..(1447)
<223> mature 0768 gtf

<400> 1

Asp Gln Asn Val Asn Asp Pro Ser Val Ala Thr Thr Thr Gln Asn Val
1 5 10 15
Val Thr Asp Gln Asp Thr Ser Ile Asp Ala Ser Val Ala Thr Thr Val
20 25 30
Asn Pro Asn Leu Asp Asp Thr Gln Ala Asp Asn Thr Asn Ile Gln Thr
35 40 45
Pro Thr Asp Gln Asn Asp Glu Ser Lys Asp Thr Thr Pro Lys Val Glu
50 55 60
Thr Gly Asp Thr Thr Asn Ser Gln Ser Thr Glu Ala Gln Glu Thr Thr
65 70 75 80
Ala Gln Thr Asn Asn Asp Val Glu Thr Pro Gln Asn Ser Asp Ala Ala
85 90 95
Ile Glu Thr Gly Leu Leu Thr Thr Asn Asn Gln Ile Arg Tyr Val Asn
100 105 110
Pro Asp Gly Thr Val Leu Thr Gly Ala Tyr Lys Thr Ile Asn Gly Asn
115 120 125
Thr Tyr Tyr Phe Asp Asp Asp Ser Gly Val Ala Leu Val Gly Leu His
130 135 140
Lys Ile Gly Asp Thr Leu Lys Gly Phe Ser Leu Asn Gly Val Gln Val
145 150 155 160
Lys Gly Asp Tyr Leu Thr Ala Ala Asn Gly Asp Lys Tyr Tyr Phe Asp
165 170 175
Ser Asn Gly Asn Ala Val Ser Gly Val Gln Gln Ile Asn Gly Lys Thr
180 185 190
Tyr Tyr Phe Asp Ser Thr Gly Lys Leu Met Lys Gly Tyr Thr Ala Val
195 200 205
Leu Asn Gly Val Val Thr Phe Phe Asn Ser Thr Thr Gly Glu Ala Asp
210 215 220
Asn Thr Asp Ala Ser Thr Ile Lys Thr Gly Val Thr Ile Asp Asn Ser
225 230 235 240
Asp Tyr Thr Val His Asn Ala Ala Tyr Asp Asn Thr Ala Ala Ser Phe
245 250 255
Asp Asn Ile Asn Gly Tyr Leu Thr Ala Glu Ser Trp Tyr Arg Pro Lys
260 265 270
Glu Ile Leu Glu Asn Gly Glu Ser Trp Arg Pro Ser Thr Ala Glu Asp
275 280 285
Lys Arg Pro Ile Leu Ile Thr Trp Gln Pro Asp Ile Val Thr Glu Val
290 295 300
Asn Tyr Leu Asn Met Met Ala Ala Asn Gly Leu Leu Ser Ile Asn Ala

20151105_CL6294WOPCT_SequenceListing

305 Pro Phe Thr Thr Ala Ser Asp Leu Ala Ile Met Asn Asp Ala Val Arg
 310 325 330 335
 Ala Val Gln Lys Asn Ile Glu Met Arg Ile Ser Gln Glu Lys Ser Thr
 340 345 350
 Asp Trp Leu Lys Ala Leu Met Thr Gln Phe Ile Asn Thr Gln Pro Gln
 355 360 365
 Trp Asn Glu Val Ser Glu Ser Pro Ser Asn Asp His Leu Gln Gly Gly
 370 375 380
 Ala Leu Thr Tyr Val Asn Ser Pro Leu Thr Pro Asp Ala Asn Ser Asn
 385 390 395 400
 Phe Arg Leu Leu Asn Arg Thr Pro Thr Asn Gln Ser Gly Thr Thr Arg
 405 410 415
 Tyr Asp Thr Asp Lys Ser Lys Gly Gly Phe Glu Leu Leu Leu Ala Asn
 420 425 430
 Asp Val Asp Asn Ser Asn Pro Val Val Gln Ala Glu Gln Leu Asn Trp
 435 440 445
 Leu Tyr Tyr Leu Met Asn Phe Gly Ser Ile Thr Ala Asn Asp Pro Thr
 450 455 460
 Ala Asn Phe Asp Gly Ile Arg Val Asp Ala Val Asp Asn Val Asp Ala
 465 470 475 480
 Asp Leu Leu Gln Ile Ala Ser Asp Tyr Phe Lys Leu Ala Tyr Gly Thr
 485 490 495
 Ser Leu Ser Asp Thr Asn Ala Asn Gln His Leu Ser Ile Leu Glu Asp
 500 505 510
 Trp Ser Ala Asn Asp Ala Glu Tyr Met Ser Lys Thr Gly Ser Asn Gln
 515 520 525
 Leu Thr Met Asp Thr Tyr Thr Gln Gln Gln Leu Leu Phe Ser Leu Thr
 530 535 540
 Lys Gln Val Gly Asn Arg Ala Asp Met Arg Arg Phe Leu Glu Tyr Phe
 545 550 555 560
 Met Ile Asn Arg Ala Asn Asp Ser Thr Glu Asn Val Ala Thr Pro Asn
 565 570 575
 Tyr Ser Phe Val Arg Ala His Asp Ser Glu Val Gln Thr Val Ile Ala
 580 585 590
 Thr Ile Ile Lys Asp Leu His Pro Asp Val Val Asn Ser Leu Ala Pro
 595 600 605
 Thr Gln Ala Gln Leu Glu Glu Ala Phe Ala Val Tyr Asn Ala Asp Met
 610 615 620
 Asn Arg Val Asp Lys Gln Tyr Thr Gln Tyr Asn Met Pro Ser Ala Tyr
 625 630 635 640
 Ala Met Leu Leu Thr Asn Lys Asp Thr Ile Pro Arg Val Tyr Tyr Gly
 645 650 655
 Asp Leu Tyr Thr Asp Asp Gly Glu Tyr Met Gly Thr Gln Thr Pro Tyr
 660 665 670
 Tyr Asp Ala Ile Val Asn Leu Leu Gln Ser Arg Val Lys Tyr Val Ala
 675 680 685
 Gly Gly Gln Ser Met Ala Val Asp Gln His Asp Ile Leu Thr Ser Val
 690 695 700
 Arg Tyr Gly Lys Asn Leu Ala Asp Ala Asn Ala Thr Ser Asp Asp Leu
 705 710 715 720
 Thr Ser Ile Asn Ser Gly Ile Gly Val Ile Val Ser Asn Asn Pro Asn
 725 730 735
 Leu Ser Leu Ala Ser Gly Glu Thr Val Val Leu His Met Gly Ile Ala
 740 745 750
 His Ala Asn Gln Val Tyr Arg Glu Ile Leu Glu Thr Thr Asp Asn Gly
 755 760 765
 Ile Ala Asn Asn Thr Asp Ile Phe Lys Thr Thr Asp Ser Asn Gly Asp
 770 775 780
 Leu Ile Phe Thr Ala Ser Glu Ile His Gly Tyr Ser Asn Val Gln Val
 785 790 795 800
 Ser Gly Phe Leu Ser Val Trp Ala Pro Lys Asp Ala Thr Asp Asp Gln
 805 810 815
 Asp Val Arg Thr Ala Ala Ser Glu Ser Thr Ser Asn Asp Gly Asn Thr
 820 825 830
 Leu His Ser Asn Ala Ala Leu Asp Ser Asn Leu Ile Tyr Glu Gly Phe
 835 840 845
 Ser Asn Phe Gln Ser Thr Pro Gln Ser Glu Ser Glu Phe Ala Asn Val

20151105_CL6294WOPCT_SequenceListing

850		855		860											
Lys	Ile	Ala	Ala	Asn	Val	Asn	Leu	Phe	Lys	Ser	Trp	Gly	Val	Thr	Ser
865					870				875						880
Phe	Gln	Met	Ala	Pro	Gln	Tyr	Arg	Ser	Ser	Thr	Asp	Thr	Ser	Phe	Leu
					885				890						895
Asp	Ser	Ile	Ile	Gln	Asn	Gly	Tyr	Ala	Phe	Thr	Asp	Arg	Tyr	Asp	Leu
					900				905						910
Gly	Phe	Glu	Thr	Pro	Thr	Lys	Tyr	Gly	Thr	Asp	Gln	Gln	Leu	Arg	Asp
					915				920						925
Ala	Ile	Lys	Ala	Leu	His	Ala	Asn	Gly	Ile	Gln	Ala	Met	Ala	Asp	Phe
					930				935						940
Val	Pro	Asp	Gln	Ile	Tyr	Asn	Leu	Pro	Gln	Thr	Glu	Leu	Val	Ser	Val
					945				950						960
Ser	Arg	Thr	Asp	Ser	Leu	Gly	Asn	Gln	Ser	Ala	Asn	Ser	Asn	Ala	Ala
					965				970						975
Asn	Val	Leu	Tyr	Val	Ser	His	Thr	Val	Gly	Gly	Gly	Glu	Tyr	Gln	Ser
					980				985						990
Lys	Tyr	Gly	Gly	Glu	Phe	Leu	Ala	Ile	Ile	Lys	Ser	Lys	Tyr	Pro	Ser
					995				1000						1005
Leu	Phe	Lys	Thr	Ile	Gln	Val	Ser	Thr	Gly	Leu	Pro	Ile	Asp	Asp	
					1010				1015						1020
Ser	Thr	Lys	Ile	Lys	Glu	Trp	Ser	Ala	Lys	Tyr	Phe	Asn	Gly	Ser	
					1025				1030						1035
Asn	Ile	Gln	Gly	Arg	Gly	Phe	Gly	Tyr	Val	Leu	Ser	Asp	Gly	Gly	
					1040				1045						1050
Thr	Gln	Asn	Tyr	Phe	Lys	Val	Ile	Ser	Asn	Ser	Thr	Asp	Asp	Asp	
					1055				1060						1065
Phe	Leu	Pro	Asn	Gln	Leu	Thr	Gly	Lys	Pro	Thr	Met	Thr	Gly	Phe	
					1070				1075						1080
Glu	Gln	Thr	Ser	Lys	Gly	Ile	Val	Tyr	Tyr	Ser	Lys	Ser	Gly	Ile	
					1085				1090						1095
Gln	Ala	Lys	Asn	Gln	Phe	Val	Lys	Asp	Asp	Val	Ser	Gly	Asn	Tyr	
					1100				1105						1110
Tyr	Tyr	Phe	Asn	Lys	Asn	Gly	Leu	Met	Thr	Val	Gly	Ser	Lys	Thr	
					1115				1120						1125
Ile	Asn	Gly	Lys	Asn	Tyr	Met	Phe	Leu	Pro	Asn	Gly	Val	Glu	Leu	
					1130				1135						1140
Arg	Gly	Ser	Phe	Leu	Gln	Thr	Ala	Asp	Gly	Thr	Val	Asn	Tyr	Tyr	
					1145				1150						1155
Ala	Thr	Asn	Gly	Ala	Gln	Val	Gln	Asp	Ser	Tyr	Val	Thr	Asp	Thr	
					1160				1165						1170
Glu	Gly	Asn	Ser	Tyr	Tyr	Phe	Asp	Gly	Asp	Gly	Glu	Met	Val	Thr	
					1175				1180						1185
Gly	Thr	Tyr	Thr	Val	Asp	Gly	His	Ala	Gln	Tyr	Phe	Asp	Val	Asn	
					1190				1195						1200
Gly	Val	Gln	Thr	Lys	Gly	Ala	Ile	Ile	Thr	Leu	Gly	Gly	Val	Gln	
					1205				1210						1215
Arg	Tyr	Tyr	Gln	Ala	Gly	Asn	Gly	Asn	Leu	Ala	Thr	Asn	Gln	Tyr	
					1220				1225						1230
Val	Ser	Tyr	Asn	Asn	Ser	Trp	Tyr	Tyr	Ala	Asn	Thr	Lys	Gly	Glu	
					1235				1240						1245
Leu	Val	Thr	Gly	Val	Gln	Ser	Ile	Asn	Gly	Asn	Val	Gln	Tyr	Phe	
					1250				1255						1260
Ala	Ser	Asn	Gly	Gln	Gln	Ile	Lys	Gly	Gln	Ile	Val	Val	Thr	Gly	
					1265				1270						1275
Asn	Gln	Lys	Ser	Tyr	Tyr	Asp	Ala	Asn	Thr	Gly	Asn	Leu	Ile	Lys	
					1280				1285						1290
Asn	Asp	Phe	Leu	Thr	Pro	Asp	Gln	Gly	Lys	Thr	Trp	Tyr	Tyr	Ala	
					1295				1300						1305
Asp	Gln	Asp	Gly	Asn	Leu	Val	Val	Gly	Ala	Gln	Glu	Val	Asn	Gly	
					1310				1315						1320
His	Lys	Leu	Tyr	Phe	Asp	Asp	Asn	Gly	Ile	Gln	Ile	Lys	Asp	Gln	
					1325				1330						1335
Ile	Ile	Ser	Asn	Asp	Gly	Gln	Gln	Tyr	Tyr	Tyr	Gln	Gly	Gly	Asn	
					1340				1345						1350
Gly	Asp	Leu	Val	Thr	Asn	Arg	Tyr	Ile	Ser	Tyr	Asn	Asp	Ser	Trp	
					1355				1360						1365
Tyr	Tyr	Ala	Asp	Ala	Thr	Gly	Val	Leu	Val	Thr	Gly	Gln	Gln	Ile	

20151105_CL6294WOPCT_SequenceListing

1370	Ile	Asn	Gly	Glu	Thr	Gln	Tyr	Phe	Arg	Thr	Asp	Gly	Arg	Gln	Val
1385							1375					1380			
1390								1390				1395			
1400	Lys	Gly	Gln	Ile	Ile	Ala	Asp	Gly	Asp	Lys	Gln	His	Tyr	Tyr	Asp
1405								1405				1410			
1410												1410			
1415	Ala	Asp	Ser	Gly	Asn	Leu	Val	Lys	Asn	Asn	Phe	Val	Thr	Val	Asp
1420								1420				1425			
1425												1425			
1430	Gln	Gly	Lys	Thr	Trp	Tyr	Tyr	Ala	Asp	Gln	Asp	Gly	Asn	Leu	Ser
1435							1435					1440			
1445	Leu	Val													

<210> 2
<211> 1457

<212> PRT
<213> Artificial sequence

<220>
<223> 0768 gtf mature protein with start codon and other added sequences

<400> 2
Met Ala Ser Ala Asp Gln Asn Val Asn Asp Pro Ser Val Ala Thr Thr
1 5 10 15
Thr Gln Asn Val Val Thr Asp Gln Asp Thr Ser Ile Asp Ala Ser Val
20 25 30
Ala Thr Thr Val Asn Pro Asn Leu Asp Asp Thr Gln Ala Asp Asn Thr
35 40 45
Asn Ile Gln Thr Pro Thr Asp Gln Asn Asp Glu Ser Lys Asp Thr Thr
50 55 60
Pro Lys Val Glu Thr Gly Asp Thr Thr Asn Ser Gln Ser Thr Glu Ala
65 70 75 80
Gln Glu Thr Thr Ala Gln Thr Asn Asn Asp Val Glu Thr Pro Gln Asn
85 90 95
Ser Asp Ala Ala Ile Glu Thr Gly Leu Leu Thr Thr Asn Asn Gln Ile
100 105 110
Arg Tyr Val Asn Pro Asp Gly Thr Val Leu Thr Gly Ala Tyr Lys Thr
115 120 125
Ile Asn Gly Asn Thr Tyr Tyr Phe Asp Asp Asp Ser Gly Val Ala Leu
130 135 140
Val Gly Leu His Lys Ile Gly Asp Thr Leu Lys Gly Phe Ser Leu Asn
145 150 155 160
Gly Val Gln Val Lys Gly Asp Tyr Leu Thr Ala Ala Asn Gly Asp Lys
165 170 175
Tyr Tyr Phe Asp Ser Asn Gly Asn Ala Val Ser Gly Val Gln Gln Ile
180 185 190
Asn Gly Lys Thr Tyr Tyr Phe Asp Ser Thr Gly Lys Leu Met Lys Gly
195 200 205
Tyr Thr Ala Val Leu Asn Gly Val Val Thr Phe Phe Asn Ser Thr Thr
210 215 220
Gly Glu Ala Asp Asn Thr Asp Ala Ser Thr Ile Lys Thr Gly Val Thr
225 230 235 240
Ile Asp Asn Ser Asp Tyr Thr Val His Asn Ala Ala Tyr Asp Asn Thr
245 250 255
Ala Ala Ser Phe Asp Asn Ile Asn Gly Tyr Leu Thr Ala Glu Ser Trp
260 265 270
Tyr Arg Pro Lys Glu Ile Leu Glu Asn Gly Glu Ser Trp Arg Pro Ser
275 280 285
Thr Ala Glu Asp Lys Arg Pro Ile Leu Ile Thr Trp Gln Pro Asp Ile
290 295 300
Val Thr Glu Val Asn Tyr Leu Asn Met Met Ala Ala Asn Gly Leu Leu
305 310 315 320
Ser Ile Asn Ala Pro Phe Thr Thr Ala Ser Asp Leu Ala Ile Met Asn
325 330 335
Asp Ala Val Arg Ala Val Gln Lys Asn Ile Glu Met Arg Ile Ser Gln
340 345 350
Glu Lys Ser Thr Asp Trp Leu Lys Ala Leu Met Thr Gln Phe Ile Asn
355 360 365

20151105_CL6294WOPCT_SequenceListing

Thr Gln Pro Gln Trp Asn Glu Val Ser Glu Ser Pro Ser Asn Asp His
 370 375 380
 Leu Gln Gly Gly Ala Leu Thr Tyr Val Asn Ser Pro Leu Thr Pro Asp
 385 390 395 400
 Ala Asn Ser Asn Phe Arg Leu Leu Asn Arg Thr Pro Thr Asn Gln Ser
 405 410 415
 Gly Thr Thr Arg Tyr Asp Thr Asp Lys Ser Lys Gly Gly Phe Glu Leu
 420 425 430
 Leu Leu Ala Asn Asp Val Asp Asn Ser Asn Pro Val Val Gln Ala Glu
 435 440 445
 Gln Leu Asn Trp Leu Tyr Tyr Leu Met Asn Phe Gly Ser Ile Thr Ala
 450 455 460
 Asn Asp Pro Thr Ala Asn Phe Asp Gly Ile Arg Val Asp Ala Val Asp
 465 470 475 480
 Asn Val Asp Ala Asp Leu Leu Gln Ile Ala Ser Asp Tyr Phe Lys Leu
 485 490 495
 Ala Tyr Gly Thr Ser Leu Ser Asp Thr Asn Ala Asn Gln His Leu Ser
 500 505 510
 Ile Leu Glu Asp Trp Ser Ala Asn Asp Ala Glu Tyr Met Ser Lys Thr
 515 520 525
 Gly Ser Asn Gln Leu Thr Met Asp Thr Tyr Thr Gln Gln Gln Leu Leu
 530 535 540
 Phe Ser Leu Thr Lys Gln Val Gly Asn Arg Ala Asp Met Arg Arg Phe
 545 550 555 560
 Leu Glu Tyr Phe Met Ile Asn Arg Ala Asn Asp Ser Thr Glu Asn Val
 565 570 575
 Ala Thr Pro Asn Tyr Ser Phe Val Arg Ala His Asp Ser Glu Val Gln
 580 585 590
 Thr Val Ile Ala Thr Ile Ile Lys Asp Leu His Pro Asp Val Val Asn
 595 600 605
 Ser Leu Ala Pro Thr Gln Ala Gln Leu Glu Glu Ala Phe Ala Val Tyr
 610 615 620
 Asn Ala Asp Met Asn Arg Val Asp Lys Gln Tyr Thr Gln Tyr Asn Met
 625 630 635 640
 Pro Ser Ala Tyr Ala Met Leu Leu Thr Asn Lys Asp Thr Ile Pro Arg
 645 650 655
 Val Tyr Tyr Gly Asp Leu Tyr Thr Asp Asp Gly Glu Tyr Met Gly Thr
 660 665 670
 Gln Thr Pro Tyr Tyr Asp Ala Ile Val Asn Leu Leu Gln Ser Arg Val
 675 680 685
 Lys Tyr Val Ala Gly Gly Gln Ser Met Ala Val Asp Gln His Asp Ile
 690 695 700
 Leu Thr Ser Val Arg Tyr Gly Lys Asn Leu Ala Asp Ala Asn Ala Thr
 705 710 715 720
 Ser Asp Asp Leu Thr Ser Ile Asn Ser Gly Ile Gly Val Ile Val Ser
 725 730 735
 Asn Asn Pro Asn Leu Ser Leu Ala Ser Gly Glu Thr Val Val Leu His
 740 745 750
 Met Gly Ile Ala His Ala Asn Gln Val Tyr Arg Glu Ile Leu Glu Thr
 755 760 765
 Thr Asp Asn Gly Ile Ala Asn Asn Thr Asp Ile Phe Lys Thr Thr Asp
 770 775 780
 Ser Asn Gly Asp Leu Ile Phe Thr Ala Ser Glu Ile His Gly Tyr Ser
 785 790 795 800
 Asn Val Gln Val Ser Gly Phe Leu Ser Val Trp Ala Pro Lys Asp Ala
 805 810 815
 Thr Asp Asp Gln Asp Val Arg Thr Ala Ala Ser Glu Ser Thr Ser Asn
 820 825 830
 Asp Gly Asn Thr Leu His Ser Asn Ala Ala Leu Asp Ser Asn Leu Ile
 835 840 845
 Tyr Glu Gly Phe Ser Asn Phe Gln Ser Thr Pro Gln Ser Glu Ser Glu
 850 855 860
 Phe Ala Asn Val Lys Ile Ala Ala Asn Val Asn Leu Phe Lys Ser Trp
 865 870 875 880
 Gly Val Thr Ser Phe Gln Met Ala Pro Gln Tyr Arg Ser Ser Thr Asp
 885 890 895
 Thr Ser Phe Leu Asp Ser Ile Ile Gln Asn Gly Tyr Ala Phe Thr Asp
 900 905 910

20151105_CL6294WOPCT_SequenceListing

Arg Tyr Asp Leu Gly Phe Glu Thr Pro Thr Lys Tyr Thr Asp Gln
 915 920 925
 Gln Leu Arg Asp Ala Ile Lys Ala Leu His Ala Asn Gly Ile Gln Ala
 930 935 940
 Met Ala Asp Phe Val Pro Asp Gln Ile Tyr Asn Leu Pro Gln Thr Glu
 945 950 955 960
 Leu Val Ser Val Ser Arg Thr Asp Ser Leu Gly Asn Gln Ser Ala Asn
 965 970 975
 Ser Asn Ala Ala Asn Val Leu Tyr Val Ser His Thr Val Gly Gly Gly
 980 985 990
 Glu Tyr Gln Ser Lys Tyr Gly Gly Glu Phe Leu Ala Ile Ile Lys Ser
 995 1000 1005
 Lys Tyr Pro Ser Leu Phe Lys Thr Ile Gln Val Ser Thr Gly Leu
 1010 1015 1020
 Pro Ile Asp Asp Ser Thr Lys Ile Lys Glu Trp Ser Ala Lys Tyr
 1025 1030 1035
 Phe Asn Gly Ser Asn Ile Gln Gly Arg Gly Phe Gly Tyr Val Leu
 1040 1045 1050
 Ser Asp Gly Gly Thr Gln Asn Tyr Phe Lys Val Ile Ser Asn Ser
 1055 1060 1065
 Thr Asp Asp Asp Phe Leu Pro Asn Gln Leu Thr Gly Lys Pro Thr
 1070 1075 1080
 Met Thr Gly Phe Glu Gln Thr Ser Lys Gly Ile Val Tyr Tyr Ser
 1085 1090 1095
 Lys Ser Gly Ile Gln Ala Lys Asn Gln Phe Val Lys Asp Asp Val
 1100 1105 1110
 Ser Gly Asn Tyr Tyr Tyr Phe Asn Lys Asn Gly Leu Met Thr Val
 1115 1120 1125
 Gly Ser Lys Thr Ile Asn Gly Lys Asn Tyr Met Phe Leu Pro Asn
 1130 1135 1140
 Gly Val Glu Leu Arg Gly Ser Phe Leu Gln Thr Ala Asp Gly Thr
 1145 1150 1155
 Val Asn Tyr Tyr Ala Thr Asn Gly Ala Gln Val Gln Asp Ser Tyr
 1160 1165 1170
 Val Thr Asp Thr Glu Gly Asn Ser Tyr Tyr Phe Asp Gly Asp Gly
 1175 1180 1185
 Glu Met Val Thr Gly Thr Tyr Thr Val Asp Gly His Ala Gln Tyr
 1190 1195 1200
 Phe Asp Val Asn Gly Val Gln Thr Lys Gly Ala Ile Ile Thr Leu
 1205 1210 1215
 Gly Val Gln Arg Tyr Tyr Gln Ala Gly Asn Gly Asn Leu Ala
 1220 1225 1230
 Thr Asn Gln Tyr Val Ser Tyr Asn Asn Ser Trp Tyr Tyr Ala Asn
 1235 1240 1245
 Thr Lys Gly Glu Leu Val Thr Gly Val Gln Ser Ile Asn Gly Asn
 1250 1255 1260
 Val Gln Tyr Phe Ala Ser Asn Gly Gln Gln Ile Lys Gly Gln Ile
 1265 1270 1275
 Val Val Thr Gly Asn Gln Lys Ser Tyr Tyr Asp Ala Asn Thr Gly
 1280 1285 1290
 Asn Leu Ile Lys Asn Asp Phe Leu Thr Pro Asp Gln Gly Lys Thr
 1295 1300 1305
 Trp Tyr Tyr Ala Asp Gln Asp Gly Asn Leu Val Val Gly Ala Gln
 1310 1315 1320
 Glu Val Asn Gly His Lys Leu Tyr Phe Asp Asp Asn Gly Ile Gln
 1325 1330 1335
 Ile Lys Asp Gln Ile Ile Ser Asn Asp Gly Gln Gln Tyr Tyr Tyr
 1340 1345 1350
 Gln Gly Gly Asn Gly Asp Leu Val Thr Asn Arg Tyr Ile Ser Tyr
 1355 1360 1365
 Asn Asp Ser Trp Tyr Tyr Ala Asp Ala Thr Gly Val Leu Val Thr
 1370 1375 1380
 Gly Gln Gln Ile Ile Asn Gly Glu Thr Gln Tyr Phe Arg Thr Asp
 1385 1390 1395
 Gly Arg Gln Val Lys Gly Gln Ile Ile Ala Asp Gly Asp Lys Gln
 1400 1405 1410
 His Tyr Tyr Asp Ala Asp Ser Gly Asn Leu Val Lys Asn Asn Phe
 1415 1420 1425

20151105_CL6294wOPCT_SequenceListing

Val	Thr	Val	Asp	Gln	Gly	Lys	Thr	Trp	Tyr	Tyr	Ala	Asp	Gln	Asp
1430					1435						1440			
Gly	Asn	Leu	Ser	Leu	Val	Asp	Arg	His	His	His	His	His	His	His
1445					1450						1455			

<210> 3
<211> 4347
315

<212> DNA

<213> Weis

<213> Weissella cibaria

<400> 3

atgtacaagt	ccggaaagtt	ttgggtagct	gccggtgct	tgttgg	gctggcattc
gcttgtaaca	cgaggcgtga	tactgtatta	ccaagtgaac	aacgtgcaac	ggagacgaca
cagacgacac	agaccagtga	agacacgtcc	gccactaaga	cgccggcatc	ggcgtcgaact
tcaagctcg	tcaatgtga	cacgagtgac	ctgcctgaca	gttcaagtgac	gttagttgat
agtacaagt	caagtgcgaag	cgtagtgagt	gatagcgtcg	ctgtgccaga	tactggatca
caatttacga	gttcgtcagg	gtcaatgtca	tcatcatttg	ttaagtcatc	actagcgcga
acaactagt	atgcttctgg	cagtcaatcg	gcccgcgtga	ctagcgcac	cgttagttcg
gtggccacga	gtatgtcage	atcttcatgt	acaacagcca	caaggaatc	agcagtata
agcagcccg	tgtcagatgg	ttaccatgtat	gaaggtgggt	attgggtcta	ttatcgact
ggaaaaaaagt	tagtcggtcg	acaaaacattt	gatacggtt	cggttactt	tgacgcccgt
ggcaaacaag	tcaagggtga	ttggcgtgaa	agtatgttga	accgtgcgt	ttatgtatgg
caagaaggac	gaggattaaac	gcaaaacgca	cgatcgtat	cggtttataat	cggtttataat
caaaggcgct	atcaaataat	gaatgattt	ggccaaacacag	cgaatcgaga	tacgtattat
ttcgcacgcac	aagggtatgt	tgtcacggga	atccaaacaa	ttgcaaaacaa	ggtttatgat
tttgcgtatgc	aagggtcgat	gctgaaaggc	attgcccacgt	cagttatgt	caagatgtat
tatttgcgtat	atcaaatacagg	tggtggacaa	ccggctgatc	atccgtat	caaccctgaa
acggaaacgg	ttcctgacga	caatataaa	cataatgcag	cacatggtac	gacaccagca
gattttgatt	cgatggctgg	ctacctgacg	gctgatactt	ggtatcgccc	aaccgtatatt
ttggaaaatg	gtgagacgtg	gcmcgaatcg	caaccaactg	aatttcgacc	actgttagca
acttgggtgc	caacaaaaca	aactcaggcc	gattacgtga	actacatgaa	tcacgcatta
gatatgtcaa	atgcaatgtt	gtcagctgcc	gattcagaag	ccacgctaac	tgcggcaacc
gatgttattc	aagcggccgt	tgagcaccaa	attacggtgc	gccaatcaac	ggcctggta
cgtgaattaa	tggccgcgtt	tgttgcaca	cagccacagt	ggaataaaac	cagtgaagat
gttaatgtatg	atcatttgc	aggtggggcg	ctaacattt	agaataacgg	cgacacagac
gctaaatcg	attatcgctt	catgaatcgc	acgccaacaa	atcagactgg	tgaacgcttg
tatcacattt	atgactcgct	tggcggttac	gaattatttg	tggcaaatga	cgttgacat
tcaaaatccac	aagttcaggc	agaacaattt	aattgggtt	actacttgc	gcattttggg
gatattacag	ctgtatgtcc	ggatcgaat	tttgcgtcc	tacgattgt	tgcggcgtat
aatgtcgatg	ctgatttact	tcaactagca	gctcgtattt	tccgtatgc	ctatggcatt
gccacgtg	acgcgcacat	aaataagcat	tttcaat	ttgaggattt	gagccataac
gatccggcgt	atatgcagc	acacgcatt	gatcaattaa	cgatggat	ttatatgcac
acacagttga	tttggtcatt	aaccaagcca	gaggcacaac	gtggcaccat	ggcacgcctt
atggacttct	atctcaccat	ccgtgtaat	gatgatacag	aaaacacggc	gcaacctagt
tactcggtt	tgctgcccc	tgatagcgaa	gtgcaacacag	tcattgctga	aatcgtgacg
aagctacatc	cagaagcagg	aaacgggta	atgcctacgg	aagaacaaat	ggcagaagcg
ttaaagattt	acaatgcgg	ccaaaagaag	gccgttaaaa	cttacacgc	ctacaatatg
ccatctgcat	acgcccgtct	gttaacgaac	aggatgtt	ttccacgat	ttactatgtt
gacttgtaca	ctgacgatgg	gcaattcatg	gccccaaat	caccctattt	tcatgcattt
tcggctatgt	tacaagcgc	cacgaagtat	gtagctgg	gacaaacgat	ggcgggttgc
cagcacgacg	tcttgactag	cgttcggtt	gttaagggtt	ccatgacggc	cagtgattt
ggaaatgtcg	agactcggac	tgagggtgt	gatattat	ttacaacaa	cccaaagg
caatttggac	aacaagataa	cgtgggtt	cacatgggac	ttgcgcacgc	gaatcaagca
ttcccgagcag	ttgtactaac	gaccgcgacc	gatattacca	tttataatga	cgatgtatgc
ccaattcg	ataccgataa	taagggtat	ttaattttca	ataaccatga	cgttatatggc
gtgttgta	cacaagtgtc	aggcttctt	gcaatgtgg	tgccaaactgg	tgccacagcg
aaccaggatg	cgcgtatctac	tgcgtcaacc	aacagttcaa	cggtatggatc	tgcctaccat
tctaatacg	ctttagatag	tcaagtcatc	tttgaatcat	tttgcattt	ccaggctatg
ccaacaagcc	atgacacgt	caccaacgtt	gtttagcc	atcatgctga	ccagttcac
gatttgggaa	taacttgcgt	acagttagcg	ccacaatacc	ggtcttacac	cgacggaaacc
tttttgcgtat	cgtatttca	aatgtatct	gccttact	accgttat	tttagggttt
ggtagccaa	ctaaatgtat	ggatgatacg	gatgtcg	acgtcatca	agcattgtat
gcaaaatggca	tgcgaaat	ggctgat	gtgcccgt	aattgtat	attaccagg
aaggaaatgg	tacaagtac	ccgaacaaac	aatatgggt	agccagatac	acactctgac
atccaacata	ttttatgtat	gacgagact	ccgggttggc	gtgagttatca	gaaacagttac
ggtgtgtatgt	tccttgagcg	gtatgattca	gtaaaaat	aagaatggtc	gacacgtcaa
atttcaaccg	gacaaaccat	aqgcccgtq	qctqqctatq	tgctacgtqa	taatqgtaca
ttqaatqgt	ccqcaattca				

20151105_CL6294WOPCT_SequenceListing

aatgcttatt	acaagggtgac	ggcaaatgac	ggtaatgtga	acttaccaa	gcaattactc	3480
ggacaaaccag	tgatgaccgg	attctatcac	gaggcagatg	gttatcatt	tgaacattg	3540
agtggtaacgt	cggccaaaga	tgccttcatt	atgggtgacg	atggggcgct	gtatttttt	3600
gatgatcagg	gcgtcatggt	aacggtaag	caacgtgtc	accaagagca	gtatttctc	3660
ctaccaaacg	gtattgtct	gacggatg	tttgcataaa	gtgcggatgg	tcaacgtcag	3720
tactatgata	aaacagggtcg	cctggtcatt	aatcaatatg	tgactgacca	ccaagcaa	3780
gcgttccggg	ttgatgcaga	cggtaacgtt	gttcgttaacc	aagctttgac	tgttgcacggc	3840
catgaacaat	atttcgac	aaacgggtgc	caagcggaa	cagtgcctat	tcgaactgac	3900
gataatcagg	cacggtaact	cgaagccaa	agtggtaatc	tcgtgaagca	acagttatt	3960
cttgatacag	atggacattt	gttgcacggc	gatgctgcag	gagacttggc	acgcggacaa	4020
attacggtt	gccaagacac	gttgcatttt	gatgataata	atcatcaggt	aaaagatgat	4080
tttgcattat	atactaacgg	tgtcattat	tttaatggca	caacaggcgc	tgaatcaaa	4140
caagattacg	cgttcatga	tggcaatgg	tactatttt	atgatttggg	acgaatggta	4200
accggtttgc	agcgtattaa	tggtagtat	cgctatttt	atgctaattgg	tgtgcaacta	4260
aagggtggta	ccgtgaccga	tccactaacg	caccaaact	acacttttga	tgcgcaact	4320
ggtgggtggta	cgttggtgac	gttttaa				4347

<210> 4
 <211> 1448
 <212> PRT
 <213> Weissella cibaria

<400> 4
 Met Tyr Lys Ser Gly Lys Phe Trp Val Ala Ala Gly Ala Leu Phe Val
 1 5 10 15
 Gly Leu Ala Phe Ala Gly Asn Thr Gln Ala Asp Thr Val Leu Pro Ser
 20 25 30
 Glu Gln Arg Ala Thr Glu Thr Thr Gln Thr Thr Gln Thr Ser Glu Asp
 35 40 45
 Thr Ser Ala Thr Lys Thr Pro Ala Ser Ala Ser Thr Ser Ser Ser Val
 50 55 60
 Asn Val Asp Thr Ser Asp Leu Pro Asp Ser Ser Ser Thr Val Val Asp
 65 70 75 80
 Ser Thr Ser Ala Ser Ala Ser Val Val Ser Asp Ser Val Ala Val Pro
 85 90 95
 Asp Thr Gly Ser Gln Phe Thr Ser Ser Ser Gly Ser Met Ser Ser Ser
 100 105 110
 Phe Val Lys Ser Ser Leu Ala Ala Thr Thr Ser Asp Ala Ser Gly Ser
 115 120 125
 Gln Ser Ala Ala Val Thr Ser Ala Thr Val Ser Ser Val Ala Thr Ser
 130 135 140
 Ser Ser Ala Ser Ser Val Thr Thr Ala Thr Ser Glu Ser Ala Val Ile
 145 150 155 160
 Ser Ser Ala Val Ser Asp Gly Tyr His Asp Glu Gly Gly Asp Trp Val
 165 170 175
 Tyr Tyr Arg Ala Gly Lys Leu Val Gly Arg Gln Thr Ile Asp Thr
 180 185 190
 Phe Ala Val Tyr Phe Asp Ala Asp Gly Lys Gln Val Lys Gly Asp Trp
 195 200 205
 Arg Glu Ser Asp Gly Asn Arg Ala Tyr Tyr Asp Gly Gln Glu Gly Arg
 210 215 220
 Ala Leu Thr Gln Thr Gln Ala Val Asn Gly Val Ile Tyr Gly Phe Asn
 225 230 235 240
 Gln Ser Gly Tyr Gln Ile Lys Asn Asp Phe Gly Gln Thr Ala Asn Arg
 245 250 255
 Asp Thr Tyr Tyr Phe Asp Ala Gln Gly His Val Val Thr Gly Ile Gln
 260 265 270
 Thr Ile Ala Asn Lys Val Tyr Asp Phe Asp Glu Gln Gly Arg Met Leu
 275 280 285
 Lys Gly Ile Ala Thr Ser Val Asp Asp Lys Met Met Tyr Phe Asp Asp
 290 295 300
 Gln Thr Gly Val Gly Gln Pro Ala Asp His Pro Glu Phe Asn Pro Glu
 305 310 315 320
 Thr Glu Pro Val Pro Asp Asp Asn Ile Lys His Asn Ala Ala His Gly
 325 330 335
 Thr Thr Pro Ala Asp Phe Asp Ser Met Ala Gly Tyr Leu Thr Ala Asp
 340 345 350
 Thr Trp Tyr Arg Pro Thr Asp Ile Leu Glu Asn Gly Glu Thr Trp Arg

20151105_CL6294WOPCT_SequenceListing

355	Glu	Ser	Gln	Pro	Thr	Glu	Phe	Arg	Pro	Leu	Leu	Ala	Thr	Trp	Trp	Pro
370	370	370	370	370	370	370	370	370	370	370	370	370	370	370	370	370
385	385	385	385	385	385	385	385	385	385	385	385	385	385	385	385	385
Asp	Met	Ser	Asn	Ala	Ser	Val	Ser	Ala	Ala	Asp	Ser	Glu	Ala	Thr	Leu	400
405	405	405	405	405	405	405	405	405	405	405	405	405	405	405	405	405
420	420	420	420	420	420	420	420	420	420	420	420	420	420	420	420	420
435	435	435	435	435	435	435	435	435	435	435	435	435	435	435	435	435
450	450	450	450	450	450	450	450	450	450	450	450	450	450	450	450	450
His	Leu	Gln	Gly	Gly	Ala	Leu	Thr	Phe	Glu	Asn	Asn	Gly	Asp	Thr	Asp	480
465	465	465	465	465	465	465	465	465	465	465	465	465	465	465	465	465
Ala	Asn	Ser	Asp	Tyr	Arg	Leu	Met	Asn	Arg	Thr	Pro	Thr	Asn	Gln	Thr	495
485	485	485	485	485	485	485	485	485	485	485	485	485	485	485	485	485
Gly	Glu	Arg	Leu	Tyr	His	Ile	Asp	Asp	Ser	Leu	Gly	Gly	Tyr	Glu	Leu	500
500	500	500	500	500	500	500	500	500	500	500	500	500	500	500	500	500
Leu	Leu	Ala	Asn	Asp	Val	Asp	Asn	Ser	Asn	Pro	Gln	Val	Gln	Ala	Glu	515
515	515	515	515	515	515	515	515	515	515	515	515	515	515	515	515	515
Gln	Leu	Asn	Trp	Leu	Tyr	Tyr	Leu	Met	His	Phe	Gly	Asp	Ile	Thr	Ala	530
530	530	530	530	530	530	530	530	530	530	530	530	530	530	530	530	530
Asp	Asp	Pro	Asp	Ala	Asn	Phe	Asp	Ala	Ile	Arg	Ile	Asp	Ala	Val	Asp	545
545	545	545	545	545	545	545	545	545	545	545	545	545	545	545	545	545
Asn	Val	Asp	Ala	Asp	Leu	Leu	Gln	Leu	Ala	Ala	Gln	Tyr	Phe	Arg	Asp	565
565	565	565	565	565	565	565	565	565	565	565	565	565	565	565	565	565
Ala	Tyr	Gly	Met	Ala	Thr	Thr	Asp	Ala	Thr	Ser	Asn	Lys	His	Leu	Ser	580
580	580	580	580	580	580	580	580	580	580	580	580	580	580	580	580	580
Ile	Leu	Glu	Asp	Trp	Ser	His	Asn	Asp	Pro	Ala	Tyr	Met	Gln	Ala	His	605
595	595	595	595	595	595	595	595	595	595	595	595	595	595	595	595	595
Gly	Asn	Asp	Gln	Leu	Thr	Met	Asp	Asp	Tyr	Met	His	Thr	Gln	Leu	Ile	610
610	610	610	610	610	610	610	610	610	610	610	610	610	610	610	610	610
Trp	Ser	Leu	Thr	Lys	Pro	Glu	Ala	Gln	Arg	Gly	Thr	Met	Ala	Arg	Phe	625
625	625	625	625	625	625	625	625	625	625	625	625	625	625	625	625	625
Met	Asp	Phe	Tyr	Leu	Thr	Asn	Arg	Ala	Asn	Asp	Asp	Asp	Thr	Glu	Asn	645
645	645	645	645	645	645	645	645	645	645	645	645	645	645	645	645	645
Ala	Gln	Pro	Ser	Tyr	Ser	Phe	Val	Arg	Ala	His	Asp	Ser	Glu	Val	Gln	660
660	660	660	660	660	660	660	660	660	660	660	660	660	660	660	660	660
Thr	Val	Ile	Ala	Glu	Ile	Val	Thr	Lys	Leu	His	Pro	Glu	Ala	Gly	Asn	675
675	675	675	675	675	675	675	675	675	675	675	675	675	675	675	675	675
Gly	Leu	Met	Pro	Thr	Glu	Glu	Gln	Met	Ala	Glu	Ala	Phe	Lys	Ile	Tyr	690
690	690	690	690	690	690	690	690	690	690	690	690	690	690	690	690	690
Asn	Ala	Asp	Gln	Lys	Lys	Ala	Val	Lys	Thr	Tyr	Thr	His	Tyr	Asn	Met	705
705	705	705	705	705	705	705	705	705	705	705	705	705	705	705	705	705
Pro	Ser	Ala	Tyr	Ala	Met	Leu	Leu	Thr	Asn	Lys	Asp	Val	Ile	Pro	Arg	725
725	725	725	725	725	725	725	725	725	725	725	725	725	725	725	725	725
Ile	Tyr	Tyr	Gly	Asp	Leu	Tyr	Thr	Asp	Asp	Gly	Gln	Phe	Met	Ala	Thr	740
740	740	740	740	740	740	740	740	740	740	740	740	740	740	740	740	740
Lys	Ser	Pro	Tyr	Phe	Asp	Ala	Ile	Ser	Ala	Met	Leu	Gln	Ala	Arg	Thr	755
755	755	755	755	755	755	755	755	755	755	755	755	755	755	755	755	755
Lys	Tyr	Val	Ala	Gly	Gly	Gln	Thr	Met	Ala	Val	Asp	Gln	His	Asp	Val	770
770	770	770	770	770	770	770	770	770	770	770	770	770	770	770	770	770
Leu	Thr	Ser	Val	Arg	Phe	Gly	Lys	Gly	Ala	Met	Thr	Ala	Ser	Asp	Leu	785
790	790	790	790	790	790	790	790	790	790	790	790	790	790	790	790	790
Gly	Asn	Ala	Glu	Thr	Arg	Thr	Glu	Gly	Val	Gly	Leu	Ile	Ile	Ser	Asn	805
805	805	805	805	805	805	805	805	805	805	805	805	805	805	805	805	805
Asn	Pro	Lys	Leu	Gln	Leu	Gly	Gln	Gln	Asp	Asn	Val	Val	Leu	His	Met	820
820	820	820	820	820	820	820	820	820	820	820	820	820	820	820	820	820
Gly	Leu	Ala	His	Ala	Asn	Gln	Ala	Phe	Arg	Ala	Val	Val	Leu	Thr	Thr	835
840	840	840	840	840	840	840	840	840	840	840	840	840	840	840	840	840
Ala	Thr	Gly	Leu	Thr	Ile	Tyr	Asn	Asp	Asp	Asp	Ala	Pro	Ile	Arg	Tyr	850
855	855	855	855	855	855	855	855	855	855	855	855	855	855	855	855	855
Thr	Asp	Asn	Lys	Gly	Asp	Leu	Ile	Phe	Asn	Asn	His	Asp	Val	Tyr	Gly	865
870	870	870	870	870	870	870	870	870	870	870	870	870	870	870	870	870
Val	Leu	Asn	Pro	Gln	Val	Ser	Gly	Phe	Leu	Ala	Met	Trp	Val	Pro	Thr	885
885	885	885	885	885	885	885	885	885	885	885	885	885	885	885	885	885
Gly	Ala	Pro	Ala	Asn	Gln	Asp	Ala	Arg	Ser	Thr	Ala	Ser	Thr	Asn	Ser	895

20151105_CL6294WOPCT_SequenceListing

	900	905	910												
Ser	Thr	Asp	Gly	Ser	Ala	Tyr	His	Ser	Asn	Ala	Ala	Leu	Asp	Ser	Gln
915				920			925								
Val	Ile	Phe	Glu	Ser	Phe	Ser	Asn	Phe	Gln	Ala	Met	Pro	Thr	Ser	His
930				935			940								
Asp	Thr	Tyr	Thr	Asn	Val	Val	Leu	Ala	Asn	His	Ala	Asp	Gln	Leu	His
945				950			955			960					
Asp	Trp	Gly	Ile	Thr	Ser	Val	Gln	Leu	Ala	Pro	Gln	Tyr	Arg	Ser	Ser
965				970			975								
Thr	Asp	Gly	Thr	Phe	Leu	Asp	Ala	Ile	Ile	Gln	Asn	Gly	Tyr	Ala	Phe
980				985			990								
Thr	Asp	Arg	Tyr	Asp	Leu	Gly	Phe	Gly	Thr	Pro	Thr	Lys	Tyr	Gly	Asp
995				1000			1005								
Asp	Thr	Asp	Leu	Arg	Asn	Val	Ile	Lys	Ala	Leu	His	Ala	Asn	Gly	
1010				1015			1020								
Met	Gln	Val	Met	Ala	Asp	Phe	Val	Pro	Asp	Gln	Leu	Tyr	Thr	Leu	
1025				1030			1035								
Pro	Gly	Lys	Glu	Leu	Val	Gln	Val	Thr	Arg	Thr	Asn	Asn	Met	Gly	
1040				1045			1050								
Glu	Pro	Asp	Thr	His	Ser	Asp	Ile	Gln	His	Ile	Leu	Tyr	Val	Thr	
1055				1060			1065								
Ser	Thr	Arg	Gly	Gly	Gly	Glu	Tyr	Gln	Lys	Gln	Tyr	Gly	Gly	Glu	
1070				1075			1080								
Phe	Leu	Glu	Arg	Leu	Arg	Ala	Leu	Tyr	Pro	Asp	Leu	Phe	Thr	Thr	
1085				1090			1095								
Arg	Gln	Ile	Ser	Thr	Gly	Gln	Thr	Ile	Asp	Asp	Ser	Val	Lys	Ile	
1100				1105			1110								
Lys	Glu	Trp	Ser	Ala	Lys	Tyr	Leu	Asn	Gly	Thr	Ala	Ile	Gln	Gly	
1115				1120			1125								
Arg	Gly	Ala	Gly	Tyr	Val	Leu	Arg	Asp	Asn	Gly	Thr	Asn	Ala	Tyr	
1130				1135			1140								
Tyr	Lys	Val	Thr	Ala	Asn	Asp	Gly	Asn	Val	Asn	Leu	Pro	Lys	Gln	
1145				1150			1155								
Leu	Leu	Gly	Gln	Pro	Val	Met	Thr	Gly	Phe	Tyr	His	Glu	Ala	Asp	
1160				1165			1170								
Gly	Tyr	His	Phe	Glu	Thr	Leu	Ser	Gly	Thr	Ser	Ala	Lys	Asp	Ala	
1175				1180			1185								
Phe	Ile	Met	Gly	Asp	Asp	Gly	Ala	Leu	Tyr	Tyr	Phe	Asp	Asp	Gln	
1190				1195			1200								
Gly	Val	Met	Val	Thr	Gly	Lys	Gln	Arg	Val	His	Gln	Asp	Gln	Tyr	
1205				1210			1215								
Phe	Phe	Leu	Pro	Asn	Gly	Ile	Ala	Leu	Thr	Asp	Ala	Phe	Val	Gln	
1220				1225			1230								
Ser	Ala	Asp	Gly	Gln	Arg	Gln	Tyr	Tyr	Asp	Lys	Thr	Gly	Arg	Leu	
1235				1240			1245								
Val	Ile	Asn	Gln	Tyr	Val	Thr	Asp	His	Gln	Ala	Asn	Ala	Phe	Arg	
1250				1255			1260								
Val	Asp	Ala	Asp	Gly	Asn	Val	Val	Arg	Asn	Gln	Ala	Leu	Thr	Val	
1265				1270			1275								
Asp	Gly	His	Glu	Gln	Tyr	Phe	Gly	Thr	Asn	Gly	Val	Gln	Ala	Lys	
1280				1285			1290								
Ala	Val	Leu	Ile	Arg	Thr	Asp	Asp	Asn	Gln	Ala	Arg	Tyr	Tyr	Glu	
1295				1300			1305								
Ala	Asn	Ser	Gly	Asn	Leu	Val	Lys	Gln	Gln	Phe	Ile	Leu	Asp	Thr	
1310				1315			1320								
Asp	Gly	His	Trp	Leu	Tyr	Ala	Asp	Ala	Ala	Gly	Asp	Leu	Ala	Arg	
1325				1330			1335								
Gly	Gln	Ile	Thr	Val	Gly	Gln	Asp	Thr	Leu	Tyr	Phe	Asp	Asp	Asn	
1340				1345			1350								
Asn	His	Gln	Val	Lys	Asp	Asp	Phe	Val	Tyr	Asp	Thr	Asn	Gly	Val	
1355				1360			1365								
His	Tyr	Phe	Asn	Gly	Thr	Thr	Gly	Ala	Glu	Ile	Lys	Gln	Asp	Tyr	
1370				1375			1380								
Ala	Phe	His	Asp	Gly	Lys	Trp	Tyr	Tyr	Phe	Asp	Asp	Leu	Gly	Arg	
1385				1390			1395								
Met	Val	Thr	Gly	Leu	Gln	Arg	Ile	Asn	Gly	Glu	Tyr	Arg	Tyr	Phe	
1400				1405			1410								
Asp	Ala	Asn	Gly	Val	Gln	Leu	Lys	Gly	Gly	Thr	Val	Thr	Asp	Pro	

20151105_CL6294WOPCT_SequenceListing

1415	1420	1425	
Leu	Thr His Gln Thr Tyr	Thr Phe Asp Ala Gln	Thr Gly Val Gly
1430	1435	1440	
Thr	Leu Val Thr Phe		
1445			

<210> 5
<211> 1422
<212> PRT
<213> Weissella cibaria

<220>
<221> MISC_FEATURE
<222> (1)..(1422)
<223> mature 2919 gtf

<400> 5
Asp Thr Val Leu Pro Ser Glu Gln Arg Ala Thr Glu Thr Thr Gln Thr
1 5 10 15
Thr Gln Thr Ser Glu Asp Thr Ser Ala Thr Lys Thr Pro Ala Ser Ala
20 25 30
Ser Thr Ser Ser Val Asn Val Asp Thr Ser Asp Leu Pro Asp Ser
35 40 45
Ser Ser Thr Val Val Asp Ser Thr Ser Ala Ser Ala Ser Val Val Ser
50 55 60
Asp Ser Val Ala Val Pro Asp Thr Gly Ser Gln Phe Thr Ser Ser Ser
65 70 75 80
Gly Ser Met Ser Ser Phe Val Lys Ser Ser Leu Ala Ala Thr Thr
85 90 95
Ser Asp Ala Ser Gly Ser Gln Ser Ala Ala Val Thr Ser Ala Thr Val
100 105 110
Ser Ser Val Ala Thr Ser Ser Ala Ser Ser Val Thr Thr Ala Thr
115 120 125
Ser Glu Ser Ala Val Ile Ser Ser Ala Val Ser Asp Gly Tyr His Asp
130 135 140
Glu Gly Gly Asp Trp Val Tyr Tyr Arg Ala Gly Lys Lys Leu Val Gly
145 150 155 160
Arg Gln Thr Ile Asp Thr Phe Ala Val Tyr Phe Asp Ala Asp Gly Lys
165 170 175
Gln Val Lys Gly Asp Trp Arg Glu Ser Asp Gly Asn Arg Ala Tyr Tyr
180 185 190
Asp Gly Gln Glu Gly Arg Ala Leu Thr Gln Thr Gln Ala Val Asn Gly
195 200 205
Val Ile Tyr Gly Phe Asn Gln Ser Gly Tyr Gln Ile Lys Asn Asp Phe
210 215 220
Gly Gln Thr Ala Asn Arg Asp Thr Tyr Tyr Phe Asp Ala Gln Gly His
225 230 235 240
Val Val Thr Gly Ile Gln Thr Ile Ala Asn Lys Val Tyr Asp Phe Asp
245 250 255
Glu Gln Gly Arg Met Leu Lys Gly Ile Ala Thr Ser Val Asp Asp Lys
260 265 270
Met Met Tyr Phe Asp Asp Gln Thr Gly Val Gly Gln Pro Ala Asp His
275 280 285
Pro Glu Phe Asn Pro Glu Thr Glu Pro Val Pro Asp Asp Asn Ile Lys
290 295 300
His Asn Ala Ala His Gly Thr Thr Pro Ala Asp Phe Asp Ser Met Ala
305 310 315 320
Gly Tyr Leu Thr Ala Asp Thr Trp Tyr Arg Pro Thr Asp Ile Leu Glu
325 330 335
Asn Gly Glu Thr Trp Arg Glu Ser Gln Pro Thr Glu Phe Arg Pro Leu
340 345 350
Leu Ala Thr Trp Trp Pro Thr Lys Gln Thr Gln Ala Asp Tyr Val Asn
355 360 365
Tyr Met Asn His Ala Leu Asp Met Ser Asn Ala Ser Val Ser Ala Ala
370 375 380
Asp Ser Glu Ala Thr Leu Thr Ala Ala Thr Asp Ala Ile Gln Ala Ala
385 390 395 400
Val Glu His Gln Ile Thr Val Arg Gln Ser Thr Ala Trp Leu Arg Glu

20151105_CL6294WOPCT_SequenceListing

405 Leu Met Ala Ala Phe Val Val Thr Gln Pro Gln Trp Asn Lys Thr Ser 420 425 430 435 440 445 450 455 460 Glu Asp Val Asn Asp Asp His Leu Gln Gly Gly Ala Leu Thr Phe Glu 465 470 475 480 Asn Asn Gly Asp Thr Asp Ala Asn Ser Asp Tyr Arg Leu Met Asn Arg 485 490 495 500 505 510 Thr Pro Thr Asn Gln Thr Gly Glu Arg Leu Tyr His Ile Asp Asp Ser 515 520 525 530 535 540 545 550 555 560 Leu Gly Gly Tyr Glu Leu Leu Ala Asn Asp Val Asp Asn Ser Asn 565 570 575 580 585 590 595 600 605 Pro Gln Val Gln Ala Glu Gln Leu Asn Trp Leu Tyr Tyr Leu Met His 610 615 620 625 630 635 640 Phe Gly Asp Ile Thr Ala Asp Asp Pro Asp Ala Asn Phe Asp Ala Ile 645 650 655 660 665 670 675 680 685 Arg Ile Asp Ala Val Asp Asn Val Asp Ala Asp Leu Leu Gln Leu Ala 690 695 700 705 710 715 720 Ala Gln Tyr Phe Arg Asp Ala Tyr Gly Met Ala Thr Thr Asp Ala Thr 725 730 735 740 745 750 755 760 765 Ser Asn Lys His Leu Ser Ile Leu Glu Asp Trp Ser His Asn Asp Pro 770 775 780 785 790 795 800 Ala Tyr Met Gln Ala His Gly Asn Asp Gln Leu Thr Met Asp Asp Tyr 805 810 815 820 825 830 835 840 845 Met His Thr Gln Leu Ile Trp Ser Leu Thr Lys Pro Glu Ala Gln Arg 850 855 860 865 870 875 880 885 890 895 Gly Thr Met Ala Arg Phe Met Asp Phe Tyr Leu Thr Asn Arg Ala Asn 900 905 910 915 920 925 930 935 940 945 Asp Asp Thr Glu Asn Thr Ala Gln Pro Ser Tyr Ser Phe Val Arg Ala His Asp Ser Glu Val Gln Thr Val Ile Ala Glu Ile Val Thr Lys Leu His Pro Glu Ala Gly Asn Gly Leu Met Pro Thr Glu Glu Gln Met Ala Glu Ala Phe Lys Ile Tyr Asn Ala Asp Gln Lys Lys Ala Val Lys Thr Tyr Thr His Tyr Asn Met Pro Ser Ala Tyr Ala Met Leu Leu Thr Asn Lys Asp Val Ile Pro Arg Ile Tyr Tyr Gly Asp Leu Tyr Thr Asp Asp Gly Gln Phe Met Ala Thr Lys Ser Pro Tyr Phe Asp Ala Ile Ser Ala Met Leu Gln Ala Arg Thr Lys Tyr Val Ala Gly Gln Thr Met Ala Val Asp Gln His Asp Val Leu Thr Ser Val Arg Phe Gly Lys Gly Ala Met Thr Ala Ser Asp Leu Gly Asn Ala Glu Thr Arg Thr Glu Gly Val Gly Leu Ile Ile Ser Asn Asn Pro Lys Leu Gln Leu Gly Gln Gln Asp Asn Val Val Leu His Met Gly Leu Ala His Ala Asn Gln Ala Phe Arg Ala Val Val Leu Thr Thr Ala Thr Gly Leu Thr Ile Tyr Asn Asp Asp Asp Ala Pro Ile Arg Tyr Thr Asp Asn Lys Gly Asp Leu Ile Phe Asn Asn His Asp Val Tyr Gly Val Leu Asn Pro Gln Val Ser Gly Phe Leu Ala Met Trp Val Pro Thr Gly Ala Pro Ala Asn Gln Asp Ala Arg Ser Thr Ala Ser Thr Asn Ser Ser Thr Asp Gly Ser Ala Tyr His Ser Asn Ala Ala Leu Asp Ser Gln Val Ile Phe Glu Ser Phe Ser Asn Phe Gln Ala Met Pro Thr Ser His Asp Thr Tyr Thr Asn Val Val Leu Ala Asn His Ala Asp Gln Leu His Asp Trp Gly Ile Thr Ser Val Gln Leu Ala Pro Gln Tyr Arg Ser Ser Thr Asp Gly Thr Phe Leu Asp Ala Ile Ile

20151105_CL6294WOPCT_SequenceListing

945 Gln Asn Gly Tyr Ala Phe Thr Asp Arg Tyr Asp Leu Gly Phe Gly Thr
 950 955 960
 965 970 975
 Pro Thr Lys Tyr Gly Asp Asp Thr Asp Leu Arg Asn Val Ile Lys Ala
 980 985 990
 Leu His Ala Asn Gly Met Gln Val Met Ala Asp Phe Val Pro Asp Gln
 995 1000 1005
 Leu Tyr Thr Leu Pro Gly Lys Glu Leu Val Gln Val Thr Arg Thr
 1010 1015 1020
 Asn Asn Met Gly Glu Pro Asp Thr His Ser Asp Ile Gln His Ile
 1025 1030 1035
 Leu Tyr Val Thr Ser Thr Arg Gly Gly Gly Glu Tyr Gln Lys Gln
 1040 1045 1050
 Tyr Gly Gly Glu Phe Leu Glu Arg Leu Arg Ala Leu Tyr Pro Asp
 1055 1060 1065
 Leu Phe Thr Thr Arg Gln Ile Ser Thr Gly Gln Thr Ile Asp Asp
 1070 1075 1080
 Ser Val Lys Ile Lys Glu Trp Ser Ala Lys Tyr Leu Asn Gly Thr
 1085 1090 1095
 Ala Ile Gln Gly Arg Gly Ala Gly Tyr Val Leu Arg Asp Asn Gly
 1100 1105 1110
 Thr Asn Ala Tyr Tyr Lys Val Thr Ala Asn Asp Gly Asn Val Asn
 1115 1120 1125
 Leu Pro Lys Gln Leu Leu Gly Gln Pro Val Met Thr Gly Phe Tyr
 1130 1135 1140
 His Glu Ala Asp Gly Tyr His Phe Glu Thr Leu Ser Gly Thr Ser
 1145 1150 1155
 Ala Lys Asp Ala Phe Ile Met Gly Asp Asp Gly Ala Leu Tyr Tyr
 1160 1165 1170
 Phe Asp Asp Gln Gly Val Met Val Thr Gly Lys Gln Arg Val His
 1175 1180 1185
 Gln Asp Gln Tyr Phe Phe Leu Pro Asn Gly Ile Ala Leu Thr Asp
 1190 1195 1200
 Ala Phe Val Gln Ser Ala Asp Gly Gln Arg Gln Tyr Tyr Asp Lys
 1205 1210 1215
 Thr Gly Arg Leu Val Ile Asn Gln Tyr Val Thr Asp His Gln Ala
 1220 1225 1230
 Asn Ala Phe Arg Val Asp Ala Asp Gly Asn Val Val Arg Asn Gln
 1235 1240 1245
 Ala Leu Thr Val Asp Gly His Glu Gln Tyr Phe Gly Thr Asn Gly
 1250 1255 1260
 Val Gln Ala Lys Ala Val Leu Ile Arg Thr Asp Asp Asn Gln Ala
 1265 1270 1275
 Arg Tyr Tyr Glu Ala Asn Ser Gly Asn Leu Val Lys Gln Gln Phe
 1280 1285 1290
 Ile Leu Asp Thr Asp Gly His Trp Leu Tyr Ala Asp Ala Ala Gly
 1295 1300 1305
 Asp Leu Ala Arg Gly Gln Ile Thr Val Gly Gln Asp Thr Leu Tyr
 1310 1315 1320
 Phe Asp Asp Asn Asn His Gln Val Lys Asp Asp Phe Val Tyr Asp
 1325 1330 1335
 Thr Asn Gly Val His Tyr Phe Asn Gly Thr Thr Gly Ala Glu Ile
 1340 1345 1350
 Lys Gln Asp Tyr Ala Phe His Asp Gly Lys Trp Tyr Tyr Phe Asp
 1355 1360 1365
 Asp Leu Gly Arg Met Val Thr Gly Leu Gln Arg Ile Asn Gly Glu
 1370 1375 1380
 Tyr Arg Tyr Phe Asp Ala Asn Gly Val Gln Leu Lys Gly Gly Thr
 1385 1390 1395
 Val Thr Asp Pro Leu Thr His Gln Thr Tyr Thr Phe Asp Ala Gln
 1400 1405 1410
 Thr Gly Val Gly Thr Leu Val Thr Phe
 1415 1420

<210> 6
 <211> 4269
 <212> DNA
 <213> Artificial sequence

20151105_CL6294WOPCT_SequenceListing

<220>

<223> 2919 gtf with heterologous signal sequence

<400> 6

gacacagtcc	ttccgtcaga	acaaagagcc	acggagacga	cacagacaac	acaaacaagc	60
gaagacacaa	gcgccacaaa	gacgcctgct	agcgttcaa	cgagcagctc	agtgaacgtg	120
gacacatcg	atcttccgga	cagctcaagc	acgggtgtgg	attcaacgtc	agcctcagca	180
agcgtcgtgt	cagactcagt	cgtgtccct	gatacggat	cacagttcac	atcatcaagc	240
ggcagcatgt	caaggcgtt	tgtaaaagc	tcactggcag	ctacgacgtc	agatgctca	300
ggctcacaaa	gcgcgcgtgt	gacatcagca	acagttcaa	gcgtggcag	gagctcatca	360
gcgtcatcg	ttacaacacg	cacgagcga	tcagcgtt	ttagctcagc	agtttagcgt	420
ggctatcag	atgaaggagg	cgattgggt	tactacagag	ctggcaaaaa	actgggtggc	480
agacaaacga	ttgatacatt	tgccgtttac	ttcgtatcag	atggaaaaca	ggttaaagga	540
gactggagag	agtcagacgg	aaacagagcg	tactatgatg	gccaagaagg	cagagccctt	600
acgcaaacac	aggcagttaa	cggagtcatc	tatggattta	atcaatcagg	atatcagatt	660
aagaacgatt	tcggccagac	ggctaacaga	gacacgtatt	actttgatgc	tcaaggacat	720
gtggttacgg	gcatccagac	aatgcaat	aaagttatg	atttcgtatg	acaagaaga	780
atgctgaaag	gaattgcac	gtcagtgcac	gataaaatga	tgtatccg	cgacccaaacg	840
ggcgtgggcc	aacctgcga	ccaccctgg	ttaatccgg	aaacggagcc	ggtccggat	900
gacaacatta	aacataacgc	tgcgcacgg	acgacacctg	ctgatccgt	tagcatggcc	960
ggatcaccta	cggcgatata	atgtataga	cctacagaca	tttggagaaa	tggcgaaaca	1020
tggagagaaa	gccagcctac	ggagttcaga	ccgcttctt	ccacatgg	gcctacgaaa	1080
caaacgcaag	cagattatgt	taattacatg	aaccatgtc	tgatatgtc	aatgcgagc	1140
gtgagcgtg	ccgatagcga	ggcaacactt	acagccgca	cgtatgtcc	ccaagctgca	1200
gtcgaacatc	aaattacagt	gagacagtca	acggatggc	tttagagaact	tatggcggca	1260
tttgcgtga	cgcaaccgca	gtgaaataaa	acatcaagg	atgtcaacga	cgatcacctg	1320
caaggaggag	cgcttacatt	cgaaaataac	ggcgatacgg	acgcaaatag	cgattacaga	1380
cttatgaata	gaacgcctac	aaaccaaaca	ggagaaagac	tttaccacat	tgacgactca	1440
cttggaggat	acgaactgct	tctggcaac	gatgttata	acagcaatcc	tcaagtgcag	1500
gctgagcaac	ttaattggct	ttattacgt	atgcatttt	gcgatattac	agctgacgac	1560
cctgacgcca	acttcgacgc	gattagaatc	gatgcgtcg	ataatgtcga	cgcagacctt	1620
cttcaactgg	ctgctcaata	tttcagagac	gcatacggaa	tggcaacaac	agacgctaca	1680
agcaataaac	atctgtcaat	tcttgaagac	ttgtcacata	atgatccggc	gtacatgcaa	1740
gctcatggaa	acgatcaact	tacatggat	gactatatgc	acacacaact	tatgggtca	1800
ctgacaaaac	cggaggctca	aagaggaaca	atggctagat	ttatggactt	ttatcttaca	1860
aatagagcga	acgatgatac	agaaaatacg	gctcaacctt	catattcatt	cgttagagca	1920
catgattcg	aagttcaac	agtattgtca	gaaattgtt	caaactgtca	tcctgaggcg	1980
ggcaatggac	tgatggcgcac	agaagagcaa	atggcagaag	cccttaagat	ctataatgcc	2040
gatcagaaaa	aagcagtgaa	aacatataca	cactacaata	tgccttcagc	ttatgtcaat	2100
ctgcttacat	ataaagacgt	cattcctaga	atttactatg	gagatcttta	tacagatgt	2160
ggacaattca	tggctacaaa	gtcacctt	tttgacgcta	tcagcgcgt	gctcaagcg	2220
agaacgaagt	atgtcgccagg	cggccagacg	atggcagtgg	atcagcacga	cgtcgttaca	2280
agcgtgagat	ttggcaaaagg	cgcaatgaca	gcatcagacc	tggcaatgc	agagacaaga	2340
acggagggag	ttggccttat	catttcaat	aatccgaaac	tgcaactggg	ccagcaggat	2400
aacgtcggtc	ttcatatggg	cctggcgcac	gcaaaccagg	cccttagagc	agttgttctt	2460
acaacagcga	cgggcctgac	aatctacaat	gacgatgtg	caccgattag	atatacagac	2520
aataaaggcg	acctgattt	caacaaccat	gatgtctacg	gcttcctgaa	ccgcaggtt	2580
tcaggcttcc	tggccatgt	ggttcctaca	ggcgcacctg	ctaaccaga	tgcttagatca	2640
acagcaagca	caaactcatc	aacggatggc	tcagcatatc	attcaaatgc	tgcgtggat	2700
tcacaagttt	tttgcatac	attctcaat	ttccaagcaa	tggcgcgtc	acatgacaca	2760
tacacgaatg	tggttctggc	caaccacgccc	gaccagttc	acgattgggg	cattacatca	2820
gtgcagctgg	caccgcagta	tagaagctca	acagacggca	cgttcctgga	tgcaattatc	2880
cagaatggct	atgccttcac	agatagatac	gatcttggct	ttggcacacc	tacaaaatac	2940
ggcgcacgaca	cggatctgag	aatgtgatt	aaggcgttc	atgccaacgg	catgcagggt	3000
atggccgact	tcgtcccgga	ccaaacttat	acacttccgg	gaaaagagct	ggtcaagtc	3060
acgagaacga	ataacatggg	cgaacctgtat	acacactcg	acattcaaca	tattctgtac	3120
gttacgtcaa	cgagaggccgg	aggagaataat	aaaaaacagt	atggcggcga	gtttcttga	3180
agactgagag	cactgtaccc	tgacctttt	acgacaagac	aaattagcac	aggccaaaca	3240
attgacgatt	cagtgaagat	caaagagtgg	tcagctaagt	actgtcaacgg	cacagctatc	3300
caaggaagag	gcccaggctt	tgttctgaga	gataatggca	caaattgccta	ctacaaagt	3360
acagcgaatg	atggaaatgt	caatcttcct	aaacaacttc	ttggacagcc	ggttatgacg	3420
ggcttctacc	acgaggccga	tggatatcac	ttcgagacac	tgtcaggaac	atcagccaag	3480
gatgcgttta	tcatgggaga	tgacggagcg	ctttattact	tttagtgcacca	aggcgttatg	3540
gtgacaggaa	aacagagagt	tcatcaagac	cagtacttct	ttctgcctaa	cggaattgct	3600
ctgacagacg	cgttcggtca	atcagcagac	ggacaaagac	agtattatga	caaaacggga	3660
agacttggta	tcaaccagta	tgtgacagat	caccaagcta	atgcttttag	agtcgtatgt	3720
gatggcaacg	tggtagaaaa	ccaagcactt	acagttatg	gacacgaaca	atatttcgg	3780

20151105_CL6294WOPCT_SequenceListing

acaaaatggag	tccaggctaa	agcggttctg	attagaacag	atgataatca	agcgagatat	3840
tacgaagcta	actcaggcaa	tctggtaag	caacaattca	ttcttgacac	agatggccac	3900
tggctgtacg	ccgatgcagc	cggagatctt	gctagaggac	agattacagt	gggacaggat	3960
acactgtatt	tcgacgataa	taaccaccaa	gttaaggatg	atttgtcta	tgatacaac	4020
ggcgttcatc	atttcaatgg	aacgacagga	gctgagatta	aacaagatta	cgcatttcac	4080
gacggcaaatt	ggtactactt	cgatgatctg	ggaagaatgg	ttacaggact	gcaaagaatt	4140
aacggcgaat	atagatattt	tgacgctaat	ggcgtccaac	ttaaggggagg	aacagtacg	4200
gaccctctta	cacatcaaac	atacattt	gatgctaaa	caggcggttgg	aacgctggc	4260
acgttttga						4269

<210> 7

<211> 4392

<212> DNA

<213> Lactobacillus fermentum

<400> 7

ttgcaagacg	agtacacagaa	gttttagaaaa	aagatgtata	agtccggaaa	gttttggta	60
gctgccgtg	ctttgttgt	tgggctggca	ttcgctggta	acgcgcaggc	agatactgt	120
ttaccaagtg	aacaacgtgc	aacacagacg	acacagacga	cacagaccag	tgaagacacg	180
tccggccacta	agacggccgc	atccggctcg	acttcaact	cagacaatgt	tgacacgagt	240
gacgtccctg	acagtgcag	tgcgggtgtt	gatagtgcag	ttacaactgt	aagtacaagt	300
gcaagtgttag	tgagtgtata	cgtgcggctg	ccagatactg	gatcacaatt	tatgagttcg	360
tcagcgccag	cgtcatcagc	gtttgttaaa	ccgtcactaa	cgtcaacaac	tagtggct	420
tccggcagtc	agtcatcagc	ggtgactagc	gcaaacgata	gttcgggtgc	aacttagt	480
tcagcatctt	cagtgacaaac	agccacaagt	gaatcgctg	tgttaagcag	cgcgtgtca	540
gatggttacc	atgtgaagg	tgggtattgg	gtcttattatc	gagctgggaa	aaagttactc	600
ggtcgacaaa	cgattgatac	gttgcgggt	tactttgacg	ccgatggcaa	acaagtcaag	660
ggtgattggc	gtgaaagtga	tggtaaacgt	gcgttattatg	atggcaaga	aggacgagca	720
ttaacgcaaa	cgcaagcagt	caatggcggt	atctacggtt	ttaatcaaag	cggctatcaa	780
atcaagaatg	atttcggcca	aacagcgaat	cgagatacgt	attatttcga	cgcacaagg	840
catgttgtca	cggaaatcca	aacaattgca	aacaagttt	atgattttga	tgagcaagg	900
cgaatgctga	aaggcattgc	cacgtcagtt	gatgacaaga	tgtgttattt	tgatgtatcaa	960
acagggttt	gacaaccggc	tgatcatctt	gaattcaacc	ctgaaacgg	accgggtcct	1020
gacgacaata	tcaaacataa	tgcagcacat	ggtacgacac	cagaagattt	tgattcgat	1080
gctgactacc	tgacggctga	tacttggtat	cgcggcaacc	atattttgg	aatggtgag	1140
acgtggcg	aatcgcaacc	aactgaattt	cgaccactgt	tagcaacttg	gtggccaaca	1200
aaacaaaccc	aggccgatta	cgtgaactac	atgaatcactg	cattagat	ggcaaatgca	1260
ggtgtgttag	ctgctgtatt	agaagccacg	ttaactgcgg	caaccgtatgc	tatccaagcg	1320
gttggtagc	accaaataatc	ggtgcgtcaa	tcaacgcgtt	ggttacgtga	attatggcc	1380
gcattttgtt	tgacacagcc	acagtggaaat	aaaacaatgt	aagatgtgaa	tgatgtat	1440
ttgcaagggt	gggcatttaac	atttggaaat	aacggcgaca	cagacgttac	ttcggattat	1500
cgcctcatga	accgcacaccc	aacaaatcag	actggcgaac	gcttgcgttacca	cattgtat	1560
tcacttggtg	gttacgattt	attgtggca	aatgacgtt	acaattcaaa	tccacaagg	1620
caggcagaac	aattgtattt	gttgcgttac	ttaatgcatt	tttggggat	tacagctgt	1680
gatccggacg	caaatttga	tgcatacgg	attgtatcg	tcgataatgt	cgatgtat	1740
ttacttcaac	tagcagccca	gtatcccgg	gatgcctatg	gcatggctac	aactgacgca	1800
acatcaaata	agcatcttc	aatttttgcg	gattggagcc	ataacgtatcc	ggcgatat	1860
caagcacacg	gcaatgtaca	attaacgtat	gatgattata	tgcacacaca	gttggat	1920
tcattaaacca	agcccggggc	acaacgcggg	accatggcac	gttttatgg	cttctatctc	1980
accaaccgtg	ctaatgtga	tacagaaaac	acggcgaac	ctagttactc	gttgcgt	2040
gcccatgata	gcpaagtaca	aacagtattt	gctgagatcg	tgacgaagct	gcatccagaa	2100
gcaggaaatg	ggtaatgccc	tacggaaagaa	caaatggcag	aacggtttaa	gatttacaat	2160
gcggacaaa	agaaggccgt	taagacttac	acacattaca	atatggccatc	tgcatacg	2220
atgctgttaa	cgaacaagga	tgttatttca	cgaattttact	atggtgactt	gtacactgt	2280
gatgggcaat	tcatggcgac	aaaatcacct	tattttgtat	cgatttcgac	catgttacaa	2340
gcacgcacga	agtatgtacg	tgggtggacag	acgatggcgg	ttgaccagca	cgacgtctt	2400
actagcggtt	ggttttgttaa	ggggggccatg	acggccatgt	attttaggg	tgctgagacc	2460
cggactgttt	gtgtggggatt	aattttagtgc	aacaacccaa	atgtcaattt	gggacaacaa	2520
gacaacgtgg	tgttacacat	gggacttgcg	cacgcgaatc	aggcattccg	cgcagtcgt	2580
ctaaccgaccg	cgaccggat	aaccatttt	aatgacgtat	atgctccgt	tgcgttatacc	2640
gataataagg	gtgattttaaat	tttcaactaac	catgacgtat	atggcggtt	gaatccacaa	2700
gtgtcaggct	tcttggcaat	gtgggtgcca	actgggtcact	cagcgaacca	ggatgcgcga	2760
tctactgcgt	caaccaacat	gtcaacggat	ggatctgcct	accattctaa	tgcggcttt	2820
gatagtcaag	taatcttgc	atcattttcg	aatttccagg	ctatgccaac	aagtcatgac	2880
acatacacca	acgttgtgtt	agccaatcat	gctgaccagt	tgacgattt	gggaaataact	2940
tcggtagt	tagcaccaca	ataccggct	tcaaccgacg	gtaccttttt	agacgcgatt	3000
attcaaaaatg	gctatgcctt	cactgaccgt	tatgatttag	ggttttggta	gccaactaaa	3060
tacggggatg	atacggattt	gcgaaacgtc	atcaaagcat	tgcacat	tggcatgcaaa	3120

20151105_CL6294WOPCT_SequenceListing

gtaatggctg	attttgtgcc	ggatcaattt	tatacattac	caggttacggaa	attggtacaa	3180
gtcacccgaa	caaacaatat	gggtgagcc	gatacgcatt	ctgacatcca	acatatttt	3240
tatgtacga	gcactcgtag	tgggtgtac	tatcagaaac	agtagcgttg	tgagttcctt	3300
gcacgattgc	gtgaacgata	cccgattta	tttacgacac	gtcaaatttc	gaccggacaa	3360
acaattgtat	attcagtaaa	aattaaagaa	tggtcagcta	agtatttga	tggtaccgca	3420
attcaaggac	gtggagctgg	ctatgtctg	cgtgataatg	gtacaaatgc	ttattacaag	3480
gtgacagcaa	atgacggtaa	tgtgaactta	ccaaagaat	tactcggcca	accgggtatg	3540
accggattct	atcacgaggc	agatggttat	cattttgaaa	cattgagtgg	tacgtcggcc	3600
aaagatgcct	ttattatggg	cgacgatggg	gcactgtatt	attttgcata	tcaggggttt	3660
atggtaacgg	gtaagcaacg	tgtgcaccaa	gatcagtatt	tcttcctgccc	aatgttatt	3720
gctttgacag	atgcttcgt	acaaactgct	gatggtaac	gtcagttacta	tgataaaaaca	3780
ggtcgtctgg	tcattaatca	atatgtact	gaccaccaag	cgaatgcgtt	ccgggttgc	3840
gcagacggta	acgttgcgg	caatcaagct	ttgactgttg	acggccatga	acaatatttc	3900
ggcacaaacg	gtgtccaaac	gaaagcagt	ctcattcgaa	ctgacgataa	tcaggcgcgc	3960
tactacgaag	ccaatagtgg	taatctcg	aagcaacagt	ttattcttga	tacagatgga	4020
cattgggtgt	acgcggatgc	tgcagggtac	ttggcacgcg	gacaaattac	aattggccaa	4080
gacacgttgt	attttgcata	taataatcac	caggtaaaag	atgatttcgt	ctatgatact	4140
aacgggtgtc	attattttaa	tggcacaaca	ggcgcgtaaa	tcaaacaaga	ttacgcgttt	4200
catgatggca	aatggtacta	ttttgcata	ttgggacgaa	tggtaaccgg	cttgcagcgt	4260
attaatgggt	agtatcgta	ttttgcata	aatggtgc	aactaaaggg	cggtaccgtg	4320
accgatccac	taacgcacca	aacgtacact	tttgcata	aaactgggtc	tggtacgttg	4380
gtgacgattt	aa					4392

<210> 8
<211> 1463
<212> PRT
<213> *Lactobacillus fermentum*

<400> 8
Met Gln Asp Glu Ser Gln Lys Phe Arg Lys Lys Met Tyr Lys Ser Gly
1 5 10 15
Lys Phe Trp Val Ala Ala Gly Ala Leu Phe Val Gly Leu Ala Phe Ala
20 25 30
Gly Asn Ala Gln Ala Asp Thr Val Leu Pro Ser Glu Gln Arg Ala Thr
35 40 45
Gln Thr Thr Gln Thr Thr Gln Thr Ser Glu Asp Thr Ser Ala Thr Lys
50 55 60
Thr Pro Ala Ser Ala Ser Thr Ser Ser Asp Asn Val Asp Thr Ser
65 70 75 80
Asp Leu Pro Asp Ser Ala Ser Ala Val Val Asp Ser Ala Val Thr Ser
85 90 95
Thr Ser Thr Ser Ala Ser Val Val Ser Asp Ser Val Ala Val Pro Asp
100 105 110
Thr Gly Ser Gln Phe Met Ser Ser Ala Pro Ala Ser Ser Ala Phe
115 120 125
Val Lys Pro Ser Leu Thr Ser Thr Ser Gly Ala Ser Gly Ser Gln
130 135 140
Ser Ser Ala Val Thr Ser Ala Asn Asp Ser Ser Val Ala Thr Ser Ser
145 150 155 160
Ser Ala Ser Ser Val Thr Thr Ala Thr Ser Glu Ser Ala Val Val Ser
165 170 175
Ser Ala Val Ser Asp Gly Tyr His Asp Glu Gly Gly Asp Trp Val Tyr
180 185 190
Tyr Arg Ala Gly Lys Lys Leu Leu Gly Arg Gln Thr Ile Asp Thr Phe
195 200 205
Ala Val Tyr Phe Asp Ala Asp Gly Lys Gln Val Lys Gly Asp Trp Arg
210 215 220
Glu Ser Asp Gly Lys Arg Ala Tyr Tyr Asp Gly Gln Glu Gly Arg Ala
225 230 235 240
Leu Thr Gln Thr Gln Ala Val Asn Gly Val Ile Tyr Gly Phe Asn Gln
245 250 255
Ser Gly Tyr Gln Ile Lys Asn Asp Phe Gly Gln Thr Ala Asn Arg Asp
260 265 270
Thr Tyr Tyr Phe Asp Ala Gln Gly His Val Val Thr Gly Ile Gln Thr
275 280 285
Ile Ala Asn Lys Val Tyr Asp Phe Asp Glu Gln Gly Arg Met Leu Lys
290 295 300
Gly Ile Ala Thr Ser Val Asp Asp Lys Met Met Tyr Phe Asp Asp Gln

20151105_CL6294WOPCT_SequenceListing

305 Thr Gly Val Gly Gln Pro Ala Asp His Pro Glu Phe Asn Pro Glu Thr
 310 325 330 335
 Glu Pro Val Pro Asp Asp Asn Ile Lys His Asn Ala Ala His Gly Thr
 340 345 350
 355 360 365
 Trp Tyr Arg Pro Thr Asp Ile Leu Glu Asn Gly Glu Thr Trp Arg Glu
 370 375 380
 Ser Gln Pro Thr Glu Phe Arg Pro Leu Leu Ala Thr Trp Trp Pro Thr
 385 390 395 400
 Lys Gln Thr Gln Ala Asp Tyr Val Asn Tyr Met Asn His Ala Leu Asp
 405 410 415
 Met Ala Asn Ala Gly Val Ser Ala Ala Asp Ser Glu Ala Thr Leu Thr
 420 425 430
 Ala Ala Thr Asp Ala Ile Gln Ala Val Val Glu His Gln Ile Thr Val
 435 440 445
 Arg Gln Ser Thr Ala Trp Leu Arg Glu Leu Met Ala Ala Phe Val Val
 450 455 460
 Thr Gln Pro Gln Trp Asn Lys Thr Ser Glu Asp Val Asn Asp Asp His
 465 470 475 480
 Leu Gln Gly Gly Ala Leu Thr Phe Glu Asn Asn Gly Asp Thr Asp Ala
 485 490 495
 Asn Ser Asp Tyr Arg Leu Met Asn Arg Thr Pro Thr Asn Gln Thr Gly
 500 505 510
 Glu Arg Leu Tyr His Ile Asp Asp Ser Leu Gly Gly Tyr Glu Leu Leu
 515 520 525
 Leu Ala Asn Asp Val Asp Asn Ser Asn Pro Gln Val Gln Ala Glu Gln
 530 535 540
 Leu Asn Trp Leu Tyr Tyr Leu Met His Phe Gly Asp Ile Thr Ala Asp
 545 550 555 560
 Asp Pro Asp Ala Asn Phe Asp Ala Ile Arg Ile Asp Ala Val Asp Asn
 565 570 575
 Val Asp Ala Asp Leu Leu Gln Leu Ala Ala Gln Tyr Phe Arg Asp Ala
 580 585 590
 Tyr Gly Met Ala Thr Thr Asp Ala Thr Ser Asn Lys His Leu Ser Ile
 595 600 605
 Leu Glu Asp Trp Ser His Asn Asp Pro Ala Tyr Met Gln Ala His Gly
 610 615 620
 Asn Asp Gln Leu Thr Met Asp Asp Tyr Met His Thr Gln Leu Ile Trp
 625 630 635 640
 Ser Leu Thr Lys Pro Glu Ala Gln Arg Gly Thr Met Ala Arg Phe Met
 645 650 655
 Asp Phe Tyr Leu Thr Asn Arg Ala Asn Asp Asp Thr Glu Asn Thr Ala
 660 665 670
 Gln Pro Ser Tyr Ser Phe Val Arg Ala His Asp Ser Glu Val Gln Thr
 675 680 685
 Val Ile Ala Glu Ile Val Thr Lys Leu His Pro Glu Ala Gly Asn Gly
 690 695 700
 Leu Met Pro Thr Glu Glu Gln Met Ala Glu Ala Phe Lys Ile Tyr Asn
 705 710 715 720
 Ala Asp Gln Lys Lys Ala Val Lys Thr Tyr Thr His Tyr Asn Met Pro
 725 730 735
 Ser Ala Tyr Ala Met Leu Leu Thr Asn Lys Asp Val Ile Pro Arg Ile
 740 745 750
 Tyr Tyr Gly Asp Leu Tyr Thr Asp Asp Gly Gln Phe Met Ala Thr Lys
 755 760 765
 Ser Pro Tyr Phe Asp Ala Ile Ser Thr Met Leu Gln Ala Arg Thr Lys
 770 775 780
 Tyr Val Ala Gly Gly Gln Thr Met Ala Val Asp Gln His Asp Val Leu
 785 790 795 800
 Thr Ser Val Arg Phe Gly Lys Gly Ala Met Thr Ala Asn Asp Leu Gly
 805 810 815
 Asp Ala Glu Thr Arg Thr Glu Gly Val Gly Leu Ile Ile Ser Asn Asn
 820 825 830
 Pro Lys Leu Gln Leu Gly Gln Gln Asp Asn Val Val Leu His Met Gly
 835 840 845
 Leu Ala His Ala Asn Gln Ala Phe Arg Ala Val Val Leu Thr Thr Ala

20151105_CL6294WOPCT_SequenceListing

850	855	860													
Thr	Gly	Leu	Thr	Ile	Tyr	Asn	Asp	Asp	Asp	Ala	Pro	Ile	Arg	Tyr	Thr
865		870			875										880
Asp	Asn	Lys	Gly	Asp	Leu	Ile	Phe	Thr	Asn	His	Asp	Val	Tyr	Gly	Val
		885			890									895	
Leu	Asn	Pro	Gln	Val	Ser	Gly	Phe	Leu	Ala	Met	Trp	Val	Pro	Thr	Gly
		900			905									910	
Ala	Pro	Ala	Asn	Gln	Asp	Ala	Arg	Ser	Thr	Ala	Ser	Thr	Asn	Met	Ser
		915			920								925		
Thr	Asp	Gly	Ser	Ala	Tyr	His	Ser	Asn	Ala	Ala	Leu	Asp	Ser	Gln	Val
		930			935							940			
Ile	Phe	Glu	Ser	Phe	Ser	Asn	Phe	Gln	Ala	Met	Pro	Thr	Ser	His	Asp
		945			950						955			960	
Thr	Tyr	Thr	Asn	Val	Val	Leu	Ala	Asn	His	Ala	Asp	Gln	Leu	His	Asp
		965			970						975				
Trp	Gly	Ile	Thr	Ser	Val	Gln	Leu	Ala	Pro	Gln	Tyr	Arg	Ser	Ser	Thr
		980			985						990				
Asp	Gly	Thr	Phe	Leu	Asp	Ala	Ile	Ile	Gln	Asn	Gly	Tyr	Ala	Phe	Thr
		995			1000							1005			
Asp	Arg	Tyr	Asp	Leu	Gly	Phe	Gly	Thr	Pro	Thr	Lys	Tyr	Gly	Asp	
	1010				1015						1020				
Asp	Thr	Asp	Leu	Arg	Asn	Val	Ile	Lys	Ala	Leu	His	Ala	Asn	Gly	
	1025				1030						1035				
Met	Gln	Val	Met	Ala	Asp	Phe	Val	Pro	Asp	Gln	Leu	Tyr	Thr	Leu	
	1040				1045						1050				
Pro	Gly	Lys	Glu	Leu	Val	Gln	Val	Thr	Arg	Thr	Asn	Asn	Met	Gly	
	1055				1060						1065				
Glu	Pro	Asp	Thr	His	Ser	Asp	Ile	Gln	His	Ile	Leu	Tyr	Val	Thr	
	1070				1075						1080				
Ser	Thr	Arg	Gly	Gly	Gly	Asp	Tyr	Gln	Lys	Gln	Tyr	Gly	Gly	Glu	
	1085				1090						1095				
Phe	Leu	Ala	Arg	Leu	Arg	Glu	Arg	Tyr	Pro	Asp	Leu	Phe	Thr	Thr	
	1100				1105						1110				
Arg	Gln	Ile	Ser	Thr	Gly	Gln	Thr	Ile	Asp	Asp	Ser	Val	Lys	Ile	
	1115				1120						1125				
Lys	Glu	Trp	Ser	Ala	Lys	Tyr	Leu	Asn	Gly	Thr	Ala	Ile	Gln	Gly	
	1130				1135						1140				
Arg	Gly	Ala	Gly	Tyr	Val	Leu	Arg	Asp	Asn	Gly	Thr	Asn	Ala	Tyr	
	1145				1150						1155				
Tyr	Lys	Val	Thr	Ala	Asn	Asp	Gly	Asn	Val	Asn	Leu	Pro	Lys	Gln	
	1160				1165						1170				
Leu	Leu	Gly	Gln	Pro	Val	Met	Thr	Gly	Phe	Tyr	His	Glu	Ala	Asp	
	1175				1180						1185				
Gly	Tyr	His	Phe	Glu	Thr	Leu	Ser	Gly	Thr	Ser	Ala	Lys	Asp	Ala	
	1190				1195						1200				
Phe	Ile	Met	Gly	Asp	Asp	Gly	Ala	Leu	Tyr	Tyr	Phe	Asp	Asp	Gln	
	1205				1210						1215				
Gly	Val	Met	Val	Thr	Gly	Lys	Gln	Arg	Val	His	Gln	Asp	Gln	Tyr	
	1220				1225						1230				
Phe	Phe	Leu	Pro	Asn	Gly	Ile	Ala	Leu	Thr	Asp	Ala	Phe	Val	Gln	
	1235				1240						1245				
Thr	Ala	Asp	Gly	Gln	Arg	Gln	Tyr	Tyr	Asp	Lys	Thr	Gly	Arg	Leu	
	1250				1255						1260				
Val	Ile	Asn	Gln	Tyr	Val	Thr	Asp	His	Gln	Ala	Asn	Ala	Phe	Arg	
	1265				1270						1275				
Val	Asp	Ala	Asp	Gly	Asn	Val	Val	Arg	Asn	Gln	Ala	Leu	Thr	Val	
	1280				1285						1290				
Asp	Gly	His	Glu	Gln	Tyr	Phe	Gly	Thr	Asn	Gly	Val	Gln	Ala	Lys	
	1295				1300						1305				
Ala	Val	Leu	Ile	Arg	Thr	Asp	Asp	Asn	Gln	Ala	Arg	Tyr	Tyr	Glu	
	1310				1315						1320				
Ala	Asn	Ser	Gly	Asn	Leu	Val	Lys	Gln	Gln	Phe	Ile	Leu	Asp	Thr	
	1325				1330						1335				
Asp	Gly	His	Trp	Leu	Tyr	Ala	Asp	Ala	Ala	Gly	Asp	Leu	Ala	Arg	
	1340				1345						1350				
Gly	Gln	Ile	Thr	Ile	Gly	Gln	Asp	Thr	Leu	Tyr	Phe	Asp	Asp	Asn	
	1355				1360						1365				
Asn	His	Gln	Val	Lys	Asp	Asp	Phe	Val	Tyr	Asp	Thr	Asn	Gly	Val	

20151105_CL6294WOPCT_SequenceListing

<210> 9
<211> 1426
<212> PRT
<213> *Lactobacillus fermentum*

```
<220>
<221> MISC_FEATURE
<222> (1)..(1426)
<223> mature 2918 qtf
```

<400> 9
 Asp Thr Val Leu Pro Ser Glu Gln Arg Ala Thr Gln Thr Thr Gln Thr
 1 5 10 15
 Thr Gln Thr Ser Glu Asp Thr Ser Ala Thr Lys Thr Pro Ala Ser Ala
 20 25 30
 Ser Thr Ser Ser Asp Asn Val Asp Thr Ser Asp Leu Pro Asp Ser
 35 40 45
 Ala Ser Ala Val Val Asp Ser Ala Val Thr Ser Thr Ser Ala
 50 55 60
 Ser Val Val Ser Asp Ser Val Ala Val Pro Asp Thr Gly Ser Gln Phe
 65 70 75 80
 Met Ser Ser Ser Ala Pro Ala Ser Ser Ala Phe Val Lys Pro Ser Leu
 85 90 95
 Thr Ser Thr Ser Gly Ala Ser Gly Ser Gln Ser Ser Ala Val Thr
 100 105 110
 Ser Ala Asn Asp Ser Ser Val Ala Thr Ser Ser Ser Ala Ser Ser Val
 115 120 125
 Thr Thr Ala Thr Ser Glu Ser Ala Val Val Ser Ser Ala Val Ser Asp
 130 135 140
 Gly Tyr His Asp Glu Gly Gly Asp Trp Val Tyr Tyr Arg Ala Gly Lys
 145 150 155 160
 Lys Leu Leu Gly Arg Gln Thr Ile Asp Thr Phe Ala Val Tyr Phe Asp
 165 170 175
 Ala Asp Gly Lys Gln Val Lys Gly Asp Trp Arg Glu Ser Asp Gly Lys
 180 185 190
 Arg Ala Tyr Tyr Asp Gly Gln Glu Gly Arg Ala Leu Thr Gln Thr Gln
 195 200 205
 Ala Val Asn Gly Val Ile Tyr Gly Phe Asn Gln Ser Gly Tyr Gln Ile
 210 215 220
 Lys Asn Asp Phe Gly Gln Thr Ala Asn Arg Asp Thr Tyr Tyr Phe Asp
 225 230 235 240
 Ala Gln Gly His Val Val Thr Gly Ile Gln Thr Ile Ala Asn Lys Val
 245 250 255
 Tyr Asp Phe Asp Glu Gln Gly Arg Met Leu Lys Gly Ile Ala Thr Ser
 260 265 270
 Val Asp Asp Lys Met Met Tyr Phe Asp Asp Gln Thr Gly Val Gly Gln
 275 280 285
 Pro Ala Asp His Pro Glu Phe Asn Pro Glu Thr Glu Pro Val Pro Asp
 290 295 300
 Asp Asn Ile Lys His Asn Ala Ala His Gly Thr Thr Pro Glu Asp Phe
 305 310 315 320
 Asp Ser Met Ala Asp Tyr Leu Thr Ala Asp Thr Trp Tyr Arg Pro Thr
 325 330 335
 Asp Ile Leu Glu Asn Gly Glu Thr Trp Arg Glu Ser Gln Pro Thr Glu

20151105_CL6294WOPCT_SequenceListing

	340	345	350												
Phe	Arg	Pro	Leu	Leu	Ala	Thr	Trp	Trp	Pro	Thr	Lys	Gln	Thr	Gln	Ala
355							360				365				
Asp	Tyr	Val	Asn	Tyr	Met	Asn	His	Ala	Leu	Asp	Met	Ala	Asn	Ala	Gly
370							375				380				
Val	Ser	Ala	Ala	Asp	Ser	Glu	Ala	Thr	Leu	Thr	Ala	Ala	Thr	Asp	Ala
385							390				395				400
Ile	Gln	Ala	Val	Val	Glu	His	Gln	Ile	Thr	Val	Arg	Gln	Ser	Thr	Ala
							405				410				415
Trp	Leu	Arg	Glu	Leu	Met	Ala	Ala	Phe	Val	Val	Thr	Gln	Pro	Gln	Trp
								420				425			430
Asn	Lys	Thr	Ser	Glu	Asp	Val	Asn	Asp	Asp	His	Leu	Gln	Gly	Gly	Ala
								435				440			445
Leu	Thr	Phe	Glu	Asn	Asn	Gly	Asp	Thr	Asp	Ala	Asn	Ser	Asp	Tyr	Arg
								450				455			460
Leu	Met	Asn	Arg	Thr	Pro	Thr	Asn	Gln	Thr	Gly	Glu	Arg	Leu	Tyr	His
								465				470			480
Ile	Asp	Asp	Ser	Leu	Gly	Gly	Tyr	Glu	Leu	Leu	Leu	Ala	Asn	Asp	Val
								485				490			495
Asp	Asn	Ser	Asn	Pro	Gln	Val	Gln	Ala	Glu	Gln	Leu	Asn	Trp	Leu	Tyr
								500				505			510
Tyr	Leu	Met	His	Phe	Gly	Asp	Ile	Thr	Ala	Asp	Asp	Pro	Asp	Ala	Asn
								515				520			525
Phe	Asp	Ala	Ile	Arg	Ile	Asp	Ala	Val	Asp	Asn	Val	Asp	Ala	Asp	Leu
								530				535			540
Leu	Gln	Leu	Ala	Ala	Gln	Tyr	Phe	Arg	Asp	Ala	Tyr	Gly	Met	Ala	Thr
								545				550			560
Thr	Asp	Ala	Thr	Ser	Asn	Lys	His	Leu	Ser	Ile	Leu	Glu	Asp	Trp	Ser
								565				570			575
His	Asn	Asp	Pro	Ala	Tyr	Met	Gln	Ala	His	Gly	Asn	Asp	Gln	Leu	Thr
								580				585			590
Met	Asp	Asp	Tyr	Met	His	Thr	Gln	Leu	Ile	Trp	Ser	Leu	Thr	Lys	Pro
								595				600			605
Glu	Ala	Gln	Arg	Gly	Thr	Met	Ala	Arg	Phe	Met	Asp	Phe	Tyr	Leu	Thr
								610				615			620
Asn	Arg	Ala	Asn	Asp	Asp	Thr	Glu	Asn	Thr	Ala	Gln	Pro	Ser	Tyr	Ser
								625				630			640
Phe	Val	Arg	Ala	His	Asp	Ser	Glu	Val	Gln	Thr	Val	Ile	Ala	Glu	Ile
								645				650			655
Val	Thr	Lys	Leu	His	Pro	Glu	Ala	Gly	Asn	Gly	Leu	Met	Pro	Thr	Glu
								660				665			670
Glu	Gln	Met	Ala	Glu	Ala	Phe	Lys	Ile	Tyr	Asn	Ala	Asp	Gln	Lys	Lys
								675				680			685
Ala	Val	Lys	Thr	Tyr	Thr	His	Tyr	Asn	Met	Pro	Ser	Ala	Tyr	Ala	Met
								690				695			700
Leu	Leu	Thr	Asn	Lys	Asp	Val	Ile	Pro	Arg	Ile	Tyr	Tyr	Gly	Asp	Leu
								705				710			720
Tyr	Thr	Asp	Asp	Gly	Gln	Phe	Met	Ala	Thr	Lys	Ser	Pro	Tyr	Phe	Asp
								725				730			735
Ala	Ile	Ser	Thr	Met	Leu	Gln	Ala	Arg	Thr	Lys	Tyr	Val	Ala	Gly	Gly
								740				745			750
Gln	Thr	Met	Ala	Val	Asp	Gln	His	Asp	Val	Leu	Thr	Ser	Val	Arg	Phe
								755				760			765
Gly	Lys	Gly	Ala	Met	Thr	Ala	Asn	Asp	Leu	Gly	Asp	Ala	Glu	Thr	Arg
								770				775			780
Thr	Glu	Gly	Val	Gly	Leu	Ile	Ile	Ser	Asn	Asn	Pro	Lys	Leu	Gln	Leu
								785				790			800
Gly	Gln	Gln	Asp	Asn	Val	Val	Leu	His	Met	Gly	Leu	Ala	His	Ala	Asn
								805				810			815
Gln	Ala	Phe	Arg	Ala	Val	Val	Leu	Thr	Thr	Ala	Thr	Gly	Leu	Thr	Ile
								820				825			830
Tyr	Asn	Asp	Asp	Ala	Pro	Ile	Arg	Tyr	Thr	Asp	Asn	Lys	Gly	Asp	
								835				840			845
Leu	Ile	Phe	Thr	Asn	His	Asp	Val	Tyr	Gly	Val	Leu	Asn	Pro	Gln	Val
								850				855			860
Ser	Gly	Phe	Leu	Ala	Met	Trp	Val	Pro	Thr	Gly	Ala	Pro	Ala	Asn	Gln
								865				870			875
Asp	Ala	Arg	Ser	Thr	Ala	Ser	Thr	Asn	Met	Ser	Thr	Asp	Gly	Ser	Ala

20151105_CL6294WO_PCT_SequenceListing

	885	890	895
Tyr	His Ser Asn Ala Ala Leu Asp Ser Gln Val Ile Phe Glu Ser Phe		
	900	905	910
Ser	Asn Phe Gln Ala Met Pro Thr Ser His Asp Thr Tyr Thr Asn Val		
	915	920	925
Val	Leu Ala Asn His Ala Asp Gln Leu His Asp Trp Gly Ile Thr Ser		
	930	935	940
Val	Gln Leu Ala Pro Gln Tyr Arg Ser Ser Thr Asp Gly Thr Phe Leu		
	945	950	955
Asp	Ala Ile Ile Gln Asn Gly Tyr Ala Phe Thr Asp Arg Tyr Asp Leu		
	965	970	975
Gly	Phe Gly Thr Pro Thr Lys Tyr Gly Asp Asp Thr Asp Leu Arg Asn		
	980	985	990
Val	Ile Lys Ala Leu His Ala Asn Gly Met Gln Val Met Ala Asp Phe		
	995	1000	1005
Val	Pro Asp Gln Leu Tyr Thr Leu Pro Gly Lys Glu Leu Val Gln		
	1010	1015	1020
Val	Thr Arg Thr Asn Asn Met Gly Glu Pro Asp Thr His Ser Asp		
	1025	1030	1035
Ile	Gln His Ile Leu Tyr Val Thr Ser Thr Arg Gly Gly Gly Asp		
	1040	1045	1050
Tyr	Gln Lys Gln Tyr Gly Gly Glu Phe Leu Ala Arg Leu Arg Glu		
	1055	1060	1065
Arg	Tyr Pro Asp Leu Phe Thr Thr Arg Gln Ile Ser Thr Gly Gln		
	1070	1075	1080
Thr	Ile Asp Asp Ser Val Lys Ile Lys Glu Trp Ser Ala Lys Tyr		
	1085	1090	1095
Leu	Asn Gly Thr Ala Ile Gln Gly Arg Gly Ala Gly Tyr Val Leu		
	1100	1105	1110
Arg	Asp Asn Gly Thr Asn Ala Tyr Tyr Lys Val Thr Ala Asn Asp		
	1115	1120	1125
Gly	Asn Val Asn Leu Pro Lys Gln Leu Leu Gly Gln Pro Val Met		
	1130	1135	1140
Thr	Gly Phe Tyr His Glu Ala Asp Gly Tyr His Phe Glu Thr Leu		
	1145	1150	1155
Ser	Gly Thr Ser Ala Lys Asp Ala Phe Ile Met Gly Asp Asp Gly		
	1160	1165	1170
Ala	Leu Tyr Tyr Phe Asp Asp Gln Gly Val Met Val Thr Gly Lys		
	1175	1180	1185
Gln	Arg Val His Gln Asp Gln Tyr Phe Phe Leu Pro Asn Gly Ile		
	1190	1195	1200
Ala	Leu Thr Asp Ala Phe Val Gln Thr Ala Asp Gly Gln Arg Gln		
	1205	1210	1215
Tyr	Tyr Asp Lys Thr Gly Arg Leu Val Ile Asn Gln Tyr Val Thr		
	1220	1225	1230
Asp	His Gln Ala Asn Ala Phe Arg Val Asp Ala Asp Gly Asn Val		
	1235	1240	1245
Val	Arg Asn Gln Ala Leu Thr Val Asp Gly His Glu Gln Tyr Phe		
	1250	1255	1260
Gly	Thr Asn Gly Val Gln Ala Lys Ala Val Leu Ile Arg Thr Asp		
	1265	1270	1275
Asp	Asn Gln Ala Arg Tyr Tyr Glu Ala Asn Ser Gly Asn Leu Val		
	1280	1285	1290
Lys	Gln Gln Phe Ile Leu Asp Thr Asp Gly His Trp Leu Tyr Ala		
	1295	1300	1305
Asp	Ala Ala Gly Asp Leu Ala Arg Gly Gln Ile Thr Ile Gly Gln		
	1310	1315	1320
Asp	Thr Leu Tyr Phe Asp Asp Asn Asn His Gln Val Lys Asp Asp		
	1325	1330	1335
Phe	Val Tyr Asp Thr Asn Gly Val His Tyr Phe Asn Gly Thr Thr		
	1340	1345	1350
Gly	Ala Glu Ile Lys Gln Asp Tyr Ala Phe His Asp Gly Lys Trp		
	1355	1360	1365
Tyr	Tyr Phe Asp Asp Leu Gly Arg Met Val Thr Gly Leu Gln Arg		
	1370	1375	1380
Ile	Asn Gly Glu Tyr Arg Tyr Phe Asp Ala Asn Gly Val Gln Leu		
	1385	1390	1395
Lys	Gly Gly Thr Val Thr Asp Pro Leu Thr His Gln Thr Tyr Thr		

20151105_CL6294WOPCT_SequenceListing

1400	1405	1410										
Phe	Asp	Ala	Lys	Thr	Gly	Ala	Gly	Thr	Leu	Val	Thr	Ile
1415	1420	1425										

<210> 10
<211> 4281
<212> DNA
<213> Artificial sequence

<220>
<223> 2918 gtf with heterologous signal sequence

<400>	10	gcagacatca	60			
gatacagtgc	tgccctagcga	gcaaagagca	acacagacga	cacaacaac	gcagacatca	60
gaggatacga	gcgcgacgaa	gacaccggca	agcgcataa	cgtcaagcag	cgataacgtg	120
gatacgtcag	atcttccgga	tagcggcagc	gcagttgtcg	attcagcgg	tacatcaaca	180
agcacgtcag	cctcagtgg	gagcgatgc	gttgcagttc	cggatacggg	atcacaattt	240
atgtcatcat	cagctcctgc	gagcagcgc	tttggtaaac	ctagcctac	gtcaacgacg	300
tcaggagcga	gcccgtcaca	gagctcagca	gtgacaagcg	ccaatgattc	aagcgtcgt	360
acaagctcat	cagcttcatc	agttacgaca	gcaacaagcg	agtcaagccgt	tgtctcaagc	420
gcggtctcag	acggctatca	tgacgaagga	ggagattggg	tttactacag	agcaggaaaa	480
aaactgcttg	gaagacagac	aattgatacg	tttgcgttt	acttgcgt	tgacggaaaa	540
caagtggaaag	gcgactggag	agaatcagat	ggaaagagag	cgtattatga	tggacaagaa	600
ggaagagccc	ttacgcaaaac	gcaaggcgtt	aatggagtga	tctatggatt	caatcaatca	660
ggataccaga	tcaaaaacga	ttttggccag	acagcgaaca	gagatacata	ctacttcgac	720
gcacaaggcc	atgtggttac	aggcatccaa	acaatcgcga	ataaagtta	tgacttcgat	780
gaacaaggca	gaatgtttaa	aggaatttgc	acatcgtcg	atgacaagat	gatgtat	840
gacgatcaaa	caggcggtgg	acaacctgca	gatcaccctg	atgtaaccc	gaaacagaa	900
ccggtgctg	acgataacat	caagcataat	gcagcccacg	gcacaacacc	tgaagat	960
gatagcatgg	cggactatct	gacagctgtat	acatggtata	gacctacaga	tattctggag	1020
aatggagaaa	catggagaga	gagccaaaccg	acggaattt	gaccgctgct	ggcaacgtgg	1080
tggcctacaa	aacagacaca	agcagattat	gtgaactata	tgaaccacgc	acttgcacatg	1140
gctaattgtg	gcgttagcgc	tgccgattca	gaggcaacac	ttacagcggc	tacggatgcc	1200
attcaggctg	ttgttgagca	ccaaatttacg	tttagacaaa	gcacggcctg	gcttagagaa	1260
cttatggcgg	cttttgcgtt	tacacaacct	caatggaata	agacgagcga	agatgtcaat	1320
gatgatcacc	ttcaaggagg	cgcactgaca	tttggagaata	acggagacac	agatgcaat	1380
agcgattata	gacttatgaa	tagaacaccg	acaatcaaa	cggcgagag	actttatcat	1440
attgatgact	cactgggagg	ctacgagctg	cttcttgcaa	acgatgtgg	caactcaaac	1500
cccgagggtt	aggcgaaca	acttaactgg	ctttactatc	ttatgcattt	cggagatatt	1560
acagccgatg	accggatgc	taactttgac	gcatcgaaa	ttgacgcccgt	tgataatgtc	1620
gacgctgacc	tgcttcagct	tgctgccc	tacttttagag	atgcataatgg	aatggccaca	1680
acagacgcca	cgagcaataa	acacccatca	atccttgagg	attgagcca	taacgatcct	1740
gcttatatgc	aggcacatgg	aatgaccag	tttacatgg	atgactacat	gcacacacaa	1800
ctgattttgt	cactgacgaa	accggaaagc	caaagaggaa	cgtggcaag	atttatggac	1860
ttttatctta	caaataagac	taacgtatgat	acagaaaaca	cagcgaaccc	ttcatattca	1920
tttggtagag	cacacgactc	agaagtgcag	acagttatgg	cagaatttgt	tacgaaactt	1980
cacccggagg	caggcaacgg	cctttagcct	acggaggaac	agatggcaga	ggcggttaag	2040
atctacaatg	cagaccaaaa	gaaagcggt	aaaacatata	cacactataa	catgccttca	2100
gcctacgcta	tgctgctgac	aaataaggat	gtgattccca	gaatctacta	cggcgatctt	2160
tacacggacg	acggccagtt	catggcaaca	aagtccacgt	atttcgatgc	aatttcaaca	2220
atgctgcag	caagaacaaa	atatgttgc	ggcgacaaa	cgtggcggt	tgaccaacat	2280
gatgtcttga	cgagcgtgag	atttgcacaa	ggcgcgtatga	cagcaaatga	ccttggagac	2340
gcggaaacga	gaacagaggg	cgtggactg	atcatcaga	acaaccctaa	gctgcaactg	2400
ggacagcagg	ataacgttgt	ccttcatatg	ggcctggcac	acgcaatca	ggctttcaga	2460
gcagtcgtgc	ttacaacagc	cacaggactg	acgatctaca	acgacgatga	cgctcttatt	2520
agatatacgg	acaataaggg	cgaccgtatc	tttacgaaatc	acgatgttt	cgcggttctg	2580
aaccccgagg	ttagcggtt	ccttgcata	ttgggttccga	cgggcgacc	tgccaatcaa	2640
gacgcaagaa	gcacggcttc	aacgaatatg	tcaacggat	gatcagctta	tcattcaaac	2700
gcagctctgg	attcacaatgt	tatctttgag	tcattttgca	acttcaagc	aatgcccaca	2760
tcacacgata	catacagca	tgttgcctt	gaaaaccatg	cagaccaact	tcacgatgg	2820
ggaatttacgt	cagtgcact	tgcaccgc	tatagatcaa	gcacagacgg	aacgtttctg	2880
gatgcaat	ttcaaaaatgg	atatgtttt	acagatagat	atgatcttgg	cttggaaaca	2940
cctacgaatg	acggcgacga	cacggacctg	agaatgtga	tcaaaccctt	tcatgcacaa	3000
ggcatgcaag	tcatggcaga	tttggcttct	gatcaactgt	acacacttcc	gggcaaagaa	3060
ctgggttcaag	tgacaagaac	aaataacatg	ggcgaaccgg	atacacacag	cgatattca	3120
cacatcttgt	atgttacatc	aacaagagga	ggcggagact	atcagaaaca	atatggccgc	3180
gaatttctgg	ctagacttag	agaaagatac	ccggacctt	ttacgacgag	acaaatttagc	3240
acaqqccaaa	caattqacqa	caqcgtaaq	attaqqqat	qgtcaqcgaa	atatctqaac	3300

20151105_CL6294WOPCT_SequenceListing

ggcacagcaa	ttcaaggcag	aggcgctggc	tatgttctga	gagataatgg	aacgaatgca	3360
tactataaag	ttacggccaa	tgatggaaac	gtcaatcttc	ctaagcaact	gctgggccag	3420
ccggttatga	caggcttcta	tcacgaagca	gacggctacc	acttcgagac	actgtcaggc	3480
acatcagcca	aggacgcatt	tatcatggga	gatgtatggc	cactgtacta	tttcgatgac	3540
caaggcgtga	tggttacagg	aaaacaaaaga	gttcatcagg	atcaataactt	ttttctgccc	3600
aatggcatcg	ctctgacgga	cgcttgcgtt	caaacagctg	atggacagag	acagtactac	3660
gataaaaacag	gcagacttgt	tattaaccaa	tatgtgacag	accatcaggc	gaatgccttc	3720
agagttgtat	cggaacggaaa	tgtcgtaga	aaccaagcac	ttacagtgg	cggacatgaa	3780
cagtatttcg	gcacgaacgg	agtgcaggca	aaagcagttc	tgattagaac	ggacgataat	3840
caagcgagat	attatgaggg	aaattcaggc	aatctggtga	aacaacaatt	tatccttgcac	3900
acagatggcc	actggctgta	cgcagacgca	gcaggcgatc	ttgcttagagg	ccagattaca	3960
atcggccagg	atacgctgta	ttttagatgt	aacaatcacc	aagttaaaga	tgacttcgtt	4020
tatgatacga	atggagttca	ttacttaat	ggcacaacag	gagcagagat	taaacaagat	4080
tacgcattcc	atgacggcaa	atgttactac	ttcgcacgacc	tggaaagaat	ggtcacggga	4140
cttcaaagaa	ttaatggaga	gtatagatac	tttgacgcga	acggcgtcca	actgaaagga	4200
ggcacagtga	cggatccct	gacacatcaa	acatatacat	ttgatgcaaa	aacgggagcc	4260
ggcacgcttg	ttacaatttg	a				4281

<210> 11
<211> 4521

<212> DNA
<213> Streptococcus sobrinus

<400> 11						
atggaaaagaa	aattgcatta	caaattacac	aaggtaaaaa	aacagtgggt	aacgattgcc	60
gttgcctctg	ctggtttggc	tagattgtt	ggtgctggtt	cattaagcca	aactttct	120
gccgatgact	tagccaagga	acaagctgcg	gctagtcac	aaaaggcagc	agccaatcag	180
aatgaggacg	aagtggcttc	tgtgcagct	gatactgcta	gtgcaaaagc	gactttcgaa	240
aaagaagttg	tccaatcttc	tgatacaaat	tcagaaacta	accaagttga	aactaaagat	300
caagctagcg	ctaaggaaag	tgctgacgca	gtagccaagc	aagcaccac	agctggccct	360
gcaaccacta	gccagggtgc	aagctcagaa	agcagctctg	taggcctag	caaggaagct	420
gataaggcag	ctgctggatc	agttagccaa	aatgaagaag	aagcagccct	atcgcttgc	480
aatattaaaa	agattgtatgg	taagtattac	tatgttatgg	cagacggttc	ttataagaag	540
aactttgcca	ttacagttga	tggtcaaatg	ctttactttg	atgccaaaac	aggtgccctg	600
tcttcaacct	ctacctattc	tttgcgtcaa	gtttgacac	caattgtttc	tgatttctca	660
gtcaacaaca	aggctttcga	ttcttctgaa	aagagtttt	aattgggttga	tggctatttg	720
acagctgaaa	gctggtaccg	tccctgctaag	attcttggaaa	atggtaaaac	ttgggttcat	780
tctaaagaaa	ctgacctacg	cccaggctct	atgagctgtt	ggccaaacaa	ggatacgc	840
gttgccctacc	ttaactacat	gagaaggca	cttgggtggca	aggaagaatt	cacaactgaa	900
accttccaaat	tgaccccttggaa	tacagccgt	gagttgattc	aagctaaaat	tgaagtcgc	960
gtttctaaag	aacaaggAAC	aaagtggttg	cgtgaagcta	tggcagccct	cgtgtctacc	1020
caatctcggt	ggaataaagg	cagcgaacaa	tacgataagg	ctgaccac	gcaaggcgg	1080
gcccgtctct	ataccaataa	caacttgcgt	gagtggc	attcaaactg	gcccgtctt	1140
aaccgtaccc	caactcgta	agatggtaaa	acccattact	ctaaggctga	caaatacggt	1200
ggttatgaat	tcctcttggc	caacgacgt	gataactcta	acccagtcgt	tcaagcggaa	1260
atgctcaacc	aaatccacta	cctcatgaac	tggggtgaaa	ttgtatggg	tgataagaat	1320
gccaactttg	atggtattcg	tgtcgatgc	gtggataacg	tcaatgcaga	tactctgcaa	1380
ctctacacca	actactttaa	ttctgtttat	ggtgtcaaca	agtctgaagc	ccaagccctg	1440
gctcacatct	cagtcttgg	agcatggct	tacaatgata	atgactataa	ccaagacacc	1500
aacggggctg	ccctggctat	ggacaatgg	ctacgcttt	ccctgttta	taccttgacc	1560
cgtccgatca	atgaacggac	acctggatg	tcaaccctga	ttaaatcaga	atatgtttg	1620
actgaccgga	ctaagaatga	taagtatgg	gatacccaac	catcttatgt	ttttgttcgg	1680
gcfgcatgact	cagaagtgc	aaccgttatt	gcacaaatca	tcaaggaaaa	aattgatcca	1740
acaaccgtg	gtttcacctt	caccctggac	caattgaaac	aggccttga	aatctacaac	1800
aaggatatga	atagtgttaa	caagcactat	acccactata	atatcccac	agcctacgct	1860
gtcatgttgt	ctaataatgg	atccgttaacc	cgggttact	atggtaccc	tttcaccgat	1920
gatggtcaat	acatggcattc	taaatctcca	tattatgt	ccatcaacac	tctcttgcgg	1980
gctcgccattc	gttacgcgc	cgggtgtcaa	attatggaa	acaattctca	caaaccatca	2040
gcagccatga	aggcagctca	tccagatgt	ggtatgtcc	ttggtaacag	cgaagtctt	2100
gtatcggttc	gtttcggt	agatgtcatg	tctggccatg	atatgactgg	tggtaactg	2160
gctaagacct	ctggatgtt	caccctgtt	tctaacaacc	ctgaatttgg	attggatgtc	2220
aatgaagaaa	tcaaggtaa	cgttggtaaa	atccatgct	gccaaggccta	ccgtccctt	2280
ctttgacaa	ctgataaggg	tctgcaaaag	tatctcaatg	attctgatac	caagttgacc	2340
aagattgtcg	acaaggatgg	tttcattacc	ttcaagggtt	gcaaaatcaa	gggttacaaa	2400
caagtcgaag	tcaatggta	cctctcgtt	tgggtaccag	ttggtgctaa	ggctgacca	2460
gacattcg	tggcccctt	aacagcggct	aagggtgaaa	aggccaagac	ttacacagct	2520
agccaaagctt	tggaatcgca	attaatctac	gaaggcttct	caaacttcca	agattttgtt	2580
caaaaagatt	cccaatacac	caacaagaag	attgctgaaa	atactgac	tttcaaggct	2640

20151105_CL6294WOPCT_SequenceListing

tgggtgtta	cctcatttga	aatggcacca	caatacgaaa	cagcaaccga	tggAACCTTC	2700
ctggattcta	tcattgaaaa	cggttatgcc	ttcacccgacc	gttatgacct	tgccatgagc	2760
aagaacaata	aatacggttc	taaggaaat	ttggccaaacg	ccctcaaggc	ccttcacgca	2820
gctggtattc	aagccattgc	tgactggta	ccagacaaa	tttaccaact	gcctgttaag	2880
gaagttgtta	ccgctagccg	ggttgacaac	tacggtcgtg	tggaaagtta	ccaaccacta	2940
gttggaaaac	tttatctggc	caacaccaag	agctcaggaa	aagatttcca	agctaaatac	3000
ggtggtaat	tcttagcaga	actgcaaaag	aaatattctg	aaatgttcac	gactaagatg	3060
atttcaactg	gtaaaaccat	tgtatccatct	gtcaaaattga	aagaatggtc	tgctaagtac	3120
ttcaacggaa	ccaacgtcct	tgtatcggtt	acggactata	tccctcgtga	tgaaggtaact	3180
ggttaatact	ttaccgtcaa	tgaaaaaggt	gacttcttac	ctgcctcatt	gactgttaat	3240
aaggatgcca	agactggttt	ctacaacgat	ggtaagggca	ttgtttacta	cacaaccgccc	3300
ggttaacaagg	ctagatcagc	cttcgtaaaca	gaagcaggta	atacctatta	cttcgactac	3360
accggccata	tggtaacagg	ccctaacgtt	attaacacta	aattcttatta	cttcttgcca	3420
aatggtatca	tgcttaagga	tgcttattaa	caggatgaaa	aagggtcgtt	cgtataactac	3480
ggttaagactg	gtgttatgtt	caagggtggc	cgcgataatg	aatgggtcgc	catgacagac	3540
tctaagggtc	aaatgcgtt	ccgtcaactt	gacaggta	gcttcatgtc	tatcggttt	3600
gtaaccatca	accaaaatgt	tcagttattat	gatgaaaatg	gtttccaaat	taaaggtaaa	3660
tttgttaaccg	atcaggatgg	acaacccgt	tacttcgacc	aagggttcagg	taacttggtt	3720
aagggacaat	tcctcaacaa	ggatggcaac	tggtaatc	ttgatgacca	agggcttagtt	3780
gcttaaggag	ctcagacaat	taaaggtaaa	aagcttact	ttgacacaaa	aaccgggtgc	3840
caagttaaag	gggattttgt	aacggataaa	gatggcaata	ccttcttta	cagtggagat	3900
actggcgtt	taatcttgg	tcagttttc	tcaactggaa	ataacgttgc	ttctctatgtc	3960
gatgaaaatg	gtcatgtcgc	taaggagct	aagactatca	gaggtcagaa	gctctacttt	4020
gataaaaaaa	caggtcagc	agctaaggga	cgccttatcc	gtgtgacaa	gggggttcgt	4080
tactatgatg	ctgacacagg	taccttggta	accaacgctt	tccttggaaac	taaggctgg	4140
tctaaccat	ggtattacat	gggagcagat	ggttatgctg	tcaaggggaa	ccagaccata	4200
aaaaatcagc	acatgtattt	tgatgctgaa	actggccaa	aagctaaggg	aattatagtg	4260
acagatgcca	atggtcgaa	gtatttctat	gatacttta	ctggcagtc	tgtttaaac	4320
caatttgg	tggtaatgg	aaatttggat	ttctttgggt	atgatggagc	tgcagtaaca	4380
ggtttccatg	atatacaagg	acaacacctt	tacttcaatt	ccgatggaa	acaggccaaa	4440
gggactacgg	taaaaattgg	caatcgacgc	tataccctt	atgctcacac	tggtgagctg	4500
acatctgttc	attatggctg	a				4521

<210> 12
 <211> 1506
 <212> PRT
 <213> Streptococcus sobrinus

<400> 12
 Met Glu Arg Lys Leu His Tyr Lys Leu His Lys Val Lys Lys Gln Trp
 1 5 10 15
 Val Thr Ile Ala Val Ala Ser Ala Gly Leu Ala Ser Ile Val Gly Ala
 20 25 30
 Gly Ser Leu Ser Gln Thr Val Ser Ala Asp Asp Leu Ala Lys Glu Gln
 35 40 45
 Ala Ala Ala Ser Gln Gln Lys Ala Ala Ala Asn Gln Asn Glu Asp Glu
 50 55 60
 Val Ala Ser Asp Ala Ala Asp Thr Ala Ser Ala Lys Ala Thr Ser Glu
 65 70 75 80
 Lys Glu Val Val Gln Ser Ser Asp Thr Asn Ser Glu Thr Asn Gln Val
 85 90 95
 Glu Thr Lys Asp Gln Ala Ser Ala Lys Glu Ser Ala Asp Ala Val Ala
 100 105 110
 Lys Gln Ala Pro Gln Ala Gly Pro Ala Thr Thr Ser Gln Val Ala Ser
 115 120 125
 Ser Glu Ser Ser Val Ala Pro Ser Lys Glu Ala Asp Lys Ala Ala
 130 135 140
 Ala Gly Ser Val Ser Gln Asn Glu Glu Ala Ala Leu Ser Leu Ala
 145 150 155 160
 Asn Ile Lys Lys Ile Asp Gly Lys Tyr Tyr Val Met Ala Asp Gly
 165 170 175
 Ser Tyr Lys Lys Asn Phe Ala Ile Thr Val Asp Gly Gln Met Leu Tyr
 180 185 190
 Phe Asp Ala Lys Thr Gly Ala Leu Ser Ser Thr Ser Thr Tyr Ser Phe
 195 200 205
 Ser Gln Gly Leu Thr Pro Ile Val Ser Asp Phe Ser Val Asn Asn Lys
 210 215 220
 Ala Phe Asp Ser Ser Glu Lys Ser Phe Glu Leu Val Asp Gly Tyr Leu

20151105_CL6294WOPCT_SequenceListing

225	230	235	240												
Thr	Ala	Glu	Ser	Trp	Tyr	Arg	Pro	Ala	Lys	Ile	Leu	Glu	Asn	Gly	Lys
				245					250					255	
Thr	Trp	Val	Asp	Ser	Lys	Glu	Thr	Asp	Leu	Arg	Pro	Val	Leu	Met	Ser
				260				265					270		
Trp	Trp	Pro	Asn	Lys	Asp	Thr	Gln	Val	Ala	Tyr	Leu	Asn	Tyr	Met	Ser
				275				280					285		
Lys	Ala	Leu	Gly	Gly	Lys	Glu	Glu	Phe	Thr	Thr	Glu	Thr	Ser	Gln	Leu
					290		295				300				
Thr	Leu	Asn	Thr	Ala	Ala	Glu	Leu	Ile	Gln	Ala	Lys	Ile	Glu	Ala	Arg
					305		310			315				320	
Val	Ser	Lys	Glu	Gln	Gly	Thr	Lys	Trp	Leu	Arg	Glu	Ala	Met	Ala	Ala
					325				330					335	
Phe	Val	Ala	Thr	Gln	Ser	Arg	Trp	Asn	Lys	Asp	Ser	Glu	Gln	Tyr	Asp
					340			345					350		
Lys	Ala	Asp	His	Leu	Gln	Gly	Gly	Ala	Leu	Leu	Tyr	Thr	Asn	Asn	Asn
					355			360				365			
Leu	Thr	Glu	Trp	Ala	Asn	Ser	Asn	Trp	Arg	Leu	Leu	Asn	Arg	Thr	Pro
					370		375				380				
Thr	Arg	Gln	Asp	Gly	Lys	Thr	His	Tyr	Ser	Lys	Ala	Asp	Lys	Tyr	Gly
					385		390			395				400	
Gly	Tyr	Glu	Phe	Leu	Leu	Ala	Asn	Asp	Val	Asp	Asn	Ser	Asn	Pro	Val
					405				410					415	
Val	Gln	Ala	Glu	Met	Leu	Asn	Gln	Ile	His	Tyr	Leu	Met	Asn	Trp	Gly
					420			425				430			
Glu	Ile	Val	Met	Gly	Asp	Lys	Asn	Ala	Asn	Phe	Asp	Gly	Ile	Arg	Val
					435			440				445			
Asp	Ala	Val	Asp	Asn	Val	Asn	Ala	Asp	Thr	Leu	Gln	Leu	Tyr	Thr	Asn
					450		455			460					
Tyr	Phe	Asn	Ser	Val	Tyr	Gly	Val	Asn	Lys	Ser	Glu	Ala	Gln	Ala	Leu
					465		470			475				480	
Ala	His	Ile	Ser	Val	Leu	Glu	Ala	Trp	Ser	Tyr	Asn	Asp	Asn	Asp	Tyr
					485				490					495	
Asn	Gln	Asp	Thr	Asn	Gly	Ala	Ala	Leu	Ala	Met	Asp	Asn	Gly	Leu	Arg
					500			505					510		
Phe	Ser	Leu	Leu	Tyr	Thr	Leu	Thr	Arg	Pro	Ile	Asn	Glu	Arg	Thr	Pro
					515			520				525			
Gly	Met	Ser	Thr	Leu	Ile	Lys	Ser	Glu	Tyr	Gly	Leu	Thr	Asp	Arg	Thr
					530		535			540					
Lys	Asn	Asp	Lys	Tyr	Gly	Asp	Thr	Gln	Pro	Ser	Tyr	Val	Phe	Val	Arg
					545		550			555				560	
Ala	His	Asp	Ser	Glu	Val	Gln	Thr	Val	Ile	Ala	Gln	Ile	Ile	Lys	Glu
					565				570					575	
Lys	Ile	Asp	Pro	Thr	Thr	Asp	Gly	Phe	Thr	Phe	Thr	Leu	Asp	Gln	Leu
					580			585				590			
Lys	Gln	Ala	Phe	Glu	Ile	Tyr	Asn	Lys	Asp	Met	Asn	Ser	Val	Asn	Lys
					595			600				605			
His	Tyr	Thr	His	Tyr	Asn	Ile	Pro	Ala	Ala	Tyr	Ala	Val	Met	Leu	Ser
					610		615			620					
Asn	Met	Glu	Ser	Val	Thr	Arg	Val	Tyr	Tyr	Gly	Asp	Leu	Phe	Thr	Asp
					625		630			635				640	
Asp	Gly	Gln	Tyr	Met	Ala	Ser	Lys	Ser	Pro	Tyr	Tyr	Asp	Ala	Ile	Asn
					645				650					655	
Thr	Leu	Leu	Arg	Ala	Arg	Ile	Arg	Tyr	Ala	Ala	Gly	Gly	Gln	Ile	Met
					660			665					670		
Glu	His	Asn	Ser	Tyr	Lys	Pro	Ser	Ala	Ala	Met	Lys	Ala	Ala	His	Pro
					675			680					685		
Asp	Ala	Gly	Asn	Val	Leu	Gly	Asn	Ser	Glu	Val	Leu	Val	Ser	Val	Arg
					690		695			700					
Phe	Gly	Gln	Asp	Val	Met	Ser	Ala	Asp	Asp	Met	Thr	Gly	Gly	Lys	Leu
					705		710			715				720	
Ala	Lys	Thr	Ser	Gly	Met	Phe	Thr	Leu	Ile	Ser	Asn	Asn	Pro	Glu	Leu
					725				730					735	
Glu	Leu	Asp	Val	Asn	Glu	Glu	Ile	Lys	Val	Asn	Val	Gly	Lys	Ile	His
					740			745					750		
Ala	Gly	Gln	Ala	Tyr	Arg	Pro	Leu	Leu	Leu	Thr	Thr	Asp	Lys	Gly	Leu
					755			760					765		
Gln	Lys	Tyr	Leu	Asn	Asp	Ser	Asp	Thr	Lys	Leu	Thr	Lys	Ile	Ala	Asp

20151105_CL6294WOPCT_SequenceListing

			770	775		780										
Lys	Asp	Gly	Phe	Ile	Thr	Phe	Lys	Gly	Ser	Glu	Ile	Lys	Gly	Tyr	Lys	
785						790				795					800	
Gln	Val	Glu	Val	Asn	Gly	Tyr	Leu	Ser	Val	Trp	Val	Pro	Val	Gly	Ala	
						805				810					815	
Lys	Ala	Asp	Gln	Asp	Ile	Arg	Val	Ala	Pro	Ser	Thr	Ala	Ala	Lys	Gly	
						820				825					830	
Glu	Lys	Ala	Lys	Thr	Tyr	Thr	Ala	Ser	Gln	Ala	Leu	Glu	Ser	Gln	Leu	
						835				840					845	
Ile	Tyr	Glu	Gly	Phe	Ser	Asn	Phe	Gln	Asp	Phe	Val	Gln	Lys	Asp	Ser	
						850				855					860	
Gln	Tyr	Thr	Asn	Lys	Lys	Ile	Ala	Glu	Asn	Thr	Asp	Leu	Phe	Lys	Ala	
865						870					875					880
Trp	Gly	Val	Thr	Ser	Phe	Glu	Met	Ala	Pro	Gln	Tyr	Val	Ser	Ala	Thr	
						885				890					895	
Asp	Gly	Thr	Phe	Leu	Asp	Ser	Ile	Ile	Glu	Asn	Gly	Tyr	Ala	Phe	Thr	
						900				905					910	
Asp	Arg	Tyr	Asp	Leu	Ala	Met	Ser	Lys	Asn	Asn	Lys	Tyr	Gly	Ser	Lys	
						915				920					925	
Glu	Asp	Leu	Ala	Asn	Ala	Leu	Lys	Ala	Leu	His	Ala	Ala	Gly	Ile	Gln	
						930				935					940	
Ala	Ile	Ala	Asp	Trp	Val	Pro	Asp	Gln	Ile	Tyr	Gln	Leu	Pro	Gly	Lys	
945						950					955					960
Glu	Val	Val	Thr	Ala	Ser	Arg	Val	Asp	Asn	Tyr	Gly	Arg	Val	Lys	Val	
						965				970					975	
Asp	Gln	Pro	Leu	Val	Glu	Lys	Leu	Tyr	Leu	Ala	Asn	Thr	Lys	Ser	Ser	
						980				985					990	
Gly	Lys	Asp	Phe	Gln	Ala	Lys	Tyr	Gly	Gly	Glu	Phe	Leu	Ala	Glu	Leu	
						995				1000					1005	
Gln	Lys	Lys	Tyr	Pro	Glu	Met	Phe	Thr	Thr	Lys	Met	Ile	Ser	Thr		
						1010				1015					1020	
Gly	Lys	Thr	Ile	Asp	Pro	Ser	Val	Lys	Leu	Lys	Glu	Trp	Ser	Ala		
						1025				1030					1035	
Lys	Tyr	Phe	Asn	Gly	Thr	Asn	Val	Leu	Asp	Arg	Gly	Thr	Asp	Tyr		
						1040				1045					1050	
Ile	Leu	Ser	Asp	Glu	Gly	Thr	Gly	Lys	Tyr	Phe	Thr	Val	Asn	Glu		
						1055				1060					1065	
Lys	Gly	Asp	Phe	Leu	Pro	Ala	Ser	Leu	Thr	Gly	Asn	Lys	Asp	Ala		
						1070				1075					1080	
Lys	Thr	Gly	Phe	Tyr	Asn	Asp	Gly	Lys	Gly	Ile	Val	Tyr	Tyr	Thr		
						1085				1090					1095	
Thr	Ala	Gly	Asn	Lys	Ala	Arg	Ser	Ala	Phe	Val	Thr	Glu	Ala	Gly		
						1100				1105					1110	
Asn	Thr	Tyr	Tyr	Phe	Asp	Tyr	Thr	Gly	His	Met	Val	Thr	Gly	Pro		
						1115				1120					1125	
Asn	Val	Ile	Asn	Thr	Lys	Phe	Tyr	Tyr	Phe	Leu	Pro	Asn	Gly	Ile		
						1130				1135					1140	
Met	Leu	Lys	Asp	Ala	Ile	Lys	Gln	Asp	Glu	Lys	Gly	Arg	Ser	Val		
						1145				1150					1155	
Tyr	Tyr	Gly	Lys	Thr	Gly	Val	Met	Tyr	Lys	Gly	Gly	Arg	Asp	Asn		
						1160				1165					1170	
Glu	Trp	Phe	Ala	Met	Thr	Asp	Ser	Lys	Gly	Gln	Met	Arg	Phe	Arg		
						1175				1180					1185	
His	Phe	Asp	Arg	Tyr	Gly	Phe	Met	Ser	Ile	Gly	Leu	Val	Thr	Ile		
						1190				1195					1200	
Asn	Gln	Asn	Val	Gln	Tyr	Tyr	Asp	Glu	Asn	Gly	Phe	Gln	Val	Lys		
						1205				1210					1215	
Gly	Glu	Phe	Val	Thr	Asp	Gln	Asp	Gly	Gln	Thr	Arg	Tyr	Phe	Asp		
						1220				1225					1230	
Gln	Gly	Ser	Gly	Asn	Leu	Val	Lys	Gly	Gln	Phe	Leu	Asn	Lys	Asp		
						1235				1240					1245	
Gly	Asn	Trp	Tyr	Tyr	Leu	Asp	Asp	Gln	Gly	Leu	Val	Ala	Lys	Gly		
						1250				1255					1260	
Ala	Gln	Thr	Ile	Lys	Gly	Gln	Lys	Leu	Tyr	Phe	Asp	Thr	Lys	Thr		
						1265				1270					1275	
Gly	Val	Gln	Val	Lys	Gly	Asp	Phe	Val	Thr	Asp	Lys	Asp	Gly	Asn		
						1280				1285					1290	
Thr	Phe	Phe	Tyr	Ser	Gly	Asp	Thr	Gly	Asp	Leu	Ile	Leu	Gly	Gln		

20151105_CL6294WOPCT_SequenceListing

<210> 13
<211> 1465
<212> PRT
<213> *Streptococcus sobrinus*

```
<220>
<221> MISC_FEATURE
<222> (1)..(1465)
<223> mature 2920 gtf
```

<400> 13
 Asp Asp Leu Ala Lys Glu Gln Ala Ala Ala Ser Gln Gln Lys Ala Ala
 1 5 10 15
 Ala Asn Gln Asn Glu Asp Glu Val Ala Ser Asp Ala Ala Asp Thr Ala
 20 25 30
 Ser Ala Lys Ala Thr Ser Glu Lys Glu Val Val Gln Ser Ser Asp Thr
 35 40 45
 Asn Ser Glu Thr Asn Gln Val Glu Thr Lys Asp Gln Ala Ser Ala Lys
 50 55 60
 Glu Ser Ala Asp Ala Val Ala Lys Gln Ala Pro Gln Ala Gly Pro Ala
 65 70 75 80
 Thr Thr Ser Gln Val Ala Ser Ser Glu Ser Ser Ser Val Ala Pro Ser
 85 90 95
 Lys Glu Ala Asp Lys Ala Ala Ala Gly Ser Val Ser Gln Asn Glu Glu
 100 105 110
 Glu Ala Ala Leu Ser Leu Ala Asn Ile Lys Lys Ile Asp Gly Lys Tyr
 115 120 125
 Tyr Tyr Val Met Ala Asp Gly Ser Tyr Lys Lys Asn Phe Ala Ile Thr
 130 135 140
 Val Asp Gly Gln Met Leu Tyr Phe Asp Ala Lys Thr Gly Ala Leu Ser
 145 150 155 160
 Ser Thr Ser Thr Tyr Ser Phe Ser Gln Gly Leu Thr Pro Ile Val Ser
 165 170 175
 Asp Phe Ser Val Asn Asn Lys Ala Phe Asp Ser Ser Glu Lys Ser Phe
 180 185 190
 Glu Leu Val Asp Gly Tyr Leu Thr Ala Glu Ser Trp Tyr Arg Pro Ala
 195 200 205
 Lys Ile Leu Glu Asn Gly Lys Thr Trp Val Asp Ser Lys Glu Thr Asp

20151105_CL6294WOPCT_SequenceListing

210	215	220													
Leu	Arg	Pro	Val	Leu	Met	Ser	Trp	Trp	Pro	Asn	Lys	Asp	Thr	Gln	Val
225					230				235						240
Ala	Tyr	Leu	Asn	Tyr	Met	Ser	Lys	Ala	Leu	Gly	Gly	Lys	Glu	Glu	Phe
					245				250						255
Thr	Thr	Glu	Thr	Ser	Gln	Leu	Thr	Leu	Asn	Thr	Ala	Ala	Glu	Leu	Ile
					260				265						270
Gln	Ala	Lys	Ile	Glu	Ala	Arg	Val	Ser	Lys	Glu	Gln	Gly	Thr	Lys	Trp
					275				280						285
Leu	Arg	Glu	Ala	Met	Ala	Ala	Phe	Val	Ala	Thr	Gln	Ser	Arg	Trp	Asn
					290				295						300
Lys	Asp	Ser	Glu	Gln	Tyr	Asp	Lys	Ala	Asp	His	Leu	Gln	Gly	Gly	Ala
					305				310						320
Leu	Leu	Tyr	Thr	Asn	Asn	Asn	Leu	Thr	Glu	Trp	Ala	Asn	Ser	Asn	Trp
									325						335
Arg	Leu	Leu	Asn	Arg	Thr	Pro	Thr	Arg	Gln	Asp	Gly	Lys	Thr	His	Tyr
					340				345						350
Ser	Lys	Ala	Asp	Lys	Tyr	Gly	Gly	Tyr	Glu	Phe	Leu	Leu	Ala	Asn	Asp
					355				360						365
Val	Asp	Asn	Ser	Asn	Pro	Val	Val	Gln	Ala	Glu	Met	Leu	Asn	Gln	Ile
					370				375						380
His	Tyr	Leu	Met	Asn	Trp	Gly	Glu	Ile	Val	Met	Gly	Asp	Lys	Asn	Ala
					385				390						400
Asn	Phe	Asp	Gly	Ile	Arg	Val	Asp	Ala	Val	Asp	Asn	Val	Asn	Ala	Asp
					405				410						415
Thr	Leu	Gln	Leu	Tyr	Thr	Asn	Tyr	Phe	Asn	Ser	Val	Tyr	Gly	Val	Asn
					420				425						430
Lys	Ser	Glu	Ala	Gln	Ala	Leu	Ala	His	Ile	Ser	Val	Leu	Glu	Ala	Trp
					435				440						445
Ser	Tyr	Asn	Asp	Asn	Asp	Tyr	Asn	Gln	Asp	Thr	Asn	Gly	Ala	Ala	Leu
					450				455						460
Ala	Met	Asp	Asn	Gly	Leu	Arg	Phe	Ser	Leu	Leu	Tyr	Thr	Leu	Thr	Arg
					465				470						480
Pro	Ile	Asn	Glu	Arg	Thr	Pro	Gly	Met	Ser	Thr	Leu	Ile	Lys	Ser	Glu
					485				490						495
Tyr	Gly	Leu	Thr	Asp	Arg	Thr	Lys	Asn	Asp	Lys	Tyr	Gly	Asp	Thr	Gln
					500				505						510
Pro	Ser	Tyr	Val	Phe	Val	Arg	Ala	His	Asp	Ser	Glu	Val	Gln	Thr	Val
					515				520						525
Ile	Ala	Gln	Ile	Ile	Lys	Glu	Lys	Ile	Asp	Pro	Thr	Thr	Asp	Gly	Phe
					530				535						540
Thr	Phe	Thr	Leu	Asp	Gln	Leu	Lys	Gln	Ala	Phe	Glu	Ile	Tyr	Asn	Lys
					545				550						560
Asp	Met	Asn	Ser	Val	Asn	Lys	His	Tyr	Thr	His	Tyr	Asn	Ile	Pro	Ala
					565				570						575
Ala	Tyr	Ala	Val	Met	Leu	Ser	Asn	Met	Glu	Ser	Val	Thr	Arg	Val	Tyr
					580				585						590
Tyr	Gly	Asp	Leu	Phe	Thr	Asp	Asp	Gly	Gln	Tyr	Met	Ala	Ser	Lys	Ser
					595				600						605
Pro	Tyr	Tyr	Asp	Ala	Ile	Asn	Thr	Leu	Leu	Arg	Ala	Arg	Ile	Arg	Tyr
					610				615						620
Ala	Ala	Gly	Gly	Gln	Ile	Met	Glu	His	Asn	Ser	Tyr	Lys	Pro	Ser	Ala
					625				630						640
Ala	Met	Lys	Ala	Ala	His	Pro	Asp	Ala	Gly	Asn	Val	Leu	Gly	Asn	Ser
					645				650						655
Glu	Val	Leu	Val	Ser	Val	Arg	Phe	Gly	Gln	Asp	Val	Met	Ser	Ala	Asp
					660				665						670
Asp	Met	Thr	Gly	Gly	Lys	Leu	Ala	Lys	Thr	Ser	Gly	Met	Phe	Thr	Leu
					675				680						685
Ile	Ser	Asn	Asn	Pro	Glu	Leu	Glu	Leu	Asp	Val	Asn	Glu	Glu	Ile	Lys
					690				695						700
Val	Asn	Val	Gly	Lys	Ile	His	Ala	Gly	Gln	Ala	Tyr	Arg	Pro	Leu	Leu
					705				710						720
Leu	Thr	Thr	Asp	Lys	Gly	Leu	Gln	Lys	Tyr	Leu	Asn	Asp	Ser	Asp	Thr
					725				730						735
Lys	Leu	Thr	Lys	Ile	Ala	Asp	Lys	Asp	Gly	Phe	Ile	Thr	Phe	Lys	Gly
					740				745						750
Ser	Glu	Ile	Lys	Gly	Tyr	Lys	Gln	Val	Glu	Val	Asn	Gly	Tyr	Leu	Ser

20151105_CL6294WOPCT_SequenceListing

Val Trp Val Pro Val Gly Ala Lys Ala Asp Gln Asp Ile Arg Val Ala
 755 760 765
 770 775 780
 Pro Ser Thr Ala Ala Lys Gly Glu Lys Ala Lys Thr Tyr Thr Ala Ser
 785 790 795 800
 Gln Ala Leu Glu Ser Gln Leu Ile Tyr Glu Gly Phe Ser Asn Phe Gln
 805 810 815
 Asp Phe Val Gln Lys Asp Ser Gln Tyr Thr Asn Lys Lys Ile Ala Glu
 820 825 830
 Asn Thr Asp Leu Phe Lys Ala Trp Gly Val Thr Ser Phe Glu Met Ala
 835 840 845
 Pro Gln Tyr Val Ser Ala Thr Asp Gly Thr Phe Leu Asp Ser Ile Ile
 850 855 860
 Glu Asn Gly Tyr Ala Phe Thr Asp Arg Tyr Asp Leu Ala Met Ser Lys
 865 870 875 880
 Asn Asn Lys Tyr Gly Ser Lys Glu Asp Leu Ala Asn Ala Leu Lys Ala
 885 890 895
 Leu His Ala Ala Gly Ile Gln Ala Ile Ala Asp Trp Val Pro Asp Gln
 900 905 910
 Ile Tyr Gln Leu Pro Gly Lys Glu Val Val Thr Ala Ser Arg Val Asp
 915 920 925
 Asn Tyr Gly Arg Val Lys Val Asp Gln Pro Leu Val Glu Lys Leu Tyr
 930 935 940
 Leu Ala Asn Thr Lys Ser Ser Gly Lys Asp Phe Gln Ala Lys Tyr Gly
 945 950 955 960
 Gly Glu Phe Leu Ala Glu Leu Gln Lys Lys Tyr Pro Glu Met Phe Thr
 965 970 975
 Thr Lys Met Ile Ser Thr Gly Lys Thr Ile Asp Pro Ser Val Lys Leu
 980 985 990
 Lys Glu Trp Ser Ala Lys Tyr Phe Asn Gly Thr Asn Val Leu Asp Arg
 995 1000 1005
 Gly Thr Asp Tyr Ile Leu Ser Asp Glu Gly Thr Gly Lys Tyr Phe
 1010 1015 1020
 Thr Val Asn Glu Lys Gly Asp Phe Leu Pro Ala Ser Leu Thr Gly
 1025 1030 1035
 Asn Lys Asp Ala Lys Thr Gly Phe Tyr Asn Asp Gly Lys Gly Ile
 1040 1045 1050
 Val Tyr Tyr Thr Thr Ala Gly Asn Lys Ala Arg Ser Ala Phe Val
 1055 1060 1065
 Thr Glu Ala Gly Asn Thr Tyr Tyr Phe Asp Tyr Thr Gly His Met
 1070 1075 1080
 Val Thr Gly Pro Asn Val Ile Asn Thr Lys Phe Tyr Tyr Phe Leu
 1085 1090 1095
 Pro Asn Gly Ile Met Leu Lys Asp Ala Ile Lys Gln Asp Glu Lys
 1100 1105 1110
 Gly Arg Ser Val Tyr Tyr Gly Lys Thr Gly Val Met Tyr Lys Gly
 1115 1120 1125
 Gly Arg Asp Asn Glu Trp Phe Ala Met Thr Asp Ser Lys Gly Gln
 1130 1135 1140
 Met Arg Phe Arg His Phe Asp Arg Tyr Gly Phe Met Ser Ile Gly
 1145 1150 1155
 Leu Val Thr Ile Asn Gln Asn Val Gln Tyr Tyr Asp Glu Asn Gly
 1160 1165 1170
 Phe Gln Val Lys Gly Glu Phe Val Thr Asp Gln Asp Gly Gln Thr
 1175 1180 1185
 Arg Tyr Phe Asp Gln Gly Ser Gly Asn Leu Val Lys Gly Gln Phe
 1190 1195 1200
 Leu Asn Lys Asp Gly Asn Trp Tyr Tyr Leu Asp Asp Gln Gly Leu
 1205 1210 1215
 Val Ala Lys Gly Ala Gln Thr Ile Lys Gly Gln Lys Leu Tyr Phe
 1220 1225 1230
 Asp Thr Lys Thr Gly Val Gln Val Lys Gly Asp Phe Val Thr Asp
 1235 1240 1245
 Lys Asp Gly Asn Thr Phe Phe Tyr Ser Gly Asp Thr Gly Asp Leu
 1250 1255 1260
 Ile Leu Gly Gln Phe Phe Ser Thr Gly Asn Asn Ala Trp Phe Tyr
 1265 1270 1275
 Ala Asp Glu Asn Gly His Val Ala Lys Gly Ala Lys Thr Ile Arg

20151105_CL6294WOPCT_SequenceListing

Gly	1280	Gln	Lys	Leu	Tyr	Phe	Asp	Thr	Lys	Thr	Gly	Gln	Gln	Ala	Lys
	1285														
Gly	1295														
	1300														
Gly	1310	Arg	Phe	Ile	Arg	Asp	Asp	Lys	Gly	Val	Arg	Tyr	Tyr	Asp	Ala
	1315														
Asp	1320	Thr	Gly	Thr	Leu	Val	Thr	Asn	Ala	Phe	Leu	Glu	Thr	Lys	Ala
	1325														
Gly	1330	Ser	Asn	Gln	Trp	Tyr	Tyr	Met	Gly	Ala	Asp	Gly	Tyr	Ala	Val
	1335														
Lys	1340	Gly	Asn	Gln	Thr	Ile	Lys	Asn	Gln	His	Met	Tyr	Phe	Asp	Ala
	1345														
	1350														
Lys	1355														
Glu	1360														
	1365														
Gly	1370	Thr	Gly	Gln	Gln	Ala	Lys	Gly	Ile	Ile	Val	Thr	Asp	Ala	Asn
	1375														
Gly	1380	Arg	Lys	Tyr	Phe	Tyr	Asp	Thr	Phe	Thr	Gly	Ser	Arg	Val	Val
	1385														
Asn	1390	Gln	Phe	Val	Leu	Val	Asn	Gly	Asn	Trp	Tyr	Phe	Phe	Gly	Tyr
	1395														
Asp	1400	Gly	Ala	Ala	Val	Thr	Gly	Phe	His	Asp	Ile	Lys	Gly	Gln	His
	1405														
Asp	1410	Gly	Ala	Ala	Val	Thr	Gly	Phe	His	Asp	Ile	Lys	Gly	Gln	His
	1415														
Leu	1420	Tyr	Phe	Asn	Ser	Asp	Gly	Thr	Gln	Ala	Lys	Gly	Thr	Thr	Val
	1425														
Leu	1430	Tyr	Phe	Asn	Ser	Asp	Gly	Thr	Gln	Ala	Lys	Gly	Thr	Thr	Val
	1435														
Lys	1440	Ile	Gly	Asn	Arg	Ser	Tyr	Thr	Phe	Asp	Ala	His	Thr	Gly	Glu
	1445														
Leu	1450	Thr	Ser	Val	His	Tyr	Gly								
	1455														
	1460														

<210> 14

<211> 4398

<212> DNA

<213> Artificial sequence

<220>

<223> 2920 gtf with heterologous signal sequence

<400> 14

gatgacctgg	cgaaggaaca	agcagccgcc	tcacagcaaa	aagcagcggc	taaccagaat	60
gaagacgaag	ttgcatcaga	tgcagccgt	acagctagcg	ccaaagccac	gtcagagaaa	120
gaagtggttc	agtcaagcga	tacaaactca	gaaacaatc	aggttggagac	gaaagaccaa	180
gcatcagcta	aggagagcgc	agacgcagtc	gcgaaacaag	ctcctcaagc	aggacccggca	240
acaacgtcac	aggctcgccag	ctcagagagc	agcagcgtgg	caccgagcaa	ggaggctgac	300
aaggctgccg	caggctcagt	ctcacagaaac	gaggaggagg	cagccctttc	acttgccaaac	360
atcaagaaga	ttgacggaaa	atactattac	gttatggccg	atggaaagcta	caagaaaaac	420
tttgcgatta	cggttgtatgg	acagatgtt	tactttgtacg	caaaaacagg	cgcactttca	480
tcaacgagca	cgtatagctt	ttcacaaggc	ctgaccccga	tttgtctcaga	cttttagcgtg	540
aacaataagg	ctttcgattt	atcagaaaag	tcattttgaac	tttgtggacgg	ctacctgaca	600
gccgaaagct	ggtacagacc	ggccaaaatc	ctggaaaacg	gaaagacgtg	gttcgactca	660
aaagaaaacag	atcttagacc	tgtcctgtat	tcatgggtgc	cgaacaaaga	cacacaagtc	720
gcatatctga	attacatgtc	aaaagctctg	ggaggcaaaag	aagagtttac	gacagagaca	780
tcacaactga	cactgaatac	agccggagaa	cttattccagg	cgaagatcga	agcttagatg	840
agcaaagagc	agggcacaaaa	atggctgaga	gaagcaatgg	cagcattttgt	ggcgacgcaa	900
tcaagatgga	ataaaagattc	agagcaatat	gataaaagcag	atcatcttca	aggcggagct	960
ctgctgtaca	caaacaacaa	ccttacagaa	tgggcttaatt	caaattttggag	actgcttaat	1020
agaacaccga	cgagacagga	tggaaaaaaca	cattactcaa	aggcagataa	gtatggcgga	1080
tatgagtttc	tgctggctaa	tgtatgtcgat	aactcaaattc	cggttgcgtca	agctgaaatg	1140
cttaaccaa	ttcatttatct	tatgaatttgg	ggcgaatttgc	ttatgggcga	taagaatgt	1200
aacttcgacg	gaatcagatgt	tgtatgtcgat	gacaacgtta	atgcagatac	actgctgttt	1260
tatacaattt	acttttatag	cgtttatggta	gtcaacaatg	cagaaggcaca	ggcccttgc	1320
catatttcag	tccttggggc	atgttcatat	aatgataacg	acttataatca	ggatatacgat	1380
ggcgcagcac	ttgcgtatgg	taatggctgt	agatttcac	tttgcgtatac	gctttacaaga	1440
ccgattatgt	aaagaacgccc	tggcatggc	acactgttata	agagcgaata	cggaactgtac	1500
gatagaacga	aaaacgacaa	gtacggcgac	acgcaaccta	gctatgttctt	cggttagagca	1560
catgatagcg	aggttcaaac	gttatttgc	caaatttatca	aggagaaaaat	cgatcttaca	1620
acagatggct	ttacattttac	gttggatcaa	ctgaagcaag	ccctcgaaat	ctataacaag	1680
gacatgaact	cagtgtat	gcactacacg	cattacaata	tttctgtctgc	atacgttgc	1740
atgctgagca	acatggaaag	cgtgacaaga	gtgtactacg	gcgacctttt	tacggatgac	1800
ggccagtata	tggcaagcaa	gtcaccttat	tatgtatgtca	tcaatacact	tcttagagcg	1860
agaatttagat	acgcccgttgg	aggacaaatc	atggaacata	attcatataaa	gcccggcc	1920
gcaatgaaag	ctgcacaccc	ggacgcccggc	aacgttctgg	gcaatttgc	ggtcctggc	1980

20151105_CL6294WOPCT_SequenceListing						
tcagttagat	tcggccaaga	cgtatgtca	gcagatgata	tgacaggcg	aaaacttgcg	2040
aaaacatcg	gcatgttac	gcttattagc	aataaccgg	aacttggact	tgacgttaat	2100
gaggagatc	aagtgaatgt	ggccaaaatc	catgtggac	aagctttag	accgcttctg	2160
cttacaacag	ataagggact	tcagaagtac	cttaatgatt	cagacacaaa	actgacgaag	2220
atcgctgaca	aagacggatt	cattacattc	aaaggatcag	aaattaaggg	ctataaaca	2280
gtttaggtt	atggctac	ttcagttgg	gtcccggtt	gcgctaaagc	agaccaagat	2340
attagagtt	ccccgagac	agccgaaaa	ggagaaaagg	ctaaaacgt	tacagcatca	2400
caggctctgg	aatcacagct	tatctatgaa	ggcttctcaa	actttcaaga	ctttgttcaa	2460
aaagatagcc	aatatacgaa	taagaaaatt	gcagagaaca	cagacctgtt	taaagcatgg	2520
ggagttacgt	cattcgagat	ggctcctcaa	tatgttagcg	caacggatgg	cacattcctg	2580
gattcaatca	ttgaaaacgg	ctatgcattc	acagacagat	acgaccttgc	tatgagcaag	2640
aataacaat	atggatcaaa	agaggatctg	gctaacgcac	ttaaggcact	tcacgcagct	2700
ggcattcaag	ctattgcgga	ttgggtgcct	gaccaatct	accaactgcc	ggccaagag	2760
gtttagacag	ccagcagat	ggataactat	ggcagagtt	agttggacca	ggcgcttgc	2820
gagaagctgt	atctggcgaa	tacgaaatca	tcaggaaaag	atttccaggc	taagtacggc	2880
ggagagttcc	ttgcggagct	gcagaagaaa	tacccggaga	tgttacgac	aaaaatgatc	2940
agcacaggaa	agacaatcga	cccgctcgt	aagctgaaag	agttgtcagc	caagtacttc	3000
aatggAACGA	acgtgctgga	tagaggcaca	gactatattc	ttagcgatga	ggaaacggga	3060
aagtatttca	cagtcaacga	gaagggcgat	ttcctgcctg	cgagccttac	aggcaacaag	3120
gatgcacaaa	caggcttta	caatgacgga	aaaggaaattt	tttactacac	aacagctgga	3180
aacaaggcta	gaagcgcgtt	cgtacagag	gctggcaaca	catactattt	cgactatacg	3240
ggcccatatgg	tgacaggacc	gaatgttac	aacacaaat	tcttccaaat	tcttccaaac	3300
ggcatcatgc	tgaaggacgc	aattaagcaa	gatgaaaagg	gaagaagcgt	ttattacggc	3360
aagacaggag	ttatgtacaa	ggccggcaga	gataacaaat	ggttgcata	gacagactca	3420
aaggagacaa	tgagatttag	acatttcgat	agatatggct	tcatgtcaat	tggacttgg	3480
acaatcaacc	agaatgttca	atactatgat	gagaatggct	ttcaggtgaa	aggcgaattt	3540
gtcacagatc	aggatggaca	aacgagatac	ttcgaccaag	gctcaggcaa	tcttggtaaa	3600
ggacagtttc	ttaacaaga	tggaaaattgg	tattatctgg	atgatcaagg	actgggtgc	3660
aaaggagctc	aaacgattaa	aggccaaaaa	ctgtatttt	atacgaagac	ggcgtgcag	3720
gttaaggggag	attttgtac	ggacaaggac	ggcaatacat	tcttctata	cgagatacg	3780
ggagatctga	ttctgggaca	attttttca	acgggcaata	atgcatggtt	ttatgcggac	3840
gagaacggac	acgtcgccaa	aggcgaaaa	acaatcagag	gacagaagct	ttacttcgt	3900
acaaaaacgg	gacaacaacg	caagggcaga	ttcatcagag	acgacaagg	agtcaagatac	3960
tacgatgcag	acacgggcac	actggttaca	aacgcattt	tggagacgaa	ggcggaaagc	4020
aatcagtgg	actacatggg	cgctgatgga	tatggcgta	aggaaacca	gacgatcaag	4080
aaccacata	tgtacttta	cgctgaaaca	ggacagcaag	ctaaggaaat	catcgatc	4140
gacgcaacg	gcagaaaata	cttctatgac	acggttacgg	gctcaagagt	tgttaatcaa	4200
ttcggtctt	tgaacggaaa	ctgtacttt	tttggatacg	atggagcagc	agttacagga	4260
ttccacgata	tcaagggcca	acattttat	ttcaactcag	acggaacgc	agcgaaggc	4320
acgacagtt	agatcggaaa	tagaagctac	acattcgac	cacacacagg	cgagcttaca	4380
tcagttcatt	acggatg					4398

<210> 15
 <211> 4360
 <212> DNA
 <213> Streptococcus downei

<400> 15						
atgattttca	tggaaaagaaa	attacattac	aaattacaca	aggtcaagaa	gcagtggtt	60
accatcgctg	tcgcctctgc	tggttggcc	agcgtatcg	gtgctggctc	cttgagccaa	120
accgtttctg	ctgacgatct	tgctaaggac	caagcggcag	cgactgagca	aaaggcatca	180
gccaatcagg	aaaaagaaga	agtagttct	gatcaggtt	acacgaccag	tgccaaagca	240
acctctgaga	aggaagtgc	tcaagcttcg	gacactagtt	cagaagccaa	ccaagttcca	300
gcccaagaag	aaaagaaggc	tgaaaaggca	gctgctcctg	cgacagcgcac	accagctcca	360
cagactggtg	aaaaaaacag	ccaaacagct	agttcagaag	caccagcgcac	aagcaatcaa	420
gcaagtggaa	cagctgaaac	tggtcctt	agccaaaaag	aagaagcgc	agttcttcg	480
cttgataata	tcaagaagat	tgtggaaag	tattactat	ttatggcaga	cggctcttat	540
aagaagaact	ttgccat	tgttgatgg	caaattgttt	actttgtatgc	caaattttttt	600
gccctgtctt	caacctctac	ctatttttc	agtcaagg	tgacaccaat	tgtttctgt	660
ttctcagtca	acaataaggc	tttcgattt	tctgaaaaga	gttttggact	gttagatgg	720
tacctgacag	ctgaaaagct	gtaccgtt	gctaagttt	ttggaaaatgg	caagacctgg	780
gtggacttca	aagaaactga	ctttcgttca	gttctcatga	gctgggtggcc	aaacaaggat	840
acccaagttt	cctaccttca	ctatatgtcc	aaggcgtt	gtggcaagga	agagtttaca	900
acagaaaaccc	cttcaaaacac	tttgaataca	gctgtgtt	tgattcaac	caagattgaa	960
gctcgatattt	ctaaggaaca	agggacccaa	tggcttgc	aagctatggc	tgctttgtt	1020
gcgactcgt	ctcggttggag	ttacgctat	gagcaattt	ataaaaacga	ccacttgaa	1080
ggtgggtgtc	tccttatac	taataataaa	ttgaccaat	ggcagattc	taactatcgt	1140
ttgcttaacc	gcacccctac	ccgacaggat	ggcaaggctc	attattctaa	agctgacgaa	1200

20151105_CL6294WOPCT_SequenceListing

tacggtggtt	acgaatttcc	cttggctaat	gacgtggata	actccaaccc	agtgcgttcaa	1260
gcggaaatgc	tcaaccaaat	ccactacctg	atgaactggg	gctctattgt	catgaatgac	1320
aaggatgcca	actttgatgg	tatccgtgtg	gatgcgtgg	ataatgtcaa	tgcggatacc	1380
ctgcaactct	acactaacta	ttttaattcg	gttatggtg	tcaacaagtc	agaagccaa	1440
gccctagctc	acatttcagt	attagaagct	tggtcttata	atgataatga	ctataaccaa	1500
gataccaatg	gtgcggcctt	ggctatggac	aatggctac	gcttctccct	gctttatacc	1560
ctgacacgtc	cacttaatga	gcccactcct	ggtatgtcaa	ccttgattaa	gtcacaatat	1620
ggtttgactg	accggaccaa	ggatgacaag	tatggcgata	ctcagccatc	ctatgtcttt	1680
gttcgggctc	atgactcaga	agtcaaacc	gttattgcgc	aaatcatcaa	aaaaaaaatt	1740
gatccaacga	ctgatggctt	tacccacc	ttggaccaat	tgaacacaggc	ctttgacatc	1800
tacaataagg	atatgaatag	tgttgataag	cactataccc	actacaatat	tccagcagcc	1860
tacgctgtta	tgttgcctaa	catggaatca	gtaactcggg	tttactatgg	agacctctt	1920
accgatgatg	gtcaatacat	gaaaccaag	tctccttact	acgatgctat	caataccctc	1980
cttagggccc	ggattcgta	cgcgcgttgt	ggtcaaacca	tgaacacaa	ttccctataag	2040
gcatcagcag	ctatgaaagc	taaaaaatcct	gatagtggta	gtgtgcttgg	caacagcga	2100
gttcttgtct	ctgttcgttt	tggtaagat	gtgatgtctg	ctgacgatat	gactggttgt	2160
aagctggcta	aaacctctgg	tatgttcagc	ctgatttcca	acaaccctga	attagaattg	2220
gatgccaatg	aagaaatcag	ggtaatgtt	ggtaagattc	atgctggta	aacctaccgt	2280
ccattgtctt	tgacaaccga	taagggtctg	caaaagtacc	tcaatgattc	tgatactaag	2340
ctgaccaagg	ttgcccataa	ggatggttat	atcacccatc	agggcagtga	aatcaaggc	2400
tacaagcagg	ttgaagtc当地	tggttaccc	tctgttggg	taccatgc当地	cgcaaaggc	2460
gatcaagata	ttcgtgtgg	agcttcaact	aaggtaatg	gtaaggatga	caagacttat	2520
acagctagtc	aaggcttaga	atcacaattat	atctacaaag	gttctctaa	cttccaaagat	2580
ttcgttaaga	aggactccca	atataccat	aagaagattt	ctgaaaatac	cgacccctt	2640
aaggcctggg	gcgtgaccc	atttgaatg	gcccacaaat	acgtttccgc	aactgatggt	2700
accttcctgg	attcttattat	tgaaaatgg	tatgccttca	ccgaccgtta	tgacccgtcc	2760
atgagcaaga	acaacaagta	cggttctaa	gaagacttgg	ccaatgctct	taagggccctc	2820
cacgctgctg	gtatccaa	tatcgacag	tgggttccag	accaaattta	ccaactccca	2880
ggttaaggaag	tggtaactgc	aatgcgttt	gataactatg	gccgtgttaa	gattgaccaa	2940
ccattgttgt	aaaaacttta	cttggccaaat	accaagagct	caggaaaaga	cttccaggct	3000
aaatatgtt	gtgaatttctt	agaagacgt	caaaagcaat	accctgaaat	gtttaccgct	3060
aagatgattt	caaccggtaa	aaccattgtat	ccatctgtca	aattgaagga	atggtcagct	3120
aagtacttga	acggaacaaa	tgttctgggt	cgtgttacag	actatgtcct	cagcgtatgaa	3180
ggaactggca	aataacttac	tgttaatgaa	aagggttact	tccttaccagc	agccctgaca	3240
ggtgataggg	aaggcaagac	tggtttctac	aatgtatgtt	aggaaatgac	ctactataca	3300
acggctggta	acaaggctaa	atctgcctt	gtaaccgttag	ctggaaatac	ctattacttt	3360
gactatactg	gttatatgtt	aacaggacca	aacacgatta	acagcaaatt	ctattacttc	3420
ctgccaaatg	gggtaatgtct	caaggatgt	attaagcaag	atgagttggg	cggttccgtt	3480
tactatgtt	aaactgttac	catgtacaag	gcgacagata	aatctcaatg	gtttccatg	3540
accgactcta	agggtcaaca	acgttccgt	cacttgc当地	gcttcggat	catgtctgt	3600
ggactgggta	ccatcaatgg	tagtggtaa	tattacatgt	aagaaggctt	ccaagttaa	3660
ggcgaatttg	tcaactgataa	ggatggtcaa	acccgttact	ttgacgaagg	ttctgttaat	3720
ctggtaagg	accgcttcc	caataaggat	ggcaagtgg	actatcttga	tgataaaggc	3780
ttgctggta	agggggctca	aaccattaa	ggtcaaaaac	tctacttga	caccaagacc	3840
ggtgccaag	tcaagggtga	cttgggttcc	gacaaggatg	gcaacctgac	cttctatagt	3900
ggtgatagt	gtcaaatgg	tcaaaatgtat	ttcttctaa	caggaaataa	tgcttggttc	3960
tatgccatg	aaaatggta	tgtcgctaa	ggagcttact	ctatcagagg	tcagaagctc	4020
tacttgata	caaaaacagg	tcagcaagct	aagggtact	ttatccgtga	tgacaagggg	4080
gttcgttact	atgatgtca	cacagggtcc	ttggtaacca	acgctttcc	tgaaactaag	4140
gctggttcta	accaatgtta	ttacatggga	gcagatgtt	atgctgtcaa	ggggaaaccag	4200
accataaaaa	atcagcacat	gtatggat	gctgaaactg	gccaacaagc	taagggaaatt	4260
atagtgacag	atgccaatgg	tcgcaagtt	ttctatgata	ctttactgg	cagtcgtt	4320
gtaaaccaat	ttgttttggt	taatggaaat	tggttatttct			4360

<210> 16
 <211> 1453
 <212> PRT
 <213> Streptococcus downei

<400> 16
 Met Ile Phe Met Glu Arg Lys Leu His Tyr Lys Leu His Lys Val Lys
 1 5 10 15
 Lys Gln Trp Val Thr Ile Ala Val Ala Ser Ala Gly Leu Ala Ser Val
 20 25 30
 Val Gly Ala Gly Ser Leu Ser Gln Thr Val Ser Ala Asp Asp Leu Ala
 35 40 45
 Lys Asp Gln Ala Ala Ala Thr Glu Gln Lys Ala Ser Ala Asn Gln Glu
 50 55 60

20151105_CL6294WOPCT_SequenceListing

Lys Glu Glu Val Val Ser Asp Gln Val Asp Thr Thr Ser Ala Lys Ala
 65 70 75 80
 Thr Ser Glu Lys Glu Val Ala Gln Ala Ser Asp Thr Ser Ser Glu Ala
 85 90 95
 Asn Gln Val Pro Ala Gln Glu Glu Lys Lys Ala Glu Lys Ala Ala Ala
 100 105 110
 Pro Ala Thr Ala Thr Pro Ala Pro Gln Thr Gly Ala Lys Asn Ser Gln
 115 120 125
 Thr Ala Ser Ser Glu Ala Pro Ala Thr Ser Asn Gln Ala Ser Glu Thr
 130 135 140
 Ala Glu Thr Gly Ala Leu Ser Gln Lys Glu Glu Ala Ala Val Leu Ser
 145 150 155 160
 Leu Asp Asn Ile Lys Lys Ile Asp Gly Lys Tyr Tyr Tyr Val Met Ala
 165 170 175
 Asp Gly Ser Tyr Lys Lys Asn Phe Ala Ile Thr Val Asp Gly Gln Met
 180 185 190
 Leu Tyr Phe Asp Ala Lys Thr Gly Ala Leu Ser Ser Thr Ser Thr Tyr
 195 200 205
 Ser Phe Ser Gln Gly Leu Thr Pro Ile Val Ser Asp Phe Ser Val Asn
 210 215 220
 Asn Lys Ala Phe Asp Ser Ser Glu Lys Ser Phe Glu Leu Val Asp Gly
 225 230 235 240
 Tyr Leu Thr Ala Glu Ser Trp Tyr Arg Pro Ala Lys Ile Leu Glu Asn
 245 250 255
 Gly Lys Thr Trp Val Asp Ser Lys Glu Thr Asp Leu Arg Pro Val Leu
 260 265 270
 Met Ser Trp Trp Pro Asn Lys Asp Thr Gln Val Ala Tyr Leu Asn Tyr
 275 280 285
 Met Ser Lys Ala Leu Gly Gly Lys Glu Glu Phe Thr Thr Glu Thr Ser
 290 295 300
 Gln Thr Thr Leu Asn Thr Ala Ala Glu Leu Ile Gln Thr Lys Ile Glu
 305 310 315 320
 Ala Arg Ile Ser Lys Glu Gln Gly Thr Lys Trp Leu Arg Glu Ala Met
 325 330 335
 Ala Ala Phe Val Ala Thr Gln Ser Arg Trp Ser Tyr Ala Ser Glu Gln
 340 345 350
 Phe Asp Lys Asn Asp His Leu Gln Gly Gly Ala Leu Leu Tyr Thr Asn
 355 360 365
 Asn Lys Leu Thr Gln Trp Ala Asp Ser Asn Tyr Arg Leu Leu Asn Arg
 370 375 380
 Thr Pro Thr Arg Gln Asp Gly Lys Pro His Tyr Ser Lys Ala Asp Glu
 385 390 395 400
 Tyr Gly Gly Tyr Glu Phe Leu Leu Ala Asn Asp Val Asp Asn Ser Asn
 405 410 415
 Pro Val Val Gln Ala Glu Met Leu Asn Gln Ile His Tyr Leu Met Asn
 420 425 430
 Trp Gly Ser Ile Val Met Asn Asp Lys Asp Ala Asn Phe Asp Gly Ile
 435 440 445
 Arg Val Asp Ala Val Asp Asn Val Asn Ala Asp Thr Leu Gln Leu Tyr
 450 455 460
 Thr Asn Tyr Phe Asn Ser Val Tyr Gly Val Asn Lys Ser Glu Ala Gln
 465 470 475 480
 Ala Leu Ala His Ile Ser Val Leu Glu Ala Trp Ser Tyr Asn Asp Asn
 485 490 495
 Asp Tyr Asn Gln Asp Thr Asn Gly Ala Ala Leu Ala Met Asp Asn Gly
 500 505 510
 Leu Arg Phe Ser Leu Leu Tyr Thr Leu Thr Arg Pro Leu Asn Glu Arg
 515 520 525
 Thr Pro Gly Met Ser Thr Leu Ile Lys Ser Gln Tyr Gly Leu Thr Asp
 530 535 540
 Arg Thr Lys Asp Asp Lys Tyr Gly Asp Thr Gln Pro Ser Tyr Val Phe
 545 550 555 560
 Val Arg Ala His Asp Ser Glu Val Gln Thr Val Ile Ala Gln Ile Ile
 565 570 575
 Lys Lys Lys Ile Asp Pro Thr Thr Asp Gly Phe Thr Phe Thr Leu Asp
 580 585 590
 Gln Leu Lys Gln Ala Phe Asp Ile Tyr Asn Lys Asp Met Asn Ser Val
 595 600 605

20151105_CL6294WOPCT_SequenceListing

Asp Lys His Tyr Thr His Tyr Asn Ile Pro Ala Ala Tyr Ala Val Met
 610 615 620
 Leu Ser Asn Met Glu Ser Val Thr Arg Val Tyr Tyr Gly Asp Leu Phe
 625 630 635 640
 Thr Asp Asp Gly Gln Tyr Met Glu Thr Lys Ser Pro Tyr Tyr Asp Ala
 645 650 655
 Ile Asn Thr Leu Leu Arg Ala Arg Ile Arg Tyr Ala Ala Gly Gly Gln
 660 665 670
 Thr Met Glu His Asn Ser Tyr Lys Ala Ser Ala Ala Met Lys Ala Lys
 675 680 685
 Asn Pro Asp Ser Gly Ser Val Leu Gly Asn Ser Glu Val Leu Val Ser
 690 695 700
 Val Arg Phe Gly Gln Asp Val Met Ser Ala Asp Asp Met Thr Gly Gly
 705 710 715 720
 Lys Leu Ala Lys Thr Ser Gly Met Phe Ser Leu Ile Ser Asn Asn Pro
 725 730 735
 Glu Leu Glu Leu Asp Ala Asn Glu Glu Ile Arg Val Asn Val Gly Lys
 740 745 750
 Ile His Ala Gly Gln Thr Tyr Arg Pro Leu Leu Leu Thr Thr Asp Lys
 755 760 765
 Gly Leu Gln Lys Tyr Leu Asn Asp Ser Asp Thr Lys Leu Thr Lys Val
 770 775 780
 Ala Asp Lys Asp Gly Tyr Ile Thr Phe Lys Gly Ser Glu Ile Lys Gly
 785 790 795 800
 Tyr Lys Gln Val Glu Val Asn Gly Tyr Leu Ser Val Trp Val Pro Val
 805 810 815
 Gly Ala Lys Ala Asp Gln Asp Ile Arg Val Ala Ala Ser Thr Lys Val
 820 825 830
 Asn Gly Lys Asp Asp Lys Thr Tyr Thr Ala Ser Gln Ala Leu Glu Ser
 835 840 845
 Gln Leu Ile Tyr Glu Gly Phe Ser Asn Phe Gln Asp Phe Val Lys Lys
 850 855 860
 Asp Ser Gln Tyr Thr Asn Lys Lys Ile Ala Glu Asn Thr Asp Leu Phe
 865 870 875 880
 Lys Ala Trp Gly Val Thr Ser Phe Glu Met Ala Pro Gln Tyr Val Ser
 885 890 895
 Ala Thr Asp Gly Thr Phe Leu Asp Ser Ile Ile Glu Asn Gly Tyr Ala
 900 905 910
 Phe Thr Asp Arg Tyr Asp Leu Ala Met Ser Lys Asn Asn Lys Tyr Gly
 915 920 925
 Ser Lys Glu Asp Leu Ala Asn Ala Leu Lys Ala Leu His Ala Ala Gly
 930 935 940
 Ile Gln Ala Ile Ala Asp Trp Val Pro Asp Gln Ile Tyr Gln Leu Pro
 945 950 955 960
 Gly Lys Glu Val Val Thr Ala Ser Arg Val Asp Asn Tyr Gly Arg Val
 965 970 975
 Lys Ile Asp Gln Pro Leu Val Glu Lys Leu Tyr Leu Ala Asn Thr Lys
 980 985 990
 Ser Ser Gly Lys Asp Phe Gln Ala Lys Tyr Gly Gly Glu Phe Leu Glu
 995 1000 1005
 Asp Leu Gln Lys Gln Tyr Pro Glu Met Phe Thr Ala Lys Met Ile
 1010 1015 1020
 Ser Thr Gly Lys Thr Ile Asp Pro Ser Val Lys Leu Lys Glu Trp
 1025 1030 1035
 Ser Ala Lys Tyr Leu Asn Gly Thr Asn Val Leu Gly Arg Gly Thr
 1040 1045 1050
 Asp Tyr Val Leu Ser Asp Glu Gly Thr Gly Lys Tyr Phe Thr Val
 1055 1060 1065
 Asn Glu Lys Gly Asp Phe Leu Pro Ala Ala Leu Thr Gly Asp Arg
 1070 1075 1080
 Glu Ala Lys Thr Gly Phe Tyr Asn Asp Gly Lys Gly Met Thr Tyr
 1085 1090 1095
 Tyr Thr Thr Ala Gly Asn Lys Ala Lys Ser Ala Phe Val Thr Val
 1100 1105 1110
 Ala Gly Asn Thr Tyr Tyr Phe Asp Tyr Thr Gly Tyr Met Val Thr
 1115 1120 1125
 Gly Pro Asn Thr Ile Asn Ser Lys Phe Tyr Tyr Phe Leu Pro Asn
 1130 1135 1140

20151105_CL6294WOPCT_SequenceListing

Gly	Val	Met	Leu	Lys	Asp	Ala	Ile	Lys	Gln	Asp	Glu	Leu	Gly	Arg
1145							1150					1155		
Ser	Val	Tyr	Tyr	Gly	Lys	Thr	Gly	Thr	Met	Tyr	Lys	Ala	Thr	Asp
1160							1165					1170		
Lys	Ser	Gln	Trp	Phe	Ala	Met	Thr	Asp	Ser	Lys	Gly	Gln	Gln	Arg
1175							1180					1185		
Phe	Arg	His	Phe	Asp	Arg	Phe	Gly	Ile	Met	Ser	Val	Gly	Leu	Val
1190							1195					1200		
Thr	Ile	Asn	Gly	Ser	Val	Gln	Tyr	Tyr	Asp	Glu	Glu	Gly	Phe	Gln
1205							1210					1215		
Val	Lys	Gly	Glu	Phe	Val	Thr	Asp	Lys	Asp	Gly	Gln	Thr	Arg	Tyr
1220							1225					1230		
Phe	Asp	Glu	Gly	Ser	Gly	Asn	Leu	Val	Lys	Asp	Arg	Phe	Leu	Asn
1235							1240					1245		
Lys	Asp	Gly	Lys	Trp	Tyr	Tyr	Leu	Asp	Asp	Lys	Gly	Leu	Leu	Val
1250							1255					1260		
Lys	Gly	Ala	Gln	Thr	Ile	Lys	Gly	Gln	Lys	Leu	Tyr	Phe	Asp	Thr
1265							1270					1275		
Lys	Thr	Gly	Ala	Gln	Val	Lys	Gly	Asp	Phe	Val	Ala	Asp	Lys	Asp
1280							1285					1290		
Gly	Asn	Leu	Thr	Phe	Tyr	Ser	Gly	Asp	Ser	Gly	Gln	Met	Val	Gln
1295							1300					1305		
Ser	Asp	Phe	Phe	Ser	Thr	Gly	Asn	Asn	Ala	Trp	Phe	Tyr	Ala	Asp
1310							1315					1320		
Glu	Asn	Gly	His	Val	Ala	Lys	Gly	Ala	Lys	Thr	Ile	Arg	Gly	Gln
1325							1330					1335		
Lys	Leu	Tyr	Phe	Asp	Thr	Lys	Thr	Gly	Gln	Gln	Ala	Lys	Gly	Arg
1340							1345					1350		
Phe	Ile	Arg	Asp	Asp	Lys	Gly	Val	Arg	Tyr	Tyr	Asp	Ala	Asp	Thr
1355							1360					1365		
Gly	Ala	Leu	Val	Thr	Asn	Ala	Phe	Leu	Glu	Thr	Lys	Ala	Gly	Ser
1370							1375					1380		
Asn	Gln	Trp	Tyr	Tyr	Met	Gly	Ala	Asp	Gly	Tyr	Ala	Val	Lys	Gly
1385							1390					1395		
Asn	Gln	Thr	Ile	Lys	Asn	Gln	His	Met	Tyr	Phe	Asp	Ala	Glu	Thr
1400							1405					1410		
Gly	Gln	Gln	Ala	Lys	Gly	Ile	Ile	Val	Thr	Asp	Ala	Asn	Gly	Arg
1415							1420					1425		
Lys	Tyr	Phe	Tyr	Asp	Thr	Phe	Thr	Gly	Ser	Arg	Val	Val	Asn	Gln
1430							1435					1440		
Phe	Val	Leu	Val	Asn	Gly	Asn	Trp	Tyr	Phe					
1445							1450							

<210> 17
<211> 1409
<212> PRT
<213> Streptococcus downei

<220>
<221> MISC_FEATURE
<222> (1)..(1409)
<223> mature 2921 gtf

<400> 17
Asp Asp Leu Ala Lys Asp Gln Ala Ala Ala Thr Glu Gln Lys Ala Ser
1 5 10 15
Ala Asn Gln Glu Lys Glu Glu Val Val Ser Asp Gln Val Asp Thr Thr
20 25 30
Ser Ala Lys Ala Thr Ser Glu Lys Glu Val Ala Gln Ala Ser Asp Thr
35 40 45
Ser Ser Glu Ala Asn Gln Val Pro Ala Gln Glu Glu Lys Lys Ala Glu
50 55 60
Lys Ala Ala Ala Pro Ala Thr Ala Thr Pro Ala Pro Gln Thr Gly Ala
65 70 75 80
Lys Asn Ser Gln Thr Ala Ser Ser Glu Ala Pro Ala Thr Ser Asn Gln
85 90 95
Ala Ser Glu Thr Ala Glu Thr Gly Ala Leu Ser Gln Lys Glu Glu Ala
100 105 110

20151105_CL6294WOPCT_SequenceListing

Ala Val Leu Ser Leu Asp Asn Ile Lys Lys Ile Asp Gly Lys Tyr Tyr
 115 120 125
 Tyr Val Met Ala Asp Gly Ser Tyr Lys Lys Asn Phe Ala Ile Thr Val
 130 135 140
 Asp Gly Gln Met Leu Tyr Phe Asp Ala Lys Thr Gly Ala Leu Ser Ser
 145 150 155 160
 Thr Ser Thr Tyr Ser Phe Ser Gln Gly Leu Thr Pro Ile Val Ser Asp
 165 170 175
 Phe Ser Val Asn Asn Lys Ala Phe Asp Ser Ser Glu Lys Ser Phe Glu
 180 185 190
 Leu Val Asp Gly Tyr Leu Thr Ala Glu Ser Trp Tyr Arg Pro Ala Lys
 195 200 205
 Ile Leu Glu Asn Gly Lys Thr Trp Val Asp Ser Lys Glu Thr Asp Leu
 210 215 220
 Arg Pro Val Leu Met Ser Trp Trp Pro Asn Lys Asp Thr Gln Val Ala
 225 230 235 240
 Tyr Leu Asn Tyr Met Ser Lys Ala Leu Gly Gly Lys Glu Glu Phe Thr
 245 250 255
 Thr Glu Thr Ser Gln Thr Thr Leu Asn Thr Ala Ala Glu Leu Ile Gln
 260 265 270
 Thr Lys Ile Glu Ala Arg Ile Ser Lys Glu Gln Gly Thr Lys Trp Leu
 275 280 285
 Arg Glu Ala Met Ala Ala Phe Val Ala Thr Gln Ser Arg Trp Ser Tyr
 290 295 300
 Ala Ser Glu Gln Phe Asp Lys Asn Asp His Leu Gln Gly Gly Ala Leu
 305 310 315 320
 Leu Tyr Thr Asn Asn Lys Leu Thr Gln Trp Ala Asp Ser Asn Tyr Arg
 325 330 335
 Leu Leu Asn Arg Thr Pro Thr Arg Gln Asp Gly Lys Pro His Tyr Ser
 340 345 350
 Lys Ala Asp Glu Tyr Gly Tyr Glu Phe Leu Leu Ala Asn Asp Val
 355 360 365
 Asp Asn Ser Asn Pro Val Val Gln Ala Glu Met Leu Asn Gln Ile His
 370 375 380
 Tyr Leu Met Asn Trp Gly Ser Ile Val Met Asn Asp Lys Asp Ala Asn
 385 390 395 400
 Phe Asp Gly Ile Arg Val Asp Ala Val Asp Asn Val Asn Ala Asp Thr
 405 410 415
 Leu Gln Leu Tyr Thr Asn Tyr Phe Asn Ser Val Tyr Gly Val Asn Lys
 420 425 430
 Ser Glu Ala Gln Ala Leu Ala His Ile Ser Val Leu Glu Ala Trp Ser
 435 440 445
 Tyr Asn Asp Asn Asp Tyr Asn Gln Asp Thr Asn Gly Ala Ala Leu Ala
 450 455 460
 Met Asp Asn Gly Leu Arg Phe Ser Leu Leu Tyr Thr Leu Thr Arg Pro
 465 470 475 480
 Leu Asn Glu Arg Thr Pro Gly Met Ser Thr Leu Ile Lys Ser Gln Tyr
 485 490 495
 Gly Leu Thr Asp Arg Thr Lys Asp Asp Lys Tyr Gly Asp Thr Gln Pro
 500 505 510
 Ser Tyr Val Phe Val Arg Ala His Asp Ser Glu Val Gln Thr Val Ile
 515 520 525
 Ala Gln Ile Ile Lys Lys Ile Asp Pro Thr Thr Asp Gly Phe Thr
 530 535 540
 Phe Thr Leu Asp Gln Leu Lys Gln Ala Phe Asp Ile Tyr Asn Lys Asp
 545 550 555 560
 Met Asn Ser Val Asp Lys His Tyr Thr His Tyr Asn Ile Pro Ala Ala
 565 570 575
 Tyr Ala Val Met Leu Ser Asn Met Glu Ser Val Thr Arg Val Tyr Tyr
 580 585 590
 Gly Asp Leu Phe Thr Asp Asp Gly Gln Tyr Met Glu Thr Lys Ser Pro
 595 600 605
 Tyr Tyr Asp Ala Ile Asn Thr Leu Leu Arg Ala Arg Ile Arg Tyr Ala
 610 615 620
 Ala Gly Gly Gln Thr Met Glu His Asn Ser Tyr Lys Ala Ser Ala Ala
 625 630 635 640
 Met Lys Ala Lys Asn Pro Asp Ser Gly Ser Val Leu Gly Asn Ser Glu
 645 650 655

20151105_CL6294WOPCT_SequenceListing

Val Leu Val Ser Val Arg Phe Gly Gln Asp Val Met Ser Ala Asp Asp
 660 665 670
 Met Thr Gly Gly Lys Leu Ala Lys Thr Ser Gly Met Phe Ser Leu Ile
 675 680 685
 Ser Asn Asn Pro Glu Leu Glu Leu Asp Ala Asn Glu Glu Ile Arg Val
 690 695 700
 Asn Val Gly Lys Ile His Ala Gly Gln Thr Tyr Arg Pro Leu Leu Leu
 705 710 715 720
 Thr Thr Asp Lys Gly Leu Gln Lys Tyr Leu Asn Asp Ser Asp Thr Lys
 725 730 735
 Leu Thr Lys Val Ala Asp Lys Asp Gly Tyr Ile Thr Phe Lys Gly Ser
 740 745 750
 Glu Ile Lys Gly Tyr Lys Gln Val Glu Val Asn Gly Tyr Leu Ser Val
 755 760 765
 Trp Val Pro Val Gly Ala Lys Ala Asp Gln Asp Ile Arg Val Ala Ala
 770 775 780
 Ser Thr Lys Val Asn Gly Lys Asp Asp Lys Thr Tyr Thr Ala Ser Gln
 785 790 795 800
 Ala Leu Glu Ser Gln Leu Ile Tyr Glu Gly Phe Ser Asn Phe Gln Asp
 805 810 815
 Phe Val Lys Asp Ser Gln Tyr Thr Asn Lys Lys Ile Ala Glu Asn
 820 825 830
 Thr Asp Leu Phe Lys Ala Trp Gly Val Thr Ser Phe Glu Met Ala Pro
 835 840 845
 Gln Tyr Val Ser Ala Thr Asp Gly Thr Phe Leu Asp Ser Ile Ile Glu
 850 855 860
 Asn Gly Tyr Ala Phe Thr Asp Arg Tyr Asp Leu Ala Met Ser Lys Asn
 865 870 875 880
 Asn Lys Tyr Gly Ser Lys Glu Asp Leu Ala Asn Ala Leu Lys Ala Leu
 885 890 895
 His Ala Ala Gly Ile Gln Ala Ile Ala Asp Trp Val Pro Asp Gln Ile
 900 905 910
 Tyr Gln Leu Pro Gly Lys Glu Val Val Thr Ala Ser Arg Val Asp Asn
 915 920 925
 Tyr Gly Arg Val Lys Ile Asp Gln Pro Leu Val Glu Lys Leu Tyr Leu
 930 935 940
 Ala Asn Thr Lys Ser Ser Gly Lys Asp Phe Gln Ala Lys Tyr Gly Gly
 945 950 955 960
 Glu Phe Leu Glu Asp Leu Gln Lys Gln Tyr Pro Glu Met Phe Thr Ala
 965 970 975
 Lys Met Ile Ser Thr Gly Lys Thr Ile Asp Pro Ser Val Lys Leu Lys
 980 985 990
 Glu Trp Ser Ala Lys Tyr Leu Asn Gly Thr Asn Val Leu Gly Arg Gly
 995 1000 1005
 Thr Asp Tyr Val Leu Ser Asp Glu Gly Thr Gly Lys Tyr Phe Thr
 1010 1015 1020
 Val Asn Glu Lys Gly Asp Phe Leu Pro Ala Ala Leu Thr Gly Asp
 1025 1030 1035
 Arg Glu Ala Lys Thr Gly Phe Tyr Asn Asp Gly Lys Gly Met Thr
 1040 1045 1050
 Tyr Tyr Thr Thr Ala Gly Asn Lys Ala Lys Ser Ala Phe Val Thr
 1055 1060 1065
 Val Ala Gly Asn Thr Tyr Tyr Phe Asp Tyr Thr Gly Tyr Met Val
 1070 1075 1080
 Thr Gly Pro Asn Thr Ile Asn Ser Lys Phe Tyr Tyr Phe Leu Pro
 1085 1090 1095
 Asn Gly Val Met Leu Lys Asp Ala Ile Lys Gln Asp Glu Leu Gly
 1100 1105 1110
 Arg Ser Val Tyr Tyr Gly Lys Thr Gly Thr Met Tyr Lys Ala Thr
 1115 1120 1125
 Asp Lys Ser Gln Trp Phe Ala Met Thr Asp Ser Lys Gly Gln Gln
 1130 1135 1140
 Arg Phe Arg His Phe Asp Arg Phe Gly Ile Met Ser Val Gly Leu
 1145 1150 1155
 Val Thr Ile Asn Gly Ser Val Gln Tyr Tyr Asp Glu Glu Gly Phe
 1160 1165 1170
 Gln Val Lys Gly Glu Phe Val Thr Asp Lys Asp Gly Gln Thr Arg
 1175 1180 1185

20151105_CL6294WOPCT_SequenceListing

Tyr	Phe	Asp	Glu	Gly	Ser	Gly	Asn	Leu	Val	Lys	Asp	Arg	Phe	Leu
1190	1195					1195				1200				
Asn	Lys	Asp	Gly	Lys	Trp	Tyr	Tyr	Leu	Asp	Asp	Lys	Gly	Leu	Leu
1205	1210					1210					1215			
Val	Lys	Gly	Ala	Gln	Thr	Ile	Lys	Gly	Gln	Lys	Leu	Tyr	Phe	Asp
1220	1225					1225				1230				
Thr	Lys	Thr	Gly	Ala	Gln	Val	Lys	Gly	Asp	Phe	Val	Ala	Asp	Lys
1235	1240					1240				1245				
Asp	Gly	Asn	Leu	Thr	Phe	Tyr	Ser	Gly	Asp	Ser	Gly	Gln	Met	Val
1250	1255					1255				1260				
Gln	Ser	Asp	Phe	Phe	Ser	Thr	Gly	Asn	Asn	Ala	Trp	Phe	Tyr	Ala
1265	1270					1270				1275				
Asp	Glu	Asn	Gly	His	Val	Ala	Lys	Gly	Ala	Lys	Thr	Ile	Arg	Gly
1280	1285					1285				1290				
Gln	Lys	Leu	Tyr	Phe	Asp	Thr	Lys	Thr	Gly	Gln	Gln	Ala	Lys	Gly
1295	1300					1300				1305				
Arg	Phe	Ile	Arg	Asp	Asp	Lys	Gly	Val	Arg	Tyr	Tyr	Asp	Ala	Asp
1310	1315					1315				1320				
Thr	Gly	Ala	Leu	Val	Thr	Asn	Ala	Phe	Leu	Glu	Thr	Lys	Ala	Gly
1325	1330					1330				1335				
Ser	Asn	Gln	Trp	Tyr	Tyr	Met	Gly	Ala	Asp	Gly	Tyr	Ala	Val	Lys
1340	1345					1345				1350				
Gly	Asn	Gln	Thr	Ile	Lys	Asn	Gln	His	Met	Tyr	Phe	Asp	Ala	Glu
1355	1360					1360				1365				
Thr	Gly	Gln	Gln	Ala	Lys	Gly	Ile	Ile	Val	Thr	Asp	Ala	Asn	Gly
1370	1375					1375				1380				
Arg	Lys	Tyr	Phe	Tyr	Asp	Thr	Phe	Thr	Gly	Ser	Arg	Val	Val	Asn
1385	1390					1390				1395				
Gln	Phe	Val	Leu	Val	Asn	Gly	Asn	Trp	Tyr	Phe				
1400	1405					1405								

<210> 18

<211> 4230

<212> DNA

<213> Artificial sequence

<220>

<223> 2921 gtf with heterologous signal sequence

<400> 18

gatgatctgg	caaaggacca	agcggctgcc	acggaacaga	aggcatcagc	gaatcaagaa	60
aaggaggaag	ttgtttcaga	tcaagttgat	acgacaagcg	ccaaagcaac	gtcagaaaaaa	120
gagggtggcac	aggctagcga	tacatcatca	gaggccaacc	agttccggc	ccaagaggaa	180
aagaaaagccg	agaaggccgc	agcacctgcg	acagctacgc	cggcaccgc	aacgggagcc	240
aaaaaatagcc	aaacagcctc	aagcgaggca	ccggctacat	caaatacagc	atcagaaacg	300
gcggaaaacag	gcbcactgtc	acaaaaggaa	gaagcagctg	tcccttcact	tgataatatc	360
aaaaagattg	acggaaaata	ctactatgtt	atggctgtat	gatcatataaa	gaaaaacttt	420
gcgattacag	tcgatggcca	aatgctgtat	tttgatgcaa	aaacaggagc	tctttcaagc	480
acatcaacat	attcattttc	acaaggcctg	acaccgattt	tttagcactt	ctcagtcatt	540
aacaaggcat	ttgatagcag	cgagaaatca	ttcgaactt	tggatggata	tcttacggcc	600
gagagcttgt	acagaccggc	aaaaattctg	gagaatggaa	agacgtgggt	tgattcaaaa	660
gagacggacc	ttagaccgtt	gctgatgtca	tggtggccga	ataaggatac	gcaggttgcc	720
tacctgaact	atatgtcaaa	agcacttggc	ggcaaagagg	agtttacaac	ggagacatca	780
caaacgacac	ttaacacggc	tgctgaactt	atccagacga	agatcgaggc	aagaatttagc	840
aaagaacaag	gaacgaagt	gcttagagaa	gctatggccg	catttgtgc	tacgcagtca	900
agatggtcat	atgcgtcaga	gcagttcgat	aaaaacgatc	accttcaagg	cggagactt	960
ctgtacacaa	ataataagct	gacacaatgg	gctgactcaa	actatagact	gcttaacaga	1020
acgcctacga	gacaggatgg	aaaacctcat	tacagcaaag	cagacgagta	tggaggttat	1080
gagttcctgc	ttgcaaata	cgtcgataac	tcaaataccgg	tggttcaggc	agagatgttt	1140
aatcaaattc	actatctt	gaactggggc	tcaatttgtt	tgaatgataa	ggacgcgaat	1200
ttcgatggaa	ttagagtgg	tgcggttgac	aatgttaat	cgacacact	tcaactgtat	1260
acgaattact	ttaactcagt	ttacggcg	aacaaatcag	aagctcaggc	attgtctat	1320
atcagcggtt	ttgaagcat	gagctacaac	gacaatgatt	acaatcagga	tacaatggc	1380
gctgcactgg	ccatggataa	tggacttaga	ttcagccttc	tttacacact	gacaagaccg	1440
cttaacgaga	gaacacctgg	catgtcaaca	cttattaat	cacaatatgg	ccttacagac	1500
agaacaaaag	acgataagta	cggcgacacg	caaccgtcat	acgtgtttgt	tagactcac	1560
gacagcgaag	ttcaaacact	tattgctca	attattaaga	agaaaattga	tccgacaaca	1620
gacggattca	catttacact	ggaccaactt	aaacaagcct	tcgatatact	taacaaagat	1680

20151105_CL6294WOPCT_SequenceListing

atgaatagcg	ttgataaaca	ttacacgcac	tacaatattc	ctgcagcata	cgctgtcatg	1740
ctgtcaaaca	tggaatcagt	tacaagagtc	tattatggcg	acctgtttac	agatgacggc	1800
caatatatgg	aaacaaaatc	accgtactat	gacgcccatta	atacactgct	gagagccaga	1860
atcagatatg	cagctggcg	acaacaatg	gaacacaaca	gctataaggc	gtcagctgcf	1920
atgaaggcga	aaaaccctga	tagggctca	gtccttggca	attcagaatg	tctggtagc	1980
gttagatttgc	gacaagatgt	gatgagcgt	gacgatata	caggaggca	acttgtcaag	2040
acgtcaggaa	tgttctact	gattcaat	aatccgaaac	tgaaacttga	cgctaata	2100
gagatcagag	tgaatgttgg	aaaaatccat	gccggccaaa	cgtacagacc	tcttctgctt	2160
acgacagata	agggcctgca	aaagtatctt	aatgactcag	acacgaaact	tacgaagggt	2220
gcagataaag	atggcttat	tacatttaag	ggctcagaga	ttaaaggcta	taaacagggt	2280
gaagttaatg	gctacctgag	cgtctgggt	ccgggtggcg	ctaaagcaga	ccaagacatc	2340
agagtcgcag	cttcaacaaa	agtaatgg	aaggatgata	agacgtacac	ggcaagccaa	2400
gcacttgagt	cacagcttat	ttacgagggc	ttctcaattt	tccaagattt	cgttaagaaa	2460
gattcacaat	atacaataa	gaaaatcg	gaaaatacag	atctttca	agcatgggc	2520
gttacatcat	ttgaaatggc	gcctcagtat	gttagcgtt	cagatggcac	atttctggat	2580
agcattatcg	agaatggata	tgcatttac	gatagatatg	acctggccat	gtcaaaaaac	2640
aacaatacg	gatcaaaaga	ggatcttgc	aatgcgtt	aagctctgca	cgcagctggc	2700
attcaagcca	ttgcggatttgc	ggttcctgtat	caaatttacc	aacttcc	caaggagggt	2760
gttacagcat	caagagtgc	caattacggc	agagtgaaga	tcgaccaacc	tctggggaa	2820
aagctgtatc	tggctaacac	aaagagctca	ggcaaaagatt	ttcaggcgaa	atatggcgg	2880
gaatttcttgc	aagacctgca	gaaacagtat	cctgaatgt	ttacagcgaa	aatgatttca	2940
acagaaaaaa	cgattgtatcc	taggtttaaa	ctttagggat	ggtcagccaa	atacctgaat	3000
ggaacaaacg	tgctggaaag	aggcacat	tatgttctt	cagatgggg	aacggccaaa	3060
tactttacgg	tcaatggataa	aggcgatttgc	ctgcccgt	cacttacagg	cgatagagaa	3120
gcaaagacag	gattctataa	tgacggcaaa	ggcatgacgt	attacacaac	ggccggaaat	3180
aaggcgaaga	gcbcgttcgt	taacgtggcg	ggcaacacat	actacttgc	ttatacggg	3240
tataatggta	caggacctaa	tacaatttac	agcaagttt	actatttcc	tcctaata	3300
gttatgctga	aggatgcaat	taagcaggat	gaacttggaa	gatcagtctt	ctatggcaaa	3360
acgggaacaa	tgtataaggc	aacggataaa	tcacagtgg	tcgccccat	agatagcaag	3420
ggacaacaga	gattcagaca	ttttagat	ttcggaaatca	tgagcgttgg	acttgtcact	3480
attaatggaa	gcgtccagta	ttacgacgaa	gaaggcttc	aagtttgggg	agagttcgt	3540
acggacaaag	atggacagac	gagatatttt	gacgaggaa	gcccacact	ggttaaggac	3600
agattcctga	acaaggacgg	aaagtgttat	tacccgtac	ataaggact	gcttgtcaag	3660
ggagctcaaa	caatcaaggg	ccagaaactt	tatttcgtat	caaaaacagg	agcgcacatc	3720
aaaggagact	ttgtggctga	taaggatgg	aacctgacgt	ttttagcgg	cgattcagg	3780
caaatggtgc	agtcaagactt	ctttagcaca	ggcaacaatg	catggtttta	tgcagatgaa	3840
aacggacatg	ttgcaaaagg	cgcgaagaca	atcagaggcc	aaaaactgtt	cttcgacac	3900
aagacgggac	agcaggccaa	gggcagattt	attagagat	acaaggcgt	gagataactat	3960
gatgcagaca	caggcgcact	ggtcacaaat	gctttctgg	aaacgaaggc	tggctcaat	4020
cagtggtaact	acatgggagc	cgatggatac	gcccgttgg	gcaaccagac	gatcaagaat	4080
cagcacatgt	actttgacgc	ggagacgggc	caacaagctt	aggcgttcat	cgtcagat	4140
gcaaataatggca	gaaagtactt	ctatgacacg	ttcacgggc	gcagagttt	taaccaattt	4200
gttctgggtga	acggcaatttgc	gtacttttgc				4230